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Abstract 
Objective  
The aim was to study the course of disease activity and disability in early 
rheumatoid arthritis (RA) and the relationship between the two over 24 
months.  Baseline predictors of adverse outcome were sought as potential 
tools for targeting future therapy in RA.  
Methods 
Yorkshire Early Arthritis Register (YEAR) recruited patients with a clinician-
made diagnosis of RA and symptoms of ≤24 months.  Change in disease 
activity, measured using disease activity score from counts of 28 joints 
(DAS28) and disability, measured using the disability index component of 
the health assessment questionnaire (HAQ-DI), after 6 and 12 months, were 
outcomes in linear regression models.  In order to take advantage of the 
longitudinal data and examine change in DAS28 and HAQ-DI over time, 
latent growth curves were applied to the data.  Latent class growth analyses 
(LCGA) identified trajectories of change in DAS28 and HAQ-DI over 2 years.  
Multinomial logistic regression identified predictors of trajectory group 
membership.  Finally, a dual trajectory analysis explored the relationship 
between DAS28 and HAQ-DI trajectories. Missing data were handled using 
multiple imputation and maximum likelihood estimation.  
Results  
Data from 1416 YEAR cases were included.  Baseline fatigue visual 
analogue score (VAS) consistently predicted worse outcome including  
lesser change in DAS28 and HAQ-DI after 6 and 12 months and adverse 
DAS28 and HAQ-DI trajectories. There were 2 DAS28 and 2 HAQ-DI 
trajectories and 4 dual trajectory groups: half of patients followed the most 
favourable, low DAS28/low HAQ-DI, trajectory and only 1% followed a high 
DAS28/low HAQ-DI trajectory.  High DAS28/high HAQ-DI and low 
DAS28/high HAQ-DI trajectories were more likely for females, cases from 
more deprived socio-economic areas, and those reporting greater fatigue at 
baseline.  The high DAS28/high HAQ-DI trajectory was more likely in cases 
with higher baseline DAS28, but baseline DAS28 did not predict low 
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DAS28/high HAQ-DI trajectory group membership.  Membership of the low 
DAS28/high HAQ-DI group was more likely in cases with greater contribution 
of subjective components to baseline DAS28 . 
Conclusion 
Baseline fatigue consistently predicted adverse DAS28 and HAQ-DI over 2 
years.  In some cases, there was persistent disability and disease activity, 
whilst another group had greater disability despite less disease activity.  
Compared to those with low disease activity and disability, membership of 
these 2 groups was more likely with greater baseline fatigue.  Further 
research into the drivers of fatigue in RA may help target therapies and limit 
disability in RA.  
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Chapter 1 Introduction 
Rheumatoid arthritis (RA) is a chronic, debilitating multi-system disease 
characterised by symmetrical inflammation of synovial joints.  For the 
sufferer, it represents a potential cause of pain and disability for which 
disease modifying medication is necessary to optimise long term outcomes.  
For decades, rheumatologists have faced the challenge of reducing joint 
inflammation and pain and assisting patients to manage the resulting 
impairment of daily function.  Owing to research into the optimal 
management of RA and advances in its pharmacotherapy (which are 
discussed in Section 1.6), control of inflammation in RA has vastly improved 
over recent years.  However, despite these advances, RA is not ‘cured’ and 
continues to challenge patients and rheumatologists, in terms of suppression 
of inflammation and prevention or management of disability.  There has 
been much research into factors predicting adverse outcomes in RA 
(discussed in Sections 1.8.2 and 1.8.4), but relatively little into how disease 
activity influences disability (Section 1.8.5).  This relationship warrants 
investigation, as current therapies mainly target inflammation.  Therefore, if 
disability ensues despite the suppression of synovial inflammation, 
alternative approaches may be indicated.  Furthermore, owing to the 
heterogeneous nature of RA, outcomes are likely to vary between 
individuals.  Identification of predictors of a given outcome would be a useful 
step towards personalised medicine in RA.  The present Chapter introduces 
the history, epidemiology, pathogenesis and clinical features of RA before 
discussing methods previously described in the study of this chronic illness.  
Literature reviews of methods used to measure RA outcomes, as well as 
predictors of disease activity and disability are then presented, before the 
hypothesis central to this Thesis is outlined.   
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1.1 Rheumatoid arthritis: an ancient or modern disease? 
There has been some debate as to whether RA is an ancient disease or one 
that has emerged more recently.  Images of people with joint deformities that 
are alike those seen due to RA have been depicted by artists in work 
produced as early as 1441(Yeap, 2009).  However, it cannot be assumed 
that these images represented the true physical form and furthermore, the 
physical characteristics of RA can be similar to those of other diseases.  On 
the other hand, the appearance of joint swelling and deformity characteristic 
of RA, produced by an artist whose other works do not capture this same 
appearance of the joints (and is therefore less likely to be due to artistic 
interpretation), may be more compelling evidence (Yeap, 2009, Entezami et 
al., 2011).  The first description of RA in the medical literature has been 
attributed to Augustin Jacob Landré-Beauvais in Paris in 1800 (Landre-
Beauvais, 2001).  In his doctoral dissertation, Landré-Beauvais described a 
form of arthritis in 9 patients which he observed was different to ‘ordinary 
gout’, because it tended to affect females from poor backgrounds, was 
associated with general poor health, and had a chronic course.  He named 
this disease ‘asthenic gout’.  The name ‘rheumatoid arthritis’ was applied 90 
years later by Archibald Garrod, who believed RA was not a modern disease 
and that archaeological evidence had confirmed that the disease had 
afflicted ancient populations (Garrod, 1890).  However, archaeological 
findings can be affected by the preservation of samples and Garrod’s theory 
and the reliability of evidence gathered from skeletal remains have since 
been disputed.  In the post-mortem state, damage to the skeleton can lead 
to difficulties in differentiating RA from other inflammatory arthritidies and 
furthermore, bones of the hands and wrists, which are typically involved in 
RA, may be difficult to find in ancient skeletons (reviewed by Entezami et al., 
2011).  An alternative theory, proposed following evidence obtained from 
skeletons in North America, is that the disease originated in the ‘new world’ 
and was then transferred to the ‘old world’ following the pursuits of 
Christopher Columbus in 1492 (Rothschild et al., 1992).  Some researchers 
have suggested that the introduction of tobacco in Europe could have been 
key to the emergence of RA in the old world (Appelboom and Soyfoo, 2010).  
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Although compelling archaeological evidence (discussed in the following 
paragraph) suggests that RA was prevalent in Europe prior to the 
introduction of tobacco to the old world, this theory was popular because 
tobacco consumption is currently the strongest environmental risk factor for 
the development of RA (discussed further in Section 1.2). 
More recent evidence that RA is an ancient disease arose from the 
examination of a mummy exhumed from an Italian church (Ciranni et al., 
2002).  The so called ‘Braids Lady’ (named after her hair, which was found in 
long braids upon her chest) was believed to have died between 1550 and 
1650.  Not only were there macroscopic skeletal deformities consistent with 
RA (discussed in Section 1.5.1.1), such as subluxation and reduction in joint 
space of the metacarpophalangeal (MCP) and proximal inter-phalangeal 
(PIP) joints, ulnar deviation at the MCPs and ‘Z’ deformity of the thumb, X-
ray examination of the mummified left hand (the right was skeletonised) 
confirmed erosions of the MCP joints, which are susceptible to erosions in 
RA.  The authors concluded that this evidence of incident RA in Italy prior to 
the movement of goods such as tobacco from America to Europe 
contradicted theories that RA was either introduced to Europe through 
pathogens transported with these goods, or due to the introduction of 
tobacco.  Despite the findings presented by Ciranni, which in a live patient 
would be highly suggestive of RA, Rothschild (2002) argued that an 
alternative diagnosis could be spondyloarthropathy (SPA) with involvement 
of the small joints.  He suggested that the finding of bony fusion between 
wrist bones was a finding consistent with SPA, referencing his earlier work, 
which indicated that joint fusion in RA was a modern phenomenon resulting 
from treatment with corticosteroids.  However, confirmation that the Braids 
lady carried an allele of the Human Leucocyte Antigen DRB1 (HLA-DRB1) 
gene known to be associated with RA (0101) and absence of the HLA-B27 
allele, which is strongly associated with SPA, provided further support that 
she did indeed have RA (Fontecchio et al., 2012).  
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1.2 Epidemiology of rheumatoid arthritis 
There have been significant developments in the field of RA epidemiology 
over the last 60 years.  In the 1950s and 1960s, although the aetiology of RA 
was generally accepted as multi-factorial, there was some debate regarding 
the importance of genetics.  For example, Sidney Cobb advocated that 
genetic factors were likely to be of less importance in the development of RA 
than “faulty immune mechanisms plus infection and/or joint injury, and a 
personality plus a social environment that lead to low self-esteem and 
resentment.” (Cobb, 1965).  Cobb claimed that although evidence from 
family studies suggested a genetic predisposition to RA, such findings could 
be explained by selection bias, publication bias and shared environments 
amongst families.  However, the notion of RA as a hereditary disease 
remained popular, and even at this early stage, consideration was given to a 
separate aetiology of RA in which rheumatoid factor (RF) antibodies were 
observed: so called ‘seropositive’ RA (Lawrence, 1970).  In 1976, Stastny 
first suggested that certain HLA genes, which encode major 
histocompatibility complex (MHC) class II molecules found on the surface of 
white blood cells, were associated with susceptibility to RA (Stastny, 1976).  
This is now recognised as the most significant genetic association of RA, 
representing about 30% of the genetic risk for RA (reviewed by 
Raychaudhuri, 2010).  Later, Gregerson proposed the currently accepted 
‘shared epitope’ hypothesis, which is discussed in further detail in Section 
1.4.1.  Throughout the years, environmental risk factors for RA have 
remained under scrutiny, and although several different agents have been 
suggested as possible triggers of immunological modification and 
autoimmunity in RA, tobacco smoking is the most widely reported 
environmental association.  The association was first observed by Vessey 
and colleagues, who noted a greater prevalence of RA amongst smokers in 
their cohort of female patients enrolled into a study aimed at examining the 
relationship between oral contraceptive use and arthritis (Vessey et al., 
1987).  The discovery of these genetic and environmental associations of 
RA, which are further discussed in Section 1.4.2, has   had a significant 
impact upon the understanding of RA epidemiology. 
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The prevalence of RA varies geographically, from 0.2% to 0.3% in China 
and Japan, to 5.3% and 6.8% in Native American Pima and Chippewa 
Indians, respectively (reviewed by Silman and Pearson, 2002).  Such 
geographical variation could be due to underlying genetic or environmental 
factors that predispose certain populations to RA, and studies of the 
prevalence of RA in migrant populations may be key to understanding this 
effect.  In one study, which evaluated the prevalence of RA in a Pakistani 
population living in the United Kingdom (UK), individuals from 749 
households in Luton, south east and east London, UK were interviewed.  
One criterion for inclusion was that the senior member of the household had 
been a UK resident for at least 10 years.  The results were compared to 
those of a similar survey conducted in 1215 households in Pakistan 
(Hameed and Gibson, 1997).  The researchers uncovered 6 cases of known 
RA from the 2056 people surveyed in the UK (2 of the 6 were born in the 
UK) and 6 out of 4232 individuals in Pakistan.  Although this study did not 
prove a significantly lower prevalence of RA in Pakistani immigrants living in 
the UK compared to the native UK population (the estimated standardised 
morbidity ratio, SMR was 0.62; 95%CI 0.12 to 1.12), it did find a higher 
prevalence of RA amongst Pakistani immigrants living in the UK compared 
to the native Pakistani population surveyed (estimated SMR was 2.1; 95% 
confidence interval, CI, 1.1 to 3.1), suggesting a role for environmental 
influences on the risk for RA.  It appears that there have not been any 
attempts to replicate the work carried out by Hameed and Gibson, but the 
use of modern medical databases by UK primary care practitioners may 
facilitate a less labour intensive method for repeating part of this study that 
could also encompass a wider geographical area.  
The nature of RA as a chronic disease with variable severity and a tendency 
to flare means that prevalence has limited value for investigations of RA 
aetiology.  Although estimates of prevalence, which examine a cross section 
of a population at a given time point, can be useful when assessing the 
burden of disease in a population, there is a risk of excluding cases in 
clinical remission at the time of the study, or that more severe cases are 
omitted due to premature death.  A more useful measure, when considering 
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the aetiology of RA, is the incidence rate, which may provide some insight 
into how genetic and environmental elements interplay to make certain 
populations susceptible to RA.  The only prospective study of RA incidence 
in the UK was published two decades ago and came from the Norfolk 
Arthritis Register (NOAR) (Symmons et al., 1994).  This study recruited 
patients presenting to their primary care physician with 4 or more weeks 
history of swelling in 2 or more joints, with onset of symptoms during 1990.  
The annual incidence of RA, whose diagnosis was based upon the 1987 
American College of Rheumatology (ACR, formerly American Rheumatism 
Association) criteria proposed by Arnett and colleagues (1988) and 
described in Section 1.3, was 14 per 100,000 men and 36 per 100,000 
women.  Incidence increased with age for men, but for women, it rose until 
reaching a plateau at 45 years and then declined so that the incidence in 
elderly women was significantly less than in elderly men.  Following the joint 
publication of new classification criteria for RA by the ACR and European 
League Against Rheumatism (EULAR) in 2010 (described in Section 1.3) the 
new criteria were retrospectively applied to the same population.  At 
induction to the study, more patients met the 2010 criteria for RA; however, 
when the criteria were applied over 5 years of follow up, similar numbers of 
cases were classified as RA by both systems (Humphreys et al., 2013a).  
There have been relatively few studies exploring the trends in incidence rate 
of RA, which are difficult to carry out as they require prolonged periods of 
follow up of a large population and consistent methods of case identification.  
Doran and colleagues studied the incidence of RA in Minnesota in the 
United States of America (USA), over a 40 year period (Doran et al., 2002).  
They used medical records to identify cases of RA meeting the 1987 ACR 
criteria between 1955 and 1995 and reported a cyclical pattern of RA 
incidence, with a significant overall reduction in incidence of RA in both 
women and men.  The authors also considered a “birth cohort” effect on the 
incidence of RA and found that participants of the study who were born 
during earlier time periods were more likely to have been diagnosed with RA 
than participants who were born later, but had reached a similar age.  Such 
an effect could be explained by changing exposures to environmental 
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agents, or perhaps an infectious agent.  Later, an extension to this study 
was conducted to examine the incidence of RA between 1997 and 2005, 
and a rise in incidence amongst women was uncovered (Myasoedova et al., 
2010).  The authors commented that this trend may reflect the rates of 
smoking amongst women from the population under study, which was 
declining at a rate less marked than for men.   
These estimates of incidence of RA in Minnesota are probably under-
representative of the true value, as they were based upon the older 1987 
ACR classification criteria for the diagnosis of RA, which were based upon a 
study of patients with longstanding RA.  Therefore, early RA cases from 
Minnesota could have been missed.  The discovery of anti-citrullinated 
peptide antibodies (ACPA) (Schellekens et al., 1998), which are now 
commonly measured using the anti-cyclic citrullinated peptide (anti-CCP) 
antibody assay, (Schellekens et al., 2000) was a significant advance in RA 
diagnosis that facilitated the introduction of new criteria.  These highly 
specific antibodies (95% specificity reported in a meta-analysis by Nishimura 
et al. (2007) can be present in the blood up to 9 years prior to the 
development of clinical features of RA, (Rantapaa-Dahlqvist et al., 2003) and 
have been very useful in the diagnosis of early RA.  Clinically, the ability to 
diagnose RA at its early stages is beneficial, as there is consistent evidence 
that the initiation of early and aggressive therapy is associated with 
improved long term outcomes (Knevel et al., 2010).  In order to investigate 
the impact of treatment in patients with early RA within clinical trials, an 
updated classification system was required (Aletaha et al., 2010).   
1.3 Classification criteria for rheumatoid arthritis 
The 1987 ACR criteria (Arnett et al., 1988), which were derived in order to 
distinguish RA from other types of inflammatory arthritis, were based upon 
studies of patients with established disease and included features 
associated with long term RA, such as radiographic erosions.  To define RA, 
4 of the 7 following features must be satisfied:  
 Morning stiffness of the joints lasting at least one hour  
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 Arthritis of at least 3 joint areas simultaneously with soft tissue swelling 
observed by a physician.  Valid joint areas include MCPs, PIPs, wrists, 
elbows, knees and metatarsophalangeal joints (MTP) 
 Arthritis of the hand joints with swelling of the MCPs, PIPs and wrists  
 Symmetrical arthritis of the joint areas listed in point 2 
 Rheumatoid nodules noted by a physician 
 Serum rheumatoid factor positivity 
 Typical radiographic changes observed on posteroanterior radiographs 
of the hand and wrist, which could include erosions or periarticular 
osteopenia. 
The 2010 ACR/ EULAR classification criteria were designed so that they 
could be applied in early RA and are displayed in Table 1-1.  In order to 
classify RA, subjects must obtain a score of 6 or more, from a possible 10.  
The criteria may be applied to patients with evidence of soft tissue swelling 
of least one joint, in whom an alternative diagnosis does not offer a more 
suitable explanation of the symptoms.  For cases of RA presenting at a later 
stage, RA is also defined if there is radiographic evidence of “erosions 
typical of RA”, together with a typical clinical history for RA (Aletaha et al., 
2010).  At assessment, joints are considered involved if they are swollen or 
tender, or if there is evidence of inflammation confirmed by ultrasound 
examination.  Furthermore, the criteria distinguish between large and small 
joint involvement, where large joints are the shoulders, hips, elbows, knees 
and ankles and small joints are the MCPs, PIPs, MTPs, (2nd to 5th), wrists 
and the interphalangeal joints of the thumbs.  Further distinction is made 
between ‘low’ and ‘high’ titres for RF and ACPA.  Here, a negative result is 
one below the upper limit of normal (ULN) for the specific laboratory assay; 
low titre is above the ULN, but less than 3 times the ULN and a high titre is 
one that is greater than 3 times the ULN.  The duration of symptoms refers 
to the length of time that the involved joints (identified by the physician 
assessment) had been symptomatic for, according to the patient. 
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Table 1-1 The American College of Rheumatology / European 
League Against Rheumatism 2010 criteria for the classification of 
rheumatoid arthritis (adapted from Aletaha et al., 2010) 
ACPA, anti citrullinated peptide antibodies; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate. 
1.4 Pathogenesis of rheumatoid arthritis  
RA causes pain, swelling and stiffness of synovial joints.  Figure 1-1 is an 
illustration of a synovial joint which shows articular cartilage lining the bony 
interface and synovial membrane forming the remainder of the joint lining.  
Also called the synovium, this usually hypocellular membrane consists of 2 
layers: the superficial intimal layer which produces synovial fluid to cushion 
Joint Involvement Score 
1 Large 0 
2-10 Large 1 
1-3 small  2 
4-10 small 3 
>10 joints (including at least one small joint) 5 
Serology  Score 
Negative RF and negative ACPA 
0 
Low –positive RF or low-positive ACPA 2 
High positive RF or high positive ACPA 3 
Acute phase reactants Score 
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
Duration of symptoms Score 
<6 weeks 0 
≥6 weeks 1 
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the space between articular surfaces and the deeper, sublining layer.  The 
intimal layer is only 2 or 3 cells deep and consists of 2 cell types: fibroblast-
like synoviocytes (FLS) and macrophage –like synoviocytes (MLS) (Bartok 
and Firestein, 2010).  Bursae, found between bones and tendons or 
muscles, consist of synovial fluid encapsulated by connective tissue and 
synovial membrane which absorbs impact as the joint moves (Kapit W, 
1993).  Ligaments stabilise the joint.   
 
Figure 1-1 Diagram of a synovial joint 
Reproduced with kind permission from OpenStax College. Synovial Joints, 
OpenStax-CNX Web site. http://cnx.org/contents/6c5b58ca-6c6d-4ab3-8b41-
60c8733a3144@4.  Jun 28, 2013. 
1.4.1 Genetic influences on rheumatoid arthritis susceptibility 
A genetic component to the pathology of RA is evident from family studies, 
with twin studies showing higher concordance between monozygotic than 
dizygotic pairs (Aho et al., 1986, Lawrence, 1970, Bellamy et al., 1992, 
Silman et al., 1993).  By far the most significant genetic influence on 
susceptibility to RA is the HLA-DRB1 shared epitope, which is estimated to 
explain approximately 30-50% of this risk (reviewed by Bax et al., 2011).  
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Alleles of HLA-DR genes that are associated with RA encode a common 
peptide sequence within the third hypervariable region of the MHC class II 
molecule at positions 70 to 74.  The location of the amino acid sequences 
encoded by shared epitope alleles (including HLA DR *0101, *0102, *0401, 
*0404, *0405, *1010) is within the antigen binding grove, which could explain 
the pathogenic role of this association: that is, the shape of the antigen 
binding site, determined by the amino acid sequence, permits presentation 
of certain antigens to T-cells, resulting in downstream immune activation 
(Gregersen et al., 1987).   
In addition to the shared epitope, other genes reported to be associated with 
RA are usually involved with immune response; however, only protein 
tyrosine phosphatase receptor type 2 (PTPN22) reached genome-wide 
significance levels in the initial genome-wide association study (Consortium, 
2007), although the list continues to grow (Eyre et al., 2012).  PTPN22 
encodes lymphoid protein tyrosine phosphatase which has a role in 
signalling between B and T lymphocytes and is implicated in the 
susceptibility to other autoimmune diseases in addition to RA, although the 
exact mechanisms for this are not fully understood.  A recent meta-analysis 
found that a single nucleotide polymorphism of this gene (C1858T) 
associated with autoimmune diseases such as RA and type 1 diabetes had 
a far weaker association with autoimmune diseases that involve the skin 
(such as systemic sclerosis), gastrointestinal tract (inflammatory bowel 
disease) and diseases involving sites, such as the central nervous system, 
that are considered ‘immune privileged’: that is, sites which are regarded as 
less susceptible to the actions of immune cells (Zheng et al., 2012).  The 
authors postulated that this variation in PTPN22 influences susceptibility to 
autoimmune diseases that arise due to changes in immune cells, but not 
those that arise due to changes in target organs and tissues. 
1.4.2 Environmental influences on rheumatoid arthritis 
susceptibility 
Whilst genetic susceptibility to RA is likely due to variations in immune 
mechanisms such as antigen presentation (as in the shared epitope) and T-
cell signalling pathways (as in variations of PTPN22), environmental 
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influences may contribute to the development of autoimmunity in RA by 
modifying the epitopes which are recognised by immune cells.  Smoking is 
the strongest environmental factor associated with RA (as noted in Section 
1.2) and is implicated in the post-translational modification of proteins, 
citrullination, whereby an arginine residue of a peptide is converted to 
citrulline (reviewed by Klareskog et al., 2007).  By this mechanism, smoking 
has been linked to the formation of ACPA.  Citrullinated proteins have been 
identified in fluid from bronchiolar lavage of smokers and have also been 
observed in synovial fluid in greater quantities than in serum of patients with 
RA, suggesting they may also arise within the joints themselves (reviewed 
by Cooles and Isaacs, 2011).  A possible mechanism of RA pathogenesis in 
susceptible individuals is the formation of ACPA as a result of a gene-
environment interaction between HLA-DRB1 shared epitope alleles and 
tobacco smoke (Klareskog et al., 2006).  Klareskog and colleagues reported 
a modest increase in incidence of RA amongst smokers with no copies of 
the HLA-DRB1 shared epitope with a relative risk (RR) of 1.5, with 95% CI 
0.8–2.6, which increased for smokers with one copy of the HLA-DRB1 
shared epitope: RR of 6.5; 95% CI 3.8–11.4, and was significantly more for 
smokers with two copies of the HLA-DRB1 shared epitope: RR of 21.0; 95% 
CI 11.0–40.2.  Evidence of a biological interaction was quantified by the 
calculated attributable portion (AP) of risk of developing RA that was due to 
the interaction of the effects of HLA-DRB1 shared epitope and smoking and 
was greater than the sum of the risks conferred by these variables 
independently.  The AP is represented by a value between 0 and 1 and in 
this analysis was equal to 0.4 (95% CI 0.2, 0.7) in smokers with one copy of 
the HLA-DRB1 shared epitope and 0.7 (95% CI 0.5, 0.9) in smokers with two 
copies of the HLA-DRB1 shared epitope.   
Recent evidence points towards periodontal disease as a potential trigger for 
RA.  Although both conditions share common predisposing factors, such as 
smoking, which could explain why they often occur together, there is 
evidence of increased risk of RA in patients with periodontal disease that 
persists after age, race and smoking are controlled for (de Pablo et al., 
2008).  A micro-organism associated with periodontal disease called 
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Porphyromonas gingivalis produces its own form of the enzyme necessary 
for citrullination, peptidyl arginine deiminase, which has been shown to 
trigger citrullination of human peptides fibrinogen and α-enolase.  Infection 
with P. gingivalis has been proposed as causative in the development of  
autoimmunity and subsequent RA (reviewed by Lundberg et al., 2010). 
1.4.3 Inflammation in rheumatoid arthritis 
Both adaptive and innate immune mechanisms are involved in synovial  
inflammation in RA.  However, although the associations between RA and 
HLA-DRB1 shared epitope alleles, which are likely to directly affect antigen 
presentation, and the formation of ACPA in RA (Sections 1.4.1 and 1.4.2) 
are well recognised, their role in the pathogenesis of RA is not fully 
understood.  In early synovitis, new blood vessels are formed within the 
synovium in response to local hypoxia and the induction of angiogenic 
mediators, such as vascular endothelial growth factor (Szekanecz et al., 
2010).  This neovascularisation provides nutritional and oxidative support for 
the proliferating tissue whilst vascular endothelial cells produce cytokines 
and can present antigens (Colville-Nash and Scott, 1992).  T-lymphocytes 
are abundant in the synovium and are mainly helper T-cells (Th1 and Th17) 
with relatively few regulatory T-cells, so that the T-cell population is of a pro-
inflammatory preponderance (McInnes and Schett, 2011).  Cytokines such 
as tumour necrosis factor (TNF) and interleukin (IL) 17 are produced by 
Th17 lymphocytes and can activate chondrocytes and fibroblasts.  B 
lymphocytes are of interest in RA, owing to the association with antibodies, 
however, their role in pathogenesis is likely to extend beyond formation of 
antibodies.  Rituximab, a monoclonal antibody that depletes B cells through 
binding to CD20 (discussed in Section 1.6), is a useful treatment for RA, but 
administration of this drug results in inconsistent alterations in antibody 
levels and does not target the antibody producing plasma cells.  Thus, there 
is likely to be an alternative role of CD20 positive B cells, such as antigen 
presentation or cytokine production which is supressed by rituximab and 
leads to clinical improvement in RA (McInnes and Schett, 2011). 
Inflammation through the innate immune system is mediated by the action of 
cells such as macrophages and neutrophils.  Macrophages located within 
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the synovium are likely to play a key role in inflammation through production 
of cytokines and chemokines.  A correlation between their presence in the 
synovial biopsies and RA disease activity has been reported (Tak et al., 
1997), and furthermore, a reduction in their number has been demonstrated 
with effective treatment for RA (Haringman et al., 2005).  Neutrophils are 
found within the synovial fluid and under inflammatory conditions release 
proteases and reactive oxygen species that can cause localised tissue 
damage. Furthermore, usual mechanisms of neutrophil apoptosis are altered 
in RA so that their lifespan is prolonged and they may also adopt other roles, 
such as antigen presentation, under these conditions (Cascao et al., 2010).  
1.4.4 Synovial and cartilage responses to inflammation 
In RA there is expansion of synovial tissue to form ‘pannus’ at the interface 
of bone and cartilage, which contains macrophages, osteoclasts and FLS, 
and is instrumental for the invasion of cartilage and destruction of bone 
(Walsh and Gravallese, 2010, Bartok and Firestein, 2010).  FLS are 
responsible for direct invasion into cartilage, as demonstrated by Geiler and 
colleagues (1994), who implanted synovial tissue from RA patients into 
mice, together with normal human cartilage.  FLS also produce inflammatory 
mediators, pro-angiogenic factors and matrix metalloproteases (MMPs) (Mor 
et al., 2005).  Excess production of MMPs leads to biomechanical 
dysfunction through collagen disruption. 
1.4.5 Bony erosions in rheumatoid arthritis 
Characteristic bony erosions, first described in 1878 by Austrian pathologist 
and bacteriologist Anton Weichselbaum, are now considered pathognomonic 
of RA (reviewed by Schett et al., 2005).  They   are of importance as a sign 
of bony destruction due to RA and are associated with poor functional 
outcome (reviewed in section 1.8.4).  Therefore, the prevention or 
retardation of the erosive process is a therapeutic goal in the management 
of RA. 
Osteoclasts, derived from the monocyte cell lineage, are the only cell-type 
capable of bone resorption.  Their precursors are found within pannus and 
differentiation into mature osteoclasts occurs once intracellular signalling 
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mechanisms are triggered by activation of receptor activator of nuclear factor 
ĸβ (RANK) through binding with its ligand (RANKL) (reviewed by Schett et 
al., 2005).  RANKL, expressed by T lymphocytes and FLS, is up-regulated 
by cytokines that are abundant in the rheumatoid synovium, including IL-1, 
IL-6, IL-17 and TNF.  The formation of erosions in RA can be slowed by 
inhibition of TNF, IL-6 and RANKL; however, inhibition of RANKL does not 
reduce synovitis (reviewed by McInnes and Schett, 2011). 
1.4.5.1 Detecting erosions in rheumatoid arthritis 
Although the traditional method of detecting erosive damage is using 
radiographs, modern imaging techniques, such as magnetic resonance 
imaging (MRI) and ultrasound scanning (USS), offer more sensitive methods 
of examining structural changes within bone and also have the advantage of 
providing views of the surrounding soft tissues and synovium (reviewed by 
Conaghan et al., 1999).  Bone marrow oedema, also called osteitis, is a term 
used to describe MRI findings consistent with increased water content of the 
bone marrow, which usually has a high fat content.  It has been described in 
the joints of patients with RA, occurring more often in joints affected by 
synovitis (McGonagle et al., 1999).  Further evidence from MRI studies 
indicate that bony erosion occurs in conjunction with, and at a rate 
proportional to, the degree of synovitis within in a joint (Conaghan et al., 
2003).  The presence of bone marrow oedema at baseline assessment has 
been associated with subsequent radiographic erosions in 84 patients with 
RA (Haavardsholm et al., 2008).  Furthermore, from the same group of 
patients, time-integrated bone marrow oedema was also associated with risk 
of radiographic erosions, indicating a cumulative effect of inflammation and 
lending support to the body of evidence that erosive damage in RA occurs 
due to persistent inflammation (Boyesen et al., 2011). 
Histological examination of samples obtained from patients undergoing joint 
replacement showed that the apparent ‘oedema’ of the bone marrow in 
patients with advanced RA was consistent with histological evidence of 
inflammatory cell infiltration (Jimenez-Boj et al., 2007).  Furthermore, 
erosions identified by MRI in these patients corresponded to inflammatory 
infiltration of peripheral bone marrow, together with a breach of integrity of 
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the adjacent cortical bone.  This histological examination of the bone marrow 
in RA was the first report of inflammation occurring at a site other than the 
synovium, which is an important step in the understanding of RA 
pathogenesis.   
Progression of erosive change is slowed by disease modifying anti-
rheumatic drugs (DMARDs) (Boers et al., 2001) and studies utilising MRI 
have suggested that erosions even may be reversed by TNF inhibitors when 
used in combination with methotrexate (MTX) (For example, Ostergaard et 
al., 2011, Quinn et al., 2005).   
1.5 Clinical features of rheumatoid arthritis 
1.5.1 Musculoskeletal features 
1.5.1.1 Articular disease 
RA is a multisystem disease characterised by pain, stiffness and swelling of 
the joints in a symmetrical distribution, typically affecting the small joints of 
the hands and wrists.  Stiffness of the joints is commonly maximal on waking 
and during the early morning, and is typically prolonged (lasting more than 
one hour).  This feature can be significantly debilitating and have a 
significant impact upon daily function (da Silva et al., 2011).  If untreated, the 
synovial inflammation associated with RA can result in structural damage of 
joints and deformity.  Typical deformities associated with chronic RA include 
ulnar deviation and subluxation of the MCP joints and ‘swan neck’ 
deformities of the fingers, in which there is fixed flexion of the distal 
interphalangeal joint with hyperextension of the PIP joint.  In the early stages 
of disease, the pain and stiffness associated with joint inflammation results 
in impairment of function, whereas in the later stages of chronic RA, 
disability is correlated with structural damage and joint deformity (Reviewed 
by Smolen and Aletaha, 2004). 
1.5.1.2 Tendon disease 
Tenosynovitis of the hand and wrist is common in RA and may manifest as 
pain and tenderness with associated swelling overlying the affected area.  
There may be triggering of a finger or neurological compression (for 
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example, carpal tunnel syndrome) and if it remains untreated, tenosynovitis 
can result in tendon rupture and loss of function.  Similarly, tenosynovitis is a 
common cause of foot pain for patients with RA and can be a contributing 
factor towards foot deformity (Coakley et al., 1994). 
1.5.1.3 Bursitis 
This is common in RA and can be a cause of significant pain and loss of 
function.  Subacromial bursitis presents with pain and restricted shoulder 
movement, whilst soft tissue swelling overlying the elbow joint may be due to 
olecranon bursitis.  Tenderness overlying the greater trochanter of the 
femur, causing discomfort when lying on one side, is a feature of 
trochanteric bursitis.  Iliopsoas bursitis has been reported, which may have 
varying presentations including hip pain, (Toohey et al., 1990) femoral nerve 
palsy, (Letourneau et al., 1991) and lower limb oedema (Pellman et al., 
1986, Rodriguez-Gomez et al., 2004)   
1.5.2 Involvement of other organ systems 
1.5.2.1 Skin 
The most common skin manifestation of RA is rheumatoid nodulosis.  
Nodules mainly occur on extensor surfaces subject to pressure, such as the 
skin overlying the elbow, and are often painless, representing little more than 
a nuisance.  However they can be painful, or cause neurological 
compression, for which surgical intervention may be indicated.  Rheumatoid 
nodules are more common in patients with RF antibodies and have been 
associated with the occurrence of other extra-articular manifestations 
(reviewed by Sayah and English, 2005). 
Ulceration of the skin in a patient with RA may be due to comorbidities, such 
as diabetes mellitus, venous insufficiency or arterial disease, but may also 
be due to rheumatoid-related vasculitis.  There is evidence that the aetiology 
of skin ulceration in RA is multifactorial.  In one study, 11 of 20 RA patients 
with skin ulceration had histological evidence of vasculitis, and of these, 5 
had evidence of venous insufficiency, 2 had evidence of arterial insufficiency 
or diabetes and 3 had mixed arterial / venous disease (Oien et al., 2001).  
Pyoderma gangrenosum is another cause of cause of skin ulceration in RA.  
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Typically, lesions occur as rapidly progressive and painful areas of ulceration 
with a violaceous border.  There are no characteristic histopathologic 
findings, so diagnosis is based upon clinical features and biopsy consistent 
with sterile neutrophilic infiltration, together with exclusion of other possible 
causes, which could be venous, arterial, vasculitic, or infectious (reviewed by 
Schadt, 2012). 
1.5.2.2 Lungs  
Pulmonary involvement is relatively common in RA (reviewed by Lake and 
Proudman, 2014) and has been demonstrated as a strong predictor of 
mortality in a cohort of cases with RA (Young and Koduri, 2007).  It may 
manifest in several ways.  Interstitial lung disease (ILD) is a term that can be 
applied to a range of disorders, classified according to radiological and 
histological description, of which usual interstitial pneumonia (UIP) and non-
specific interstitial pneumonia (NSIP) are the most common.  Although NSIP 
is more frequently seen with other connective tissue diseases, UIP 
predominates in RA-associated ILD and carries a poorer prognosis 
(reviewed by Massey et al., 2012).  In one series of 81 autopsy cases with 
longstanding RA, ILD was discovered in 35% of specimens (Suzuki et al., 
1994).  Patients most at risk are those with more severe RA and a history of 
smoking tobacco.  Radiological evidence of ILD may be present in 
asymptomatic individuals and has been described in patients with recent 
onset RA (Gabbay et al., 1997). 
Rheumatoid nodules may be present in the lung parenchyma as well as the 
skin.  They are usually asymptomatic, but can sometimes rupture, resulting 
in pneumothorax or bronchopleural fistula.  Caplan’s syndrome is a condition 
originally described in coal miners with RA, in which there are multiple 
peripheral pulmonary nodules.  The syndrome may follow exposure to 
inorganic dusts such as silica, asbestos and coal dust, and may be 
accompanied by pneumoconiosis (reviewed by Schreiber et al., 2010). 
The pleura may also be involved in RA and although patients may complain 
of symptoms due to pleuritis, pleural thickening is often asymptomatic.  
Pleural effusions are frequently unilateral and can be recurrent.  
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Pseudochylothorax (a milky pleural effusion with high cholesterol content) is 
a recognised, but rare association of RA.  
1.5.2.3 Cardiovascular system 
Premature death in patients with RA is often due to ischaemic heart disease 
(IHD). There are many potential factors that may contribute towards the 
increased incidence of IHD in RA, such as treatment with non-steroidal anti-
inflammatory drugs (NSAIDs) and corticosteroids, hypertension (Panoulas et 
al., 2008), dyslipidaemia (van Halm et al., 2007) and the metabolic 
syndrome (da Cunha et al., 2012).  Although shared risk factors for RA and 
IHD, such as smoking, may partially explain the association of these two 
conditions, persistent inflammation in RA is thought to accelerate the 
development of coronary artery disease.  Levels of inflammatory markers 
have been associated with cardiovascular events in RA; however, the exact 
mechanisms linking inflammation and accelerated atherosclerosis are 
incompletely understood (reviewed by Kerola et al., 2012).   
There is evidence that coronary micro-vascular dysfunction, which has been 
shown to precede the onset of atherosclerotic cardiovascular disease, is 
present in asymptomatic patients with RA.  For example, coronary flow 
reserve (a ratio of maximal coronary blood flow to diastolic coronary blood 
flow where values ≥2 are considered normal) measured by transthoracic 
Doppler echocardiography was lower in 22 RA patients compared to 52 
healthy controls (2.36 compared to 2.71, p=0.002) (Ciftci et al., 2008).  In 
this study, the group of RA patients were similar to the control group in terms 
of proportion of males and means of age, body mass index (BMI), blood 
pressure, and blood lipids, homocysteine and insulin levels and all 
participants were non smokers at the time of the study (defined as current 
non-smoking); however, numbers of patients with a previous history of 
smoking were not mentioned in the paper.  Further work has shown that 
asymptomatic patients with RA and carotid plaques identified on ultrasound 
were more likely than control subjects with similar traditional cardiovascular 
risk factors to have coronary arterial disease identified on dopamine stress 
echocardiography in small study involving 18 patients with RA (Toutouzas et 
al., 2013).  Of the 8 RA patients who then had coronary angiography, 
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significant obstructive lesions that explained the ischaemic findings were 
identified in only 2 cases, compared to 8 of 11 control subjects.  The authors 
of this hypothesis- generating study proposed that in patients with RA, 
coronary ischaemia may be due to causes other than obstructive coronary 
vessel disease.  Although these studies are small, the evidence presented 
here suggests that further investigations into coronary microvascular 
changes in RA are warranted in order to further investigate the aetiology of 
cardiovascular disease in RA.  
1.5.2.4 Neurological  
Commonly observed neurological associations of RA result from 
neurological compression due to synovial inflammation.  Carpal tunnel 
syndrome, due to compression of the median nerve at the wrist, and ulnar 
nerve entrapment at the elbow are two common examples.   A well 
recognised complication of RA is atlanto-axial subluxation, which occurs due 
to rheumatoid involvement of the joint between the first 2 cervical vertebrae 
and the surrounding structures leading to instability and subsequent 
neurological impingement (Robinson, 1966).  There may also be 
compression of the vertebral artery, leading to symptoms that include 
vertigo, confusion and syncope (Jones and Kaufmann, 1976).  Mononeuritis 
multiplex describes sensory and motor impairment of one or more peripheral 
nerves resulting from vasculitis of the vasa nervorum.  Its onset is often 
rapid, affecting one distal nerve initially, but further neuropathy may develop 
if treatment is delayed or unsuccessful.  Central nervous system vasculitis 
has been described in RA, but is uncommon (Gobernado et al., 1984).   
1.5.2.5 Ocular  
Rheumatoid disease may be associated with eye conditions, causing 
redness, pain, impaired vision and sometimes blindness.  One of the more 
common ocular manifestations of RA is dryness of the eyes, or kerato-
conjunctivitis sicca (KCS), which occurs due to impaired lacrimal gland 
function in secondary Sjogren’s syndrome.  Occasionally occurring in 
conjunction with KCS, peripheral ulcerative keratitis (PUK) is an ocular 
manifestation of rheumatoid vasculitis that requires prompt immune-
suppressive treatment in order to prevent visual loss (Squirrell et al., 1999).  
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In PUK, there is vasculitis affecting the peripheral cornea (the avascular 
centre of this structure is unaffected) manifesting as inflammation of the 
episclera, conjunctiva and sclera, which can lead to perforation of the cornea 
(corneal melt) (reviewed by Messmer and Foster, 1999).  Due to its 
association with systemic vasculitis, PUK is linked to high mortality and 
emphasis has been placed upon prompt and aggressive treatment for 
patients with this condition (Foster et al., 1984). 
A painful red eye in a patient with RA may be due to inflammation of the 
sclera (scleritis) or episclera (episcleritis).  Episcleritis is uncomfortable, but 
usually self limiting with no long-term sequelae.  Conversely, scleritis can be 
associated with significant morbidity.  Different types of scleritis have been 
described, including diffuse anterior, nodular anterior, necrotising anterior 
and posterior (which can also be further categorised into nodular, diffuse and 
necrotising).  Of these, the diffuse anterior type is most common and usually 
responds well to treatment, but can cause visual loss.  Posterior types are 
associated with significant risk of visual impairment and require prompt 
treatment (McCluskey et al., 1999).  Necrotising anterior scleritis can be 
further categorised into two types, the “inflammatory” variant presents with 
severe pain that improves with treatment, whereas the rarer variant, 
scleromalacia perforans, is usually painless.  Scleromalacia perforans may 
present as an area of blue discolouration where underlying choroid becomes 
visible through thinned sclera and perforation has been reported in some 
cases (Stone and Dana).    
1.5.2.6 Systemic features 
Systemic symptoms may include fatigue, weight loss and episodes of 
sweating and there may also be an associated normocytic, normochromic 
anaemia of chronic disease.  Fatigue in RA is recognised as a common and 
intrusive symptom, the cause of which is likely to be multifactorial (Repping-
Wuts et al., 2009).  In recognition of the impact of fatigue on wellbeing in RA, 
it has become a focus of research activity and was identified as an important 
outcome for measurement in RA studies by an Outcome MEasures in 
Rheumatology Clinical Trials (OMERACT) consensus group (Kirwan et al., 
2007).   
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In a conceptual model of fatigue in RA described by Hewlett and colleagues 
(2011), biological factors related to RA (such as those due to drug side 
effects, pain, disturbed sleep, anaemia of chronic disease, and alteration in 
cortisol response of the hypothalamic-pituitary-adrenal axis) were 
considered as contributing to fatigue, alongside cognitive and behavioural 
factors including anxiety and depression, as well as personal factors such as 
work, caring responsibilities and level of social support.  In the proposed 
model, it was suggested that factors contributing to the development of 
fatigue may impact upon one another (for example, pain may adversely 
effect sleep, and vice versa) and furthermore, fatigue itself may perpetuate 
possible triggers of fatigue, such as depression and poor sleep.  The 
contributions of RA disease activity, sleep disturbance and mood 
disturbance to RA fatigue were tested in a structural equation model that 
included data from 106 patients (Nicassio et al., 2012).  This model 
explained 62% of variance in fatigue and demonstrated that increased RA 
disease activity was associated with mood disturbance, which in turn 
influenced sleep quality, which was associated with fatigue.  There were also 
direct effects of disease activity and mood on fatigue. 
The term ‘rheumatoid cachexia’ is used to describe the loss of muscle mass 
with stable or increased fat mass that is attributable to the inflammatory state 
and protein catabolism associated with RA.  It has been associated with 
increased morbidity and mortality and although it is proposed to affect up to 
two thirds of patients with RA (Rall and Roubenoff, 2004), several methods 
of assessing nutritional status in patients with RA have been described 
(Summers et al., 2008) and at present there are no definitive criteria for the 
diagnosis of rheumatoid cachexia, so its prevalence is difficult to quantify.  
Criteria for the diagnosis of cachexia have been published (Evans et al., 
2008).  However, in one recent study of 103 patients with RA in which the 
median disease duration was 8 years and mean disease activity score, 
based upon assessment of 28 joints (DAS28) was 3.32, only one patient met 
the criteria for cachexia and one met the criteria for ‘pre-cachexia’ (van 
Bokhorst-de van der Schueren et al., 2012).  Other patients in the cohort 
exhibited observations associated with cachexia such as reduced fat free 
23 
 
muscle index, increased fat mass index and reduced grip strength, so the 
authors concluded that the new criteria for cachexia did not perform well for 
patients with RA.  However, these measures of nutritional status have yet to 
be validated in the RA population and therefore further research is required. 
1.6 Treatment of rheumatoid arthritis 
There has been enormous progress in the pharmacological management of 
RA over the last 60-70 years, beginning with the use of synthetically 
produced corticosteroids in 1948 (reviewed by Weiss, 1989).  Although 
steroid therapy produces rapid and dramatic improvement in synovitis and 
can also retard erosive damage in RA (Kirwan, 1995, van Everdingen et al., 
2002, Bakker et al., 2012), long term use is associated with considerable 
side effects (reviewed by Weiss, 1989).  Current EULAR guidelines 
recommend the concomitant use of low dose corticosteroid and DMARD in 
early RA (Gaujoux-Viala et al., 2014).   
“DMARD” was a term initially applied to drugs used for the treatment of RA 
that reduce levels of acute phase reactants such as erythrocyte 
sedimentation rate (ESR), but has since been applied to drugs that limit the 
progression of RA and in particular, radiographic erosion (Goldbach-Mansky 
and Lipsky, 2003).  In the late 1980’s and early 1990’s, treatment of RA 
usually followed a ‘step-up’ approach, where DMARDs such as gold, D-
penicillamine, hydroxychloroquine (HCQ), azathioprine, cyclosporine, MTX 
and sulphasalazine (SSA) were used as second line agents once 
conservative measures such as the use of physiotherapy, NSAID and aspirin 
had failed to provide symptomatic benefit (Ward, 1988, Furst, 1990).  
Evidence published in the new millennium lead to a ‘paradigm shift’ in 
treatment strategies for RA, as it was demonstrated that early and 
aggressive treatment with DMARDs was superior to the traditional approach, 
with less radiographic progression amongst patients treated more 
aggressively, compared to traditional methods (Lard et al., 2001, Nell et al., 
2004).  The term ‘window of opportunity’ is often used to describe the period 
in early RA during which aggressive DMARD therapy is essential to reduce 
risk of joint damage; usually between 3 and 24 months of symptom onset 
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(reviewed by Smolen and Aletaha, 2015).  Today, a ‘treat to target’ approach 
is employed, whereby therapy is initiated as early as possible and adjusted 
with the aim of achieving remission (which is defined as absence of 
symptoms or signs of RA) (Smolen et al., 2010) 
SSA is cleaved into 5-aminosalicyclic acid and sulphapyridine in the colon, 
and both of these constituents, together with SSA itself, may modify disease 
activity in RA via several mechanisms.  This drug exerts weak anti-
inflammatory properties via inhibition of cyclo-oxygenase and also inhibits 
the release of pro-inflammatory mediators such as IL-1, IL-6 and TNF 
(reviewed by Smedegard and Bjork, 1995).  Evidence from long term studies 
of patients with RA have shown that MTX, and to some extent SSA, can 
retard the formation of erosions when used in early disease (reviewed by 
Pincus et al., 2002).  MTX is currently the first line treatment of choice for RA 
in the UK (according to treatment guidelines summarised in Figure 1-2).  It 
has various actions that may account for its disease modifying properties 
such as reducing cell proliferation, promoting T-cell apoptosis and increasing 
adenosine production, which is an anti-inflammatory substance (Wessels et 
al., 2008). 
The paradigm shift in treatment strategies for RA was accompanied by the 
evolution and application of ‘biologic agents’ etanercept and infliximab, 
which antagonise the effects of TNF.  Etanercept is a fusion protein 
consisting of the Fc portion of human immunoglobulin G1 and two molecules 
of the soluble TNF receptor, which binds to TNF in the circulation and 
prevents interaction with cell surface TNF receptors (Breedveld, 1998).  
Infliximab is a human / mouse chimeric monoclonal antibody that binds both 
soluble and membrane bound forms of TNF (Elliott et al., 1994).  Several 
additional TNF inhibitors have since been developed and applied to clinical 
practice, including adalimumab (Lorenz, 2002), golimumab (Zhou et al., 
2007) and certolizumab (Choy et al., 2002).  Other cytokines have also been 
the targets of drug therapies for RA including interleukin 1 (IL-1) (anakinra, 
(Arend, 1993)) and IL-6 (tocilizumab, (Ding and Jones, 2003).  Co-
stimulation of T-cells is inhibited by abatacept (Harper et al., 1991), which 
binds to CD80 and CD86 on the surface of T cells.  Rituximab (Anderson et 
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al., 1997) reduces circulating B cells through binding to CD20.  The 
application of biological therapies over recent decades has significantly 
improved disease control and long term outcomes for patients with RA.  
However, these drugs are costly and, due to their immune suppressive 
mode of action, are associated with significant risk of infection.  At present, 
their use in the UK is monitored and restricted to patients with ‘severe’ RA.  
Figure 1-2 summarises current National Institute for Health and Care 
Excellence (NICE) guidelines on the use of biological therapies for UK 
patients with RA.  These guidelines exclude anakinra which is not 
recommended by NICE for treatment of RA. 
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Figure 1-2 National Institute of Health and Care Excellence on the 
use of biological treatments in rheumatoid arthritis 
*Adalimumab, certolizumab and etanercept may be used as 
monotherapy in patients unable to take MTX.  
DAS28, disease activity score based upon counts of 28 swollen and 
tender joints; DMARDs, disease modifying anti rheumatic drugs; MTX, 
methotrexate; RA, rheumatoid arthritis; TNFi, tumour necrosis factor 
inhibitor.  (Adapted from technology appraisals: National Institute for Health and 
Care Excellence, 2009, 2010, 2012, 2013, 2007, and  2011) 
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1.7 Epidemiological methods in rheumatoid arthritis 
research 
1.7.1 Disease registers and inception cohorts 
Inflammatory arthritis disease registers have provided invaluable information 
about the treatment and outcomes in RA that would not have been possible 
to obtain from randomised controlled trials alone.  For some registries, 
established to investigate the disease course of RA, meeting classification 
criteria is a pre-requisite for subject inclusion, whilst other cohorts have 
broader inclusion principles and include all cases with inflammatory arthritis 
suspicious of RA so that questions such as the incidence of RA and 
prognostic markers for the development of RA in such patients can be 
addressed.  Examples of the latter include NOAR from the UK and the 
French study ESPOIR (Etude et Suivi des Ployarthrites Indefferénciées 
Récentes) (Table 1-2).  Inception cohorts are designed to capture patient 
data from the very early stages of disease and follow their progress through 
medical care that reflects routine clinical practice.  In some cases, the 
capture of long term data for such patients has spanned many years.  These 
registers have allowed researchers to address questions such as the 
incidence of RA, how the disease course changes over time and what 
factors contribute to mortality.  Table 1-2 summarises UK RA disease 
registers and inception cohorts, together with worldwide registries mentioned 
elsewhere in this Thesis.  Baseline values for mean age, gender and RF are 
given, but as most cohorts are ongoing and the data are continuously 
updated, these values are approximate.  Furthermore, researchers have 
often published work using data from a subset of the whole cohort and 
therefore the values in Table 1-2 reflect the most recent or most complete 
published data.  Cohorts such as NOAR and the Canadian early arthritis 
cohort, CATCH, have fewer cases who are RF positive at baseline, which is 
probably because these cohorts have captured inflammatory polyarthritis 
that is not always RA.  The reason for the low numbers of RF positivity in the 
older Middlesex cohort is not clear, but may be due to different laboratory 
techniques for measuring RF.  The mean baseline age of the cohorts is quite 
consistent, at 51-58 years, although the Brigham and women’s hospital 
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rheumatoid arthritis sequential study (BRASS) included all prevalent cases 
of RA and therefore the age at inclusion was not the age of disease onset.  
Furthermore, there were more women in the BRASS study, which was 
possibly because the hospital at which it was based was formed by the 
merger of 3 hospitals, including one women’s hospital, in 1980; however, the 
authors did not comment on the relatively high proportion of females in their 
sample. 
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Table 1-2 Rheumatoid arthritis disease registers and inception cohorts 
Name of cohort 
(references) 
Year of 
initiation  
Number of cases (N) and 
entry criteria 
Centres 
(location) 
% 
Female 
Mean age at 
presentation  
% RF positive 
baseline 
Notes 
UK Registers        
Bath  
(Jacoby et al., 1973) 
1957 100 
Seen within 1 year of onset 
of RA 
Fulfilling ARA criteria for RA 
(1958) 
Single (Bath, UK) 64 51 76 (within 12 months)  
Middlesex 
(Corbett et al., 1993) 
1966  102 
Disease duration < 1 year 
Single (Middlesex, 
UK) 
57 51 41 Patients recruited 
1966 -1971 Followed 
until 1984 
ERAS and ERAN 
(Young et al., 2000, 
Young et al., 2011) 
1986 (ERAN 
from 2002) 
2866 (up to 2009) 
Diagnosis of RA made by 
rheumatologist 
Disease duration < 2 years 
DMARD naïve  
 
9 (ERAN)  
30 (ERAS) 
(both UK) 
66 
 
55 70  
 
 
NOAR 
(Symmons and 
Silman, 2003, 
Humphreys et al., 
2014) 
1990 2519 
Age >16 years 
2 or more swollen joints  
lasting 4 or more weeks 
Onset since 1.1.1989 
Presenting to primary or 
secondary care 
Multiple: recruited 
from primary care in 
Norwich (UK)  
65 55 55 (of those meeting 
2010 EULAR/ACR 
criteria for RA) 
1419 cases fulfilled 
the 2010 EULAR/ 
ACR criteria for RA at 
baseline.  
       
       
       
       
       
+ 
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Table 1-2 continued       
Name of cohort 
(references) 
Year of 
initiation 
Cases (N) 
Entry criteria 
Centres 
(location) 
% 
Female 
Mean age at 
presentation 
% RF positive 
baseline 
Notes 
Worldwide registers       
Leiden EAC 
(van Aken et al., 
2003, van Nies et al., 
2010) 
1993 2079 (in 2008) 
Recent onset arthritis (<2 
years) 
Single (The 
Netherlands) 
69 57 58  
CATCH 
(Arnold et al., 2014) 
2007 1821 
Age >16 
6 weeks to 12 months 
persistent synovitis, plus 
one or more of:  
RF, ACPA, EMS ≥45 
minutes, response to 
NSAIDs, painful MTP 
squeeze.  
17 (Canada) 73 53 44 1152 cases fulfilled 
the 2010 EULAR/ 
ACR criteria for RA at 
baseline. 
        
BARFOT 
(Forslind et al., 2007, 
Andersson et al., 
2013) 
1992 2800 
>18 years old 
Early RA meeting 1987 
ACR criteria 
Disease duration ≤ 2 years 
6 (Sweden) 64 58 60  
        
BRASS 
(Lu et al., 2014) 
2003 1100 
All cases with RA attending 
the Brigham and women’s 
arthritis centre. 
Single (USA) 81-85 54-61 73 Mean disease 
duration 15 years 
ACPA, anti citrullinated peptide antigen; ACR, American College of Rheumatology; ARA, American rheumatism association; BARFOT, Better Anti-
Rheumatic FarmacOTherpay; BRASS, Brigham and women’s hospital Rheumatoid Arthritis Sequential Study; DMARD, disease modifying anti rheumatic 
drug; EMS, early morning stiffness; ERAN, Early RA Network; ERAS, Early RA Study; ESPOIR, Etude et Suivi des POlyarthrites Indefferénciées Récentes; 
EULAR/ACR, EUropean League Against Rheumatism / American College of Rheumatology; MTP, metatarsophalangeal; NOAR, NOrfolk Arthritis Register; 
NSAID, non steroidal anti-inflammatory drug; RA, rheumatoid arthritis; RF, rheumatoid factor; UK, United Kingdom; USA, United States of America.
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1.7.2 Statistical methods in rheumatoid arthritis epidemiology 
1.7.2.1 Cross sectional and longitudinal analysis 
A cross-sectional analysis uses absolute change between two time points as 
an outcome variable.  It is limited because variation in the outcome between 
the two time points is unaccounted for and important changes can be 
overlooked.  Examples of cross sectional analyses applied to RA include 
linear regression analyses where the outcome variable is a change in 
DAS28 or HAQ between two time points, such as the linear regression 
analyses described in this Thesis.  Longitudinal analysis is of particular 
importance to RA research, as activity of this disease is known to wax and 
wane: sometimes a ‘flare’ of arthritis can occur without an obvious 
precipitating cause, or it can be in response to intercurrent illness; for 
example, a viral infection.  Similarly, treatment with corticosteroids and 
DMARDs are expected to reduce disease activity.  A longitudinal analysis 
can capture these fluctuations, which are ignored in a cross-sectional 
analysis. 
1.7.2.2 The problem of missing data in cohort studies 
Missing data is a common problem encountered in analysis of longitudinal 
data (Haukoos and Newgard, 2007).  A common approach to analysis of 
data with missing values is complete case analysis, whereby cases with 
missing data are simply excluded.  However, this method has several 
drawbacks: the number of incomplete (and therefore excluded) cases 
increases with the number of covariates analysed and results in loss of 
statistical power.  Furthermore, if the cases with complete data are not a true 
representation of the whole sample, there is greater probability of obtaining 
biased results (Mackinnon, 2010, Janssen et al., 2010, Olsen et al., 2012).  
Other approaches to managing missing data include the missing indicator 
method (in which a dummy variable indicating missingness of a given 
covariate is included in the analysis) and imputation techniques such as 
using the mean value of a variable wherever it is missing, or the last 
observation carried forward method (reviewed by Horton and Kleinman, 
2007).  These older approaches to handling missing data are often still used 
in contemporary studies, but results can be biased (Knol et al., 2010).  
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Modern techniques including multiple imputation (MI) and maximum 
likelihood estimation perform better (van der Heijden et al., 2006, Greenland 
and Finkle, 1995).  For these approaches to be suitable certain assumptions 
must be met and the first of these is that the data are missing at random 
(MAR).  Three mechanisms, or causes, of missing data have been described 
(reviewed by Graham, 2009).  The first of the three mechanisms is the least 
common and is called missing completely at random (MCAR). It occurs, for 
example, when a single specimen is lost on the way to the laboratory. The 
fact that this piece of data is missing, together with its value (had it been 
possible to record), is unrelated to the values of the other observed 
variables.  If analysis of the complete cases (CC) was undertaken, the 
results would not be biased, but power may be diminished.  The second 
pattern of missing data is called missing not at random (MNAR) and is 
problematic.  This occurs when missingness of a value is directly related to 
its value: for example, if people with higher salaries are less likely to answer 
a survey question asking about income than other respondents.  The third 
mechanism of missing data is MAR, which occurs when the fact that a piece 
of data is missing, or its value, is related to observed variables.  For 
example, missing blood test results could be described as MAR if these data 
were more likely to be missing in patients with higher levels of anxiety 
recorded as part of the study.  This is considered the most common type of 
missing data and both MI and maximum likelihood estimation are used 
under the assumption that data is MAR.  
It is not possible to test whether data is MNAR, although sensitivity analyses 
have been described by Carpenter et al. (2007), which are post-hoc tests to 
determine how the results of a study would have differed had the MAR 
assumption not been met.  Although MI applications are now incorporated 
into many commonly used statistical packages, sensitivity analysis to check 
the validity of the MAR assumption is a complex procedure that is 
infrequently reported from studies where this method of missing data 
management has been applied.  However, as the application of MI continues 
to grow, we may anticipate the emergence of sensitivity analysis within 
statistical packages.   
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The overall pattern of missing data determines which type of imputation is 
suitable and is either monotone or non-monotone.  A monotone missing data 
pattern requires a simpler imputation method, but is uncommon.  It can 
occur due to participants dropping out of a study.  When the pattern of 
missing data is monotone, the missingness of variable, Vn, predicts that all 
subsequent variables (Vn+1, Vn+2, etc.) will be missing and similarly, if Vn is 
non-missing, all preceding values (Vn-1, Vn-2 etc.) will also be non-missing.  
Missing data patterns are illustrated in Figure 1- 3 and methods for 
managing missing data are further described in Section 2.5.5.  
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Figure 1-3 Illustrative example of monotone and non monotone missing 
data patterns.   
Grey bars indicate values missing from the dataset, whilst white bars indicate 
observed values.  Columns represent variables and are ordered such that the 
frequency of missingness increases from left to right (variable 1 is the least 
frequently missing and variable 5 is the most frequently missing.)  Rows represent 
patterns of missing data within the dataset and are arranged from top to bottom, 
starting with groups of cases with least missing data for the far right variable, and 
then the next most frequently missing variable, and then the next and so on.   
1.8 Outcomes in rheumatoid arthritis 
There are several measures by which outcome in RA may be quantified, 
with different outcome measures suiting different research purposes.  For 
example, when assessing the efficacy of a DMARD or biologic drug, a 
composite measure of RA disease activity is useful.  For researchers 
investigating the economic burden of disease relating to RA, a work 
productivity or instability scale may be required, and for investigating the 
impact of RA on general wellbeing, a quality of life questionnaire may be 
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useful.  In 1992, the first OMERACT conference was held, with the aims of 
reviewing the use of outcome measures in RA and agreeing which should be 
recommended for use in RA research.  This was so that results from 
different studies could be compared and meta-analyses conducted. It 
culminated in the publication of a ‘core set’ of International League Against 
Rheumatism and World Health Organisation recommended outcome 
measures for RA studies (Boers et al., 1994).  As scales for measuring 
outcome in RA are so numerous, the present Section will focus on the two 
outcomes that are the focus of this Thesis: disease activity and disability.   
1.8.1 Measures of disease activity in rheumatoid arthritis 
Disease activity in RA may be measured by a multitude of parameters, for 
example, numbers of swollen and tender joints, duration of early morning 
stiffness (EMS), pain, and functional impairment.  Whilst all of these 
indicators may inform clinical decision making, the perceived importance of 
different indicators of disease activity varies between physicians (Kirwan et 
al., 1983a, Kirwan et al., 1983b).  Monitoring of disease activity has been 
standardised through the development and application of composite indices 
and furthermore, comparison of results from clinical trial results has been 
simplified by application of measures such as the disease activity score 
(DAS) (van der Heijde et al., 1990). 
The DAS and its abbreviated form, the DAS28 (Prevoo et al., 1995) are 
measures of RA disease activity that encompass the swollen joint count 
(SJC) from a total count of 44 joints for DAS, or 28 joints for DAS28.  Also 
included in calculation of the indices are tender joint count (TJC) from 28 
joints for DAS28, or for DAS, Ritchie articular index (RAI) (Ritchie et al., 
1968), which grades tenderness from examination of 55 joints; plus a 
laboratory measure of systemic inflammation (ESR or C-reactive protein 
(CRP)) and a patient reported measure of disease activity, recorded on a 
100 millimetre (mm) visual analogue scale (VAS).  These variables are 
applied to formulae (shown Table 1-3), which are available on the internet:  
(http://www.das-score.nl/das28/DAScalculators/dasculators.html), or a 
specific calculator can be used.  The DAS28 is quicker to use in clinical 
practice, because examination of only 28 joints is required, compared to 44 
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and 55 swollen and tender, respectively, for the DAS.  The DAS and DAS28 
were also described using formulae with 3 variables (shown in Table 1-3), 
with omission of the VAS (van der Heijde et al., 1990).  A study of 227 RA 
patients in remission according to American Rheumatism Association (ARA, 
which later became ACR) preliminary criteria was published in 1996 (Prevoo 
et al., 1996).  The authors found that a DAS of <1.6 represented remission 
well; however, the preliminary ARA criteria for remission to which DAS was 
compared were poorly defined.  A lower DAS28 definition of remission has 
been proposed (Sheehy et al., 2014).  One of the problems with DAS28 is 
that it incorporates subjective measures, TJC and VAS, which may be 
influenced by co-existent conditions such as chronic pain and fibromyalgia, 
and does not solely reflect inflammation due to RA.  An index to reflect pain 
in RA due to non-inflammatory causes was described by McWilliams and 
colleagues (2012), who used all components of the 4 variable DAS28, to 
produce DAS28-P, which was weighted in favour of the patient-reported 
measures.  Higher DAS28-P at baseline predicted less reduction in pain 
(measured using the short form 36 bodily pain score) after 1 year, 
independent of DAS28 score, indicating that DAS28-P measured non 
inflammatory causes of pain in these patients from the Early RA Network 
(ERAN, described in Table 1-2). 
Newer and more simple composite measures of disease activity include the 
simplified disease activity index (SDAI) (Smolen et al., 2003), and the clinical 
disease activity index (CDAI) (Aletaha et al., 2005).  The SDAI is calculated 
using the sum of: SJC (out of 28), TJC (out of 28), VAS representing 
patient’s own assessment of global health, VAS representing physician’s 
assessment of patient’s global health (both measured in centimetres, cm, 
from a total possible score of 10 cm), and CRP value (measured in 
milligrams per decilitre, mg/dl).  The CDAI uses the same parameters as the 
SDAI, but excludes CRP.  The obvious advantage of these two measures is 
that they are easy to calculate; however, they are not normally distributed, 
which can add complexity to statistical analyses.  Both SDAI and CDAI are 
more stringent than DAS28 when used to define remission (Klarenbeek et 
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al., 2011).  The different measures of disease activity are compared in Table 
1-3. 
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Table 1-3 Characteristics of composite measures of rheumatoid arthritis disease activity 
  
 DAS DAS28 SDAI CDAI 
Formula 0.54x√(RAI) + 0.065 (SJC) + 0.33x 
Ln(ESR) +0.00722 x (VASmm) 
Or (3 variable): 
0.54x√(RAI) + 0.065 (SJC) + 0.33x 
Ln(ESR)+0.22 
Or (4 variable, CRP): 
0.54x√(RAI) + 0.065 (SJC) + 0.17x 
Ln(CRP+1)+0.0072*(VASmm)+0.45 
Or (3 variable, CRP): 
0.54x√(RAI) + 0.065 (SJC) + 0.17x 
Ln(CRP+1)+0.65 
0.56√(TJC)+0.28√(SJC) 
+0.7*ln(ESR)+0.014(VASmm)+0.96 
Or (3 variable): 
[0.56√(TJC)+0.28√(SJC) 
+0.7*ln(ESR)]*1.08+0.16 
Or (4 variable, CRP): 
0.56√(TJC)+0.28√(SJC) 
+0.36*ln(CRP+1)+0.014(VASmm)+0.96 
Or (3 variable, CRP): 
[0.56√(TJC)+0.28√(SJC) 
+0.36*ln(CRP+1)]*1.10+1.15 
 
TJC+SJC+VASpatientcm 
+VASphysiciancm +CRP 
 
TJC+SJC+VASpatientcm 
+VASphysiciancm 
 
Advantages 
 
Normally distributed variable 
 
Only 28 joints are assessed 
Widely applied and understood 
Normally distributed variable 
 
Only 28 joints are 
assessed 
Simple to apply 
Only 28 joints are 
assessed 
Simple to apply 
No need for blood 
tests 
Disadvantages Complicated formula.  
Requires assessment of 44 joints 
for swelling, plus RAI  
 
Complicated formula 
 
 
Not normally 
distributed 
 
Not normally 
distributed 
 
Applications  
 
EULAR response criteria 
Applied in NICE criteria for use of 
biologics 
Applied as an outcome measure in 
clinical trials 
Used in the 
ACR/EULAR definition 
of remission for clinical 
trials  
 
Outcome measure in 
clinical trials 
 
Range of values 
 
0.23-9.87 
 
0.49-9.07 
 
0-86 
 
0-76 
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Table 1-3, continued 
 
   
 DAS DAS28 SDAI CDAI 
Definitions of:     
Remission <1.6 ≤2.6 ≤3.3 ≤2.8 
Low 
disease 
activity 
1.7-2.4 2.6-3.2 3.4-11 2.9-10 
Moderate 
disease 
activity 
2.5-3.7 3.2-5.1 12-26 11-22 
High 
disease 
activity 
>3.7 >5.1 >26 >22 
ACR, American College of Rheumatology; CDAI, clinical disease activity index; cm, centimetres; CRP, C-reactive protein; DAS, disease activity score; 
DAS28, disease activity score using counts of 28 joints; ESR, erythrocyte sedimentation rate; EULAR, EUropean League Against Rheumatism; mm, 
millimetres; NICE, National Institute of health and Care Excellence; RAI, Ritchie articular index; SDAI, simplified disease activity index; SJC, swollen joint 
count; TJC, tender joint count; VAS, visual analogue score.
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1.8.1.1 Definitions of response for rheumatoid arthritis clinical trials 
In 1995, in order to define response to treatment in RA clinical trials, the 
ACR published criteria that allowed researchers to categorise patients 
according to whether ‘ACR20’ response was achieved or not (Felson et al., 
1995).  An ACR20 response was defined as a 20% improvement in TJC, 
SJC, and 3 of the 5 remaining core outcome measures: physician 
assessment of disease activity, patient assessment of global disease activity 
(both measured using either VAS or Likert scale), patient assessment of 
pain (VAS or Likert scale), a validated measure of physical function and 
either ESR or CRP.  ACR response criteria are commonly reported in clinical 
trials, and are easily interpreted as 20%, 50% or 70% improvement, for 
ACR20, ACR50, and ACR70 responses, respectively.  As well as the ACR 
definition of response in RA, EULAR defined disease activity in RA as either 
low, moderate or high according to DAS as follows: ≤2.4 is low disease 
activity, >2.4 and ≤3.7 is moderate disease activity and >3.7 is high disease 
activity (van Gestel et al., 1996).  The ‘EULAR response’, a classification of 
response to treatment using ‘simplified’ disease activity measures (that is, 
using counts of 28 joints) is now widely applied in research (van Gestel et 
al., 1998).  It is summarised in Table 1-4. 
Table 1-4 Definitions of response according to European League 
Against Rheumatism criteria using simplified joint counts (adapted 
from van Gestel et al., 1998) 
 Good  Moderate Non 
 
DAS/DAS28 
change 
 
 
≥1.2 
 
 
≥1.2 
 
 
>0.6, but 
<1.2,  
 
 
<0.6 
 
 
 and and and and 
Disease  
activity 
Low  
DAS ≤ 2.4  
DAS28 ≤ 
3.2 
Moderate or high 
DAS >2.4  
DAS28 >3.2 
Low or 
moderate 
DAS ≤3.7  
DAS28 ≤5.1  
 
High 
DAS>3.7 
DAS28 >5.1 
DAS, disease activity score: DAS28, disease activity score based upon counts of 
28 joints. 
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Once remission in RA became a realistic goal owing to newer therapies, 
ACR and EULAR jointly proposed a definition of remission of SDAI ≤ 3.3, or 
when SJC, TJC (both from 28 joints), CRP (in mg/dl) and patient global 
assessment (measured in cm, using a 10cm VAS) are all ≤ 1 (Felson et al., 
2011).  
One drawback of these criteria is that they dichotomise (into responders vs. 
non-responders in the case of ACR or remission criteria) or categorise 
outcome (in terms of low / medium / high disease activity in the case of 
EULAR response criteria), which is associated with loss of statistical power 
and loss of information about change in outcome measures for individual 
patients (Felson and Lavalley, 2014).   
1.8.2 Factors influencing disease activity in rheumatoid arthritis 
Information on predictors of disease activity in RA comes from both 
observational studies, which are more likely to reflect true clinical practice 
and also clinical trials.  DAS28 is often reported from clinical trials and 
EULAR response, which uses DAS28, is one of the most commonly reported 
measures of outcome (Fransen and van Riel, 2009).  The different factors 
impacting upon disease activity in RA are discussed below, in sections 
1.8.2.1 to 1.8.2.7 and summarised in Table 1-5, which is divided according 
to risk factors.  As shown in Table 1-5, outcome measures used differed 
between studies.  Although remission has been defined in terms of values of 
composite indices, the context in which remission was declared also varied 
between studies.  Some authors have included patients who have achieved 
remission only if they are DMARD-free for a given time-period, whilst others 
have included patients on DMARDs within this category.  Furthermore, the 
duration for which a patient is required to be ‘in remission’ in order to have 
reached the desired outcome has varied.  Some studies have used 
sustained remission for a specified duration as an outcome, whilst others 
have observed whether there is incident remission at a specified time point. 
1.8.2.1 Age and gender  
The effect of age and gender on disease activity in RA has been well 
documented, with female gender and increased age at onset of disease 
associated with lesser improvement in disease activity.  In the UK based 
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Early RA Study (ERAS, described in Table 1-2) remission (defined by 
DAS<1.6) in 704 patients followed for a minimum of 5 years was associated 
with male gender (odds ratio, OR 2.64; 95% CI: 1.54, 4.54; p<0.001) 
(Jayakumar et al., 2012).  Using data from 378 patients recruited to the 
CARDERA (combination of anti-rheumatic drugs in RA) trial, Ma and 
colleagues (2012) formulated a prediction model for remission at 24 months 
from baseline and then validated their model using data from ERAN.  They 
found that significant predictors of remission (DAS28<2.6) were lower age 
(OR for age in years: 0.98; 95% CI 0.95, 0.99), male gender (OR 3.14; 95%, 
CI 1.80, 5.46) and lower TJC at baseline (OR 0.94; 95% CI 0.90, 0.98).  
Their prediction model for remission at 24 months was specific (98%), but 
not sensitive (13%), suggesting that other factors influencing disease activity 
were unaccounted for.  A recent study of Canadian patients with suspected 
early RA investigated how DAS28 was influenced by gender and age 
(Arnold et al., 2014).  After one year, mean change in DAS28 was 
significantly lower in women (a decrease of 1.8 units, versus 2.5 for males, p 
< 0.008) and remission at 12 months, defined by DAS28 ≤2.6, was less likely 
in older patients (OR 0.97, 95% CI 0.96, 0.98, p= 0.001), females (OR 0.39, 
95% CI 0.28, 0.54, p = 0.001) and those with higher baseline DAS28 (OR 
0.75, 95% CI 0.68, 0.83, p = 0.001).   
1.8.2.2 Genetics 
The most significant genetic risk factor for RA lies within the Major 
Histocompatibility Complex (MHC) centred on the HLA-DRB1 locus, 
representing about 30% of the genetic risk for RA (reviewed by 
Raychaudhuri, 2010).  The HLA-DRB1 alleles associated with RA encode a 
common a peptide sequence within the third hypervariable region at 
positions 70 to 74, which is commonly referred to as the shared epitope.  As 
well as increasing the risk of development of RA, there is also evidence to 
suggest that the shared epitope is associated with worse prognosis in terms 
of increased risk of erosions and poorer response to therapy.  In an analysis 
involving 178 Spanish patients with RA meeting 1987 ACR criteria, 
possession of 2 HLA-DRB1 shared epitope alleles was associated with 
increased likelihood of ‘severe disease’, which was classified as requiring 
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treatment with cyclosporine in addition to MTX and HCQ (Gonzalez-Gay et 
al., 2002).  In a logistic regression analysis that controlled for age, gender 
and disease duration, but not antibody status, OR of requiring cyclosporine 
for patients with 2 HLA-DRB1 shared epitope alleles was 2.4 (95% CI; 1.03, 
5.7; p= 0.025).  In another study of 124 Japanese patients with RA, where 
the outcome was DMARD resistance defined as indication for biologics 
within 2 years of DMARD initiation (excluding those who discontinued 
DMARDs because of adverse effects), DMARD resistance was predicted by 
the presence of HLA-DRB1 *0404 shared epitope alleles (OR 2.89; 95% CI 
1.28, 6.5; p=0.011 ) and ACPA (OR 6.31; 95%CI 1.23, 32.34; p=0.027) (Mori 
et al., 2010).  Further evidence was presented from the NOAR cohort in a 
study to determine whether it was possible to predict failure of MTX 
monotherapy due to inefficacy or side effects (Hider et al., 2009).  In a 
logistic regression model of inefficacy of the drug that controlled for age, 
gender, duration of symptoms and use of steroid, HLA-DRB1 shared epitope 
positivity was a significant predictor after 1 year (OR 5.88; 95% CI 1.32 to 
26.25; p=0.02) and 2 years (OR 3.04; 95% CI 1.21, 7.62, p= 0.02), but was 
not a significant predictor in the model to predict adverse events due to 
MTX.  There was no significant difference in the numbers of RF positive 
cases in whom MTX monotherapy was successful or not; however, ACPA 
were not reported.  It is possible that the reported associations of shared 
epitope alleles and treatment failure are mediated by ACPA, the influence of 
which are discussed in 1.8.2.3. 
1.8.2.3 Antibody status 
Seropositivity for either RF or ACPA is associated with reduced likelihood of 
remission in RA, as demonstrated in two studies involving cases from the 
Leiden early arthritis clinic (described in Table 1-2).  The first study, 
published in 2009, examined factors predictive of remission in patients with 
RA according to ACR 1987 classification criteria from both the Leiden clinic 
in the Netherlands and the UK based ERAS, in which remission was 
declared by the rheumatologist if there were no swollen joints in a patient not 
taking DMARD therapy for ≥12 months (van der Woude et al., 2009).  
Predictors of remission in the 454 cases from the Leiden clinic included 
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ACPA (hazard ratio, HR, 0.09; 95% CI 0.04, 0.20; p<0.001).  The results 
were strengthened by replication of the findings using data from ERAS: 
ACPA data were not available for ERAS cases, but RF was associated with 
reduced chance of remission (HR 0.28; 95% CI 0.16, 0.49; p<0.001).  These 
findings were further supported by the second study, published in 2012, 
aimed at comparing remission in those treated according to the standard 
treatment of the Leiden cohort with remission in cases who received 
treatment adjusted according to DAS in the Dutch Behandel Straregieen 
study (best treatment strategy in RA, BeSt) (van der Woude et al., 2012).  
The 508 BeSt study participants also had RA according to 1987 ACR 
classification criteria and a symptom duration of less than 2 years at 
baseline and predictors of remission in both cohorts included lack of 
antibodies to citrullinated proteins, or RF. Other significant predictors of 
remission in both of these cohorts were male gender and shorter symptom 
duration at baseline.  
1.8.2.4 Periodontal disease 
Factors known to increase the risk of developing RA have attracted attention 
as possible drivers of disease activity.  Periodontal disease is commonly 
seen in patients with RA and the bacterium Porphyromonas gingivalis, a key 
pathogen in periodontal disease, produces peptidyl arginine deaminase 
(PAD) enzymes that facilitate citrullination (reviewed by Koziel et al., 2014).   
In a randomised study of the effect of treatment for periodontal disease on 
DAS28, Al-Katma and colleagues (2007) examined the difference in DAS28 
between 19 patients randomly assigned to receive either no intervention, or 
instruction on oral hygiene together with scaling of the teeth to remove 
plaque.  They found that disease activity improved more often in the 
treatment group and that mean DAS28 was significantly different between 
the 2 groups after the intervention: 4.3 in the treatment group versus 5.1 in 
the non treatment group (p<0.05).  The small number of cases included in 
this study was a significant limitation and was due to poor uptake: initially, 
319 cases were invited to participate; and also drop-out: of 38 cases 
randomised, 7 from the control group dropped out as they failed to attend 
their appointments (4) or changed treatment for RA (3) and 2 from the 
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treatment group were lost, one of whom failed to attend follow up and the 
other was excluded for not complying with the intervention.  Sampling bias 
could have affected the results of this trial, which due to the nature of the 
intervention, could not be blinded.  Further bias may have been introduced 
when the results were analysed, which was not on an intention to treat basis. 
However, these results are interesting because they imply that interventions 
in oral hygiene may have a positive impact on disease activity in RA and 
furthermore, there have been consistent results from other small studies.   
Further work from the same research group showed that periodontal 
intervention resulted in improved DAS28 after 6 weeks, regardless of 
whether RA treatment was with or without anti-TNF agents, and that anti-
TNF agents did not improve periodontal disease (Ortiz et al., 2009).  
However, this study was also limited by a small number of cases (40 cases 
in total, 10 in each treatment group, divided according to whether they 
received the intervention, and whether they were receiving anti-TNF 
treatment) and furthermore, DAS28 was higher in the 2 groups receiving 
periodontal treatment, which may have confounded the results.  In the 
periodontal treatment groups mean DAS28 were 4.96 and 5.01 for those 
receiving and not receiving anti-TNF, respectively, compared to 4.34 and 
4.29 in the non-periodontal treatment groups taking and not taking anti-TNF 
treatments, respectively.  Although the authors reported no statistically 
significant difference between DAS28 in the treatment groups at baseline, 
this appears to have been in reference to an analysis of DAS28 
dichotomised into ‘severe’ and ‘moderate’ categories and as there were only 
10 cases in each group, there may not have been sufficient power for this 
analysis.  Stable treatment throughout the study was not specified and it is 
possible that the patients with higher DAS28 scores used more medication, 
such as steroid, for example, which may also have accounted for the 
reported findings.   
A Brazilian study investigated outcome at 3 and 6 months after 
randomisation to receive either treatment for periodontal disease or no 
treatment.  A further group of patients had no native dentition (used full 
dentures).  Again, the number of cases in each treatment group were small 
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(15 in each), but there was no difference in DAS28 between the RA cases 
receiving periodontal treatment compared to those with no intervention 
(Pinho Mde et al., 2009).  In addition, the authors of this study found no 
difference in ESR with treatment of periodontal disease, which is in contrast 
to findings reported by Ribeiro et al (2005) who found significantly fewer 
patients with high ESR (> 28) in 26 of 42 cases randomised to receive 
intensive treatment for periodontal disease (54% versus. 75% of those not 
receiving treatment for periodontal disease, p<0.05).   
The conflicting results of these studies means that the effect of periodontal 
disease on RA disease activity remains uncertain.  It may be that the benefit 
of periodontal treatment is short-term, with a positive impact on DAS28 that 
only lasts for a few weeks.  A French open–label randomised control trial 
that has been recruiting patients since 2012 will examine the difference in 
DAS28 at 3 months in 40 RA patients with and without treatment for 
periodontal disease and will hopefully add further information (the ESPERA 
trial, Monsarrat et al., 2013).  In this study, rheumatologists assessing and 
recording DAS28 will be blinded to the treatment group, which was not a 
condition specified by the other papers mentioned here.  Due to the nature 
of interventions for periodontal disease, it is not possible for these studies to 
be double-blinded and as there is no suitable placebo or sham treatment, 
these investigations are vulnerable to placebo effect. 
1.8.2.5 Socioeconomic status 
Socioeconomic status (SES) can be measured by numerous different  
methods and indices, which are broadly categorised into person-level, 
reflecting the education and income level of an individual, and area-level, 
which reflects the affluence or deprivation of the geographical area in which 
a person lives.  There is a well-recognised association between lower SES 
and adverse health outcomes in general, and RA is no exception to this rule 
(reviewed by Calixto and Anaya, 2014).  This phenomenon, which occurs 
internationally and within individual countries, may exist because healthcare 
is less accessible in poorer communities.  The use of non-conventional or 
cultural treatments for health conditions is more common amongst ethnic 
minorities from deprived areas and furthermore, less education presents a 
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barrier to early recognition of ailments, understanding optimal management 
of chronic conditions, adherence to therapy, and maintenance of a healthy 
lifestyle.  However, the relationship between lower SES and poor outcome 
may be the other way around: low SES can occur as a consequence of 
lower income after loss of function and work capacity due to RA .  Evidence 
that disease activity in RA is influenced by economic status on an 
international level was presented by investigators from the quantitative 
standard monitoring of patients with RA (QUESTRA) study, who found an 
association of DAS28 with gross domestic product (GDP, measured in 1000 
USA dollars per capita) (Sokka et al., 2009).  The QUESTRA study collected 
data from consecutive, unselected patients with RA from 71 individual 
centres spanning 25 different counties from 2005 to 2006.  Data from a total 
of 6004 cases were included in a regression model that confirmed the 
observed relationship between GDP and DAS28 and explained 61% of the 
variation in DAS28.  Each additional 1000 euro in GDP was associated with 
a reduction in DAS28 of 0.10 units (95% CI 0.06, 0.13).  Although there was 
no difference in use of DMARDs between countries, the authors were 
concerned that (unavoidable) bias may have occurred due to preferable 
presentation of severe cases compared to mild cases in countries with lower 
GDP.  They also found that mean DAS28 in patients not using biologic 
agents was higher in countries with low GDP (mean DAS28 for non-biologic 
cases low GDP countries 5.2, compared to 3.7 in high GDP countries), 
which implied there was a higher threshold for the use of biologics in poorer 
countries, possibly related to their financial cost.  The authors also 
commented that psychological distress appeared to be greater in patients 
from countries with lower GDP, which in turn may have influenced disease 
activity and mediated the relationship between GDP and DAS28.  
International inequality in the treatment of RA was recently confirmed in a 
study involving 46 European countries which found that responsibility for the 
cost of treatment was more likely to fall to individual patients in countries 
with lower GDP and furthermore, there was an inverse relationship between 
drug costs and GDP which was more pronounced for biological therapies, 
and reduced the cost effectiveness of these agents (Putrik et al., 2014). 
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Area-level deprivation was associated with increased baseline DAS28 in a 
randomised control trial of patients with longstanding RA (Harrison et al., 
2005).  At baseline, patients from the British rheumatoid outcome study 
group (BROSG), which recruited 446 patients from 1998 to 2001 and studied 
outcome after 3 years of either symptomatic or aggressive treatment for RA, 
had a greater DAS28 if they resided in more deprived areas: mean DAS28 
was 4.8 in ‘most deprived’, compared to 4.0 in least deprived areas 
(p=0.002).  This finding was attributed to the TJC, which was only 
component of DAS28 significantly different between the SES groups: mean 
TJC 6 in most deprived, compared to 3 in least deprived (p<0.001).  
Differences in baseline DAS28 and TJC were confirmed after controlling for 
age, gender, smoking status, treatment centre, disease duration, and 
treatment.  Interestingly, there was no difference in DAS28 at 3 years 
between levels of SES and this could have been because all participants 
were followed up in line with the trial protocol and more closely monitored 
than in routine clinical care (participants from the more deprived areas were 
more likely to drop out, but this was controlled for in the analysis).  This 
study also found that greater deprivation was associated with more pain, 
loss of function, co-morbidities and poorer quality of life.   
Person-level SES has also been shown to affect disease activity in RA.  In a 
Dutch observational study of 869 RA cases from rheumatology clinics with 
median disease duration of 8.7 years, who completed postal questionnaires 
to measure disability, depression and quality of life, low SES (measured 
according to level of education) was associated with higher DAS28 at 
baseline (OR =2.8; 95% CI 1.2, 6.4), where DAS28 >3.3 was considered 
high (Jacobi et al., 2003).  A second questionnaire was completed 2 years 
later by 674 cases and differences in those who achieved a reduction in 
DAS28 of ≥1.2 from baseline and those who did not were examined.  
Although there were more cases with low SES who had high DAS28 after 2 
years (62 % of those with low SES compared to 37% with high SES), there 
were no statistically significant differences in those who improved and those 
who did not between the SES groups.  The authors did not report the 
absolute change in DAS28 within the groups of this study and concluded 
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that SES influenced disease activity, but the difference between SES groups 
reduced with time.  What is not clear from this cohort is whether DAS28 was 
significantly different between the groups at 2 years, nor why the 
discrepancies in disease activity should reduce between the 2 time points in 
this cohort of patients with different disease durations in whom no changes 
to therapy were initiated as part of the study.  An additional finding was that 
patients with low levels of education were less likely to access care delivered 
by allied health professionals, such as physiotherapists, occupational 
therapists and chiropodists, despite no additional financial costs for patients 
using these services.  This may reflect more active coping mechanisms in 
those with higher levels of education, more awareness of available 
therapies, or perhaps that such individuals are more able to articulate their 
medical needs.  Area level deprivation has been associated with RF, but not 
ACPA positivity in an analysis of 6298 patients with RA (Mackie et al., 2012).  
In this analysis, Townsend index was used as a measure of deprivation and 
the OR for RF positivity was 1.14 (95% CI 1.01, 1.29) per Townsend index 
tertile.  This effect was independent of smoking and gender. 
There are relatively few observational studies examining the impact of SES 
on disease activity after initial presentation in RA and most studies have 
focused on the effect of social deprivation on disability or joint erosion.  
However, data from ERAS suggested that ‘joint scores’ (both RAI and 
counts of the numbers of swollen and tender joints) were worse with 
increasing area level deprivation at presentation and also after 3 years follow 
up (ERAS Study Group, 2000).  Furthermore, in a subset of individuals for 
whom data on education level were available, lower person-level SES was 
also associated with less favourable joint score (although ESR was not).  In 
contrast, the Swedish Better Anti-Rheumatic FarmacOtherapy (BARFOT) 
observational study of early RA found no association between SES and 
EULAR response at 3 and 6 months, and 1, 2, 5 and 8 years (Andersson et 
al., 2013).  The study recruited 2800 patients between 1992 and 2006 and 
collected data on SES retrospectively, in 2010, via a postal questionnaire 
sent to all living participants, and data from the 1460 respondents were 
analysed.  Confounding by indication may have biased the results of this 
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study, as participant death could have been related to more severe disease 
and data from those who died were not included in the analysis.  Further 
bias was also introduced because the 579 cases who did not respond to the 
questionnaire had higher baseline parameters including: mean DAS28, 
general health VAS, pain VAS, and SJC, and more were smokers at 
baseline.  It is quite possible that non responders to the postal questionnaire 
had lower SES.  Person-level SES was used in this study and was 
categorised according to the Swedish classification of occupation: self-
employed, upper-white collar workers, lower white collar workers, blue collar 
workers and ‘other’, which included non-working individuals such as 
housewives and students.  It is not clear whether the ‘other’ category could 
also have included cases not working due to ill health, but although it only 
encompassed 24 individuals, the ‘other’ category was significantly 
associated with non-achievement of good EULAR response at 5 years: OR 
of good EULAR response 0.15 (95% CI 0.04, 0.67).  Furthermore, there 
were 302 cases who did not complete the question on employment and who 
were therefore excluded from this analysis.  The authors concluded that their 
findings were due to better health equality in Sweden than in the UK or USA; 
however, there were several sources of bias that may have influenced the 
results.  
Although there is consistent evidence that disease activity is worse with 
lower area and person level SES at disease onset, the influence of SES on 
disease activity in the longer term during routine clinical care is less clear.  
Data from ERAS suggest that the disparity continues after at least 3 years of 
follow up, but other studies have not yet confirmed this.    
1.8.2.6 Smoking 
Cigarette smoking has been proposed as a driver disease activity in RA and 
evidence for this is discussed within this section.  Most studies have found 
that smokers tend to respond less well to treatment; however, the evidence 
should be interpreted with caution as potential confounders such as SES 
and antibody status were not controlled for in every analysis.   
A prospective study of the effect of smoking and RF on disease activity in 
100 consecutive patients ‘recently’ (recent was not defined) diagnosed with 
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RA and ultimately meeting 1987 ACR criteria (described in Section 1.3) used 
multifactorial ANOVA to analyse differences in SJC, TJC and pain VAS 
across 3 different categories of smoking: current, previous and never (CRP 
was not different between the groups at any time point and results of 
individual analyses of CRP were not reported) (Manfredsdottir et al., 2006).  
Using data from 3 time points: baseline, 6 and 24 months and 100, 89 and 
85 cases, respectively, the authors found a significant difference between 
smoking groups with highest values for current, then previous, then never 
smokers: p<0.001, 0.02 and 0.005 for SJC, TJC and VAS, respectively.  
They also performed an ordinary least square regression analysis of 
predictors of SJC at 6 months, which included potential confounders age, 
gender, caffeine intake and RF positivity, and there were no statistically 
significant predictors at the 5% level when all predictors were included in the 
model, but smoking and a past history of smoking were both significant 
predictors in a model that excluded other covariates through backwards 
elimination.  This difference may reflect a lack of statistical power in the 
earlier model.  It is not clear why SJC was chosen as an indicator of disease 
activity for this analysis, although it may have been preferred as a more 
objective measure than TJC and pain VAS.  This study was possibly under-
powered and did not use a composite measure of disease activity, so 
although the results pointed towards a significant effect of smoking on 
disease activity, further evidence was required to confirm this effect.  
Investigators from the BARFOT study analysed data from 1787 cases with 
early RA and found an association of smoking at the time of study entry with 
less improvement in DAS28 (Soderlin et al., 2011).  At 12 months, the mean 
reduction in DAS28 from study entry was 1.71 units in those who reported 
current smoking at study entry, compared to 1.99 in never smokers and 2.14 
in previous smokers (p=0.0001).  Furthermore, current smoking at baseline 
predicted lack of EULAR response (as described in 1.8.1.1) at 12 months 
(OR for achieving EULAR response 0.69; 95% CI 0.50-0.93; p=0.02), 6 
months (OR 0.66; 95% CI 0.48, 0.91; p=0.011) and 3 months (OR 0.64; 95% 
CI 0.47-0.87; p=0.004).  These results were from logistic regression models 
that included potential confounders such as symptom duration, age at 
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baseline, gender, RF, baseline HAQ and DAS28, and treatment, but not 
SES.   
Evidence of a relationship between ‘dose’ of smoking and reduced response 
to TNF inhibitors was presented from an observational study of 154 cases 
starting treatment at Staffordshire (UK) hospital (Mattey et al., 2009).  In this 
study, where 103 cases had a history of smoking and 38 cases were current 
smokers, change in DAS28 at 3 months was less marked in those with a 
history of smoking (a reduction of 2.07 in smokers, compared to 2.64 in non-
smokers, p=0.01).  There was also a correlation between number of pack 
years smoked and improvement in DAS28 at 3 months: Spearman 
correlation was -0.28, p=0.002, and reduced likelihood of achieving EULAR 
response in cases with >30 pack years of smoking.  After controlling for age, 
gender, baseline DAS28, baseline disability, disease duration, presence of 
nodules, RF positivity, number of previous DMARDs and current smoking 
(but not SES), the OR for failure of anti-TNF therapy after 3 months was 
1.95 (95% CI 1.11, 3.46) per additional pack year category, which were 0, 1-
15, 15-30 and >30, where one pack year was quantified as 20 cigarettes per 
day for a year.  Current smoking as a binary variable was not a significant 
predictor in the model of response at 3 months, but was significant in the 
model of response at 12 months (OR for non-response 2.7; 95% CI 1.2-5.9; 
p=0.01); however, current smokers were also more likely to have a smoking 
history of >30 pack years, which may explain this observation.  Whilst lack of 
response to both etanercept and infliximab after 12 months was more likely 
with increasing quantity of cigarettes smoked, this trend was significant at 3 
months in the group treated with infliximab, but not etanercept.   
These findings were in keeping with results from a study of 1267 cases 
taking etanercept and 1612 cases taking infliximab, registered with the 
British Society for Rheumatology Biologics Register, BSRBR (Hyrich et al., 
2006).  In this investigation of factors predictive of response to TNF 
inhibitors, current smoking at baseline was associated with reduced 
likelihood of good EULAR response (OR 0.77; 95% CI 0.60 to 0.99), 
although the influence of quantity smoked was not assessed, and 
furthermore, SES was not controlled for, so may have confounded the 
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results.  Other predictors of poorer response included female gender and 
number of previous DMARDs used, whilst lower baseline disability, 
measured by HAQ, and concurrent use of NSAIDs and MTX were 
associated with better response.   
There is also evidence that smoking has an adverse effect on response to 
treatment with MTX when used as monotherapy and in combination with 
SSA.  In an investigation of 405 patients taking MTX monotherapy for 3-4 
months as part of the Swedish FarmacOtherapy (SWEFOT) study in early 
RA, predictors of EULAR non-response included current smoking at study 
entry (OR for good response 0.35; 95% CI 0.20, 0.63), but not previous 
smoking (Saevarsdottir et al., 2011).  Additional factors that predicted poorer 
outcome in this study included female gender, increased symptom duration, 
and DAS28, and disability at baseline, but SES was not controlled for in this 
analysis.  In a cohort of Mexican patients with early RA (<12 months) treated 
with a combination of MTX and SSA, plus oral Prednisolone if clinically 
indicated, current smoking at baseline predicted lack of ACR50 response at 
6 months (OR 3.91, 95% CI 1.41, 10.81) (Rojas-Serrano et al., 2011).   
In contrast to the evidence presented so far, recently published results from 
BRASS indicated no significant association with smoking and DAS28 
measured 1 year later and a weak association of moderate alcohol 
consumption and lower DAS28 (Lu et al., 2014).  The authors used data 
from 662 cases with RA, recruited to the register and followed up annually 
from 2003 for up to 7 years, with a median follow up time of 4 years.  There 
are several possible reasons for the different smoking related result from this 
study.  Unlike other papers reviewed in the present section, this analysis 
was adjusted for education level (a dichotomous variable separating those 
with an education level of high school graduate or higher from lower levels), 
which is an indicator of SES, and lower education level was associated with 
past or current smoking.  Furthermore, the analysis in this paper was 
longitudinal and used general linear mixed models to determine how 
smoking and alcohol consumption influenced DAS28 a year later, so that 
data from all time points were used with adjustment for repeated measures.  
This approach is different to the cross sectional approaches reported in most 
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of the other papers presented here, where outcome at one or more time 
points were analysed and variations between these points were not 
accounted for.  Furthermore, the BRASS cohort was more heterogeneous, 
owing to differences in the selection and treatment of patients.  Most of the 
other studies focused on early RA, whereas mean disease duration in 
BRASS was 15 years with a standard deviation of 12 years, so some cases 
will have been treated in line with modern management principles, whilst 
others with a longer disease duration will have been treated according the 
older ‘step up’ approach (described in Section  1.6).  Additionally, cases in 
this study were taking various different DMARDs and / or biologic agents, 
whereas other studies have involved patients treated with similar therapies, 
for example, MTX monotherapy in the SWEFOT trial and TNF inhibitors in 
the BSRBR.   
In summary, the evidence points towards a deleterious effect of smoking on 
disease activity in RA, but this effect may have been confounded by SES in 
some studies.  The BRASS study did control for SES, but due to differences 
in study design, its results are difficult to compare to those of other studies.  
The strength of association between smoking and ACPA in patients with the 
HLA-DRB1 shared epitope (discussed Section 1.4.1), together with the 
immune-modulatory effects of cigarette smoke (reviewed by Baka et al., 
2009), provide a reasonable biological basis for increased disease activity in 
smokers with RA.  The effects of smoking on disease activity seem to be 
important in early disease and following initiation of MTX or TNF inhibitors, 
particularly infliximab, although the strength of association here may not be 
strong.  This effect has been observed in current smokers and is probably 
also pertinent for those with a past history of smoking.  In addition, the total 
cumulative exposure to cigarette smoke may be an important influence of 
disease activity, with heavier smoking associated with worse outcome.   
 
1.8.2.7 Obesity 
Obesity has been linked to poor response to treatment with biological agents 
in RA.  A study of 641 cases with RA according to 1987 ACR criteria 
recruited to an Italian arthritis register found that remission, defined as 
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DAS28 < 2.6 for at least 3 months, was less likely in obese individuals, 
where obesity was defined as BMI>30 kilograms per metre squared (kg/m2) 
(Gremese et al., 2013).  In a multivariate analysis, the OR of achieving 
remission in obese subjects was 0.89 (95% CI 0.81,0.99, p=0.02).  In this 
study, remission was also less likely with greater baseline DAS28.  A later 
study by Rodrigues and colleagues (2014), which involved cases from a 
Portuguese register of RA patients, did not confirm this association with 
remission (possibly due to reduced power in this study, which included 317 
patients), however DAS28 measured 6 months after the initiation of 
biological treatment was significantly greater in obese patients (obesity 
defined as body mass index, BMI >30kg/m2): the regression coefficient from 
a multivariable analysis was 0.412; p=0.028.   
Obesity is associated with elevated levels of CRP and a recent meta-
analysis found a Pearson correlation of 0.36 (95% CI 0.30, 0.42) between 
CRP and BMI (Choi et al., 2013).  This association is likely to be related to 
the higher levels of inflammatory cytokines such as IL-6 and TNF in the 
serum and adipose tissue of obese, compared to non-obese, individuals 
(Bastard et al., 2000).  Although it is difficult to determine the magnitude of 
the effect of obesity on CRP, one study found that obesity was associated 
with both detectable levels of CRP, compared to undetectable (with a cut-off 
of 0.22 miligrams per decilitre, mg/dL) and clinically significant levels of 
elevated CRP, defined as 1.00 mg/dL (Visser et al., 1999).  Thus, as the 
DAS28 uses a measurement of CRP measured in miligrams per litre (mg/L), 
the CRP could possibly vary by as much as 10mg/L between an obese and 
non-obese subject, resulting in a hypothetical difference in DAS28 of 0.95 
units.  There is also a reported association between obesity and ESR (Leff 
and Akre, 1986, Pasulka et al., 1985) and this may be partially explained by 
the association of obesity and hypercholesterolemia, which in turn can 
elevate the ESR (Sox and Liang, 1986).  Although Gremese and colleagues 
did not specify which variables were used to calculate DAS28, ESR was 
mentioned as the inflammatory marker used in a separate analysis, so was 
possibly included in the DAS28 calculation.  Whichever inflammatory marker 
was used, elevation of its value as a result of obesity may have effected 
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DAS28 and therefore confounded the results.  Similarly, Rodrigues (2014) 
also did not specify which  parameters were used to calculate DAS28 in this 
article, which was published as an abstract of the European Workshop for 
Rheumatology Research in 2014.  Another possible reason for the lack of 
response seen in obese individuals could be reduced bioavailability of 
DMARDS in patients with greater volumes of adipose tissue, although there 
is no published evidence to confirm this for MTX in RA.   
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Table 1-5 Evidence for factors influencing disease activity in rheumatoid arthritis 
Authors Year Subjects Outcome 
measure 
Outcome time point Baseline predictors of greater 
disease activity 
Age and gender 
(Jayakumar et 
al.) 
2012 704 cases from ERAS, 
with RA, DMARD naïve 
and with less than 2 
years’ symptom duration 
at baseline, followed for 
at least 5 years 
 
DAS remission 
(<1.6) whilst on 
DMARDs  
Incident remission and 
sustained remission 
present at 3,4 and 5 years 
Female gender 
Longer symptom duration 
Higher TJC 
(Ma et al.) 2012 379 cases with RA, < 2 
years duration from 
CARDERA trial (initial 
analysis) 
194 cases of newly 
diagnosed RA from 
ERAN (validation cohort) 
 
DAS28 remission 
(<2.6) whilst on 
DMARDs 
Incident remission at  2 
years 
Increasing age 
Female gender 
Higher TJC  
(Arnold et al.) 2014 1144 patients with early 
inflammatory arthritis 
(CATCH cohort). 
Change in DAS28 12 months Mean change in DAS28 less in females 
(Age had no significant effect) 
 
DAS28 remission  
(≤2.6) 
Incident remission at  
12 months 
Increasing age 
Female gender 
(Baseline) DAS28 
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Table 1-5 continued     
Authors Year Subjects Outcome 
measure 
Outcome time  Baseline predictors of greater 
disease activity 
HLA-DRB1 shared epitope 
(Gonzalez-Gay 
et al.) 
2002 178 unselected Spanish 
cases with RA according 
to 1987 ACR criteria 
Severe RA, 
defined as disease 
requiring treatment 
with Cyclosporine 
in addition to MTX 
and HCQ. 
 
Variable (cross sectional 
study) 
Possession of 2 HLA-DRB1 shared 
epitope alleles 
(Hider et al.) 2009 309 cases with 
inflammatory polyarthritis 
(NOAR cohort) 
Failure of MTX 
monotherapy due 
to inefficacy 
 
1 and 2 years  HLA-DRB1 shared epitope 
(Mori et al.) 2010 124 Japanese cases 
with RA, meeting 1987 
ACR criteria 
DMARD failure 
(need for 
biological therapy) 
2 years  HLA-DRB1*04 alleles 
ACPA 
Autoantibody status 
(van der Woude 
et al.) 
2009 454 cases from the 
Leiden clinic with RA 
according to 1987 ACR 
criteria and  
 
 
 
Remission defined 
by rheumatologist 
in cases with no 
swollen joints and 
free from DMARD 
for ≥ 12 months 
Variable  
 
 
 
ACPA positive 
RF positive 
Higher symptom duration 
(van der Woude 
et al.) 
2012 508 cases from the BeSt 
study with RA according 
to 1987 ACR criteria and  
424 cases from the 
Leiden clinic (as above). 
Cases followed for up to 5 
years 
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Table 1-5 continued     
Authors Year Subjects Outcome 
measure 
Outcome time  Baseline predictors of greater 
disease activity 
The influence of periodontal disease 
      
(Ribeiro et al.) 2005 42 RA cases, aged >40. After 
randomisation, 16 received 
professional tooth cleaning 
and instructions on oral 
hygiene, whilst the remainder 
received the same treatment, 
plus additional full mouth 
scaling and root planing (i.e. 
more intensive treatment for 
periodontal disease). 
ESR 3 months ESR fell more with more intensive 
treatment for periodontal disease 
      
(Al-Katma et al.) 2007 29 cases with established RA 
according to 1987 ACR 
criteria, randomised to 
receive oral hygiene 
intervention or no intervention 
 
DAS28  8 weeks Reduction in DAS28 significantly lower 
in non-treatment group, who did not 
receive periodontal therapy 
(Ortiz et al.) 2009 40 non smoking cases 
aged >30 with active RA, of 
whom 20 were receiving 
DMARDS plus anti-TNF and 
20 DMARDS alone. Cases 
were randomised within the 
TNF/ non-TNF groups to 
receive treatment for 
periodontal disease or not.  A 
total of 4 groups of 10 cases.  
DAS28 6 weeks Treatment of periodontal disease 
improved DAS28 in those taking anti-
TNF and not taking anti-TNF.  
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Table 1-5 continued    
Authors Year Subjects Outcome 
measure 
Outcome time point Baseline predictors of greater 
disease activity 
 
(Pinho Mde et 
al.) 
 
2009 
 
45 non smoking RA cases 
from Brazil with periodontal 
disease, 15 controls without 
RA and with periodontal 
disease and 15 controls 
without either condition. 
Of the RA cases, 15 received 
treatment for periodontal 
disease, 15 received no 
treatment and 15 had dental 
extractions and dentures. 
 
DAS28 
 
3 months 
 
Improved DAS28 in treatment group 
 
 
6 months 
 
No difference in DAS28 between 
treatment and non treatment groups 
 
Socioeconomic status 
 
(ERAS study 
Group) 
2000 869 cases from ERAS 
(newly diagnosed RA 
with symptoms for <2 
years, DMARD naïve) 
 
Joint count 
(explained in 
section 1.8.2.5) 
and RAI, ESR 
Baseline Lower SES  
3 years  Lower SES influenced joint scores, but 
not ESR. 
(Jacobi et al.) 2003 869 questionnaire 
respondents from the 
Netherlands, median 
disease duration 8.7 
years. 
 
DAS28 Baseline  Low SES (measured by education level) 
Fall in DAS28 of 
≥1.2 
2 years No difference across SES categories 
(Harrison et al) 2005 446 patients recruited to 
a RCT (BROSG) 
DAS28 Baseline Area level social deprivation (at 
baseline) 
3 years No difference between levels of 
deprivation (after 3 years) 
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Table 1-5 continued     
Authors Year Subjects Outcome 
measure 
Outcome time  Baseline predictors of greater 
disease activity 
      
(Sokka et al.) 2009 6004 unselected RA 
cases from 71 centres, 
across 25 countries 
(QUESTRA) 
DAS28 Cross sectional Low GDP of country of residence 
 
(Andersson et 
al.) 
 
2013 
 
1460 cases with early 
RA, recruited to 
BARFOT between 1992 
and 2006 and completed 
questionnaire in 2010 
 
EULAR response 
 
5 years 
 
Unemployment (in 2010) 
Female gender  
Longer disease duration 
Smoking (baseline) 
More treatment  
 
8 years 
 
Older age  
Female gender 
More treatment  
RF positivity 
Smoking (baseline) 
Smoking  
 
(Hyrich et al.) 2006 2879 RA cases 
prescribed anti-TNF 
treatment (BSRBR) 
EULAR response 6 months Current smoking 
Female gender 
Number of previous DMARDs 
Higher baseline disability 
 
(Mattey et al.) 
 
2009 
 
147 cases with RA, 
starting anti-TNF 
treatment for the first 
time, having met NICE 
criteria for this treatment.  
 
DAS28 
EULAR response 
 
3 months 
 
DAS28 higher in smokers 
Response less likely with greater 
amount of cigarettes smoked 
 
12 months 
 
Response less likely with greater 
amount of cigarettes smoked and in 
current smokers 
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Table 1-5 continued     
Authors Year Subjects Outcome 
measure 
Outcome time point Baseline predictors of greater 
disease activity 
      
(Saevarsdottir 
et al.) 
2011 405 early RA cases 
taking MTX 
monotherapry from 
SWEFOT study. 
EULAR response 3-4 months Current smoking 
Female gender 
Increased symptom duration 
(baseline) DAS28 
HAQ 
(Soderlin et al.) 2011 1787 cases with early 
RA fulfilling 1987 ACR 
criteria from the Swedish 
BARFOT study  
 
DAS28 
EULAR response 
12 months Current smoking  
(Rojas-Serrano 
et al.) 
2011 144 patients with early 
RA (<12 months) 
attending a Mexican 
rheumatology clinic. 
ACR50 6 months Current smoking  
(low level of education was almost 
significant) 
(Lu et al.) 2014 662 cases with RA from 
BRASS, mean disease 
duration 15 years.  
DAS28 Mean follow up 4 years 
Outcome was DAS28 12 
months after smoking data 
collected. 
No association with smoking 
Weak ‘J-shaped’ relationship with 
alcohol. 
      
Obesity      
(Gremese et al.) 2013 641 cases with RA 
according to 1987 ACR 
criteria, failed MTX and 
taking anti-TNF agents  
DAS28 remission 
(<2.6) for at least 3 
months  
6, 9 and 12 months Obesity (BMI >30) 
Higher baseline DAS28 
(Rodrigues et 
al.) 
2014 317 cases with RA using 
biological treatment after 
failure of DMARD 
DAS28  6 months Obesity (BMI >30) 
No significant relationship between 
obesity and remission (DAS28<2.6) 
      
ACPA, anti citrullinated peptide antibody; ACR, American College of Rheumatology; BMI, body mass index; BARFOT, Better Anti-Rheumatic 
FarmacOTherapy; BRASS, Brigham and women’s hospital Rheumatoid Arthritis Sequential Study; BROSG, British Rheumatoid Outcome Study Group; 
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BSRBR, British Society for Rheumatology Biologics Register; CARDERA, Combination of Anti Rheumatic Drugs in Rheumatoid Arthritis; CATCH, Canadian 
Early Arthritis Cohort; DAS28, disease activity score based upon counts from 28 joints; DMARD, disease modifying anti rheumatic drug; ERAN, Early 
Rheumatoid Arthritis Network; ERAS, Early Rheumatoid Arthritis Study; EULAR, European League Against Rheumatism; HCQ, Hydroxychloroquine; MTX, 
methotrexate; NICE, National Institute for Health and Care Excellence; NOAR, NOrfolk Arthritis Register; QUESTRA, QUantitative STandard monitoring of 
patients with RA; RA, rheumatoid arthritis; RCT, randomised controlled trial; RF, rheumatoid factor; SWEFOT, Swedish FarmacOtherapy; TNF, tumour 
necrosis factor.
63 
 
1.8.3 Measurement of disability in rheumatoid arthritis 
The Stanford Health Assessment Questionnaire (HAQ) (Fries et al., 1980) 
was formulated in order to assess outcome, including functional impairment, 
in patients with arthritis and was later modified so that the questions were 
more readily interpreted by British patients (Kirwan and Reeback, 1986).  It 
is now a validated and widely used tool for the measurement of outcome in 
RA that is easily reproducible and sensitive to change (reviewed by Bruce 
and Fries, 2003).  Furthermore, it is recommended by OMERACT as a 
method of obtaining a patient reported measure of functional ability (Felson 
et al., 1993).  The full HAQ, which was designed to assess 5 aspects of 
outcome (disability, discomfort, drug side effects, financial cost and death), 
assesses disability and also includes a pain VAS, details of drug side effects 
measured using a toxicity index, details of hospital admissions, drugs used 
and procedures (so that financial cost can be calculated), and time and 
cause of death if applicable.  The disability component of the questionnaire 
is easy and quick to complete, consisting of 2 or 3 questions within 8 
categories of daily activity: dressing and grooming, rising, eating, walking, 
hygiene, reach, grip and activities.  There are 4 possible responses to each 
question (0 to 3), so that the patient can indicate how difficult they find a 
given activity.  The highest score from each category is used to calculate the 
total score, (unless devices or personal assistance are used for one of the 
categories, in which case category scores of 0 or 1 are increased to 2 in 
order to better represent the level of disability), so the highest possible value 
is 24 and the lowest is zero.  These questions comprise the disability index 
component of the HAQ, sometimes abbreviated to HAQ-DI, and the total 
score is usually divided by 8 to give the average response over all 
categories, with 25 possible scores ranging from 0-3.  One difficulty relating 
to the use of HAQ-DI as an outcome is that it is an ordinal variable (Tennant 
et al., 1996).  That is, a change in value at either end of the scale does not 
represent the same difference in disability as a numerically equivalent 
change in the middle of the scale.  In order to overcome this, many authors 
categorise or dichotomise HAQ-DI, resulting in loss of information and 
statistical power.  A further problem of HAQ-DI is that it does not detect low 
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levels of disability well and may score some patients as having no functional 
impairment when in fact some is present.  One of several versions of the 
HAQ, formulated 24 years after its original description, overcomes these 
issues.  The 10 item ‘HAQ-II’, produced by Wolfe and colleagues (2004), 
involves fewer questions and is therefore faster to complete than the 
original.  In addition, it was developed using a Rasch model so that its 
scores represent a linear scale more closely and furthermore, it is more 
sensitive at detecting lesser degrees of disability.  With these advantages 
over HAQ-DI, the HAQ-II can be used as an outcome variable for parametric 
analyses. 
Numerous other methods of measuring functional outcome have been 
validated for use in RA research including: the arthritis impact measurement 
scale (Meenan et al., 1980), which is also recommended by OMERACT to 
assess disability in clinical trials, short form-36 health survey (Weinberger et 
al., 1991), Barthel index (Mahoney and Barthel, 1965), and the recent onset 
arthritis disability questionnaire (ROAD) (Salaffi et al., 2005).  Despite the 
plethora of indices available to quantify disability in RA, the HAQ and its 
modified versions are the most widely reported.  A systematic review of the 
measurement properties of different tools to measure patient reported 
disability in RA concluded that the HAQ was one of the most reliable in 
terms of validity, internal consistency, reproducibility, responsiveness and 
interpretability (Oude Voshaar et al., 2011).  However, in this review, the 
HAQ was also one of the most comprehensively investigated scales.  This 
possibly reflects its popularity as well as its suitability as an outcome 
measure, and in time, there may be more evidence in favour of the newer 
scales such as the HAQ-II and ROAD. 
1.8.4 Factors influencing disability in rheumatoid arthritis 
Disability due to RA contributes a significant financial burden incurred 
through both direct health care costs and indirect costs due to loss of 
workforce (Hallert et al., 2004, Puolakka et al., 2005, Bansback et al., 2012), 
and also has an adverse impact upon the overall wellbeing and mental 
health of individuals (Nicassio, 2010).  Loss of physical function due to RA 
has been the focus of much research and longitudinal studies have explored 
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factors influencing functional impairment, both in the short-term and long 
term following an initial diagnosis of RA.  However, it is difficult to compare 
the results of such studies, owing to significant differences in their design, 
including length of follow up, measures of disability used, statistical analysis 
and even patient population.  There is considerable inter-individual variation 
in HAQ over time (Drossaers-Bakker et al., 1999), with age and gender 
affecting outcome such that female patients and those whose onset of RA is 
at an older age seem to do worse.  In a study of 732 cases with RA 
according to 1987 ACR criteria who were recruited to ERAS, females were 
more likely than males to have worse function after 5 years’ follow-up (OR, 
1.6, 95% CI 1.3-2.9) (Young et al., 2000).  In a 15 year longitudinal study of 
HAQ over time in an inception cohort of patients presenting to their general 
practitioner with early inflammatory polyarthritis, women had higher HAQ 
scores at each measurement point (mean difference 0.29, 95% CI 0.25- 
0.34) and furthermore, although baseline HAQ scores were lower in males 
over 75 than younger males (mean difference 0.14, 95% CI 0.29, 0.001), 
HAQ deteriorated at a greater rate in all patients whose arthritis presented at 
an age over 75 years (Camacho et al., 2011).  These findings were 
confirmed by results from a French cohort of patients with possible early RA, 
in which HAQ at 5 years was more likely to be greater than the median value 
of HAQ, in older patients (OR 1.91, 95% CI 1.32-1.77) or females (OR 1.02, 
95% CI 1.02-2.50) (Combe et al., 2013). 
With respect to the change in level of disability over time, an initial fall 
followed by a gradual increase with time: a ‘J-shaped curve’, has been 
described (reviewed by Toussirot, 2010).  This pattern of change, or 
trajectory, was recently confirmed in a comprehensive analysis of change in 
HAQ over 10 years using data from patients recruited to ERAS (Norton et 
al., 2013).  In this study, growth mixture modelling was used to describe 4 
distinct trajectories or classes of change in HAQ over 10 years.  Whilst the 
largest of the 4 trajectories (including 46% of cases) described a J shape, 
with a greater rate of decline in function compared that associated with 
normal ageing, there were 2 classes with more stable progression: ‘low 
stable’, representing 6% of cases and ‘moderate stable’, representing 28% 
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of cases.  The fourth class described a less favourable change in HAQ over 
time (the ‘high stable’ class), in which the patients were more likely to be 
female, have lower level of education, higher ESR at baseline and more 
evidence of radiographic erosion at 3 years.  There was also greater co-
morbidity at 3-5 years within this group (but not at baseline) and an 
increased mortality amongst patients in this category, highlighting once 
again the importance of function as an outcome measure in RA.  Table 1-6 
summarises the evidence for predictors of disability in RA and is divided 
according to whether disability was a short term outcome (within 2 years of 
study entry) or a long term outcome, after 2 years. 
1.8.4.1 Disease activity and disability 
Disease activity, with inflammation and pain in the joints, contributes 
significantly towards disability throughout follow up, whereas joint damage 
indicated by radiographic change influences disability in established RA 
(reviewed by Bombardier et al., 2012).  At baseline, disability measured by 
HAQ was influenced by RA disease activity and inflammation measured by 
CRP in a study of 133 cases with RA and less than 3 years symptom 
duration (Jansen et al., 2000).  This was in keeping with the findings in a 
cohort of 112 female patients from the Leiden clinic in the Netherlands in 
which there was a significant correlation between DAS and HAQ at baseline 
(Spearman’s correlation 0.68, p<0.001) (Drossaers-Bakker et al., 1999).   
1.8.4.2 Autoantibodies 
The effect of autoantibodies on disability is not entirely clear: some studies 
have concluded RF and ACPA predict worse outcome, whilst others have 
suggested no effect.  One explanation of these different outcomes is that 
antibodies are associated with worse (more rapid) radiological progression, 
which in turn is associated with poorer long-term functional status (Figure 1-
4).  Dirven and colleagues (2012) proposed that predictors of short term 
HAQ were different to those of rapid radiological damage.  They studied 508 
cases with RA according to the 1987 ACR criteria from the BeSt study and 
concluded that RF and ACPA did not predict HAQ ≥1 at 3 months, whilst 
RAI, baseline HAQ and baseline pain did.  These findings were supported 
when further analysis of the BeSt cohort showed that rapid radiological 
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progression predicted worse HAQ after 8 years (van den Broek et al., 2012).  
The BeSt study was a randomised trial of different treatment strategies and 
patients received either MTX alone; MTX, SSA and prednisolone; or MTX 
plus Adalimumab.  The different treatments received and the fact that the 
subjects were part of a trial make these results difficult to compare to other 
studies, as care delivered as part of a rigorous drug-trial protocol is very 
different to that provided for subjects enrolled in observational studies, which 
are more representative of ‘real life’ clinical settings.  Furthermore, the HAQ 
outcome was dichotomised, which could have reduced the study’s power to 
detect a difference in HAQ according to autoantibody status.  Despite these 
limitations, the evidence from the BeSt study provides an attractive and 
plausible explanation for differences between studies that have investigated 
the relationship between auto antibodies and functional outcome.  Similarly, 
the change in treatment for RA over time (discussed in Section 1.6) may 
have also impacted upon results from observational studies: the use of 
biologic agents and combination therapies should have reduced or slowed 
radiological progression, which in turn would result in improved functional 
outcome (Figure 1-4) and therefore, autoantibodies would be expected to 
predict functional outcome more often in older than modern observational 
studies. 
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Figure 1-4 Schematic representation of the postulated relationship 
between auto antibodies and functional outcome in rheumatoid 
arthritis 
DMARD, disease modifying anti rheumatic drug 
 
There have been relatively few studies with HAQ before 12 months as an 
outcome; however, contrary to the evidence presented from the BeSt trial, 
other investigators have found an association between auto-antibodies and 
worse HAQ as early as 12 months from baseline.  In a small study that 
included 182 cases with RA according to 1987 ACR criteria, Quinn et al 
(2006) found that improvement in HAQ from baseline to 12 and 24 months 
was less likely in RF positive cases and furthermore, in the 67 RF negative 
cases from this group, high titre of ACPA (>100) was associated with 
absence of improvement in function.  In addition to the differences in timing 
of the outcome, the difference between this result and that of the BeSt study 
could also be related to the outcome measures used, which was HAQ ≥1 at 
3 months in the Dutch study.  Graell and colleagues (2009) also found that 
RF predicted worse functional outcome after 2 years: OR for modified HAQ 
(mHAQ) >0 after 2 years was 3.77 in RF positive patients; 95% CI 1.20, 
11.81; p = 0.023.  The population investigated here were part of an open 
label study of different treatments for RA, which should be borne in mind 
when interpreting the results: they may not be as generalizable as those 
from observational studies which mirror ‘real life’ more closely.  Furthermore, 
the use of the mHAQ, which is less frequently used as an outcome measure, 
Autoantibodies 
Increased 
radiological 
progression 
 Worse 
functional 
outcome  
Biological treatment 
Combination DMARD 
therapy 
  
Time 
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has limitations and cannot be directly compared to HAQ.  It is limited by a 
large ‘floor’ effect, with a relatively large number of cases scoring the lowest 
possible value (zero), so that gain in function may not be captured in some 
individuals, despite clinical improvement.  Thus, mHAQ is also not as 
sensitive to change, so small improvements may not be captured (reviewed 
by Maska et al., 2011).  
1.8.4.3 Psychosocial influences on disability 
The influences of psychosocial factors on functional impairment have been 
investigated by researchers working on the NOAR cohort.  Recently, 
Camacho and colleagues (2012) published evidence that ‘learned 
helplessness’, a psychological state in which the subject feels unable to 
control the course of their disease, is associated with worse function in 
patients with inflammatory polyarthritis.  Using data from 447 NOAR cases 
with available HAQ data, they described a median increase in HAQ score 
(where the maximum possible score was 3) of 1.12 (95% CI 0.82, 1.41) for 
those with high, compared to ‘normal’ learned helplessness.  Furthermore, a 
similar effect was seen in those with low, compared to normal learned 
helplessness, with a median decrease of 0.39 units (95% CI -0.69, -0.10).  
The authors proposed that learned helplessness mediated their observed 
association of social deprivation with poor functional outcome.  The impact 
of psychosocial factors was also considered by Drossaers–Bakker et. al. 
(1999), in the previously mentioned 12 year study involving 112 females with 
RA.  Psychosocial functioning was measured using a combination of 
assessments including components of the Dutch version of the arthritis 
impact measurement scale 2 and parts of the RAND-36 measure of health 
related quality of life.  In a multivariable regression model that controlled for 
the effects of age, disease duration, disease activity, (radiological) joint 
destruction, pain VAS and comorbidity, psychosocial functioning at 12 years 
was a significant indicator of HAQ at 12 years.  
1.8.4.4 Smoking  
The relationship between smoking and susceptibility to RA is well 
documented, as is the interaction between smoking and HLA-DRB1 shared 
epitope alleles, which was discussed in Section 1.4.2.  There is some 
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evidence that smoking is associated with worse functional outcome in RA.  
Masdottir et. al. (2000) reported increased median HAQ values associated 
with heavy smoking (≥20 pack years) in one study of 63 women with RA: 
median HAQ in heavy smokers 1.1, compared to 0.5 in smokers of <20 pack 
years (p = 0.002).  This effect was also seen in a retrospective analysis of 
data from BRASS, where current smoking was associated with higher mean 
mHAQ one year later (Lu et al., 2014).  Both of these studies were 
retrospective, using data from patients with established RA.  In Mansdottir’s 
study, the disease duration ranged from 5 to 21 years and in the analysis of 
the BRASS data, mean disease duration was 15 years.  These results may 
have been confounded by radiological damage, as smokers are more likely 
to have antibodies to citrullinated peptides, which in turn may increase the 
risk of erosive damage.  Lu et al. (2014) also investigated the effects of 
alcohol consumption on functional outcome in RA and found that compared 
to cases who consumed no alcohol, mHAQ was significantly lower in cases 
who consumed 5.0 to 10.0g of alcohol per day.  Their analysis controlled for 
potential confounders, including education level (as a marker of socio-
economic status) and autoantibody status.  
1.8.4.5 Obesity 
Obesity was also investigated by the NOAR team who reported that morbid 
obesity (BMI ≥35 kg/m2) was associated with worse HAQ score in their study 
of 1246 patients with inflammatory polyarthritis, of whom 87 (7%) were 
morbidly obese (Humphreys et al., 2013b).  In an analysis that controlled for 
the effects of age, gender, DAS28, smoking and treatment, the relationship 
between morbid obesity and HAQ tertile was described by an OR of 1.94 
(95% CI 1.17, 3.24).   
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Table 1-6 Studies investigating predictors of disability in rheumatoid arthritis 
 
Prospective studies of short-term‎(≤‎2‎years)‎disability 
   
Authors Date Subjects Outcome 
measure(s) 
Outcome times Predictors of 
disability 
Limitations  
(Jansen et al.) 2000 133 untreated prospective 
outpatients meeting ACR 
criteria for RA, 
<3 years symptom 
duration   
HAQ (DI) 
dichotomised into 
‘less disabled’ 
(<median value) or 
‘more disabled’ 
(>median value) 
 
Baseline  High DAS28 at 
baseline 
High CRP at 
baseline  
 
Both predictors and 
outcomes dichotomised 
for regression analyses, 
limiting power 
1 year Baseline HAQ  
Baseline pain VAS  
(Quinn et al.) 2006 298 cases with either 
CTD (116) or RA 
according to ACR criteria 
(182) 
HAQ (DI) -quartiles 1 and 2 years Baseline HAQ 
RF positivity 
ACPA positivity in 
RF negative RA 
patients (n=67) 
 
Study population not 
exclusively RA. Predictors 
of disability not main 
study outcome. 
(Graell et al.) 2009 105 cases enrolled onto 
an open label study using 
step-up treatment with 
Gold and MTX.  ACR 
criteria for RA were met, 
<24 months’ symptom 
duration at baseline 
mHAQ, 
dichotomised into 0= 
no disability and >0 
= disability 
2 years Older age 
RF positive 
Baseline mHAQ>0 
Dichotomised outcome 
variable limited power.  
Where cases dropped 
out, they were not 
included in analysis, 
which is a potential 
source of bias. 
Problems associated with 
mHAQ include less 
sensitivity to change and 
increased floor effect 
compared to HAQ-DI. 
       
       
       
72 
 
Table 1-6 continued     
Authors Date Subjects Outcome 
measure(s) 
Outcome times Predictors of 
disability 
Limitations  
       
(Camacho et al.) 2012 553 consecutive cases 
with recent onset IP 
presenting to primary care 
(NOAR cohort) Symptom 
duration less than 2 
years. 
HAQ (DI) -
continuous 
Baseline Greater social 
deprivation and 
learned 
helplessness. 
Learned helpless 
possibly mediated 
the relationship 
between deprivation 
and HAQ 
 
Area level deprivation 
used (not person level) 
(Dirven et al.) 2012 497 patients from the 
Dutch BeSt study. 
Treatment naïve, recent 
onset RA, meeting ACR 
criteria  
HAQ (DI), 
dichotomised into 
HAQ ≥1 or HAQ<1 
3 months Baseline HAQ 
Baseline Pain 
Baseline RAI 
Less aggressive 
study treatment 
group   
(Baseline RF, 
ACPA and 
presence of 
erosions were not 
predictive of 
disability) 
 
Dichotomised outcome 
variable and some 
predictor variables 
reduced power.  
This study was a post-hoc 
analysis from a 
randomised study of 
different treatment 
method for RA. 
(Humphreys et al.) 2013 1246 consecutive cases 
with recent onset IP 
presenting to primary care 
(NOAR cohort) Symptom 
duration less than 2 years 
HAQ (DI)- divided 
into tertiles 
Baseline  Highest HAQ tertile 
associated with 
morbid obesity (BMI 
≥35) 
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Table 1-6 continued 
Prospective studies of long-term (> 2 years) disability 
Authors Date Subjects Outcome 
measure(s) 
Outcome times Predictors of 
disability 
Limitations  
(Drossaers-Bakker et al.) 1999 112 consecutive female 
patients diagnosed with 
RA at the Leiden medical 
clinic from 1982 to 1986 
 
HAQ (DI) –
continuous  
Baseline, 3, 6 
and 12 years 
Concurrent disease 
activity, 
Concurrent 
radiological damage 
(at 12 years), 
Psychosocial 
parameters 
Related to problems 
associated with the use of 
HAQ-DI as a continuous 
variable. 
(Young et al.) 2000 732 consecutive 
outpatients with RA 
according to ACR criteria. 
(ERAS) 
Functional grades i-
iv 
5 years Female gender 
HAQ>1 at baseline 
Dichotomised outcome 
variable limited power. 
Potential bias as cases 
who dropped out not 
included in analysis. 
Requirement for aids 
/ appliances/ home 
modifications 
5 years Female gender 
HAQ>1 at baseline 
Age >60 years at 
presentation 
 
(Combe et al.) 2003 191 consecutive 
outpatients with RA 
according to ACR criteria, 
DMARD naïve, diagnosed 
less than 1 year 
previously 
HAQ (DI) -
continuous 
5 years Baseline HAQ, 
ESR,CRP, RAI and 
presence of 
erosions. 
(Sex, age, RF and 
HLA class II alleles 
did not predict 
disability) 
Related to problems 
associated with the use of 
HAQ-DI as a continuous 
variable.  
 
(Harrison et al.) 2005 466 cases from the UK 
BROSG trial.  Disease 
duration >5 years, ACR 
criteria for RA were met. 
HAQ (DI) -
continuous 
Baseline  Increased area 
level social 
deprivation  
Assumed a linear change 
in HAQ over time.  
Treated HAQ as a 
continuous variable 
Analysis limited to area-
level social deprivation. 
3 years Increased area 
level social 
deprivation 
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Table 1-6 continued 
Authors Date Subjects Outcome 
measure(s) 
Outcome times Predictors of 
disability 
Limitations  
(Camacho et al.) 2011 3666 consecutive cases 
with recent onset IP 
presenting to primary 
care. (NOAR cohort) 
HAQ (DI) -
continuous  
Baseline, 
1,5,10,15 years 
Female gender (all 
time points) 
Late onset IP (>75 
years age 
compared to <55 
years)  
 
Related to problems 
associated with the use of 
HAQ-DI as a continuous 
variable. Attrition, as 
expected with long term 
follow up. 
(van den Broek et al.) 2012 465 patients from the 
Dutch BeSt study. 
Treatment naïve, recent 
onset RA, meeting ACR 
criteria 
 
HAQ (DI)- 
continuous 
8 years Rapid radiological 
progression in the 
first year. 
Related to problems 
associated with the use of 
HAQ-DI as a continuous 
variable 
(Combe et al., 2013) 2013 573 patients with possible 
early RA (ESPOIR cohort) 
HAQ (DI) 
dichotomised 
according to whether 
above or below 
meadian value 
5 years Baseline HAQ  
Older age 
Female gender 
Baseline pain VAS 
Dichotomised outcome 
variable reduced power. 
Cohort had early 
inflammatory arthritis 
rather than RA 
 
(Norton et al.) 2013 1460 cases with RA, from 
ERAS  
Symptoms <2 years 
HAQ-(DI)-continuous 
 
Baseline to 10 
years, described 
as 4 distinct 
trajectories of 
change (classes) 
Worse prognostic 
class predicted by: 
Female gender 
Lower education 
level 
Increased 
radiographic damage 
at 3 years 
(No difference in RF, 
ANA, SE, year of 
first visit, or whether 
biologics used)  
Related to problems 
associated with the use of 
HAQ-DI as a continuous 
variable. Attrition, as 
expected with long term 
follow up. 
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ACPA, anti citrullinated peptide antibody; ACR, American College of Rheumatology; ANA, Anti nuclear antibodies; BeSt, Behandel Straregieen; BMI, 
body mass index; BROSG, British Rheumatoid Outcome Study Group; CRP, C-reactive protein; CTD, connective tissue disease; DAS28, disease 
activity score based upon counts of 28 joints; DMARD, disease modifying anti- rheumatic drug; ERAN, Early Rheumatoid Arthritis Network; ERAS, 
Early Rheumatoid Arthritis Study; ESPOIR, Etude et Suivi des POlyarthritis IndiffeRencieesˑ ESR, erythrocyte sedimentation rate; HAQ (DI), health 
assessment questionnaire (disability index); HLA, Human leucocyte antigen; IP, inflammatory polyarthritis; mHAQ, modified health assessment 
questionnaire; MTX, Methotrexate; NOAR, NOrfolk Arthritis Register; RA, rheumatoid arthritis; RAI, Ritchie articular index; RF, rheumatoid factor; SE, 
HLA-BRB1 shared epitope; UK, United Kingdom; VAS, visual analogue score.
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1.8.5 The relationship between disease activity and disability in 
rheumatoid arthritis 
The evidence presented so far (in Section 1.8.4) suggests that disease activity 
influences disability in early RA and that with time joint damage, indicated by 
erosions on radiographs, shows increasing correlation with disability.  Although 
disease activity is likely to impact upon function at any time during the course of 
RA, the exact relationship between these outcomes is not entirely clear.  
Disease activity may have less of an influence on disability with increasing age 
and co-morbidity, or the relationship between these two may be different in men 
and women.  To date, there have been few studies to investigate how DAS28 
affects HAQ.  In an analysis of cases from Yorkshire Early Arthritis Register 
(YEAR, the cohort which is the focus of this Thesis), Conaghan and colleagues 
(2010) showed that moderate DAS28 (that is, where DAS28 was between 3.2 
and 5.1 at 12 months from baseline and at least once between baseline and 12 
months) was associated with a HAQ at 12 months that was ≥0.49 units worse 
than at baseline in 10.7% of cases, which was comparable to the rate for cases 
with a persistently high (>5.1) DAS28 (11.1%).  Thus, disease activity between 
disease onset and 12 months influenced HAQ at 12 months.  Data from ERAN 
confirmed these findings.  In a study that analysed DAS28 and HAQ at 1,2 and 
3 years, Kiely and colleagues (2011) showed that patients with moderate or 
high DAS28 at 12 months were less likely to have a HAQ score of <1.25 at 2 
and 3 years than cases with a low DAS28 at 12 months.  Of those with high, 
moderate and low DAS28 at 12 months, 25%, 52% and 79% respectively 
achieved HAQ<1.25 at 2 years and 26%, 47% and 81% at 3 years, 
respectively.  A recent study from a Canadian observational cohort examined 
correlations between DAS28 and HAQ in early RA (<12 months symptom 
duration) from baseline to 2 years (Boyd et al., 2013).  Over the 2 years of 
follow up, Pearson correlation ranged from 0.3 to 0.59 and was strongest at 
baseline and in RF positive patients, where the correlation between mean 
DAS28 and mean HAQ was 0.63, compared to 0.47 in RF negative patients 
(significance of difference, p = 0.004).  The authors also reported that 
correlations were slightly weaker for those aged >65, although this difference 
was not statistically significant (overall correlation between DSA28 and HAQ 
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0.50 in those under 65, vs. 0.48 in those aged over 65, p=0.49).  The problem 
with using Pearson’s correlation coefficient to report the relationship between 
HAQ and DAS28 is that it measures the strength of a linear relationship 
between the two variables at a given point in time and does not indicate how 
change in one variable influences the other, and furthermore, it assumes that 
both are normally distributed interval data, which the HAQ is not (discussed 
in  1.8.3).  However, this analysis does provide evidence of a relationship 
between disease activity and disability and raises questions such as why there 
should be a stronger correlation between DAS28 and HAQ in RF positive 
patients.  This result could simply be due to type 1 error: the study included data 
from 1143 cases at baseline, but this number reduced with time and at 24 
months, data from only 214 cases were available.  Apparently this was not due 
to attrition, but because the study was ongoing at the time of publication of the 
article and therefore many patients had not completed 2 years’ follow up. 
1.9 Summary  
The present chapter has reviewed the history, epidemiology, clinical 
presentation, treatment, measurement of outcomes and prediction of disease 
activity and disability in RA.  Early, aggressive treatment of RA is essential to 
prevent irreversible structural damage and disability in the longer term.  
Therefore, early disease is an important focus for research.  The hypotheses 
under scrutiny in this Thesis relate to outcomes in early RA, specifically to 
disease activity and disability.  Much work has already been completed on 
factors influencing outcome in RA and so far there is evidence that disease 
activity and disability over time are less favourable for females than males and 
people from more socially deprived backgrounds.  An additional adverse effect 
has also been seen for smoking, which is possibly worse with increasing 
amount smoked, and furthermore, autoantibodies in RA seem to be associated 
with less chance of remission.  Other influences such as periodontal disease 
and alcohol consumption may also impact upon outcomes in RA, although 
further studies are necessary to clarify these effects.  Much of the research in 
this area has been ‘cross sectional’ in nature; that is, the primary outcome is 
often the absolute change in an outcome measure between two time points.  
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This approach, although a common technique reported in RA research, does 
not examine the fluctuation in outcome variable between time points examined.  
Outcomes in RA vary widely between individuals, which is perhaps another 
reason why relatively few predictors of RA outcome can be applied in clinical 
practice.  To date, there have been few studies describing how fluctuation in 
disease activity impacts upon function in RA over time, although some have 
reported on correlations between function and disease activity at distinct time 
points.  The relationship between DAS28 and HAQ-DI merits further 
exploration.  Current treatment strategies focus on minimising (or eliminating) 
disease activity in RA and whilst there is strong evidence for the importance of 
suppressing inflammation in RA, it is not clear whether this is enough to prevent 
disability.  Evidence reviewed in Section 1.8.5 indicates that “moderate DAS28 
is not benign” (Conaghan et al., 2010) and although biological therapies are 
reserved for cases with severe disease activity (DAS28 > 5.1) in the UK, a 
significant number of patients with ‘moderate’ disease activity suffer impaired 
functional outcome.  This raises the question of whether present NICE 
guidelines are adequate and indicates shortcomings specific to certain patients 
whose DAS28 scores persistently fall between 3.2 and 5.1.   
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1.10 Hypothesis 
The work within this Thesis addresses some of the gaps in present knowledge 
of outcome in early RA and in particular, the relationship between disease 
activity and disability.  It is anticipated that in early RA, treatment of disease 
activity will result in less disability.  A discrepancy in the relationship between 
these variables would indicate that influences other than RA disease activity 
contribute to disability in early disease.  In other words, whilst suppression of 
inflammation in early RA is clearly important, there may be other causes of 
disability, which may be amenable to intervention within the rheumatology clinic.   
Modern statistical techniques may be employed to explore change DAS28 and 
HAQ-DI and their relationship over time.  Current evidence suggests that 
change in function with time is non- linear and fluctuation in outcome between 
time points is expected.  Therefore, traditional, cross sectional statistical 
approaches like regression analysis may not accurately represent changes in 
the outcome under scrutiny.  Longitudinal analysis is expected to better 
describe changes in disease activity and function with time.   
Trajectories of change in HAQ have been described, whereby individual 
patients can be classified according to pattern of change in HAQ over time.  
Trajectories have also be described for disease activity (Siemons et al., 2013), 
with some patients falling into a poorer prognostic category of DAS28.  The 
trajectory of DAS28 is likely to influence the HAQ trajectory, with cases from the 
least favourable DAS28 categories also doing less well in terms of HAQ.  
Furthermore, cases with persistently moderate DAS28 are also expected to 
experience significant loss of function over time.  Thus, the hypotheses tested 
are: 
 Change in DAS28 and HAQ-DI over the first 24 months in early RA can be 
described by growth trajectories, with some patients falling into more 
favourable trajectory groups. 
 Those in less favourable trajectory groups of DAS28 and HAQ-DI are more 
likely to be female, have lower SES, antibodies to RF or ACPA, have a 
higher BMI, and be heavier smokers. 
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 Trajectory of change in DAS28 has a direct influence on change in HAQ-DI 
over the first 24 months of treatment in early RA, with HAQ-DI following a 
similar trend to DAS28.  
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Chapter 2 Patients and methods 
 
2.1 Introduction to Yorkshire Early Arthritis Register  
A register of patients with RA was established in Yorkshire in 1995, as part of 
Leeds Early Arthritis Project.  A register of this sort continues to the present 
day, although considerable changes were made as the project evolved with 
time, reflecting changes in both contemporary understanding of the disease 
process and treatment of RA.  The initial 330 cases recruited to the study 
between 1995 and 1997 were designated the ‘YEAR A cohort’.  Drawing on 
experiences gained through the collection of data for this initial, pilot cohort, 
YEAR B was established in 1997.  This register recruited patients from hospital-
based rheumatology centres (Figure 2-1) in Yorkshire from 1997 until 2002.  All 
patients aged 18 years or older, within 12 months of diagnosis of RA (based 
upon the judgement of the treating consultant) were asked to join the register 
and consent to data collection at baseline, 3, 6, 12, 18 and 24 months.  Further 
details of data collected are presented in Section 2.2.  Treatment was based 
upon, but not restricted to, a regionally agreed treatment protocol, for which the 
main DMARD was SSA (described in more detail in Section  2.3).  The study 
was approved by the Northern and Yorkshire Main Research Ethics Committee 
(Main Research Ethics Committee reference number: MREC99/3/48). 
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Figure 2-1  Locations of Yorkshire Early Arthritis Register centres 
Centres are denoted by this symbol:    .  .  Centres included:  Airedale hospital, Keighley; Barnsley hospital; Calderdale royal hospital, Halifax; Chapel 
Allerton hospital, Leeds (YEAR C only); Friarage hospital, Northallerton; Harrogate district hospital; Hull Royal infirmary; Huddersfield royal infirmary; 
Leeds general infirmary (YEAR B only); Pinderfields hospital, Wakefield; Seacroft hospital, Leeds (YEAR B only); St Luke’s hospital, Bradford; St 
James’s hospital, Leeds (YEAR B only); Wharfedale hospital, Otley, Leeds (YEAR B only); York hospital.  Image adapted from original with kind 
permission www.picturesofengland.com 
Northallerton 
Harrogate York 
Keighley 
Bradford Leeds (4 centres) 
Wakefield 
Hull 
Dewsbury 
Halifax 
Huddersfield 
Barnsley 
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YEAR C was established in 2002 and data collection continued until 2009.  
Due to re-location of the rheumatology department within Leeds Teaching 
Hospitals NHS trust, patients from Leeds were recruited from Chapel 
Allerton Hospital rather than Leeds General Infirmary, St James’s University 
Hospital, Seacroft and Wharfedale hospitals, as for YEAR B.  The main 
difference between YEAR B and C was that for the later cohort, the 
treatment protocol was based upon MTX (Section 2-3).  There were also 
differences in data collection, with an additional data collection time point at 
9 months, and changes to some questions.  For example, in YEAR B, data 
collectors were asked to record whether the patient was a smoker or a non-
smoker, but the question was interpreted differently by staff at different 
centres: some recorded the contemporary smoking habits of individual 
patients and others asked about previous smoking history.  Figure 2-2 
demonstrates how the percentage of patients classified as ‘smoker’ varied 
according to centre.  For example, at Harrogate where 84 cases were 
recruited and Seacroft where 13 cases were recruited, only 25% from each 
centre were included in the ‘smoker’ category, suggesting that ex-smokers 
from Harrogate and Seacroft were classified in the ‘non-smoker’ category.  
This compares to Wakefield (75 cases) and Bradford (24 cases), where 41% 
and 58% of cases were classified as smokers, respectively, suggesting that 
staff as these centres included ex-smokers in the ‘smoker’ category. 
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Figure 2-2 Bar chart to show how smoking and non-smoking was 
captured by individual Yorkshire Early Arthritis Register B centres.  
(Numbers in brackets after the centre names represent the total of cases 
recruited from that centre).  
For YEAR C, smoking history was recorded in more detail, including 
information about past history of smoking and whether patients considered 
themselves to be smokers at the time of data collection.  This change was 
implemented to avoid ambiguity and to allow information concerning 
cardiovascular risk factors to be captured in YEAR C.  The different YEAR 
cohorts are compared in Table 2-1.  YEAR C was closed in 2009 and 
replaced by the Inflammatory Arthritis CONtinuum (IACON) register, which is 
recruiting at the time of writing.  This register is based in Leeds and aims to 
capture patients with early inflammatory arthritis as close as possible to the 
time of presentation to the arthritis clinic.  Data collected from YEAR B and 
YEAR C were included in the present study and details of methods used in 
these 2 cohorts will be discussed in further detail.  
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Table 2-1 Differences between the Yorkshire Early Arthritis Register 
cohorts. 
 YEAR A YEAR B YEAR C 
Dates of data 
collection 
 
1995-1997 
 
1997-2002 
 
2002-2009 
 
Inclusion criteria 
 
Considered likely 
to have RA 
 
Consultant made 
diagnosis of RA 
 
Consultant made 
diagnosis of RA 
 
Initial treatment  
 
Not specified 
 
SSA 
 
MTX 
 
Follow up time  
 
12 months 
 
24 months 
 
24 months 
 
Number recruited 
 
330 
 
774 
 
807 
MTX, methotrexate; RA, rheumatoid arthritis; SSA, sulphasalazine; YEAR, 
Yorkshire Early Arthritis Register. 
2.2 Data Collection 
Informed consent was obtained from each patient at the baseline visit and 
data were collected by trained research nurses and rheumatology doctors.  
Details were written onto pre-printed clinical record forms, which were then 
transferred to a spread sheet by data entry clerks. Although there were no 
official strategies to promote attendance at each data collection visit, the 
databases were reviewed periodically, and if an appointment had been 
missed, the patient was contacted by telephone and asked to attend for the 
next visit.  At the baseline visit demographic details, indicators of lifestyle 
and past medical history were noted and at every visit details of patient 
reported outcomes and clinical examination findings were recorded.  Blood 
samples were taken at each visit, to check for markers of inflammation.  
Samples were also obtained to check for the presence of autoantibodies.   
Some of the data were applied in other projects; however, the remainder of 
this Section will discuss the collection of data that was subsequently 
analysed as part of the present study. 
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2.2.1 Baseline data: lifestyle and medical history 
Details of past medical history were collected for both YEAR B and C 
cohorts as described in Table 2-2.  Smoking data were collected and for 
YEAR C, alcohol consumption, height and weight were also recorded.  The 
patient was asked to recall the month and year of onset of symptoms of 
arthritis.  Further details of the data collected at the baseline visit of each 
cohort are provided in Table 2-2, which also highlights the differences in 
baseline data collection between the two cohorts. 
 
2.2.2 Patient reported outcome measures 
At every visit, patients were asked how long their joints were stiff for in the 
morning (EMS), and if greater than 15 minutes, this duration in minutes was 
recorded.  VAS were used to quantify disease activity, pain and fatigue.  For 
fatigue, YEAR B cases were asked whether they experienced “abnormal 
fatigue” (further clarification of this question was left to the discretion of the 
data collector) and in YEAR C, this question was worded thus: “do you feel 
unusually tired?”.  Positive responses to these questions prompted 
completion of the VAS, whereas negative responses were translated as a 
score of 0 on the VAS.  In YEAR B, all cases were asked to complete the 
VAS for pain, but in YEAR C, only cases who responded positively to the 
question: “Do you have pain associated with your rheumatoid arthritis?” were 
asked to complete the pain VAS.  Each VAS was represented by a printed 
horizontal line, 10 cm in length, where 0 cm represented no disease activity, 
pain, or fatigue, and 10 cm represented pain or fatigue (tiredness was the 
word used in YEAR C) “as bad as it could be”, or extremely active disease.  
Participants were asked to indicate how active they felt their disease was, or 
how much pain or fatigue they had experienced, over the last 7 days, by 
placing a mark on the line.  At most YEAR visits (listed in Table 2-3), 
participants were asked to complete a HAQ, which is shown in Appendix 1.   
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Table 2-2 Data collected at baseline in the Yorkshire Early Arthritis 
Register B and C cohorts 
 
Variable type 
Details of data collection at baseline 
YEAR B YEAR C 
Demographic details Gender defined by patient 
Date of birth 
Address including post 
code 
Ethnic origin defined by 
patient:  
White, Afro-Caribbean or 
Asian 
Gender defined by patient 
Date of birth 
Address including post code 
Ethnicity defined by patient: 
White, Black, Asian, Asian-
eastern, or mixed ethnicity; 
each category was further 
defined. 
Smoking  Smoker / Non-smoker Non-smoker/ Ex-smoker / 
Smoker 
If ever smoked, how long for 
and how many cigarettes per 
day. 
Co-existent medical 
problems:  Patients 
were asked whether 
they had any of these 
conditions (Yes/No). 
Any prompting 
questions or 
explanations were at 
the discretion of the 
data collector. 
 
Hypertension (Including 
patients on 
antihypertensive 
medication), 
Ischaemic heart disease, 
Diabetes (Not further 
defined),  
Chronic airways disease 
requiring medication,  
Renal disease,  
Cerebrovascular disease,  
Peripheral vascular 
disease,  
Chronic liver disease,  
Other (to specify). 
Alongside each condition, 
there was space to record 
comments. 
Hypertension, (Including 
patients on antihypertensive 
medication),  
Ischaemic heart disease,  
Diabetes (Further defined as 
IDDM/ NIDDM),  
Chronic airways disease 
requiring medication,  
Renal disease,  
Cerebrovascular disease,  
Peripheral vascular disease,  
Chronic liver disease.  
 
 
Cardiovascular risk 
factors: 
Any prompting 
questions or 
explanations were at 
the discretion of the 
data collector. 
 
Not specifically collected  
In addition to above, patients 
were asked whether they had: 
hyperlipidaemia (don’t 
know/yes/no)- if prescribed 
lipid lowering medication, a 
‘yes’ was recorded; a family 
history of ischaemic heart 
disease (don’t know /yes/no). 
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Table 2-2 continued 
 
Variable type 
Details of data collection at baseline 
YEAR B YEAR C 
Height (cm) and weight 
(Kg) 
Not collected Recorded 
Alcohol consumption Not collected Quantified* according to 
gender :  
Less than 2-3 units per day for 
women, or 
more than 2-3 units per day 
for women.  
Less than 3-4 units per day for 
men, or 
more than 3-4 units per day 
for men. 
Or: 
Weekends only (both men and 
women): if so,  
Less than 8 units per day, or 
More than 8 units per day. 
Family history Not collected RA: yes /no/ unknown. 
If yes: child, sibling, parent, 
grandparent, great 
grandparent, other (described)  
Other autoimmune conditions 
(e.g. MS, CTD, Diabetes): yes/ 
no/ unknown. 
Vascular disease (including 
IHD peripheral vascular 
disease, stroke): yes/ no/ 
unknown. 
*A guide to the number of units of alcohol within defined measures of beer, cider, wine, 
champagne, port, sherry, liqueur and spirits was included within the appendix of the 
clinical record form.  
cm, centimetres; CTD, connective tissue disease; IDDM, Insulin Dependent Diabetes 
Mellitus; IHD, ischaemic heart disease; Kg, Kilograms; MS, multiple sclerosis; NIDDM, 
Non Insulin Dependent Diabetes Mellitus (No further questions were asked to 
determine whether the patient had type one or type 2 diabetes mellitus); RA, 
rheumatoid arthritis; YEAR, Yorkshire Early Arthritis Register. 
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Table 2-3 Clinical data, patient reported outcomes and laboratory 
measures acquired at Yorkshire Early Arthritis Register visits 
 
Data captured 
Baseline 3 
months 
6 
months 
9 
months
†
 
12 
months 
18 
months 
24 
months 
B C B C B C B C B C B C B C 
Joint counts       X        
Patient 
VAS: 
Pain 
Disease 
Activity 
Fatigue 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
X 
X 
X 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Early morning 
stiffness  
(duration in 
minutes) 
      X        
HAQ   X    X        
DMARD prescribed 
this visit 
      X    X    
DMARD prescribed 
previously 
 X X  X  X    X    
DMARD side 
effects 
X X X  X  X    X    
NHS 
Blood 
tests 
RF 
CRP 
ESR 
 
 
 
 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
 
 
 
 
Serum stored   X X X X X X   X X   
† There was no YEAR B visit at 9 months.  
CRP, C-reactive protein; DMARD, disease modifying anti rheumatic drug; ESR, erythrocyte 
sedimentation rate; HAQ, health assessment questionnaire; NHS, National Health Service; 
RF, rheumatoid factor; VAS, visual analogue score. 
 
2.2.3 Clinical data collection 
At the baseline visit, participants were asked to recall the date of onset of RA 
symptoms.  At every visit, the study doctor or nurse recorded the swollen and 
tender joints diagrammatically.  A table was used for this purpose throughout 
YEAR B, whereas for YEAR C, these details were recorded with the aid of a 
homunculus diagram (see Appendices 2 and 3).  Details of all medications 
taken by the subject were noted on the clinical record form at baseline, 6 and 12 
months for YEAR B.  For each visit, there was a prompt in the YEAR C clinical 
record form to remind the study nurse to complete an appendix detailing any 
concomitant medication, doses and subsequent changes.  The recommended 
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treatment regimes were different between the 2 cohorts and are detailed in 
Section 2.3.  Whilst the YEAR B clinical record form simply asked for details of 
reasons behind deviation from this protocol, the medications section of the 
YEAR C clinical record form (shown in Appendix 4) was more detailed and 
asked which DMARDs were taken, their doses, and for how long they were 
taken, together with details of any DMARD side effects experienced by the 
patient. 
2.2.4 Laboratory measures 
2.2.4.1 Antibodies and inflammatory markers 
On the same day as the patient interview and clinical assessment, blood 
samples were acquired and analysed within the standard National Health 
Service (NHS) laboratories of the participating hospitals.  These investigations 
included CRP and ESR, which were later used to calculate DAS28, and IgM 
RF, measured using standard nephelometric assays.   
Samples of serum for storage (minus 20 degrees centigrade, oC) were also 
acquired at the baseline, 12 and 24 month YEAR visits.  These samples were 
later defrosted and used for ACPA determination, which was not available as a 
routine NHS test at the time of data collection.  This analysis was performed by 
a member of the YEAR Consortium and has been described previously (Morgan 
et al., 2009).  
2.2.4.2 Human Leucocyte Antigen-DRB1 genotyping 
Stored samples of ethylenediaminetetraacetic acid (EDTA) anti-coagulated 
blood were used to extract deoxyribonucleic acid (DNA) and a semi-automated 
polymerase chain reaction (PCR) technique was employed to determine the 
number of copies of the shared epitope and HLA–DRB1 subtype, as previously 
described (Morgan et al., 2009).  
2.2.4.3 Absence of stored samples 
In cases where no stored blood samples were available, patients were 
contacted by post and asked to attend a local phlebotomist to have a blood 
sample taken, which was then returned by post to the research laboratory at 
Chapel Allerton Hospital.  These samples were then processed, as described 
above, to determine HLA-DRB1 genotype and ACPA status. 
  
91 
 
2.2.5 Cases excluded from Yorkshire Early Arthritis Register C 
At the time of recruitment to YEAR C, there were three randomised control trials 
also recruiting Leeds patients with RA who had not taken DMARDs before.  The 
initial intention was to consent suitable patients for inclusion within YEAR as 
well as the trials and include patient data collected via the randomised trials in 
the YEAR C database.  However, because YEAR was set up to observe the 
course of early RA in a realistic clinic setting, this decision was later revised and 
cases eligible for trials were not included in the YEAR database.  As these 
selected cases were excluded, there is a potential impact on the findings of the 
study: YEAR C did not represent all cases of incident RA in Yorkshire at the 
time of data collection.  The three studies recruiting at the time of YEAR C data 
collection were:  
 PRevention Of Work Disability (PROWD).  This study recruited 145 
Yorkshire patients between 2003 and 2004.  One inclusion criteria for the 
study was that patients had a ‘self-reported work impairment due to RA’ 
(Bejarano et al., 2008). 
 Infliximab as inDuction therapy in Early Arthritis (IDEA).  This study recruited 
112 patients with ‘active’ RA (defined as disease activity score based upon 
44 joints of at least 2.4) from Leeds, Harrogate, Huddersfield and Bradford 
between 2006 and 2009 (Nam et al., 2014a).  
 Etanercept and Methotrexate in Patients to Induce Remission in Early 
inflammatory arthritis (EMPIRE).  This study recruited 110 cases from 
Leeds, Huddersfield, Harrogate and York between 2006 and 2009 (Nam et 
al., 2014b). 
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2.3 Treatment protocols 
Consultant rheumatologists from the rheumatology centres agreed upon a ‘step-
up’ treatment approach using DMARDs SSA, MTX and HCQ which was in 
keeping with contemporary best practice.  For YEAR B, the initial drug of choice 
was SSA, whilst for YEAR C, this was changed to MTX.  One other key 
difference between the treatment protocols of 2 cohorts was the administration 
of intramuscular steroid in the form of 120 mg of methylprednisolone at the 
baseline visit in YEAR C.  The treatment protocols, which are shown in Figure 
2-3, were intended for guidance only and deviations to meet the needs of 
individual patients were expected.  Such changes could be documented in the 
clinical record forms; no limitations were placed on concomitant treatment with 
other medication such as anti-inflammatory drugs or oral or parenteral 
corticosteroids.  Whilst YEAR data collection was on-going, the treatment of RA 
was evolving, owing to the introduction of biological therapies such as TNF 
inhibitors.  If cases met criteria for this treatment, it was initiated in line with UK 
guidelines.  
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YEAR B treatment protocol  YEAR C treatment protocol 
SSA 2g od    
 
    MEP 120mg im 
MTX 7.5 to 15mg 
SSA 3g od    
 
     MTX 20mg 
pw (oral) 
SSA 3g od 
MTX 10mg 
pw (oral) 
    
 
      
Add SSA  
2g od 
Add HCQ 
200mg od 
No visit  
scheduled 
 
 
      im MTX 
No guidance in 
protocol 
 
 
   Consider                                          
Leflunomide 
Figure 2-3 Yorkshire Early Arthritis Register treatment protocols 
ACR, American College of Rheumatology; g, grams; HCQ, Hydroxychloroquine;  
i.m., intramuscular;  MEP, methylprednisolone; mg, milligrams; MTX, Methotrexate;  
od, once daily; pw, per week; SSA, Sulphasalazine; YEAR, Yorkshire Early Arthritis 
Register. 
 
2.4 Data Validation 
Following the collection and entry of data onto a database, the information was 
reviewed to determine: 
 How much of the original data were missing 
 Whether it was possible to recover any of the missing values retrospectively, 
using hospital notes or computer systems.  
 The error rate associated with transcribing information from clinical record 
forms to the database for YEAR C. 
Validation of the YEAR B data was undertaken by the YEAR data entry team 
towards the end of the data collection period in 2001 and 2002.  On each 
occasion, a random sample of 10% of cases was selected and the data 
recorded electronically were compared to data captured on the clinical record 
forms.  Unfortunately, no formal record of the validation process of YEAR B 
3 months 
 
6 months 
 
If no ACR  
remission 
If no ACR  
remission 
If no ACR  
50% 
response 
If no ACR  
remission 
Baseline 
 
9 months 
 
If no ACR  
remission 
12 months 
 
If no ACR  
remission 
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data was made and the error rate associated with transcribing data from the 
clinical record forms to the electronic database was not calculated.  For 
validation of the data in the YEAR C database, which was undertaken in 2010 
by Dr Hensor, the method of data entry verification described by Mullooly (1990)  
was applied.  A random sample of 10% of patients who had attended at least 6 
YEAR visits was selected for comparison of the written and electronic records.  
As an error rate of 0.71% was discovered, a random sample of 200 of the 
remaining clinical record forms were selected for further verification of the 
corresponding electronic records.  This number was slightly greater than the 
25% of records suggested by Mullooly.   
When data in either cohort were missing, the recruiting centres were contacted 
and efforts were made to recover missing values through inspection of hospital 
notes, or in the case of blood test results, hospital results servers.  If this data 
could not be captured, the reason for this was noted.  For YEAR B, I undertook 
a second-wave validation in 2010 to specifically address inaccuracies in 
recorded age, symptom duration and clinical data.  This involved checking data 
entered onto the database against clinical record forms where entries were 
ambiguous or missing.  If the clinical record form did not contain the desired 
information, hospital records or electronic records (for blood test results) were 
inspected, where available.  For the analyses presented in this Thesis, where 
the focus is on early RA, it was especially important to check that symptom 
duration was accurately recorded.  In some cases, it appeared that the 
symptom duration was far longer than the study protocol had indicated for 
inclusion in the cohort (12 months or less).  In other cases, recorded symptom 
durations were improbable: the date of onset of symptoms appeared to be after 
the date of the baseline visit.  Wherever medical records were available, these 
inaccuracies were checked.  Patient age was usually accurate, however in 
some cases the year of birth was entered inaccurately.  This problem was 
overcome by using hospital records to check actual date of birth. 
2.5 Statistical analysis 
The hypotheses tested in this Thesis concerned early RA, so patients with 
symptoms for over 24 months were excluded from the analyses.  The pragmatic 
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decision to use 24 months as a cut-off meant that whilst a large number of 
cases were retained for analysis, the focus of the study was early RA.  Similarly, 
cases were also excluded if symptom duration was missing.  In cases of 
missing or long symptom duration, efforts were made to capture this data or 
confirm that the recorded symptom duration was accurate (as described in 2.4).  
In total, 98 cases were excluded due to missing symptom duration and 51 were 
excluded due to excessive symptom duration (detailed in Chapter 3, Paragraph 
3.4 and Figure 3-1).  Although patients recruited to the cohort were from a 
diverse population and included individuals from different ethnic backgrounds, 
the majority considered themselves to be ‘white Caucasian’ and numbers of 
individuals from other ethnicities were small (detailed in Chapter 3, Table 3-1). 
All subjects were included in the analyses within this Thesis, regardless of 
ethnicity, in order to maximise the number of cases included. 
2.5.1 Outcome variables 
As mentioned above, the YEAR cohort was established in order to answer the 
question:  “Do conventional prognostic factors predict the clinical outcome as 
measured by the response criteria of early RA patients treated in a standardised 
‘step-up’ fashion?”  Therefore outcome and predictor variables were selected 
for inclusion in statistical analyses if they were considered pertinent to 
answering this question.  Clinical outcome can be measured using a variety of 
methods (Chapter 1, Section 1.8), some of which were included in the YEAR 
clinical record forms.  In the UK, DAS28 is currently used to guide treatment 
with biologic therapy such as TNF inhibitors, as outlined in Chapter 1, Section 
1.6 and Figure 1-2.  Capture of DAS28 was a target for data collection in the 
YEAR cohort and has been used as the primary outcome measure in the 
statistical analyses.  To minimise the impact of missing variables disease 
activity VAS and ESR, the 3 variable DAS28, using CRP was calculated for the 
analyses in this Thesis (described in Section 1.8.1 and Table 1-5).   
Disability was also selected for analysis and was captured using HAQ-DI 
(Chapter 1, 1.8.3).  The questionnaire completed by YEAR participants is 
shown in Appendix 1.  As HAQ-DI represents an ordinal scale, Rasch analysis 
was applied (as discussed by Tennant and Conaghan, 2007), so that the 
transformed HAQ-DI could be analysed as an interval variable.  This 
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transformation was performed by the data analyst from the YEAR Consortium, 
Dr Elizabeth Hensor, and is described in detail in Appendix 5.  Where HAQ-DI 
was only partially completed by the patient (item non response), the whole 
score was treated as missing (handling of missing values is described in ‎2.5.5). 
Predictors of DAS28 and HAQ-DI at 6 and 12 months were analysed.  These 2 
time points were selected because they were both within the ‘window of 
opportunity’ for RA treatment (described in Section 1.6) and furthermore, 
disease activity at these time points have been demonstrated to predict future 
joint damage (Combe et al., 2014).  Therefore, predictors of outcome at 6 and 
12 months are of interest as they may be useful to inform management 
decisions in RA.  
2.5.2 Predictor variables  
Predictor variables are summarised in Table 2-4.  Known predictors of outcome 
in RA were selected for inclusion in the statistical models, based upon the 
evidence presented in Chapter 1, 1.8.2 and 1.8.4, and dependent upon baseline 
data collected.  In addition, patient reported outcomes at baseline were included 
in the cross-sectional analyses of change in DAS28 and HAQ-DI at 6 and 12 
months to investigate their suitability as predictors of outcome.  These included 
duration of EMS (measured in minutes), VAS pain and VAS fatigue (both VAS 
were measured in cm).  As duration of EMS was not a continuous variable 
(patients tended to report EMS in terms of 10, or 30 minute intervals), it was 
collapsed into categories, using the ‘Xtile’ Stata command. Four categories 
were selected so that each represented a suitable proportion of cases (an 
unusually small category could result in skewing of the results when entered 
into the regression model).  The categories were 0-35 minutes, 40-75 minutes, 
90-210 minutes and 220 minutes or more.  The postal codes of participants’ 
home addresses, supplied at the baseline visit, were used to derive their 
corresponding index of multiple deprivation (IMD), an indicator of area-level 
SES.  The IMD was developed to enable the targeting of resources towards 
deprived areas, but has been adopted for use in research.  Geographically 
determined areas, called lower layer super output areas (LSOA), are allocated 
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IMD scores based upon information from seven different domains, which 
contribute to the final score as follows: 
 Income     22.5% 
 Employment     22.5% 
 Health and disability   13.5% 
 Education, training and skills  13.5% 
 Barriers to housing and services 9.3% 
 Living environment   9.3% 
 Crime     9.3% 
In England there are 32,482 LSOAs, which are ranked according to IMD, where 
rank 1 is most deprived and rank 32,482 is least deprived.  For the present 
study, the English index of deprivation (Department For Communities and Local 
Government, 2004) was utilised.  This version of the IMD used data collected 
during 2001, and included data from the national census.  For the present 
study, the IMD rank was divided into quartiles for application in regression 
analyses.  
It was not possible to apply the smoking variable to all analyses as patients 
included in YEAR B were not explicitly asked about a past history of smoking 
(explained in Section 2.1).  Similarly, data on BMI were not collected at all for 
YEAR B and furthermore, data on comorbidities were incomplete in many more 
cases from YEAR B than YEAR C (detailed in Chapter 3, Section 3.4).  
Therefore, a YEAR C sub analysis was carried out that included these variables 
as predictors of outcome, which is described in 2.5.4.3.1.  Smoking was added 
to regression models as a continuous variable, which was an estimate of the 
quantity of cigarettes smoked by the participant, measured as pack years, 
where one pack year is the equivalent of having smoked 20 cigarettes every 
day for one year.  As data on comorbidities was limited to the presence or 
absence of the ailments listed in Table 2-2, and severity of these conditions 
were not considered, the ‘comorbidity’ variable was simplified and included as a 
binary variable (comorbidities present / absent) in the regression models.  
 
  
98 
 
Table 2-4 Predictor variables included in statistical models 
Type of variable known 
to influence outcome in 
RA  
Predictor variables 
included in statistical 
models 
Type of variable  
Genetic HLA-DRB1 “shared 
epitope” 
Dichotomous 
(present / absent) 
   
Environmental Smoking  Continuous 
(pack years) 
   
Biological Age Interval  (years) 
Gender Dichotomous (male / 
female) 
Antibody 
 
RF (IgM) Dichotomous 
(Present / absent) 
Antibody ACPA Dichotomous 
(present / absent) 
   
Patient reported EMS 
Fatigue VAS 
Pain VAS 
Categorical  
Interval (cm) 
Interval (cm) 
 
Social  Socioeconomic status, 
measured by index of 
multiple deprivation 
Categorical 
(quartiles) 
Multifactorial Body mass index Continuous 
 Comorbidities Dichotomous  
(present / absent) 
ACPA, anti-citrullinated peptide antibodies, cyclic citrullinated peptide; cm, centimetres; 
EMS early morning stiffness; IgM, Immunoglobulin M; HLA-DRB1, human leucocyte 
antigen DRB1; RA, rheumatoid arthritis; RF, rheumatoid factor; VAS, visual analogue 
score. 
 
2.5.3  Summary statistics and missing values 
The data were summarised using means and standard deviations for normally 
distributed variables and percentages for dichotomous or categorical data.  The 
software used was IBM SPSS statistics version 20.0.0.1, (SPSS Inc. Chicago, 
Illinois, 2011).  Differences between the 2 cohorts were anticipated, as 
advances in contemporary treatment strategies were expected to have 
improved outcome with time, and therefore, the summary statistics were 
compared across YEAR B and YEAR C.  Although data from YEAR B and C 
were analysed together, differences between the cohorts were accounted for in 
the analysis, as described in section 2.5.4.1.  The quantity of missing data was 
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summarised as percentage of values missing overall and then percentage of 
values missing per variable.  The number and percentage of patients who 
dropped out of the study were also reported, together with reasons for dropping 
out.  Handling of missing values for the analysis of these data is discussed in 
2.5.5  
2.5.4 Statistical models 
2.5.4.1 Cross sectional analysis: linear regression 
Change in DAS28 and HAQ-DI were determined by subtracting these values at 
baseline from those at 6 and 12 months.  Predictor variables were all added to 
the model simultaneously and included: age, gender, symptom duration, RF, 
duration of EMS, pain VAS, fatigue VAS, baseline DAS28, and for the analyses 
of change in HAQ-DI, baseline HAQ-DI was also included.  Due to differences 
between cohorts, YEAR cohort (B or C) was also included as a covariate in the 
regression models and furthermore, in order determine whether the effects of 
the covariates in the models were different between the cohorts, interaction 
terms between cohort and each covariate were also included.  The interaction 
terms were sequentially discarded if not statistically significant (the least 
significant terms were removed first, using a statistical significance, p ≤0.100), 
until only significant interactions remained in the model.  For EMS duration, 
which represented more than one category, a Wald test was used to determine 
whether the group effect of EMS category differed according to YEAR cohort 
and the interaction terms between cohort and EMS categories were discarded if 
p>0.100.  Missing data within the outcome and predictor variables were handled 
using multiple imputation, which is described in detail in 2.5.5.  Analysis of the 
data with complete cases was also reported, for comparison.  
Several measures were taken to confirm that the assumptions of linear 
regression were not violated.  Correlations between the variables were checked 
and correlation of >0.7 was considered too high for the assumption of 
multicollinearity.  Histograms of the residual values, (where residuals were 
calculated by subtracting the value of the dependent variable predicted by the 
model from the actual value of the dependent variable) were used to judge 
adherence to the assumption of multivariate normality.  For good model fit, 
residuals should be normally distributed with equal variance (homoscedasticity).  
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The latter was judged by examining plots of the residual versus fitted values, 
whereby no discernible pattern indicated homoscedasticity.  The presence of 
outliers was detected by obtaining the standardised residual values, which were 
calculated by dividing the value of each residual by its standard error (SE)  
Observations with standardised residual values less than -3.3 or greater than 
3.3 were considered to be outliers, as suggested by Pallant (2010). 
Where available, R square values were determined in order to judge how much 
of the variance of the outcome parameter was explained by the models.  
Regression coefficients were recorded, along with SE and statistical 
significance, p, where p<0.05 was considered to be statistically significant.  This 
analysis was performed using Stata, version 11.1, (Stata Corporation, College 
Station, Texas, USA 2009). 
2.5.4.2 Longitudinal analysis: latent growth curve analysis 
In structural equation modelling, path analysis and regression modelling are 
combined to test hypotheses relating to the ‘causal’ relationships between 
variables (Byrne, 2010).  From this statistical technique latent growth analysis 
was developed, which facilitates analysis of change in a variable over time.  
Time is included in the model as a latent variable (a latent variable is one that is 
not directly measured) and the effect of time on the outcome variable is 
estimated.  In its simplest, linear, form the latent growth curve describes the 
trajectory of a variable, y in terms of its intercept (value at baseline) and slope 
(rate of change).  Thus: 
𝑦 = 𝑎 + 𝑏𝑥 
Where 𝑎 is the value of the dependent variable, 𝑦 at baseline (that is, when 
time, 𝑥 =0) and 𝑏 is the change in 𝑦 per unit of time (𝑥).  In this example, a 
negative value of 𝑏 indicates that 𝑦 decreases with time, whilst a positive value 
indicates an increase.   
The complexity of the model can be increased if necessary to include 
polynomial functions which describe non-linear change in a variable.  For 
example, a quadratic growth curve is described as: 
𝑦 = 𝑎 + 𝑏𝑥 + 𝑐𝑥2  
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Here, the value of c indicates how the rate of change, b, alters with time.  A 
negative value of 𝑐 suggests that the rate of change of 𝑦 slows with time, 
whereas a positive value indicates that the rate increases with time.  Addition of 
further polynomial growth factors is possible, (𝑥3, 𝑥4, 𝑥5given an adequate 
number recorded values of variable 𝑦, but interpretation of the resulting model 
becomes complex.   
Another type of longitudinal analysis is multilevel modelling (MLM).  MLM is 
similar in many respects to the latent growth curve method and analysis of the 
same data in a multilevel regression model would yield similar estimates.  
Differences between multilevel models and latent growth curve models exist 
due to historical differences in the application of both techniques and the 
capabilities of each method within statistical packages.  However, such 
differences and the distinction between the 2 methods are becoming less 
apparent with time (Hox and Stoel, 2005, Preacher et al., 2008). 
For the present study, three separate latent growth curve models were 
considered: 
 A latent growth curve model of change in DAS28 over 24 months. 
 A latent growth curve model of change in HAQ-DI over 24 months.  
 A parallel process latent growth curve model to observe how HAQ-DI 
varies with DAS28 over 24 months. 
Linear models were tested initially and then, in order to improve model fit, 
quadratic and then ‘freed loading’ models were tested.  In the freed loading 
model, two of the factor loadings relating to linear slope were constrained and 
the remainder were freely estimated by the model.  The effect of time on the 
outcome was fixed at zero for baseline measurement (0% of the change has 
occurred) and 1 for the outcome at 24 months (100% of the change has 
occurred).  The other factor loadings were estimated by the model and 
represented a proportion of the total change; for example, a factor loading of 0.5 
at 12 months would imply that half of the total change has occurred at this point.  
The final models were selected based upon indices of model fit (described in 
Section 2.5.4.2.1), whether the model was in keeping with expectations from 
published evidence, and with preference for a parsimonious model.  The results 
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of the analyses were reported in terms of the intercepts, which represented the 
mean baseline DAS28 and HAQ-DI for the population, and the linear and 
quadratic slope parameters, which represented the changes in the outcome 
variable with time.  The resulting model-implied growth curves were then plotted 
and compared to the observed mean values from the sample population.  The 
variances of the latent variables were also noted, together with the indices of 
model fit.   
Next, latent growth curves of DAS28 and HAQ-DI were applied to the data 
simultaneously and co-variances between the latent time variables (intercepts 
and slopes) were estimated.  Thus, it was possible to determine how change in 
DAS28 affected change in HAQ-DI.  The three linear models are shown in 
Figures 2-4 to 2-6. 
The latent growth analysis was carried out using Mplus version 6.1 [Muthén, L. 
K., & Muthén, B. O. (1998-2011). Mplus User's Guide. Sixth Edition. Los 
Angeles, CA: Muthén & Muthén.]  
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Figure 2-4 Latent growth curve model of change in Disease Activity Score 
from 28 joints (DAS28) over 24 months 
See next paragraph for explanation of the model 
DAS28, disease activity score from 28 joints; E1 to E5, error terms; IMean, mean 
intercept; IVariance, variance of intercept; SMean, slope mean; SVariance, slope 
variance. 
 
Figure 2-4 is a path diagram representing the latent growth curve analysis of 
change in DAS28.  Variables in rectangles are directly measured, whereas 
those in circles are latent variables (not directly observed).  The influence of 
time on DAS28 is represented by the intercept (value of DAS28 at baseline) and 
linear slope (linear change in DAS28 per unit time).  E1 to E5 represent the 
measurement error associated with DAS28 from baseline to 24 months, 
respectively.  Parameters estimated by the model include the means and 
variances of the latent variables, plus the covariance of these.  The numbers 
above the arrows from linear slope to DAS28 represent units of time elapsed 
since baseline: that is, 0, 0.5, 1, 1.5, 2 for baseline, 6 months, 12 months, 18 
months, 24 months, respectively.  The numbers above the arrows from the 
intercept to DAS28 are all set at 1. 
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Figure 2-5 Latent growth curve of change in Disability Index of the Health 
Assessment Questionnaire (HAQ-DI) over 24 months  
E1 to E5, error terms; HAQ-DI, disability index component of the health 
assessment questionnaire; IMean, mean intercept; IVariance, variance of intercept; 
SMean, slope mean; SVariance, slope variance. 
 
Figure 2-5 is a path diagram of the latent growth curve analysis of change in 
HAQ-DI over 24 months and is similar to that of change in DAS28 shown in 
Figure 2-4.  An amalgamation of these 2 models, illustrated in Figure 2-6, 
determined the effect of change in disease activity on change in disability. 
The co-variances between intercepts and slopes, as shown in the above 
diagram, reflect how change in one variable is affected by the other. 
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Figure 2-6 Parallel process growth model of change in Disease Activity Score from 28 joints (DAS28) and Disability Index of the 
Health Assessment Questionnaire (HAQ-DI) over 24 months 
DAS28, disease activity score from 28 joints; E1 to E5, error terms; HAQ-DI, disability index component of the health assessment 
questionnaire; IMean, mean intercept; IVariance, variance of intercept; SMean, slope mean; SVariance, slope variance 
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2.5.4.2.1 Measures of model fit. 
The fit of a structural equation model to the data to which it is applied can be 
judged using indices of fit, although there is much debate surrounding which 
are the best to use and how they should be interpreted.  The chi square (2) 
statistic is a well-established measure, calculated from the formula: (𝑁 −
1)𝐹𝑀𝐿, where N is the sample size and FML is the minimum fit function under 
maximum likelihood estimation.  If the sample size is large, it follows a central 
chi-square distribution with a number of degrees of freedom equal to that of 
the model under evaluation.  A small value of 2 indicates superior fit of the 
model.  From the central chi-square distribution, the 2 statistic, together with 
the number of degrees of freedom (df) of the model, can be used to obtain the 
probability, p, that the specified model is appropriate and could be applied to 
another sample of the same population and achieve a 2 statistic that is the 
same, or greater.  Thus, a higher value of p indicates superior model fit 
(Byrne, 2010).  A significance level of p>0.05 is often chosen.  Although the 2  
value is frequently used to assess model fit, there are some difficulties 
associated with its use, as discussed by Kline (2011): the value of  2  can be 
elevated by sample size and therefore, for very large samples (Kline suggests 
N≈5000), a significant p value can be obtained, despite good fit.  Further 
problems discussed by Kline include inflated or reduced values of this statistic 
when the assumption of multivariate normality is not met and higher values if 
correlations between variables are high.  Furthermore, if a study is under 
powered, the risk of accepting a poorly fitting model is high. 
In contrast to the chi square statistic, which compares the covariance matrix 
implied by the model to that of the sample population and identifies 
discrepancies in excess of what would be expected by chance, or due to 
sampling error, the root mean square error of association (RMSEA) does not 
distinguish between model fit and discrepancy due to sampling error and is 
considered to be an approximate fit index.  The RMSEA is derived from the 
formula: 
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𝑅𝑀𝑆𝐸𝐴 =  √

𝑀
2 − 𝑑𝑓𝑀
𝑑𝑓𝑀(𝑁 − 1)
 
Where 
𝑀
2 is the chi-square value for the model; dfM is the number of degrees 
of freedom of the model and N is the sample size.  Values of RMSEA that are 
closer to 0 indicate superior fit.  Byrne (2010) has summarised popular 
interpretation of the RMSEA value as follows: <0.05 indicates good model fit; 
0.05 to 0.08 is ‘reasonable’; 0.08 to 0.1 ‘mediocre’ and >0.1 is poor.  However, 
cautious interpretation of all fit indices is advocated, as it may not be 
appropriate to apply rules such as these to all models or all studies (Kline, 
2011).  RMSEA and other indices of fit should be interpreted alongside 
measures of overall model fit and consideration of whether the results of the 
model are in keeping with researcher’s expectations and contemporary 
evidence. 
The comparative fit index (CFI) is a measure of how well a model performs, 
relative to a baseline (or independence) model, in which covariances between 
variables from the sample population are assumed to be zero.  It is derived 
from the formula:  
𝐶𝐹𝐼 =

𝑀
2 − 𝑑𝑓𝑀

𝐵
2 − 𝑑𝑓𝐵
 
Where 
𝑀
2  is the chi-square value for the model under scrutiny; dfM is the 
number of degrees of freedom of this model; 
𝐵
2  is the chi-square value for the 
baseline model; and dfB is the respective number of degrees of freedom.  The 
three measures discussed here (chi square, RMSEA and CFI) were chosen to 
describe model fit of the latent growth curve analyses of DAS28 and HAQ-DI.  
In addition, the standardised residuals covariances, which are a measure of 
the residual difference between the model implied covariances and those 
derived from the sample population, were also reported. The assumption of 
multivariate normality was checked for the models.  
2.5.4.3 Latent class growth analysis.  
Latent growth curve models describe change in outcome over time, but the 
sample population is treated as one large group and the results represent 
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mean change for the whole cohort.  Clinical experience demonstrates that 
inter-individual variation in RA outcome is likely to be significant.  For example, 
some patients may have more aggressive forms of RA and experience greater 
disease activity than others.  Similarly, patients respond differently to 
treatment with the same medication.  Latent class growth analysis (LCGA) can 
be applied to test the hypothesis that there are distinct groups of cases within 
a population, whereby each group follows a defined growth curve, or 
trajectory. LCGA is a specific form of growth mixture modelling (GMM), in 
which groups of patients following a specific trajectory are identified, but the 
variation within groups is assumed to be zero. That is, the values of the mean 
intercept, linear and quadratic slopes are estimated for each group, but the 
variances of these parameters are constrained to zero (Dalhy, 2012).  There is 
some debate surrounding the most suitable indicator of the optimal number of 
growth trajectories, but the  Bayesian Information Criterion (BIC) is popular as 
it has been shown to perform well  (Jung and Wickrama, 2008).  Furthermore, 
the number of trajectories should be chosen with consideration of additional 
factors, including parsimony and interpretability of the model.   
The present analyses were performed to test the hypotheses that there are 
distinct groups of patients with early RA, with each group following a defined 
growth curve, or trajectory for DAS28 and HAQ-DI.  The values of Akaike 
information criterion (AIC) and BIC were compared for models with successive 
numbers of trajectories and smaller values of BIC and AIC indicated improved 
fit.  In addition entropy, Lo, Mendell and Rubin likelihood ratio test (LMR-LRT) 
and the bootstrap likelihood ratio test (BLRT) were also considered.  For the 
latter 2 tests, a significance level of p<0.05 was selected to indicate that the 
model fit was superior to a model with one less trajectory.  Entropy is not 
exactly an indicator of model fit, but indicates how well subjects from the 
sample are classified into the trajectories described.  It ranges from 0 to 1, 
with values approaching 1 indicating superior classification (Celeux and 
Soromenho, 1996).  
The results of the LCGA were reported in terms of: 
 The number of trajectory classes identified 
 The number of cases allocated to each class 
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 Average latent class probabilities for most likely latent class 
membership  
 A description of each trajectory 
 A graphical representation of each trajectory, compared to the mean 
values observed for cases grouped into each class 
Once the number of trajectories was identified and each trajectory class 
described as above, variables predictive of class membership were tested 
using multinomial logistic regression.  Predictor variables applied to this 
analysis were: YEAR cohort, gender, RF positivity, ACPA positivity, HLA-
DRB1-shared epitope positivity, and IMD quartile.  A sub-analysis of YEAR C 
data was also carried out to test the hypothesis that DAS28 and HAQ-DI are 
influenced by the three additional variables: smoking (pack years), obesity 
(BMI), and comorbidities (present or absent). 
Using the numbers of trajectories for DAS28 and HAQ-DI identified by the 
latent class growth analyses, a dual trajectory analysis (Nagin and Tremblay, 
2001) was conducted.  That is, the trajectories of DAS28 and HAQ-DI were 
estimated simultaneously by a model that combined the parallel process 
model described in Section 2.5.4.2 and LCGA.  The trajectories estimated by 
the model were described and compared to previous trajectories of DAS28 
and HAQ-DI identified by the LCGA.  It was then possible to determine the 
probability of a patient being assigned to one HAQ-DI trajectory group, based 
upon their DAS28 trajectory group.  Predictors of DAS28 / HAQ-DI dual 
trajectory class were obtained using multinomial logistic regression. 
2.5.4.3.1 Post-hoc analysis: non-inflammatory causes of patient reported disease 
activity and disability 
Once the trajectory groups were identified, consideration was given to 
potential factors contributing to HAQ-DI, other than inflammation due to RA. 
These included increased age, comorbidity and non-inflammatory causes of 
pain and disability such as psychological distress and passive coping.  Whilst 
age in years was readily available in this cohort, data were not collected on 
indices of psychological distress and data on comorbidity were limited.  As an 
indicator of non-inflammatory components of disease, a ‘DAS28-P’ index was 
calculated, which was similar to the index described by McWilliams and 
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colleagues (reviewed in Chapter 1, Section 1.8.1).  In YEAR, baseline ESR 
was missing in 36% of cases, compared to 8% missing for CRP, so a DAS28-
P index was calculated using the CRP instead of ESR, by modifying the 
formula described by McWilliams et al.  Thus, the DAS28-P(CRP) index was 
calculated as follows: 
 _______________(0.56 x √TJC28) + (0.014 x VAS) ___________________ 
(0.28 x √SJC28) + (0.56 x √TJC28) + 0.36 x Ln(CRP+1) + (0.014 x VAS) +0.96  
The DAS28-P(CRP) index was included as a covariate in the multinomial 
logistic regression model of predictors of DAS28/HAQ-DI dual trajectory.   
Due to the limited information collected on co-morbidities (described in Table 
2-2), and the large quantity of missing data on this variable (described in 
Chapter 3, Section 3.4), it was not possible to add this covariate into the 
regression models.  Instead, numbers of co morbidities were compared across 
DAS28 / HAQ-DI dual trajectory groups.  
The LCGA, multinomial logistic regression analyses and dual trajectory 
analysis were carried out using Mplus version 6.1 [Muthén, L. K., & Muthén, B. 
O. (1998-2011). Mplus User's Guide. Sixth Edition. Los Angeles, CA: Muthén 
& Muthén.]. 
2.5.5 Handling of missing data 
All subjects who gave consent to participate in YEAR B or C, with recorded 
symptom durations of 24 months or less, were included in the linear 
regression analyses, regardless of the quantity of missing data.  For the latent 
growth curves and LCGA, a small number of cases could not be included as 
there were no recorded DAS28 or HAQ-DI values available (detailed in 
Chapter 3, Section 3.4).  
The data were inspected in order to determine whether variables were 
normally distributed and the pattern of missingness and any causes for 
missing values were determined.  Data were assumed to be MAR.  To 
account for missing data in the linear regression analysis, MI was carried out 
using Stata for windows version 21.1 (Statacorp LP, Texas, USA), whilst 
maximum likelihood estimation was used for the latent growth curve models 
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and LCGA.  Maximum likelihood was chosen for this analysis as evidence 
from simulation studies indicate that it is as robust as multiple imputation 
(Chapter 1 paragraph.1.7.2.2.) and in addition, it is the default method for 
handling missing data used by the Mplus program.   
2.5.5.1 Auxiliary variables 
Auxiliary variables are collected from the sample population and are not 
covariates in the final statistical model; they are either correlated with the 
value of the variable(s) with missing data, or are correlated with the fact that it 
is missing.  Including auxiliary variables in the imputation model reduces bias 
in the estimates obtained from the analysis model and ideally, collection of 
auxiliary variables should be considered during the design of a study.  For 
example, ESR can be a used as an auxiliary variable in an imputation model 
for CRP.  Auxiliary variables were investigated in a simulation study by Collins 
et al. (2001), who concluded that an ‘inclusive approach’, in which all auxiliary 
variables were incorporated into the imputation model, produced less bias 
than more conservative methods.  
In the YEAR dataset, variables had not been collected specifically to include 
as auxiliary components to imputation models.  Pearson correlations between 
variables in the analysis models and others in the dataset were used to judge 
which would be suitable for application as auxiliary variables and are 
presented in Chapter 3, 3.5.  Initially, the suggested correlation of r ≥0.5 
proposed by Graham (2009) was considered as a cut- off for inclusion of an 
auxiliary variable.  However, as this approach would have resulted in the 
inclusion of 12 auxiliary variables in the MI model in addition to the 11 
variables already included in the linear regression analysis, a more 
conservative cut-off of a Pearson correlation of ≥0.7 was used instead.  This 
approach was adopted in order to avoid bias which can occur if too many 
auxiliary variables are included in an MI model, especially where the 
correlation between variables is low (less than 0.7) and the ratio of complete 
cases to variables in the model is also low, resulting in too many parameters 
in the regression model (Hardt et al., 2012).  As the auxiliary variables 
selected also contained missing data, there was an additional potential for 
bias if too many auxiliary variables were included.  In addition to correlation 
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with imputed variables, auxiliary variables were also considered if they were 
predictive of missingness, which was determined using logistic regression. 
Auxiliary variables were selected if odds ratios for predicting missingness were 
statistically significant and either less than 0.9 or greater than 1.2.   
2.5.5.2 Multiple imputation 
The MI model included all variables in the analysis model (including outcome 
variables) and auxiliary variables from the YEAR dataset, as discussed in 
paragraph  2.5.5.1.  Imputed variables were baseline RF, ACPA, pain and 
fatigue VAS, DAS28, EMS, and HAQ-DI, 6 month DAS28 and HAQ-DI, and 12 
month DAS28 and HAQ-DI.  Ten imputed datasets were generated, via an 
iterative Marcov-chain Monte Carlo method using chained equations with 
predictive mean matching (pmm) for continuous variables (DAS28, HAQ-DI, 
EMS baseline fatigue VAS and baseline pain VAS) and logistic regression for 
baseline RF and ACPA status.  To account for differences between the 2 
cohorts, the imputation model included a ‘by’ specification, so that data from 
YEAR B was used to impute missing YEAR B variables and the same rule 
applied for YEAR C data.  EMS was imputed as a continuous variable and 
then collapsed into categories.  Changes in DAS28 after 6 and 12 months 
were calculated as separate variables in the imputed dataset, to be applied as 
the outcome variable in the linear regression analyses that followed.  The 
Stata syntax for the MI procedure for the YEAR dataset is shown in Box 1.  
Here, the initial command ‘mi impute chained’ instructed the program to 
impute missing values using chained equations.  This was followed by the 
type of model used for imputation, predictive mean matching: ‘(pmm)’ and 
then the variables to be imputed.  Where ‘(Logit)’ was specified, logistic 
regression was used to impute RF and ACPA.  As mentioned above, the 
‘by(YEAR_cohort)’command was added so that missing data from YEAR B 
or C were only imputed using data from the same cohort.  Finally, the ‘add 
(10)’component of the syntax was included to indicate that 10 imputations 
were to be added.  Auxiliary variables were included in the imputation models, 
as described in Paragraph  2.5.5.1, but these variables also contained missing 
data and were therefore imputed alongside the variables for the analysis 
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model.  If the auxiliary variables were not imputed, the resulting datasets 
contained missing values.    
 
Box 1 Stata syntax for multiple imputation of Yorkshire Early Arthritis 
Register data 
See text (Section 2.5.5.2) for explanation of syntax. 
Variables were coded as follows: ACPA,anti-citrullinated peptide antibodies (positive or 
negative); AgeBL, patient age (in years) at baseline; EMS1, early morning  
stiffness at baseline (minutes); FATIGUE_RANGE1, Fatigue visual analogue score at 
baseline; DAS28CRP3v_1, DAS28CRP3_3, DAS28CRP3_6, DAS28CRP3_12, 
disease activity score based upon count of 28 joints and C-reactive protein at baseline, 
3, 6 and 12 months, respectively; PAIN_RANGE1, pain visual analogue score at 
baseline; RaschHAQ_1, RaschHAQ_6, RaschHAQ_12, Rasch transformed health  
assessment questionnaire score at baseline, 6 and 12 months, respectively; RF1, 
rheumatoid factor positive or negative at baseline; S_D, symptom duration at baseline; 
SJC28_6, SJC28_12, swollen joint count (from a total of 28 joints) at 6 and 12 months, 
respectively; TJC28_1, TJC28_6, TJC28_12, tender joint count (from a total of 28  
joints) at baseline, 6 and 12 months, respectively;  YEAR_cohort, Yorkshire Early  
Arthritis Register cohort (B or C). 
 
Variables with fewest missing values were imputed first, which is the default 
order of the Stata program.  For YEAR B, the order of imputation was: 
baseline TJC, baseline EMS, pain VAS, HAQ-DI (baseline), RF, fatigue VAS, 
DAS28 (baseline), TJC (6 months), SJC (6 months), HAQ-DI (6 months), TJC 
(12 months), SJC (12 months), HAQ-DI (12 months), DAS28 (3 months),  
DAS28 (6 months), DAS28 (12 months) and then ACPA.  For YEAR C, the 
imputation order was: EMS, HAQ-DI (baseline), baseline TJC, pain VAS, RF, 
fatigue VAS, DAS28 (baseline), DAS28 (3 months), TJC (12 months), HAQ-DI 
(6 months), SJC (12 months),  HAQ-DI (12 months), SJC (6 months), TJC (6 
months), DAS28 (12 months), DAS28 (6 months), then ACPA.  Following 
imputation of missing values and generation of 10 complete datasets, the data 
were summarised using means of continuous variables and percentages of 
categorical variables.  These statistics were then compared to those of the 
original dataset to demonstrate that imputed values were reasonable.  
mi impute chained (pmm) DASCRP3v_1 PAIN_RANGE1 
FATIGUE_RANGE1 RaschHAQ_1 EMS1 DAS28CRP3_6 RaschHAQ_6 
DAS28CRP3_12 RaschHAQ_12 (logit) RF1 ACPA(pmm) DAS28CRP3_3  
TJC28_1 TJC28_6 SJC28_6 TJC28_12 SJC28_12 = Gender AgeBL S_D, 
by (YEAR_cohort) add (10) 
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Linear regression models of predictors of baseline DAS28, HAQ-DI and 
change in these outcomes at 6 and 12 months were applied to the dataset and 
the estimates were merged, as described by Rubin (1987).  The MI results 
were compared to those of a complete case analysis and explanations sought 
for any differences in results between the 2 analyses, as suggested in 
published guidelines on the reporting of MI analyses (Sterne et al., 2009).  The 
reasons for conducting this comparison were twofold: firstly, to see how 
missing data may have affected the analysis and second, to check for 
discrepancies that may highlight flaws in the imputation model, such as those 
identified by Hippisley-cox and colleagues (2007), which resulted in revision of 
their cardiovascular risk model.   
2.5.5.3 Maximum likelihood estimation for incomplete data. 
This default method for handling missing data employed by statistical 
packages with structural equation modelling capacity was utilised when the 
latent growth curve models and LCGA models were estimated.   
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2.6 Summary of analytical approach 
The statistical techniques used to analyse the YEAR data in this Thesis are 
both cross section and longitudinal.  An initial exploration of baseline 
predictors of change in DAS28 and HAQ-DI after 6 and 12 months, which is 
cross sectional, used linear regression.  To avoid bias caused by missing 
data, MI was employed for these analyses.  The longitudinal analyses of 
change in DAS28 and HAQ-DI over 24 months included latent growth models, 
which described change over time, and LCGA, which identified trajectory 
classes of change in outcome within the sample population.  These models 
used maximum likelihood estimation to avoid bias due to missing data.  
Multinomial logistic regression was used to identify baseline predictors of 
trajectory class.  The following chapters contain the results of the analysis of  
YEAR data, starting with a description of the cohort and an explanation of how 
auxiliary variables (for missing data management) were selected, in Chapter 
3.  Chapter 4 addresses change in disease activity, whilst change in disability 
is described in Chapter 5.  The final results Chapter 6 addresses how change 
in disease activity influenced change in disability, using a parallel process 
growth curve model and dual trajectory analysis to describe this relationship. 
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 Methods 2: summary statistics and missing data  Chapter 3
3.1 Introduction 
The objectives of the present Chapter are to summarise the baseline 
demographic and clinical characteristics of cases recruited to YEAR, 
account for missing values and explain how auxiliary variables were sought 
from all available data so that missing values could be handled in 
subsequent statistical models.  Methods applied to manage missing data for 
analyses within this Thesis were detailed in 2.5.5, including the use of 
auxiliary variables to reduce bias.  The quantity of missing data are 
presented and reasons for missingness are given, where possible.  Patterns 
of missing data are described and also correlations between auxiliary 
variables and variables used as covariates in the analyses.  Furthermore, 
results of logistic regression analyses that were completed in order to 
identify predictors of missing values are also presented here. 
3.2 Description and comparison of Yorkshire Early Arthritis 
Register B and C cohorts 
Between 1997 and 2002, 783 RA patients were recruited to YEAR B, and 
831 were recruited to YEAR C between 2002 and 2009.  Of these cases, 18 
withdrew consent and were therefore excluded from YEAR B and 9 withdrew 
consent from YEAR C.  During the course of follow up of some patients, an 
alternative diagnosis became apparent and the previous diagnosis of RA 
was considered to be no longer valid: such patients were removed from the 
database.  In YEAR B, there were 16 cases of alternative diagnosis, which 
included; osteoarthritis (6), psoriatic arthritis (2), gout (1), fibromyalgia (1), 
ankylosing spondylitis (1) and in 5 cases, the alternative diagnosis was 
unrecorded.  In YEAR C, alternative diagnoses included; osteoarthritis (2), 
psoriatic arthritis (2), reactive arthritis (1) and one unrecorded alternative 
diagnosis.  Cases excluded because symptom duration exceeded 24 
months totalled 26 from YEAR B and 25 from YEAR C.  Although the 
selection criteria for entry into the YEAR cohort included patients with a 
symptom duration of less than 12 months, this part of the criteria was 
occasionally overlooked in practice, and patients were included despite 
 117 
 
documented symptom durations of up to 15 years in YEAR B (median 
symptom duration 6.5 months, range 1 to 180 months) and 13 years in 
YEAR C (median symptom duration 7.2 months, range 1 to 156 months).  In 
such cases, YEAR clinical record forms (and hospital records, where 
available) confirmed that individuals had a longstanding consultant- made 
diagnosis of RA and / or had received treatment with DMARDs for several 
years.  Although such deviations from the protocol occurred infrequently, 
they highlighted the importance of regular training for data collectors, 
especially as new study nurses and doctors became involved as the study 
progressed.  Patients with symptom durations exceeding that specified by 
the protocol were more likely to be included in YEAR if they were recruited 
from Airedale hospital (where the mean symptom duration of the 18 patients 
included was 16.0 months), St James’s hospital, (mean from 22 cases was 
10.7 months), or Barnsley hospital (mean symptom duration of 51 cases was 
10.0)  Forty one (YEAR B) and 57 (YEAR C) cases excluded because 
symptom duration was not recorded.  A total of 691 cases from YEAR B and 
725 cases from YEAR C were therefore included in the analyses.  This 
information is illustrated in Figure 3-1.  
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Figure 3-1 Diagram to illustrate the numbers of cases included in 
the analyses of data from Yorkshire Early Arthritis Register 
YEAR, Yorkshire Early Arthritis Register   
YEAR B and C can be considered consistent with other early RA cohorts, 
(reviewed in 1.7.1 and Table 1-2) with 65-67% females, 70-71% RF positive 
and 64-65% of those tested ACPA positive; however, there were some 
differences between the 2 YEAR cohorts.  As detailed in Table 3-1, which 
gives summary statistics for YEAR B and YEAR C, participants of YEAR C 
had lower DAS28 and HAQ-DI at baseline, 6 and 12 months.  This 
difference is most likely due to the fact that some patients, who could have 
been recruited to YEAR C, were instead enrolled into the randomised 
controlled trials described in Chapter 2, Paragraph 2.1.1, and that for 2 of 
these studies, baseline disease activity was higher than that of patients from 
the YEAR C cohort.  The mean baseline DAS28 of 145 cases in the 
PROWD study (Bejarano et al., 2008) was 6.0 and the mean baseline 
DAS28 of 112 cases included in the IDEA study (Nam et al., 2014a) was 5.0 
in cases who received MTX and 5.5 in those who received Infliximab.  
However, in the EMPIRE study, mean baseline DAS28 was lower than that 
Recruited to YEAR 
B = 783 
Withdrew consent = 9 
Alternative 
diagnosis = 16 
Symptom duration >24 
months = 36 
Or missing = 41 
Total = 67 
(Lost to follow up 
during study =270) 
Included in 
data analysis 
= 691 
Alternative 
diagnosis = 6 
Withdrew consent = 18 
Recruited to 
YEAR C = 831 
Symptom duration >24 
months = 25 
Or missing = 57 
Total = 82 
(Lost to follow up 
during study =192) 
Included in 
data analysis 
= 725 
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of the YEAR C cohort: the study recruited 110 cases and the mean baseline 
DAS28 was 4.17 in the placebo group and 4.10 in the treatment group (Nam 
JL 2013).  The mean symptom duration at baseline was longer for YEAR C 
participants (7.5 months, compared to 6.5 months), which was unexpected: 
prompt referral from primary care should facilitate early treatment and 
therefore, with improved treatment strategies and communication with 
primary care, reduced baseline symptom duration with time was anticipated.   
3.2.1 Biological therapies 
During follow up, 7 YEAR C patients started treatment with TNF inhibitors. In 
1 case, infliximab was started 9 months after the baseline visit and in 2 
cases it was started after 12 months.  Etanercept was started after 18 
months in 3 cases and one further case started adalimumab  after 12 
months.  All were included in subsequent analyses  No subjects in YEAR B 
started treatment with biological therapies during the 24 month follow up 
period. 
 120 
 
Table 3-1 Description of Yorkshire Early Arthritis Register B and C 
cohorts 
 
 YEAR B 
N=691 
YEAR C 
N=725 
Categorical data: N (%) 
    
Female gender 448 (65) 485 (67) 
Ethnicity: Caucasian 641 (97) 672 (95) 
 Non Caucasian 22 (3) 35 (5) 
Comorbidities: None 241 (35) 363 (50) 
 Any 104 (15) 250 (34) 
 Hypertension 86 (12) 163 (23) 
Ischaemic heart disease 31 (5) 77 (10) 
 Diabetes 23 (3) 43 (6) 
Chronic airways disease 50 (7) 84 (12) 
 Renal disease 5 (1) 17 (2) 
Cerebrovascular disease 5 (1) 29 (4) 
Peripheral vascular disease 4 (1) 25 (3) 
Chronic liver disease 1 (0) 6 (1) 
RF positive 448 (71) 465 (70) 
ACPA positive 244 (65) 309 (64) 
HLA-DRB1 ‘Shared Epitope’ positive 266 (72) 421 (66) 
Current or ex-smoker Not available 433 (61) 
Baseline EMS 0-35 minutes 158 (23) 255 (35) 
40-75 minutes  170 (25) 159 (22) 
90-210 minutes  231 (33) 140 (19) 
 ≥220 minutes  132 (19) 171 (24) 
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Table 3-1, continued.   
 
YEAR B YEAR C 
Continuous data: mean (SD)     
Age (years) 57.7 (14.3) 57.6 (14.1) 
Symptom duration (months) 6.5 (4.3) 7.5 (4.3)  
Baseline VAS pain (cm)  6.3 (2.7) 5.8 (2.6) 
Baseline VAS fatigue (cm)  4.8 (3.2) 4.5  (3.3) 
Body mass index (Kg/m2) Not available 27.3 (6.0) 
DAS28    Baseline 5.3 (1.3) 4.7 (1.5) 
 6 months 3.8 (1.6) 3.5 (1.5) 
 12 months 3.4 (1.5) 3.0 (1.4) 
HAQ-DI Baseline  10.2 (4.5) 9.4 (4.6) 
 6 months 8.1 (5.1) 7.4 (5.1) 
 12 months 7.6 (5.0) 6.7 (5.1) 
Missing values were excluded from total number of cases when percentages were 
calculated.  Percentages given are rounded to nearest per cent and standard 
deviations to one decimal place. 
ACPA, anti-citrullinated peptide antibodies, cm, centimetres; DAS28, disease 
activity score based upon count of 28 joints; EMS, early morning stiffness; HAQ-DI, 
disability index of health assessment questionnaire; HLA-DRB1, human leucocyte 
antigen DRB1 gene; Kg/m2, kilograms per metre squared; N, number of 
participants; RF, rheumatoid factor; SD, standard deviation; VAS, visual analogue 
score; YEAR, Yorkshire Early Arthritis Register. 
3.3 Variable distributions. 
Histograms of continuous variables revealed that age, DAS28 and HAQ-DI 
at baseline were approximately normally distributed for both YEAR cohorts 
(Appendix 6, Figures 6A to 6G).  The histograms of symptom duration at 
baseline (Figure 6B) showed positively skewed distributions, with more 
patients having shorter symptom duration at baseline (cases with symptom 
duration of over 24 months were excluded as described in 3.2 and Chapter 
2, 2.5).  The distributions of pain and fatigue VAS (Figure 6C and 6D, 
respectively) were affected by the modal values for these variables: for 
fatigue, the most commonly recorded VAS was 0 cm (148 cases in YEAR B 
and 159 in YEAR C), whilst for pain, this value was 10 cm, reported by 62 
patients in YEAR B and 46 in YEAR C.  The histograms of change in HAQ-
DI after 6 and 12 months (Figures 6F and 6G) revealed that the most 
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common value was 0, or no change from baseline.  For YEAR B, there was 
no change in HAQ-DI in 54 and 45 cases after 6 and 12 months, 
respectively, whilst in YEAR C there was no change in HAQ-DI for 79 cases 
after 6 months and 57 cases after 12 months.  As expected HAQ-DI 
improved for most cases (so that there was negative change), and therefore 
these distributions were all negatively skewed.  Although some variables 
were not normally distributed, they were not transformed prior to inclusion in 
the regression models so that results were more readily interpreted.  
Instead, multivariate normality was assessed after the linear regression 
models were applied to the data of the complete cases. 
3.4 Missing data 
Missing values for the analyses in this Thesis are listed in Table 3-2.  From a 
possible 41,789 observations (20,039 from YEAR B and 21,750 from YEAR 
C), there were 9,105 (22%) missing.  It is difficult to compare the quantity of 
missing data to that of other cohorts as it is not often reported, or if it is, the 
rate of missingness usually refers to a single variable.  For example, in 
ERAS, drug start and stop dates were the most frequently missing at around 
10% and the main clinical and laboratory measures were non-missing in 
94% of cases (Young et al., 2011).  These data suggest that YEAR 
contained more missing values than ERAS and it is likely that the methods 
of data management, including reminding patients to attend appointments, 
were more effective in ERAS.  
As illustrated in Table 3-2, more data were missing from YEAR B than YEAR 
C (29% vs. 15%, respectively).  The most frequently missing data were 
presence or absence of comorbidities in YEAR B, with up to 51% of values 
not recorded (Table 3-2).  Data on the presence of the HLA-DRB1 shared 
epitope and ACPA were more frequently missing from YEAR B than YEAR 
C (46% vs. 14% and 46%  vs. 33%, respectively).  As mentioned in 2.2.4.3, 
some of this information was obtained from analysis of stored blood 
samples, but if no stored sample was available, patients were contacted and 
asked to provide them retrospectively.  This was more successful for the 
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patients from YEAR C, who had been involved with the YEAR project more 
recently.  Therefore, this discrepancy was expected.  
In some cases, either DAS28 or HAQ-DI was not captured at any point 
during follow up and in 1 case, neither DAS28 nor HAQ-DI were captured.  
In YEAR B, there were 6 cases where DAS28 was never captured and 5 
cases where HAQ-DI was missing at all visits.  In YEAR C, there were 12 
cases where no DAS28 was recorded and 1 case with no HAQ-DI values.  
Such cases were excluded from the latent growth curve and LCGA analyses 
because, although missing data were accounted for using maximum 
likelihood estimation in the growth curve analyses, (outlined in Section 
2.5.5.3), this was not possible for cases where all values of the outcome 
variable were missing.  
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Table 3-2 Missing values in Yorkshire Early Arthritis Register   
 Missing observations: N (%) 
 
Variables  
YEAR B 
(Total N=691) 
YEAR C 
(Total N=725) 
Female gender  0 (0) 0 (0) 
Ethnicity 28 (4) 18 (3) 
Age in years  0 (0) 0 (0) 
Symptom duration in months  0 (0) 0 (0) 
Current or ex-smoker  Not available  17 (2) 
Index of multiple deprivation 55 (8) 35 (5) 
Comorbidities Hypertension 319 (46) 72 (10) 
 Ischaemic heart disease 332 (48) 58 (8) 
 Diabetes 332 (48) 65 (9) 
 Chronic airways disease 354 (45) 60 (8) 
 Renal disease 356 (49) 59 (8) 
 Cerebrovascular disease 356 (49) 59 (8) 
Peripheral vascular disease 339 (49) 6 (8) 
 Chronic liver disease 338 (51) 57 (8) 
Baseline EMS 12 (2) 33 (5) 
RF 25 (4) 57 (8) 
ACPA 315 (46) 239 (33) 
HLA-DRB1 Shared Epitope 320 (46) 105 (14) 
Baseline VAS pain 13 (3) 54 (7) 
Baseline VAS fatigue  38 (5) 94 (13) 
DAS28  Baseline 55 (8) 102 (14) 
 3 months 219  (32) 104 (14) 
 6 months 229 (33) 221 (31)  
 12 months 229 (33) 182 (25)  
 18 months 337 (49) 242 (33)  
 24 months 323 (47) 244 (30)  
HAQ-DI  Baseline 25 (4) 47 (6) 
 6 months 160 (23) 143 (20)  
 12 months 199 (29) 146 (20)  
 18 months 279 (40) 199 (27)  
 24 months 288  (42) 512 (30)  
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Table 3-2, continued      
Total observations expected: N 20039 21750 
Total observations missing: N (%) 5875 (29) 3230 (15) 
ACPA, anti-citrullinated peptide antibodies; DAS28, disease activity score based 
upon count of 28 joints; EMS, early morning stiffness; HAQ-DI, disability index of 
health assessment questionnaire; HLA-DRB1, human leucocyte antigen DRB1; N, 
number of observations; RF, rheumatoid factor; SD, standard deviation; VAS, visual 
analogue score; YEAR, Yorkshire Early Arthritis Register. 
 
3.4.1 Reasons for missing values 
The most common reason for missing data was failure to attend scheduled 
appointments.  The numbers of cases from YEAR B and C who attended at 
each data collection time point are listed in Table 3-3.  For YEAR B, the 
number of cases with data recorded for each visit declined from baseline, 
until the final, 24 month visit.  Data collection for YEAR C declined until 12 
and 18 months, with numbers of cases captured at these time points 
exceeding that of the previous, 9 month visit.  These fluctuations in numbers 
of patients attending appointments likely reflect the efforts of the study team 
to contact non- attenders and encourage attendance at subsequent visits.  
Table 3-3 Numbers of cases attending data collection visits in the 
Yorkshire Early Arthritis Register  
 
Time 
 
YEAR B 
 
YEAR C Total YEAR 
(B+C) 
Baseline 691 725 1416 
3 months 606 621 1227 
6 months 564 597 1161 
9 months No visit 556 556 
12 months 514 617 1131 
18 months 430 558 988 
24 months 421 532 1016 
YEAR, Yorkshire Early Arthritis Register. 
 
3.4.1.1 Loss to follow up 
In some cases, patients recruited to the YEAR cohorts were lost to follow up 
altogether, which was also frequently due to non-attendance.  The numbers 
of cases lost to follow up increased with time, as shown in Table 3-4, and 
were greater in YEAR B than C.  This is likely due to improved data 
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management in YEAR C, where patients were more often contacted in the 
event of failure to meet a scheduled appointment.  A total of 270 (40%) 
patients were lost to follow up from YEAR B and as mentioned above, the 
most common reason for this was non-attendance at scheduled 
appointments.  Attrition occurred when patients moved away (10), died (9), 
withdrew from the study when they no longer wished to participate in data 
collection (9), required biological therapy (3), or if co-morbid conditions such 
as cancer (2) or dementia (1) made attendance and data collection difficult.  
For all other cases lost to follow up from YEAR B (236), no reasons other 
than non-attendance at scheduled appointments were recorded.  From 
YEAR C, 193 (26%) cases were lost to follow up.  This occurred if subjects 
died (15), moved away (9), required biological therapy (9), or decided not to 
continue with data collection (8).  The remaining 151 cases lost to follow up 
were unexplained despite attempts to uncover reasons behind such attrition 
through hospital records. 
Table 3-4 Cumulative numbers of cases lost to follow up 
 YEAR B 
N=691 
Lost to follow up (%) 
YEAR C 
N=725 
Lost to follow up (%) 
Baseline  0 (0) 0 (0) 
3 months 33 (5) 23 (3) 
6 months 71 (10) 35 (5) 
9 months No visit 55 (8) 
12 months 135 (20) 69 (10) 
18 months 206 (30) 113 (16) 
24 months 270 (40) 192 (26) 
N, total number of cases; YEAR, Yorkshire Early Arthritis Register 
Cases lost to follow up were slightly younger than those who were not (mean 
age of 56.9, versus 58.1 years).  They also had a slightly higher baseline 
HAQ-DI (10.2, compared to 9.6), baseline pain VAS (6.2, versus 6.0cm) and 
duration of EMS (154 minutes, compared to 142).  However, baseline 
DAS28 and fatigue VAS were the same (5.0 and 5.3cm, respectively), 
irrespective of whether cases completed 24 months’ of follow up.   
3.4.1.2 Incomplete data collection and missing data patterns 
Another cause of missing data, other than non- attendance at appointments, 
was omission by the data collector.  When this occurred some, but not all, of 
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the data for a specific visit were recorded.  This is evident from the patterns 
of missing data, which are shown in Figure 3-2 (A and B).  In this Figure, 
missing values are indicated by a red bar and observed values are white.  
Missing data patterns, which represent groups of cases with identical 
combinations of missing observations, are numbered for descriptive 
purposes.  The overall missing data patterns were non- monotone.  In YEAR 
B over 80% of cases had no missing data at baseline (corresponding to 
pattern 1, shown in Figure 3-2 (A), YEAR B), but the most common pattern 
of missingness, which represented 6% of cases at baseline, was missing 
CRP and DAS28 (corresponding to pattern 15 in Figure 3-2 (A) YEAR B), 
despite efforts to look up CRP values on hospital databases during the data 
validation and cleaning process.  A likely explanation for this is that, at the 
time of data collection, some of the hospital laboratories had a cost-saving 
policy of measuring only one inflammatory marker and therefore only ESR 
was available in some cases.  At the baseline visit, CRP was missing for 
22%, 20% and 15% of cases from Dewsbury, York and Halifax hospitals, 
respectively, which represented a total of 38 (5%) cases.  In all except one 
of these cases, ESR was available at the baseline visit, indicating that a 
blood sample had been taken at the time, yet CRP was unavailable.  The 
next most common pattern of missingness of YEAR B baseline data was 
absence of the fatigue variable only (pattern 8), which occurred in 4% and 
was likely due to omission by the patient.  In YEAR B, comorbidity data were 
frequently missing (Table 3-2) because the yes / no tick boxes on the clinical 
record forms were unfilled.  In 282 cases from YEAR B, there were no 
available data on comorbidities, possibly indicating that this question was 
overlooked altogether.  This is likely as there were fewer co- existent 
medical problems recorded for the whole of YEAR B compared to YEAR C 
(Table 3-1): for example, only 12% of YEAR B cases had hypertension, 
compared to 23% in YEAR C.  However, in another 60 cases, one or two 
comorbidities were present and no information was provided for the 
remainder, suggesting that this section of the clinical record form was 
incomplete in some instances where a negative response was intended.  
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For 78% of cases in YEAR C, baseline data were complete, and this 
corresponds to pattern 1 in the YEAR C section of Figure 3-2 (A).  The most 
common missing data patterns here were for EMS and RF to be missing 
concurrently (4%, represented by pattern 7), or for CRP, TJC, SJC, DAS28, 
RF and EMS to be missing (4%, represented by pattern 26).   
Missing data patterns for the longitudinal data, including measurement of 
DAS28 and HAQ at 6 and 12 months, are illustrated in Figure 3-2 (B).  
Again, the most commonly occurring pattern from both cohorts was for no 
data to be missing, and this is represented by pattern 1 for YEAR B and C in 
Figure 3-2 (B).  In YEAR B, the next most common pattern of missingness 
occurred in 14% of cases, when DAS28 and HAQ-DI at 6 and 12 months 
were all missing (pattern 64).  Given that, at 6 months, 10% of cases in 
YEAR B were lost to follow up, this common missing data pattern was 
anticipated.  The next most common pattern of missing data (9%) included 
missing DAS28 and HAQ-DI at 6 months (pattern 26).  In YEAR C, the most 
common pattern was missing HAQ-DI and DAS28 at 6 months (8% of cases, 
pattern 45), followed by missing HAQ-DI and DAS28 at 12 months (7% of 
cases, pattern 29). 
3.4.1.3 Item non-response 
In some cases, participants did not answer the entire HAQ and only part of 
the questionnaire was completed.  Of the 7215 questionnaires, 1% were 
partially complete and therefore treated as missing.  
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Figure 3-2 (A) Missing data patterns from Yorkshire Early Arthritis 
Register B and C at baseline  
Red bars indicate values missing from the baseline data collection visit, whilst white 
bars indicate observed values.  Variables are ordered such that the frequency of 
missingness increases from left to right: In YEAR C, EMS is the least frequently missing 
variable, whilst DAS28 at is the most frequently missing.  The missing data patterns are 
labelled with numbers and are arranged from top to bottom, starting with groups of 
cases with least missing data for the far right variable, and then the next most 
frequently missing variable, and then the next and so on.  All variables are at baseline.   
 
YEAR B 
YEAR C 
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Figure 3-2 (B) Missing data patterns from Yorkshire Early Arthritis 
Register B and C including 6 and 12 month disease activity and Health 
Assessment Questionnaire 
Red bars indicate values missing from the baseline data collection visit, whilst white 
bars indicate observed values.  Variables are ordered such that the frequency of 
missingness increases from left to right: EMS is the least frequently missing variable, 
YEAR B 
YEAR C 
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whilst DAS28 at 12m is the most frequently missing.  The missing data patterns are 
labelled with numbers and are arranged from top to bottom, starting with groups of 
cases with least missing data for the far right variable, and then the next most 
frequently missing variable, and then the next and so on.   
Variables are at baseline, unless otherwise stated.   
CRP, C-reactive protein; DAS28, disease activity score based upon count of 28 joints 
and using CRP measurement; EMS, early morning stiffness; HAQ-DI, disability index 
component of the health assessment questionnaire; m, months; RF, rheumatoid factor; 
SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue score. 
 
3.5 Auxiliary variables 
3.5.1 Auxiliary variables for multiply imputed data 
The methods for selection of auxiliary variables were described in Chapter 2, 
2.5.5.1.  Auxiliary variables were similar for YEAR B and YEAR C.  Baseline 
disease activity VAS was correlated with baseline pain VAS, but the 2 
variables were always missing together and therefore the former was not a 
suitable auxiliary variable for pain VAS.  With the exception of baseline 
DAS28, where correlation with SJC was 0.69 (YEAR B) and 0.64 (YEAR C), 
tender and swollen joint counts at a given time point were highly correlated 
(Pearson correlation, r ≥0.7) with DAS28 calculated at the same time.  ESR 
and CRP were not strongly correlated with corresponding DAS28.  This 
likely reflects the method of calculation of DAS28, which uses the natural 
logarithm of CRP or ESR.  Disease activity VAS was not applied for 
calculation of 3 variable DAS28 used here, but is used for calculation of the 
4 variable DAS28, and did not show strong correlation with DAS28 
measured at the same time point.  Pearson correlation between HAQ-DI at 
any given time point and HAQ-DI at all previous visits was ≥0.5 in both 
cohorts and ≥0.7 in most cases in YEAR C.  Although 3 month HAQ-DI was 
strongly correlated with HAQ-DI at 6 (r = 0.78), 12 (r = 0.79), 18 (r = 0.78) 
and 24 months (r = 0.72) in YEAR C, it was not collected in YEAR B, and 
because of this, it was not a suitable auxiliary variable for the multiple 
imputation model.  Similar correlations were not observed for DAS28, where 
the strongest correlation, of 0.67, was between 18 and 24 months DAS28 in 
YEAR C.  Pearson correlations between potential auxiliary variables and 
variables included in the analyses are given in Tables 3-5 (YEAR B) and 3-6 
(YEAR C).
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Table 3-5 Pearson correlations between imputed variables and potential auxiliary variables collected in Yorkshire Early Arthritis 
Register B 
Auxiliary 
variable 
Baseline imputed variable (IV) 3m IV 6m IV 12m IV 18m IV 24m IV 
Time Variable Pain 
(1) 
Fatigue 
(1) 
EMS 
(1) 
DAS28 
(1,2) 
HAQ 
(1,2) 
DAS28 
(2) 
DAS28 
(1,2) 
HAQ 
(1,2) 
DAS28 
(1,2) 
HAQ 
(1,2) 
DAS28 
(2) 
HAQ 
(2) 
DAS28 
(2) 
HAQ 
(2) 
BL ESR 0.09 0.11 0.06 0.29 0.27 0.20 0.18 0.21 0.17 0.18 0.20 0.19 0.05 0.17 
 CRP 0.15 0.13 0.08 0.36 0.28 0.24 0.18 0.21 0.12 0.18 0.06 0.12 0.02 0.16 
 DAVAS 0.72 0.42 0.23 0.51 0.45 0.24 0.24 0.26 0.24 0.29 0.23 0.27 0.17 0.30 
 TJC 0.31 0.27 0.18 0.82 0.40 0.28 0.24 0.27 0.15 0.24 0.15 0.26 0.17 0.30 
 SJC 0.16 0.15 0.15 0.69 0.26 0.23 0.18 0.12 0.06 0.06 0.02 0.15 0.08 0.24 
 DAS28 0.42 0.30 0.21 1.00 0.41 0.33 0.25 0.24 0.17 0.20 0.11 0.21 0.14 0.27 
 HAQ 0.41 0.36 0.20 0.41 1.00 0.33 0.30 0.56 0.22 0.51 0.24 0.52 0.14 0.52 
3m* ESR x x x x x 0.13 0.06 0.06 0.05 0.06 0.03 0.05 0.03 0.02 
 CRP x x x x x 0.46 0.15 0.04 0.04 0.01 0.04 0.04 0.00 0.00 
 TJC x x x x x 0.84 0.12 0.02 0.04 0.04 0.04 0.08 0.01 0.07 
 SJC x x x x x 0.75 0.09 0.01 0.01 0.01 0.02 0.02 0.03 0.05 
 DAS28 x x x x x 1.00 0.58 0.41 0.45 0.40 0.41 0.43 0.24 0.37 
6m ESR x x x x x x 0.10 0.09 0.09 0.09 0.07 0.04 0.07 0.05 
 CRP x x x x x x 0.49 0.09 0.10 0.03 0.05 0.00 0.01 0.02 
 DAVAS x x x x x x 0.66 0.54 0.44 0.46 0.42 0.41 0.29 0.34 
 TJC x x x x x x 0.85 0.41 0.03 0.06 0.06 0.02 0.05 0.03 
 SJC x x x x x x 0.77 0.27 0.02 0.10 0.03 0.01 0.00 0.01 
 DAS28 x x x x x x 1.00 0.62 0.55 0.48 0.48 0.47 0.31 0.42 
 HAQ x x x x x x 0.62 1.00 0.43 0.76 0.41 0.69 0.23 0.65 
12m  ESR  x x x x x x x x 0.15 0.17 0.13 0.00 0.04 0.07 
 CRP x x x x x x x x 0.44 0.05 0.11 0.10 0.01 0.06 
 DAVAS x x x x x x x x 0.65 0.52 0.46 0.46 0.42 0.49 
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Table 3-5, continued       
Auxiliary 
variable 
 
Baseline imputed variable (IV) 
  
3m IV 
 
6m IV 
 
12m IV 
 
18m IV 24m IV 
Time Variable Pain Fatigue EMS DAS28 HAQ DAS28 DAS28 HAQ DAS28  HAQ DAS28 HAQ DAS28 HAQ 
12m TJC x x x x x x x x 0.83 0.34 0.15 0.04 0.11 0.05 
 SJC x x x x x x x x 0.74 0.21 0.10 0.01 0.05 0.00 
 DAS28 x x x x x x x x (1.00) 0.50 0.57 0.51 0.50 0.47 
 HAQ x x x x x x x x 0.50 (1.00) 0.49 0.80 0.32 0.73 
18m  ESR  x x x x x x x x x x 0.12 0.11 0.01 0.07 
 CRP x x x x x x x x x x 0.52 0.07 0.03 0.02 
 DAVAS x x x x x x x x x x 0.47 0.40 0.10 0.15 
 TJC x x x x x x x x x x 0.82 0.24 0.01 0.08 
 SJC x x x x x x x x x x 0.73 0.13 0.05 0.04 
 DAS28 x x x x x x x x x x 1.00 0.56 0.56 0.49 
 HAQ x x x x x x x x x x 0.56 1.00 0.33 0.80 
24m ESR  x x x x x x x x x x x x 0.10 0.07 
 CRP x x x x x x x x x x x x 0.26 0.05 
 DAVAS x x x x x x x x x x x x 0.46 0.28 
 TJC x x x x x x x x x x x x 0.84 0.14 
 SJC x x x x x x x x x x x x 0.74 0.04 
 DAS28 x x x x x x x x x x x x 1.00 0.50 
 HAQ x x x x x x x x x x x x 0.50 1.00 
Correlations between imputed variables and potential auxiliary variable that are greater than 0.7 are highlighted in grey.   
*At the 3 month visit, disease activity VAS and HAQ-DI were not collected. 
Numbers in parentheses (1,2) indicate which method was used to manage missing data, where 1 indicates that missingness of the variable was accounted for using 
multiple imputation (for the subsequent linear regression analysis detailed in Chapter 3) and 2 indicates that the missing data were handled using maximum 
likelihood estimation (in the growth curve and latent class growth analyses). 
BL, baseline; CRP, C-reactive protein; DAS28, disease activity score based upon a count of 28 swollen and tender joints and CRP; DA VAS, diseaseactivity visual 
analogue score; EMS, early morning stiffness; ESR, erythrocyte sedimentation rate; HAQ, of health assessment questionnaire (Rasch transformed variable of 
disease activity component used); IV, imputed variable; m, months; X, not applicable: variables collected at a later date were not used to predict earlier variables. 
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Table 3-6 Pearson correlations between imputed variables and potential auxiliary variables collected in Yorkshire Early Arthritis Register C 
Auxiliary variable Baseline imputed variable (IV) 3m IV 6m IV 9m IV 12m IV 18m IV 24m IV 
Time Variable Pain 
(1) 
Fatigue 
(1) 
EMS 
(1) 
DAS28 
(1,2) 
HAQ 
(1,2) 
DAS28 
(2) 
HAQ 
(2) 
DAS28 
(1,2) 
HAQ  
(1,2) 
DAS28 
(1,2) 
HAQ  
(1,2) 
DAS28 
(1,2) 
HAQ 
(1,2) 
DAS28 
(2) 
HAQ 
(2) 
DAS28  
(2) 
HAQ 
(2) 
BL ESR 0.21 0.05 0.01 0.38 0.25 0.12 0.17 0.10 0.08 0.15 0.12 0.10 0.06 0.06 0.02 0.11 0.06 
 CRP 0.21 0.10 0.09 0.45 0.26 0.17 0.19 0.25 0.17 0.24 0.17 0.19 0.13 0.17 0.17 0.15 0.11 
 DAVAS 0.78 0.48 0.31 0.46 0.51 0.15 0.27 0.21 0.29 0.21 0.28 0.18 0.23 0.22 0.26 0.17 0.25 
 TJC 0.40 0.27 0.20 0.75 0.42 0.34 0.32 0.36 0.28 0.33 0.12 0.35 0.12 0.33 0.13 0.25 0.30 
 SJC 0.32 0.13 0.18 0.64 0.28 0.23 0.16 0.22 0.10 0.21 0.30 0.19 0.33 0.12 0.31 0.07 0.12 
 DAS28 0.45 0.25 0.18 1.00 0.45 0.36 0.32 0.38 0.26 0.33 0.27 0.32 0.26 0.32 0.28 0.26 0.27 
 HAQ 0.48 0.37 0.27 0.45 1.00 0.26 0.66 0.30 0.63 0.31 0.63 0.30 0.56 0.30 0.58 0.25 0.56 
3m ESR x x x x x 0.17 0.15 0.11 0.12 0.12 0.16 0.08 0.12 0.10 0.14 0.07 0.10 
 CRP x x x x x 0.46 0.19 0.26 0.18 0.24 0.15 0.17 0.18 0.11 0.14 0.19 0.14 
 DAVAS x x x x x 0.54 0.58 0.38 0.49 0.35 0.49 0.30 0.47 0.20 0.41 0.22 0.41 
 TJC x x x x x 0.81 0.15 0.38 0.12 0.27 0.10 0.21 0.07 0.11 0.10 0.19 0.05 
 SJC x x x x x 0.72 0.06 0.26 0.15 0.16 0.16 0.13 0.13 0.04 0.04 0.12 0.12 
 DAS28 x x x x x 1.00 0.57 0.52 0.40 0.47 0.41 0.39 0.37 0.27 0.35 0.31 0.34 
 HAQ x x x x x 0.57 1.00 0.41 0.78 0.44 0.79 0.45 0.78 0.38 0.72 0.33 0.69 
6m ESR x x x x x x x 0.12 0.13 0.11 0.14 0.11 0.10 0.14 0.17 0.09 0.12 
 CRP x x x x x x x 0.49 0.20 0.18 0.12 0.14 0.13 0.17 0.15 0.19 0.12 
 DAVAS x x x x x x x 0.60 0.65 0.43 0.55 0.32 0.51 0.32 0.48 0.33 0.47 
 TJC x x x x x x x 0.83 0.20 0.31 0.13 0.26 0.10 0.15 0.13 0.16 0.07 
 SJC x x x x x x x 0.71 0.08 0.19 0.04 0.13 0.00 0.04 0.03 0.07 0.01 
 DAS28 x x x x x x x 1.00 0.62 0.66 0.50 0.57 0.48 0.49 0.44 0.46 0.41 
 HAQ x x x x x x x 0.62 1.00 0.53 0.81 0.48 0.79 0.42 0.75 0.40 0.73 
9m ESR x x x x x x x x x 0.08 0.15 0.12 0.15 0.13 0.14 0.08 0.15 
 CRP x x x x x x x x x 0.49 0.12 0.20 0.12 0.10 0.09 0.17 0.15 
 DAVAS x x x x x x x x x 0.63 0.63 0.44 0.55 0.39 0.50 0.38 0.49 
 TJC x x x x x x x x x 0.83 0.15 0.27 0.14 0.14 0.13 0.20 0.18 
 SJC x x x x x x x x x 0.70 0.07 0.17 0.09 0.07 0.06 0.13 0.08 
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Table 3-6, continued       
Auxiliary variable Baseline imputed variable (IV) 3m IV 6m IV 9m IV 12m IV 18m IV 24m IV 
Time Variable Pain Fatigue EMS DAS28 HAQ DAS28 HAQ DAS28 HAQ  DAS28 HAQ  DAS28 HAQ DAS28 HAQ DAS28  HAQ 
9m DAS28 x x x x x x x x x 1.00 0.61 0.63 0.51 0.56 0.51 0.52 0.49 
 HAQ x x x x x x x x x 0.61 1.00 0.55 0.85 0.48 0.83 0.41 0.78 
12m  ESR  x x x x x x x x x x x 0.17 0.16 0.18 0.16 0.16 0.16 
 CRP x x x x x x x x x x x 0.42 0.20 0.20 0.15 0.17 0.16 
 DAVAS x x x x x x x x x x x 0.59 0.64 0.39 0.53 0.40 0.53 
 TJC x x x x x x x x x x x 0.82 0.14 0.24 0.11 0.24 0.06 
 SJC x x x x x x x x x x x 0.72 0.06 0.12 0.02 0.11 0.02 
 DAS28 x x x x x x x x x x x 1.00 0.63 0.65 0.57 0.57 0.53 
 HAQ x x x x x x x x x x x 0.63 1.00 0.49 0.86 0.48 0.83 
18m  ESR  x x x x x x x x x x x x x 0.24 0.19 0.16 0.15 
 CRP x x x x x x x x x x x x x 0.38 0.17 0.11 0.09 
 DAVAS x x x x x x x x x x x x x 0.52 0.53 0.29 0.30 
 TJC x x x x x x x x x x x x x 0.84 0.11 0.24 0.12 
 SJC x x x x x x x x x x x x x 0.71 -0.02 0.10 0.01 
 DAS28 x x x x x x x x x x x x x 1.00 0.61 0.67 0.55 
 HAQ x x x x x x x x x x x x x 0.61 1.00 0.53 0.86 
24m ESR  x x x x x x x x x x x x x x x 0.12 0.12 
 CRP x x x x x x x x x x x x x x x 0.43 0.16 
 DAVAS x x x x x x x x x x x x x x x 0.48 0.49 
 TJC x x x x x x x x x x x x x x x 0.80 0.08 
 SJC x x x x x x x x x x x x x x x 0.70 0.00 
 DAS28 x x x x x x x x x x x x x x x 1.00 0.56 
 HAQ x x x x x x x x x x x x x x x 0.56 1.00 
Correlations between imputed variables and potential auxiliary variable that are greater than 0.7 are highlighted in grey.   
Numbers in parantheses (1,2) indicate which method was used to manage missing data, where 1 indicates that missingness of the variable was 
accounted for using multiple imputation and 2 indicates that the missing data was handled using maximum likelihood estimation. 
BL, baseline; CRP, C-reactive protein; DAS28, disease activity score based upon a count of 28 swollen and tender joints and CRP; DAVAS, disease 
activity visual analogue score; EMS, early morning stiffness; ESR, erythrocyte sedimentation rate; HAQ, of health assessment questionnaire (Rasch 
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transformed variable of disease activity component used); IV, imputed variable; m, months; X, not applicable: variables collected at a later date were 
not used to predict earlier variables.
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As well as using variables that correlated with those to be included in analyses, 
auxiliary variables were selected if they predicted missingness of a variable in 
the dataset.  Table 3-7 gives details of logistic regression analyses used 
determine which variables were associated with missingness in YEAR B and 
Table 3-8 gives the corresponding data for YEAR C.  Odds ratios that were less 
than 0.9 or greater than 1.2 were considered significant, as described in 2.5.5.1.  
In YEAR C, higher 3 month DAS28 was associated with lower likelihood of 
missing DAS28 at 6 months (OR 0.74, 95% CI 0.66-0.84), 12 months (OR 0.83, 
95% CI 0.75-0.92) and 24 months (OR 0.86, 95% CI 0.78-0.96) and lower 
likelihood of missing HAQ-DI at 6 months (OR 0.79, 95% CI 0.71-0.88), 12 
months (OR 0.84, 95% CI 0.76-0.93), 18 months (OR 0.87, 95% CI 0.78-0.96) 
and 24 months (OR 0.89, 95% CI 0.80-0.99).  
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Table 3-7 Predictors of missingness in imputed baseline to twelve month variables from the Yorkshire Early Arthritis Register B 
dataset 
 
Odds ratios of missingness in imputed YEAR B variables  (95% CI) 
PVAS 
BL 
FVAS   
BL 
DAS28 
BL 
EMS 
BL 
RF 
BL 
HAQ 
BL 
DAS28 
6m 
HAQ 
6m 
DAS28 
12m 
HAQ 
12m 
Baseline predictor variables 
TJC 0.93 
(0.86, 
1.01) 
0.97 
(0.93, 
1.01) 
0.99 
(0.95, 
1.02) 
1.00 
(0.94, 
1.07) 
1.02 
(0.97, 
1.07) 
1.01 
(0.96, 
1.07) 
1.00 
(0.99, 
1.02) 
1.00 
(0.98, 
1.03) 
0.99 
(0.22, 
1.10) 
0.99  
(0.97, 1.01) 
SJC 1.00 
(0.92, 
1.10) 
0.97 
(0.92, 
1.02) 
0.96 
(0.91, 
1.00) 
0.98 
(0.89, 
1.07) 
1.05 
(0.99, 
1.11) 
0.98 
(0.91, 
1.05) 
0.99 
(0.97, 
1.02) 
0.97 
(0.94, 
0.99) 
0.98 
(0.95, 
1.00) 
0.98 
(0.95, 1.00) 
DA 
VAS  
x 1.00 
(0.98, 
1.01) 
1.00 
(0.99, 
1.01) 
1.00 
(0.98, 
1.02) 
1.01 
(1.00, 
1.03) 
1.02 
(1.00, 
1.04) 
1.00 
(1.00, 
1.01) 
1.00 
(0.99, 
1.00) 
1.00 
(0.99, 
1.01) 
1.00 
(0.99, 1.00) 
CRP  1.01 
(0.99, 
1.02) 
1.00 
(1.00, 
1.01) 
1.00 
(0.97, 
1.03) 
0.99 
(0.96, 
1.01) 
1.00 
(0.98, 
1.01) 
1.00 
(0.99, 
1.01) 
1.00 
(0.99, 
1.00) 
1.00 
(1.00, 
1.00) 
1.00 
(1.00, 
1.01) 
1.00 
(1.00, 1.01) 
ESR 1.00 
(0.97, 
1.02) 
1.00 
(0.98, 
1.02) 
1.00 
(0.99, 
1.02) 
1.01 
(0.99, 
1.04) 
1.00 
(0.98, 
1.02) 
1.00 
(0.98, 
1.02) 
1.00 
(0.99, 
1.01) 
1.00 
(0.99, 
1.01) 
1.01 
(1.00, 
1.01) 
1.00 
(0.99, 1.01) 
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Table 3-7, continued 
        
Odds ratios of missingness in imputed YEAR B variables  (95% CI) 
 PVAS 
BL 
FVAS   
BL 
DAS28 
BL 
EMS 
BL 
RF 
BL 
HAQ 
BL 
DAS28 
6m 
HAQ 
6m 
DAS28 
12m 
HAQ 
12m 
3 month predictor variables 
PVAS 0.99 
(0.96, 
1.02) 
1.00 (0.99, 
1.01) 
0.99 (0.98, 
1.00) 
1.02 (0.99, 
1.05) 
1.02 (0.99, 
1.03) 
1.00 (0.98, 
1.01) 
1.00 (0.99, 
1.01) 
1.00 (0.99, 
1.01) 
1.00 (1.00, 
1.01) 
1.00 (1.00, 
1.01) 
FVAS 1.01 
(0.98, 
1.04) 
1.01 (1.00, 
1.02) 
1.00 (0.98, 
1.01) 
1.04 (1.00, 
1.08) 
1.01 (1.00, 
1.03) 
1.00 (0.99, 
1.02) 
1.00 (1.00, 
1.01) 
1.01 (1.00, 
1.01) 
1.01 (1.00, 
1.01) 
1.00 (1.00, 
1.01) 
EMS 1.00 
(0.99, 
1.01) 
1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
DAS28  0.89 
(0.54, 
1.45) 
0.96 (0.74, 
1.24) 
0.86 (0.66, 
1.13) 
1.18 (0.63, 
2.23) 
1.46 (0.96, 
2.22) 
0.86 (0.62, 
1.20) 
1.03 (0.89, 
1.18) 
1.01 (0.92, 
1.28) 
1.04 (0.91, 
1.18) 
1.03 (0.90, 
1.18) 
6 month predictor variables 
PVAS x x x x x x 1.00 
(0.99, 1.01) 
1.00 
(0.99, 1.01) 
1.00 
(1.00, 1.01) 
1.00 
(1.00, 1.01) 
FVAS x x x x x x 1.00 
(1.00, 1.01) 
1.00 
(0.98, 1.01) 
1.01 
(1.00, 1.01) 
1.01 
(1.00, 1.01) 
DAVAS x x x x x x 1.00 
(1.00, 1.01) 
1.00 
(0.99, 1.02) 
1.00 
(1.00, 1.01) 
1.00 
(1.00, 1.01) 
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Table 3-7, continued 
Odds ratios of missingness in imputed YEAR B variables  (95% CI) 
 PVAS 
BL 
FVAS   
BL 
DAS28 
BL 
EMS 
BL 
RF 
BL 
HAQ 
BL 
DAS28 
6m 
HAQ 
6m 
DAS28 
12m 
HAQ 
12m 
EMS x x x x x x 1.00 
(1.00, 1.00) 
1.00 
(1.00, 1.00) 
1.00 
(1.00, 1.00) 
1.00 
(1.00, 1.00) 
DAS28  x x x x x x x 0.87 
(0.63, 1.22) 
1.11 
(0.96, 1.27) 
1.10 
(0.95, 1.28) 
HAQ x x x x x x 1.03 
(0.99, 1.07) 
x 1.05 
(1.01, 1.09) 
1.05 
(1.00, 1.09) 
12 month predictor variables 
PVAS x x x x x x x X 1.01 
(1.00, 1.02) 
1.01 
(1.00, 1.03) 
FVAS X x x x x X x x 1.00 
(0.99, 1.01) 
1.01 
(1.00, 1.02) 
DAVAS X X x x x x x x 1.01 
(1.00, 1.02) 
1.02 
(1.00, 1.03) 
EMS X x x x x x x X 1.00 
(1.00, 1.00) 
1.00 
(1.00, 1.00) 
DAS28 X x x x x x x x x 1.04 
(0.76, 1.42) 
HAQ x x x x x x x x 1.04 
(0.98, 1.01) 
x 
Odds ratios were obtained using logistic regression analyses controlled for age, gender and symptom duration. Significant (OR < 0.9 or >1.2) predictors of 
missing imputed variables are highlighted in grey.  
Where pain VAS was missing for the baseline visit, disease activity VAS was also missing. 
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BL, baseline; CI, confidence interval; DAS28, disease activity score from 28 joints; DAVAS, disease activity visual analogue score; EMS, early morning 
stiffness; ESR, erythrocyte sedimentation rate; FVAS, fatigue visual analogue score; HAQ, disability index of the health assessment questionnaire (Rasch 
transformed); m, months; PVAS, pain visual analogue score; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; x, not applicable: data 
were collected at a later appointment and were therefore not used to predict missingness in earlier variables.  
Table 3-8 Predictors of missingness in imputed baseline to twelve month variables from the Yorkshire Early Arthritis Register C 
dataset 
 
 
Odds ratios of missingness in imputed YEAR C variables (95% CI) 
 PVAS 
BL 
FVAS  
BL 
DAS28 
BL 
EMS 
BL 
RF 
BL 
HAQ 
BL 
DAS28 
6m 
HAQ 
6m 
DAS28 
12m 
HAQ 
12m 
 Baseline predictor variables  
 
Smoker 1.40 (0.75, 
2.59) 
1.47 (0.91, 
2.38) 
1.36 (0.92, 
2.02) 
1.21 (0.83, 
1.76) 
0.99 (0.69, 
1.41) 
0.96 (0.68, 
1.34) 
1.04 (0.76, 
1.41) 
1.08 (0.80, 
1.47) 
1.10 (0.81, 
1.49) 
1.18 (0.87, 
1.61) 
 
TJC 0.97 (0.92, 
1.03) 
0.99 (0.96, 
1.02) 
1.00 (0.97, 
1.03) 
1.01 (0.98, 
1.03) 
1.00 (0.97, 
1.02) 
1.00 (0.97, 
1.02) 
1.01 (0.99, 
1.03) 
1.00 (0.99, 
1.02) 
1.00 (0.98, 
1.02) 
1.01 (0.99, 
1.03) 
 SJC 0.95 (0.94, 
1.06) 
1.00 (0.96, 
1.04) 
1.02 (0.98, 
1.05) 
1.01 (0.98, 
1.04) 
1.00 (0.97, 
1.03) 
1.00 (0.97, 
1.03) 
1.00 (0.98, 
1.03) 
1.00 (0.98, 
1.03) 
0.99 (0.97, 
1.01) 
1.00 (0.98, 
1.02) 
DAVAS  X 0.99 (0.98, 
1.00) 
0.99 (0.98, 
1.00) 
0.99 (0.99, 
1.00) 
1.00 (0.99, 
1.00) 
0.99 (0.99, 
1.00) 
1.00 (0.99, 
1.01) 
1.00 (0.99, 
1.01) 
1.00 (0.99, 
1.00) 
1.00 (0.99, 
1.01) 
CRP  1.00 (0.99, 
1.00 
1.00 (0.99, 
1.01) 
1.00 (0.99, 
1.00) 
1.00 (1.00, 
1.01) 
1.00 (1.00, 
1.01) 
1.00 (1.00, 
1.01) 
1.00 (1.00, 
1.01) 
1.00 (1.00, 
1.01) 
1.00 (1.00, 
1.01) 
1.00 (1.00, 
1.01) 
ESR 0.99 (0.98, 
1.00) 
1.00 (0.99, 
1.00) 
1.00 (0.99, 
1.01) 
1.00 (0.99, 
1.01) 
1.00 (1.00, 
1.01) 
1.00 (0.99, 
1.01) 
1.01 (1.00, 
1.01) 
1.01 (1.00, 
1.01) 
1.00 (1.00, 
1.01) 
1.00 (1.00, 
1.01) 
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Table 3-8, continued 
 3 month predictor variables 
 
PVAS x x x x x x 0.99 (0.99, 
1.00) 
0.99 (0.99, 
1.00) 
1.00 (0.99, 
1.00) 
1.00 (0.99, 
1.00) 
 FVAS x x x x x x 1.00 (0.99, 
1.00) 
1.00 (0.99, 
1.00) 
1.00 (1.00, 
1.01) 
1.00 (0.99, 
1.01) 
 DAVAS x x x x x x 0.99 (0.99, 
1.00) 
0.99 (0.99, 
1.00) 
1.00 (0.99, 
1.00) 
1.00 (0.99, 
1.00) 
EMS x x x x x x 1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
DAS28  x x x x x x 0.74 (0.66, 
0.84) 
0.79 (0.71, 
0.88) 
0.83 (0.75, 
0.92) 
0.84 (0.76, 
0.93) 
HAQ x x x x x x 1.00 (0.96, 
1.04) 
0.98 (0.95, 
1.02) 
0.99 (0.96, 
1.03) 
0.99 (0.96, 
1.03) 
 6 month predictor variables    
 
PVAS x x x x x  0.99 (0.99, 
1.00) 
0.99 (0.99, 
1.00) 
0.99 (0.99, 
1.00) 
0.99 (0.99, 
1.00) 
 FVAS x x x x x  1.00 (0.99, 
1.00) 
1.00 (0.99, 
1.00) 
1.00 (1.00, 
1.01) 
1.00 (1.00, 
1.01) 
 DAVAS x x x x x  0.99 (0.99, 
1.00) 
1.00 (0.99, 
1.00) 
1.00 (0.99, 
1.00) 
1.00 (0.99, 
1.00) 
EMS x x x x x  1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
DAS28  x x x x x  X 0.87 (0.76, 
1.01) 
0.89 (0.79, 
1.01) 
0.92( 0.82, 
1.04) 
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Table 3-8, continued       
HAQ x x x x x x 0.98 (0.94, 
1.03) 
x 0.98 (0.94, 
1.01) 
0.98 (0.95, 
1.01) 
 12 month predictor variables 
 
PVAS x x x x x x x x 1.00 (1.00, 
1.01) 
1.00 (1.00, 
1.00) 
 FVAS X x x x x x x x 1.00 (0.99, 
1.00) 
1.00 (0.99, 
1.00) 
 DAVAS X X x x x x x x 1.00 (1.00, 
1.01) 
1.00 (1.00, 
1.01) 
EMS X x x x x x x x 1.00 (1.00, 
1.00) 
1.00 (1.00, 
1.00) 
DAS28 X x x x x x x x x 0.96 (0.85, 
1.08) 
HAQ x x x x x x x x 0.99 (0.95, 
1.02) 
x 
Odds ratios were obtained using logistic regression analyses controlled for age, gender and symptom duration.  Significant (OR < 0.9 or >1.2) 
predictors of missing imputed variables are highlighted in grey.  
Where pain VAS was missing for the baseline visit, disease activity VAS was also missing. 
BL, baseline; CI, confidence interval; DAS28, disease activity score from 28 joints; DAVAS, disease activity visual analogue score; EMS, early 
morning stiffness; ESR, erythrocyte sedimentation rate; FVAS, fatigue visual analogue score; HAQ, disability index of the health assessment 
questionnaire (Rasch transformed); m, months; PVAS, pain visual analogue score; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint 
count; x, not applicable: data were collected at a later appointment and were therefore not used to predict missingness in earlier variables. 
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3.5.2 Auxiliary variables for missing data handled by maximum 
likelihood estimation 
Missing data were handled by maximum likelihood estimation in the latent 
growth curve and LCGA and included DAS28 values at baseline, 3,6 12, 18 and 
24 months and HAQ-DI values at baseline, 6, 12, 18 and 24 months.  
Correlations between DAS28 and HAQ-DI at these time points and other 
variables in the dataset have already been described in Tables 3-5 and  3-6.  
Variables predictive of missingness in these outcomes up to 12 months were 
given in Tables 3-7 and 3-8.  Indicators of missingness in DAS28 and HAQ-DI 
at 18 and 24 months are presented in Table 3-9.  Only 3 month DAS28 
predicted missingness in YEAR C (but not YEAR B), whereby odds of 
missingness in DAS28 and HAQ-DI were lower with increased value of 3 month 
DAS28.  Covariates in the multinomial logistic regression analysis of predictors 
of trajectory class also contained missing data and predictors of missingness in 
these variables are displayed in Table 3-10.  In YEAR B there were no 
significant predictors of missingness in covariates, however, in YEAR C higher 
baseline TJC and DAS28 were associated with less likelihood of missingness in 
IMD and higher baseline HAQ-DI  was associated with a lower likelihood of 
missing smoking status.
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Table 3-9 Predictors of missingness in imputed eighteen and twenty-four 
month variables from Yorkshire Early Arthritis Register 
 
 Odds ratios of missingness in imputed 
YEAR B variables  (95% CI) 
 
Odds ratios of missingness in imputed 
YEAR C variables  (95% CI) 
 
 DAS28 
18m 
HAQ 
18m 
DAS28 
24m 
HAQ 
24m 
DAS28 
18m 
HAQ 
18m 
DAS28 
24m 
HAQ 
24m 
Baseline predictor variables: 
TJC 0.99 
(0.97, 
1.01) 
1.00 
(0.98, 
1.02) 
0.98 
(0.97, 
1.00) 
0.98 
(0.97, 
1.00) 
1.00 
(0.99, 
1.03) 
1.01 
(0.98, 
1.03) 
1.00 
(0.98, 
1.02) 
1.01 
(1.00, 
1.02) 
SJC 0.97 
(0.95, 
0.99) 
0.98 
(0.96, 
1.00) 
0.98 
(0.96, 
1.00) 
0.98 
(0.96, 
1.00) 
1.00 
(0.98, 
1.03) 
1.01 
(0.98, 
1.03) 
0.99 
(0.96, 
1.01) 
1.00 
(1.00, 
1.01) 
DAVAS  1.00 
(0.55, 
1.20) 
1.00 
(1.00, 
1.01) 
1.00 
(0.99, 
1.00) 
0.99 
(0.99, 
1.01) 
1.01 
(1.00, 
1.02) 
1.01 
(1.00, 
1.02) 
1.01 
(1.00, 
1.01) 
1.01 
(1.00, 
1.02) 
CRP  1.00 
(0.71, 
1.09) 
1.00 
(1.00, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(0.99, 
1.00) 
1.00 
(1.00, 
1.01) 
1.00 
(0.99, 
1.01) 
1.00 
(1.00, 
1.00) 
1.00 
(1.00, 
1.00) 
ESR 0.89 
(0.62, 
1.27) 
1.00 
(0.99, 
1.00) 
1.00 
(0.99, 
1.01) 
1.00 
(0.99, 
1.01) 
1.01 
(0.99, 
1.01) 
1.01 
(1.00, 
1.01) 
1.01 
(0.99, 
1.02) 
1.01 
(0.99, 
1.01 
3 month predictor variables:      
PVAS 1.00 
(0.99, 
1.01) 
1.00 
(0.99, 
1.01) 
1.00 
(0.99, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(0.99, 
1.01) 
1.01 
(0.99, 
1.01) 
FVAS 1.00 
(0.99, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(0.99, 
1.01) 
1.00 
(0.99, 
1.01) 
1.01 
(0.99, 
1.01) 
1.01 
(0.99, 
1.01) 
1.01 
(1.00, 
1.01) 
EMS 1.00 
(0.99, 
1.00) 
1.00 
(1.00, 
1.00) 
0.99 
(1.00, 
1.00) 
1.00 
(0.99, 
1.00) 
1.00 
(0.99, 
1.00) 
1.00 
(0.99, 
1.00) 
1.00 
(0.99, 
1.00) 
1.00 
(1.00, 
1.00) 
DAS28  1.05 
(0.93, 
1.18) 
1.06 
(0.94, 
1.21) 
1.05 
(0.93, 
1.19) 
1.06 
(0.93, 
1.20) 
0.91 
(0.82, 
1.01) 
0.87 
(0.78, 
0.98) 
0.86 
(0.78, 
0.96) 
0.89 
(0.80, 
0.99) 
HAQ x x x x 1.02 
(0.98, 
1.06) 
1.01 
(0.97, 
1.05) 
1.02 
(0.98, 
1.06) 
1.03 
(0.99, 
1.07) 
6 month predictor variables:     
PVAS 1.00 
(0.99, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(1.00, 
1.01) 
1.01 
(1.00, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(0.99, 
1.01) 
1.00 
(1.00, 
1.01) 
FVAS 0.99 
(0.99, 
1.00) 
1.00 
(1.00, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(0.99, 
1.01) 
1.01 
(1.00, 
1.01) 
1.01 
(1.00, 
1.01) 
1.00 
(0.99, 
1.01) 
1.00 
(1.00, 
1.01) 
EMS 0.99 
(0.99, 
1.0) 
1.00 
(1.00, 
1.00) 
1.00 
(1.00, 
1.00) 
1.00 
(0.99, 
1.00) 
1.00 
(1.00, 
1.00) 
1.00 
(1.00, 
1.00) 
1.00 
(1.00, 
1.00) 
1.00 
(1.00, 
1.00) 
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Table 3-9, continued      
 DAS28 
18m 
HAQ 
18m 
DAS28 
24m 
HAQ 
24m 
DAS28 
18m 
HAQ 
18m 
DAS28 
24m 
HAQ 
24m 
DAS28 1.06 
(0.95, 
1.19) 
1.11 
(0.98, 
1.25) 
1.12 
(0.99, 
1.26) 
1.09 
(0.97, 
1.23) 
1.09 
(0.96, 
1.23) 
1.02 
(0.89, 
1.17) 
0.97 
(0.86, 
1.10) 
1.00 
(0.88, 
1.14) 
HAQ 1.02 
(0.98, 
1.05) 
1.03 
(1.00, 
1.07) 
1.04 
(1.01, 
1.17) 
1.04 
(1.00, 
1.08) 
1.04 
(1.00, 
1.07) 
1.05 
(1.01, 
1.10) 
1.02 
(0.98, 
1.05) 
1.03 
(0.99, 
1.07) 
9 month predictor variables  
PVAS x x x X 1.01 
(1.00, 
1.01) 
1.01 
(1.00, 
1.01) 
1.01 
(0.99, 
1.01) 
1.01 
(1.00, 
1.01) 
FVAS x x x x 1.00 
(1.00, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(0.99, 
1.01) 
1.00 
(0.99, 
1.01) 
EMS x x x x 1.00 
(1.00, 
1.00) 
1.00 
(1.00, 
1.00) 
0.99 
(0.99, 
1.00) 
1.00 
(0.99, 
1.00) 
DAS28  x x x x 1.20 
(1.03, 
1.38) 
1.08 
(0.93, 
1.27) 
1.01 
(0.92, 
1.21) 
1.19 
(1.03, 
1.37) 
HAQ     1.04 
(1.00, 
1.08) 
1.04 
(1.00, 
1.09) 
1.03 
(0.99, 
1.07) 
1.04 
(1.00, 
1.09) 
12 month predictor variables     
PVAS 1.01 
(1.00, 
1.01) 
1.03 
(0.89, 
1.19) 
1.00 
(0.99, 
1.01) 
1.00 
(1.00, 
1.01) 
1.01 
(1.00, 
1.01) 
1.01 
(1.00, 
1.02) 
1.01 
(1.00, 
1.01) 
1.01 
(1.01, 
1.02) 
FVAS 1.00 
(1.00, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(0.99, 
1.01) 
1.01 
(1.000, 
1.01) 
1.00 
(1.00, 
1.01) 
1.00 
(0.99, 
1.01) 
1.00 
(1.00, 
1.01) 
1.01 
(1.00, 
1.01) 
EMS 1.00 
(0.99, 
1.00) 
1.00 
(1.00, 
1.00) 
1.00 
(1.00, 
1.00) 
0.99 
(0.99, 
1.00) 
1.00 
(1.00, 
1.00) 
1.00 
(0.99, 
1.00) 
1.00 
(0.99, 
1.00) 
1.00 
(0.99, 
1.00) 
DAS28  1.00 
(0.89, 
1.15) 
1.03 
(0.89, 
1.19) 
0.99 
(0.87, 
1.13) 
1.06 
(0.93, 
1.22) 
1.03 
(1.19, 
0.47) 
1.06 
(0.91, 
1.23 
1.03 
(0.90, 
1.18) 
1.13 
(0.98, 
1.30) 
HAQ 1.01 
(0.97, 
1.04) 
1.01 
(0.97, 
1.06) 
1.02 
(0.99, 
1.07) 
1.03 
(0.99, 
1.07) 
1.04 
(1.01, 
1.08) 
1.05 
(1.01, 
1.10) 
1.04 
(1.01, 
1.08) 
1.07 
(1.02, 
1.11) 
18 month predictor variables     
PVAS 1.00 
(0.98, 
1.01) 
1.01 
(0.99, 
1.03) 
1.00 
(0.99, 
1.01) 
0.99 
(0.99, 
1.01) 
1.00 
(0.99, 
1.00) 
0.97 
(0.96, 
0.98) 
1.00 
(0.99, 
1.01) 
1.00 
(0.99, 
1.01) 
FVAS 1.00 
(1.00, 
1.00) 
1.00 
(0.98, 
1.00) 
0.99 
(0.98, 
1.1) 
1.00 
(0.99, 
1.00) 
1.00 
(0.99, 
1.00) 
0.97 
(0.96, 
0.98) 
1.00 
(0.99, 
1.01) 
1.00 
(0.99, 
1.01) 
EMS 1.00 
(1.00, 
1.00) 
1.00 
(0.99, 
1.00) 
1.00 
(1.00, 
1.00) 
1.00 
(1.00, 
1.00) 
1.00 
(1.00, 
1.00) 
1.00 
(0.99, 
1.00) 
1.00 
(0.99, 
1.00) 
1.00 
(0.99, 
1.00) 
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Table 3-9, continued 
 
  
 DAS28 
18m 
HAQ 
18m 
DAS28 
24m 
HAQ 
24m 
DAS28 
18m 
HAQ 
18m 
DAS28 
24m 
HAQ 
24m 
DAS28  x 1.11 
(0.79, 
1.57) 
0.95 
(0.79, 
1.14) 
0.94 
(0.76, 
1.15) 
X 0.82 
(0.60, 
1.12) 
0.97 
(0.83, 
1.13) 
1.07 
(0.91, 
1.25) 
HAQ 1.01 
(0.97, 
1.04) 
x 1.01 
(0.97, 
1.06) 
1.03 
(0.98, 
1.08) 
0.99 
(0.95, 
1.05) 
X 1.02 
(0.98, 
1.06) 
1.04 
(0.99, 
1.09) 
24 month predictor variables  
PVAS X X 0.99 
(0.98, 
1.00) 
1.01 
(0.99, 
1.02) 
  1.01 
(0.99, 
1.02) 
1.01 
(0.99, 
1.04) 
FVAS X X 1.00 
(0.99, 
1.01) 
1.00 
(0.99, 
1.12) 
  1.01 
(0.99, 
1.02) 
1.01 
(0.99, 
1.03) 
EMS X X 0.99 
(0.99, 
1.01) 
1.00 
(0.99, 
1.00) 
  0.99 
(0.99, 
1.00) 
1.00 
(1.00, 
1.00) 
DAS28 X X x 1.12 
(0.85, 
1.47) 
  X 1.12 
(0.77, 
1.63) 
HAQ x x 1.02 
(0.97, 
1.08) 
x   1.01 
(0.94, 
1.07) 
X 
Odds ratios were obtained using logistic regression analyses controlled for 
age, gender and symptom duration.  Significant (OR < 0.9 or >1.2) predictors of 
missing imputed variables are highlighted in grey. 
CI, confidence interval; CRP, C-reactive protein; DAS28, disease activity score from 28 
joints; DAVAS, disease activity visual analogue score; EMS, early morning stiffness; 
ESR, erythrocyte sedimentation rate; FVAS, fatigue visual analogue score; HAQ, 
disability index of the health assessment questionnaire (Rasch transformed); m, 
months; PVAS, pain visual analogue score; RF, rheumatoid factor; SJC, swollen joint 
count; TJC, tender joint count; x, not applicable: data were collected at a later 
appointment and were therefore not used to predict missingness in earlier variables. 
 148 
 
Table 3-10  Predictors of missingness in Yorkshire Early Arthritis Register 
B and C covariates included in the multinomial logistic regression models 
 Odds ratios of missingness in imputed YEAR B variables  (95% CI) 
 RF ACPA Shared epitope  IMD 
Baseline predictor variables 
TJC 0.85 (0.68, 
1.07) 
1.01 (0.98, 
1.07) 
1.01 (1.03, 
1.17) 
0.94 (0.93, 
1.16) 
SJC 1.04 (0.89, 
1.21) 
1.08 (1.03, 
1.14) 
1.06 (1.00, 
1.11) 
1.07 (0.98, 
1.18) 
CRP 0.99 (0.95, 
1.02) 
1.00 (0.99, 
1.01) 
1.01 (1.00, 
1.02) 
0.99 (0.97, 
1.01) 
ESR 0.99 (0.97, 
1.02) 
1.01 (0.99, 
1.02) 
1.00 (0.99, 
1.01) 
1.00 (0.98, 
1.02) 
DAS28 4.53 (0.42, 
48.9) 
0.65 (0.41, 
1.03) 
1.46 (0.53, 
4.02) 
1.46 (0.53, 
4.02) 
HAQ 1.02 (0.88, 
1.18) 
1.05 (0.98, 
1.11) 
0.99 (0.93, 
1.05) 
0.90 (0.78, 
1.02) 
 Odds ratios of missingness in imputed YEAR C variables  (95% CI) 
 RF ACPA Shared 
epitope  
IMD Smoking  BMI Co-
morbidities 
Baseline predictor variables    
TJC 1.00 
(0.91, 
1.11) 
1.00 
(0.96, 
1.05) 
1.00 
(0.96, 
1.05) 
0.84 (0.72, 
0.97) 
1.20 
(1.01, 
1.40) 
0.99 
(0.92, 
1.06) 
1.02 (0.11, 
1.05) 
SJC 0.99 
(0.89, 
1.10) 
1.00 
(0.96, 
1.04) 
1.00 
(0.96, 
1.04) 
0.93 (0.82, 
1.06) 
0.90 
(0.76, 
1.08) 
0.99 
(0.92, 
1.05) 
1.02 (0.98, 
1.05) 
CRP 1.01 
(1.00, 
1.02) 
0.99 
(0.99, 
1.00) 
0.99 
(0.99, 
1.00) 
0.99 (0.97, 
1.01) 
1.01 
(1.00, 
1.03) 
1.00 
(1.00, 
1.01) 
1.00 (0.99, 
1.00) 
ESR 1.01 
(1.00, 
1.03) 
1.00 
(0.99, 
1.01) 
1.00 
(0.99, 
1.01) 
1.00 (0.98, 
1.02) 
1.01 
(0.98, 
1.04) 
1.00 
(0.99, 
1.01) 
1.01 (0.98, 
1.01) 
DAS28 0.86 
(0.51, 
1.44) 
1.03 
(0.80, 
1.34) 
1.08 
(0.83, 
1.39) 
3.06 (1.02, 
9.19) 
0.55 
(0.23, 
1.07) 
1.06 
(0.69, 
1.62) 
1.13 (0.97, 
1.32) 
HAQ 0.90 
(0.79, 
1.02) 
1.03 
(0.98, 
1.08) 
1.02 
(0.97, 
1.08) 
0.91 (0.80, 
1.04) 
0.77 
(0.61, 
0.96) 
0.99 
(0.92, 
1.07) 
1.04 (0.99, 
1.09) 
ACPA, anti-citrullinated peptide antibodies; BMI, body mass index; CI, confidence 
interval; CRP, C-reactive protein; DAS28, disease activity score from 28 joints; ESR, 
erythrocyte sedimentation rate; HAQ, disability index of the health assessment 
questionnaire (Rasch transformed); IMD, index of multiple deprivation; RF, rheumatoid 
factor; SJC, swollen joint count; TJC, tender joint count. 
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3.5.3 Auxiliary variables summary 
There were 6 auxiliary variables selected for the linear regression analyses of 
change in DAS28 and HAQ-DI at 6 and 12 months, including TJC at baseline 
and TJC and SJC at 6 and 12 months, together with DAS28 at 3 months. There 
were 10 auxiliary variables suitable for the latent growth curve of change in 
DAS28, which were TJC at baseline and TJC and SJC at all other time points.  
For the growth curve analysis of change in HAQ-DI, the only auxiliary variable 
was DAS28 at 3 months.  Although HAQ-DI measured at any given point 
correlated with HAQ-DI at a later time, all HAQ-DI measurements were already 
included in the model and would therefore be taken into account when missing 
data were accounted for using maximum likelihood estimation.  Table 3-11 
summarises which auxiliary variables were used in the multiple imputation and 
maximum likelihood estimation models.  There are some imputed variables, 
such as HAQ-DI at baseline and covariates in the linear regression models, for 
which there were no suitable auxiliary variables.  Auxiliary variables used for 
missing covariates in the multinomial logistic regression models included 
baseline TJC and DAS28, which predicted missing IMD, and baseline HAQ-DI, 
which predicted missing smoking status.  
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Table 3-11 Summary of auxiliary variables  
Analysis Imputed variable Auxiliary variables 
Linear regression of 
change in DAS28 
DAS28 at baseline  Baseline TJC 
DAS28 at 6 months 3m DAS28 
6m TJC 
6m SJC 
DAS28 at 12 months 3m DAS28 
12m TJC  
12m SJC 
Linear regression of 
change in HAQ-DI 
HAQ-DI at 6 months 3m DAS28 
3m HAQ-DI 
HAQ-DI at 12 months 3m DAS28 
3m HAQ-DI 
6m HAQ-DI 
Latent growth curve model 
of change in DAS28 and 
LCGA 
DAS28 at baseline Baseline TJC 
DAS28 at 3 months 3m TJC 
3m SJC 
DAS28 at 6 months 3m DAS28 
6m TJC 
6m SJC 
DAS28 at 12 months 3m DAS28 
12m TJC  
12m SJC 
DAS28 at 18 months 18m TJC 
18m SJC 
DAS28 at 24 months 3m DAS28 
24m TJC 
24m SJC 
Latent growth curve model 
of change in HAQ-DI and 
LGCA. 
HAQ-DI at 6 months 3m DAS28 
3m HAQ-DI 
HAQ-DI at 12 months 3m DAS28 
3m HAQ-DI 
6m HAQ-DI 
HAQ-DI at 18 months 3m DAS28 
3m HAQ-DI 
6m HAQ-DI 
12m HAQ-DI 
HAQ-DI at 24 months 3m DAS28 
6m HAQ-DI 
12m HAQ-DI 
18m HAQ-DI 
Multinomial logistic 
regression models of 
predictors of trajectory 
class 
IMD Baseline TJC 
Baseline DAS28 
 Smoking status Baseline HAQ-DI 
BL, baseline; DAVAS, disease activity visual analogue score; DAS28, disease activity 
score based upon a count of 28 joints; HAQ-DI, disability index component of health 
assessment questionnaire; IMD, index of multiple deprivation; IV, imputed variable; 
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LCGA, latent class growth analysis; m, months; SJC, swollen joint count; TJC, tender 
joint count; VAS, visual analogue score. 
 
3.6 Summary of Yorkshire Early Arthritis Register 
characteristics 
In total, 1416 YEAR cases were included in the analyses presented here.  Of 
these, 691 cases were from YEAR B and 725 cases were from YEAR C.  The 
cohort was similar to other early RA cohorts in terms of the proportion of 
females and number of patients with positive antibodies (RF and ACPA, 
detailed in Section 3.2).  There were differences between YEAR B and C, with 
higher mean baseline DAS28 and HAQ-DI in the former cohort, which were 
likely due to differences in recruitment, where some patients were recruited to 
randomised controlled trials instead of YEAR C (discussed in 3.2).  A significant 
amount of data were missing from YEAR, which was more marked in YEAR B 
than YEAR C (29% vs. 15%, respectively).  In order to minimise the impact of 
missing data, MI and maximum likelihood estimation were applied and auxiliary 
variables (summarised in Section 3.5 and Table 3-11) were included to reduce 
the risk of bias in estimates obtained from the analyses. 
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 Change in disease activity over time Chapter 4
4.1 Introduction  
Recent decades have seen much interest in predicting drug responses and 
prognosis in early RA, owing to the availability and cost of biologic agents.  
There is strong evidence that preferable outcomes are achieved through early 
and aggressive suppression of inflammation due to RA (as stated in Chapter 1, 
1.6); however, identification of patients most likely to benefit from this approach 
remains a challenge, despite the wealth of research that has been conducted to 
define predictors of RA outcome in terms of disease activity (reviewed in 
Chapter 1, 1.8.2).  The aims of the analyses in this Chapter were to explore 
potential baseline clinical predictors of change in disease activity measured by 
DAS28, which is the parameter upon which current NICE recommendations for 
use of biologic agents in RA is based (Section 1.6 and Figure 1-2).  The first 
analysis used cross-sectional statistical methods (as described in Section 
1.7.1.2), in keeping with most of the published data on predictors of change in 
RA outcomes, and examined change after 6 and 12 months’ therapy with 
standard DMARDs, to see whether information from the YEAR cohort can add 
to previously published work.  An additional aspect to this analysis was that 
missing data were handled using MI.  Of the evidence reviewed in 1.8.2 and 
summarised in Table 1-5, some analyses were limited to cases with complete 
data, (ERAS Study Group, 2000, Jacobi et al., 2003, Hyrich et al., 2006, 
Saevarsdottir et al., 2011, Rojas-Serrano et al., 2011, Ma et al., 2012) and 2 
analyses used a ‘last observation carried forward’ approach to missing data  
(van der Woude et al., 2012, Lu et al., 2014).  However in most cases, the 
methods for handling missing data were not reported (Gonzalez-Gay et al., 
2002, Hider et al., 2009, Mattey et al., 2009, Mori et al., 2010, Soderlin et al., 
2011, Jayakumar et al., 2012, Andersson et al., 2013, Arnold et al., 2014), but 
were likely to have been complete case analyses.  The reason for this surmise 
is that other missing data management techniques are usually described, 
although it is acknowledged that this assumption may not be accurate.  Only 
two studies used modern methods of managing missing data: one used MI (van 
der Woude et al., 2009) and another used a method that was probably 
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maximum likelihood estimation (the method was described but not explicitly 
identified) (Harrison et al., 2005).  Although analysis of complete cases is 
associated with bias (reviewed in 1.7.2.2), it is not possible to say whether 
these published results are likely to have been affected in this way, as patterns 
of missing data were not reported and in all papers except one (Jayakumar et 
al., 2012), quantities of missing data were not given.  However, differences 
between the present analysis and those previously published could be 
attributed to the different missing data management techniques.  
The data were also analysed using a longitudinal approaches to describe 
change in DAS28: growth curve analysis and LCGA.  The latter identifies 
trajectories, or classes, of change in DAS28 within the sample population and 
once these are identified, baseline predictors of class membership can be 
determined using multinomial logistic regression.  The missing data were 
handled using maximum likelihood estimation to reduce bias in the estimates 
and to retain statistical power. 
4.2 Comparison of original and imputed data 
Summary statistics for the YEAR cohorts were described in Chapter 3, Table 3-
1.  Mean values of continuous imputed variables and percentages of categorical 
variables are presented in Table 4-1, which compares these values to those of 
the original dataset.  The means of the imputed values were similar to those of 
the original data, which is reassuring that imputed variables were reasonable.  
Furthermore, proportions of patients who were RF positive and who reported 
EMS duration within each of the 4 categories were similar between original and 
imputed data.  
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Table 4-1 Comparison of summary statistics of imputed and original 
Yorkshire Early Arthritis Register variables 
Categorical variables: (%) 
Original 
dataset 
Imputed 
dataset 
Female gender 66 66 
RF positive  71 72 
ACPA positive 64 64 
Baseline EMS   0-35 minutes 29 29 
40-75 minutes 23 24 
90-210 minutes 27 27 
≥220 minutes 21 20 
Continuous variables: mean (SE) 
Age (years) 57.7 (0.38) 57.7 (0.38) 
Symptom duration (months) 7.1 (0.11) 7.1 (0.11) 
Baseline VAS pain (cm) 6.0 (0.11) 5.9 (0.08) 
Baseline VAS fatigue (cm) 4.6 (0.13) 4.7 (0.08) 
DAS28  Baseline 5.0 (0.04) 5.0 (0.04) 
 6 months 3.6 (0.05) 3.6 (0.05) 
 12 months 3.2 (0.05) 3.2 (0.05) 
HAQ-DI  Baseline 9.8 (0.12) 9.8 (0.12) 
 6 months 7.7 (0.15) 7.8 (0.14) 
 12 months 7.1 (0.15) 7.2 (0.15) 
Percentages rounded to nearest percent, mean values to one decimal place and 
standard errors to two decimal places.  All variables are at baseline, unless otherwise 
stated. 
ACPA, anti-citrullinated peptide antibodies; cm, centimetres; DAS28, disease activity 
score based upon count of 28 joints; EMS, early morning stiffness; HAQ-DI, disability 
index of health assessment questionnaire; N, number of participants; RF, rheumatoid 
factor; SE, standard error of the estimate; VAS, visual analogue score; YEAR, 
Yorkshire Early Arthritis Register.  
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4.3 Baseline predictors of change in disease activity after six 
months 
The mean change in DAS28 from baseline to 6 months, estimated from the MI 
dataset, was -1.36 units (SE 0.05, negative change indicated reduction in 
score).  The linear regression model explained approximately 27% of the 
variance in change in DAS28 (equivalent to the R-square value of the complete 
case model) and the coefficient corresponding to the constant in this model 
indicated that the mean change in DAS28 after 6 months, for YEAR B, female, 
RF and ACPA negative patients with 0 to 35 minutes baseline EMS and mean 
values of symptom duration, baseline DAS28, pain and fatigue VAS (hereafter 
referred to as the ‘baseline patient’) was close to this value, at -1.37 (SE 0.13, 
p<0.0001).  The results of the linear regression analysis are shown in Table 4-2.  
The model suggested that YEAR C patients saw a 0.21 unit greater drop in 
DAS28 after 6 months than those in YEAR B (SE 0.09, p0.026).  Male gender 
was also a significant predictor of greater reduction in disease activity: on 
average, DAS28 reduced by 0.19 units more in males than females after 6 
months (SE 0.09, p=0.032).  Baseline fatigue VAS was an independently 
statistically significant predictor, not only of change in DAS28 after 6 months, 
but in all models of change in DAS28 and HAQ-DI: there was less reduction in 
disease activity and disability with greater baseline fatigue.  Each cm of 
baseline fatigue VAS predicted a 0.05 unit less reduction in DAS28 at 6 months 
(SE 0.02, p=0.007, Table 4-2).  As expected, higher baseline DAS28 was 
associated with greater subsequent fall in DAS28 (probably because the higher 
the initial recorded DAS28, the greater the possible decline after 6 and 12 
months).  There were no significant interactions between YEAR cohort and the 
other independent variables, indicating that the effects of the variables in the 
model were valid for both YEAR B and YEAR C patients.  The Wald tests for 
significance of the overall effect of the interaction between EMS categories and 
YEAR cohort confirmed that these were non-significant (F statistic 0.53, 
degrees of freedom, df 252, p 0.6606) and therefore, the interactions between 
YEAR cohort and EMS categories were not retained in the final model. 
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Table 4-2 Predictors of change in disease activity from baseline to six 
months in Yorkshire Early Arthritis Register 
 
 
 
 
 
Predictor 
Multiple imputation analysis 
N=1416 
Complete case analysis 
N=530 
Coefficient 
(β) 
SE p Coefficient 
(β) 
SE p 
YEAR C -0.21 0.09 0.026 -0.02 0.13 0.903 
Male gender -0.19 0.09 0.032 -0.23 0.13 0.082 
Age* -0.02 0.03 0.457 -0.06 0.05 0.199 
SD (months) 0.00 0.01 0.924 0.01 0.01 0.640 
RF positive 0.13 0.13 0.299 0.17 0.16 0.295 
ACPA positive 0.22 0.15 0.139 0.27 0.15 0.079 
Pain VAS  0.02 0.02 0.471 0.00 0.03 0.954 
Fatigue VAS  0.05 0.02 0.001 0.06 0.02 0.007 
EMS 40-75 
minutes 
0.03 0.12 0.824 0.03 0.17 0.840 
90-210 
minutes 
0.00 0.12 0.974 0.08 0.18 0.673 
≥220 
minutes 
-0.21 0.12 0.107 -0.28 0.21 0.172 
DAS28 -0.67 0.04 <0.0001 -0.64 0.06 <0.0001 
Constant -1.37 0.13 <0.0001 -1.52 0.19 <0.0001 
Results of linear regression analysis using centred continuous independent variables 
(value of independent variable -mean of that variable).  Outcome variable was change 
in DAS28 after 6 months (DAS28 at 6 months – baseline DAS28). 
Statistically significant (p<0.05) coefficients are highlighted in bold. 
*Age was entered into the model (as age in years)/10. 
For EMS, the referent category was 0-35 minutes. 
Independent variables were measured at baseline. 
ACPA, anti-citrullinated peptide antibodies; DAS28, disease activity score from counts 
of 28 joints; EMS, early morning stiffness duration; N, number (of cases); p, probability 
(statistical significance); RF, rheumatoid factor; SD, symptom duration; SE, standard 
error; VAS, visual analogue score (measured in centimetres); YEAR, Yorkshire Early 
Arthritis Register. 
 157 
 
The results of the MI model were compared to those of a complete case model, 
as unexplained inconsistencies may indicate errors in the imputation process 
(as described in Chapter 2, 2.5.5.2).  This revealed that regression coefficients 
and SE were similar between the 2 analyses, with slightly smaller SE in the MI 
model.  As in the MI analysis, the Wald test indicated that the interaction effect 
between cohort and categories of EMS duration was non-significant in this 
model (F statistic 1.32, 506 df, p = 0.2647).  Smaller SEs may have been 
obtained owing to the greater number of cases included in the MI model.  The 
greatest difference between coefficients was found corresponding to the effects 
of YEAR C cohort, which was greater in the MI analysis (-0.21), compared to 
the complete case analysis (-0.02, Table 4-2).  However, this difference of 0.19 
units of DAS28 was small.  
Fit of the linear regression model was checked as described in Chapter 2, 
2.5.4.1, by assessing the distribution of the standardised residual values (where 
residuals were the difference between the value of the actual outcome variable 
and that predicted by the model and the standardised residual is the value of 
the actual residual, divided by its SE) and examining the residual versus fitted 
values plot, which is shown in Figure 4-1.  This revealed that the variance of 
residual values was not dependent on the outcome variable (that is, the 
assumption of homoscedasticity was met).  The histogram in Figure 4-2 shows 
normally distributed residuals, with a mean of approximately zero.  The values 
of the standardised residuals were all within the range -3.3 to 3.3, suggesting 
that there were no outliers.  
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Figure 4-1  Residual versus fittted scatterplot for the linear regression 
model of change in Disease Activity Score using counts of 28 joints 
(DAS28) after 6 months for participants of Yorkshire Early Arthritis 
Register 
Residual values represented the difference between observed change in DAS28 and 
change in DAS28 predicted by the model, whilst fitted values are those predicted by 
the model.  
 
Figure 4-2 Histogram to show distribution of residuals from the linear 
regression analysis of change in Disease Activity Score using counts of 
28 joints (DAS28) after 6 months in Yorkshire Early Arthritis Register  
Residual values represent the difference between actual change in DAS28 and change in 
DAS28 predicted by the model. 
Range of standardised residual values (equal to actual residual divided by its standard 
error): -2.33 to 2.81.  
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4.4 Baseline predictors of change in disease activity after 
twelve months  
After 12 months, the mean reduction in DAS28, estimated from the MI data, 
was 1.75 units (SE 0.05) and overall, 33% of the variance of change in DAS28 
after 12 months was explained by the complete case linear regression analysis 
(indicated by the adjusted R square value).  Table 4-3 shows the results of the 
linear regression analysis of change in DAS28 after 12 months in which the 
change in DAS28 for the ‘baseline patient’ (defined in 4.3) was -1.78, consistent 
with the estimated mean.  The effect of gender on change in DAS28 after 12 
months almost reached statistical significance: males’ DAS28 reduced by 0.16 
units more after 12 months compared to females’ (SE 0.09, p 0.079).  One of 
the independently statistically significant variables in the model was fatigue 
VAS, also significant in the model of change in DAS28 after 6 months (4.3): 
each cm of baseline fatigue predicted a 0.03 unit less reduction in DAS28 at 12 
months (SE 0.01, 0.023).  Pain VAS was also a significant predictor of change 
in DAS28 after 12 months but its effect depended upon cohort.  On average, 
reduction in DAS28 after 12 months was 0.06 units less per cm of baseline pain 
VAS for patients in YEAR B (SE 0.03, p 0.039), but for patients in YEAR C, the 
effect of baseline pain VAS on change in DAS28 was in the opposite direction: 
each cm of baseline pain VAS was associated with a 0.01 unit fall in DAS28.  
Thus, the effect of pain VAS was negligible in YEAR C, but it was associated 
with a slightly lesser reduction in DAS28 for patients in YEAR B.  Another 
significant difference between YEAR B and C patients was found in relation to 
the effect of EMS category in this model.  Although the group of YEAR B 
patients reporting baseline EMS ≥220 minutes did not have a significantly 
different change in DAS28 after 12 months compared to those reporting EMS 0-
35 minutes, the effect was different for YEAR C patients, for whom the average 
fall in DAS28 after 12 months was 0.55 units greater if baseline EMS was ≥220 
minutes than if it was 0-35 minutes.  The effect of baseline DAS28 on change in 
DAS28 was also different between the two cohorts.  For YEAR B cases, fall in 
DAS28 was 0.87 units per unit of baseline DAS28, whereas for YEAR C cases, 
this value was 0.71 per unit of baseline DAS28.  As indicated in Table 4-1, 
mean baseline DAS28 was lower in YEAR C, so this difference may indicate a 
variable rate of change in DAS28, that is, the change in DAS28 per unit of time 
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may differ depending on baseline DAS28, or cohort, or the rate may slow down 
or speed up with time.  This will be explored further in 4.5, where growth curves 
of change in DAS28 with time are described.   
As for the linear regression model of change in DAS28 after 6 months (Section 
4.3), a Wald test was carried out to determine whether the interactions between 
cohort and different categories of EMS were significant in the MI and complete 
case models.  The results indicated that the interactions were significant in the 
MI model (F statistic 2.82, df=369, p=0.0389), but not in the model using 
complete cases, (F statistic 0.93, df= 515, p=0.4278).  Thus, these interactions 
were retained in the MI model, but not in the analysis of the complete cases and 
therefore, differences in the coefficients for EMS categories between the 2 
types of analysis were expected.  Further comparison of the complete case and 
MI analyses revealed similar coefficients and SE.  One of the more marked 
differences between the 2 analyses is found relating to the coefficients for 
ACPA, which was a significant predictor in the complete case model (DAS28 
reduction 0.32 units less in ACPA positive cases, SE 0.15, p 0.037), but not the 
MI model (DAS28 reduction 0.17 units less in ACPA positive cases, SE 0.13, p 
0.227).  ACPA status was the most frequently missing variable in the dataset 
(46% missing, Chapter 3, Table 3-2 ) and this may contribute to bias in 
estimates obtained through analysis of the complete cases.  The presence of 
auto antibodies has been linked to worse outcome, especially lower likelihood of 
remission in RA (reviewed in 1.8.2.3), but the present analysis did not support 
this finding.  The difference between results from the complete case and MI 
analyses highlights the potential for bias in complete case analysis caused by 
missing data.    
 161 
 
Table 4-3 Predictors of change in disease activity from baseline to twelve 
months in Yorkshire Early Arthritis Register  
 
 
 
Multiple imputation analysis 
N=1416 
Complete case analysis 
N=539 
Coefficient 
(β) 
SE p Coefficient 
(β) 
SE p 
Main model effects:  
YEAR C -0.19 0.17 0.268 -0.17 0.13 0.172 
Male gender -0.16 0.09 0.079 -0.40 0.13 0.002 
Age† -0.02 0.03 0.618 -0.40 0.05 0.392 
SD -0.00 0.01 0.757 0.01 0.01 0.676 
RF positive 0.11 0.12 0.347 0.07 0.16 0.667 
ACPA positive 0.17 0.13 0.227 0.32 0.15 0.037 
Pain VAS  0.06 0.03 0.041 0.06 0.04 0.098 
Fatigue VAS  0.03 0.01 0.023 0.05 0.03 0.023 
EMS 40-75 min -0.11 0.17 0.502 0.07 0.16 0.683 
90-210 min 0.16 0.16 0.328 0.22 0.17 0.201 
≥220 min 0.27 0.22 0.226 -0.26 0.20 0.180 
DAS28 -0.87 0.06 <0.00
01 
-0.90 0.09 <0.0001 
Interaction effects:        
Cohort*Pain VAS -0.07 0.04 0.096 -0.10 0.05 0.032 
Cohort*EMS:     
Not included 
in model 
40-75 min 0.18 0.81 0.417 
90-210 min -0.01 0.23 0.950 
≥220 min -0.55 0.28 0.058 
Cohort*DAS28 0.16 0.08 0.052 0.31 0.11 0.004 
Constant -1.78 0.15 <0.00
01 
-1.80 0.17 <0.0001 
Results of linear regression analysis.  Outcome variable was change in DAS28 after 12 
months (DAS28 at 12 months – baseline DAS28). 
Statistically significant (p<0.05) coefficients are highlighted in bold. 
†Age was entered into the model (as age in years)/10. 
*Indicates an interaction effect between 2 variables. 
For EMS, the referent category was 0-35 minutes. 
Independent variables were measured at baseline. 
ACPA, anti-citrullinated peptide antibodies; DAS28, disease activity score from counts 
of 28 joints; EMS, early morning stiffness duration; min, minutes; N, number (of cases); 
NS, non significant model interaction, where p ≥0.10, therefore not included in the final 
model; p, probability (statistical significance); RF, rheumatoid factor; SD, symptom 
duration; SE, standard error; VAS, visual analogue score (measured in centimetres); 
YEAR, Yorkshire Early Arthritis Register. 
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To assess the fit the linear regression model, a scatterplot of the residuals 
versus fitted values (Figure 4-3) was inspected and as there was no discernible 
pattern to the scatterplot, the assumption of homoscedasticity was met.  A 
histogram of the distribution of the residuals (Figure 4-4) showed that they were 
approximately normally distributed with a mean close to zero and that their 
range fell within -3.3 to 3.3, which confirmed that there were no outliers.  
 
 
Figure 4-3 Residual versus fittted plot for the linear regression model of 
change in Disease Activity Score using counts of 28 joints (DAS28) after 
12 months for participants of Yorkshire Early Arthritis Register 
Residual values represented the difference between observed change in DAS28 and 
change in DAS28 predicted by the model, whilst fitted values are those predicted by 
the model.  
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Figure 4-4 Histogram to show distribution of residuals from the linear 
regression analysis of change in Disease Activity using counts of 28 
joints (DAS28) after 12 months in Yorkshire Early Arthritis Register  
Residual values represent the difference between actual change in DAS28 and change 
in DAS28 predicted by the model. 
Range of standardised residual values (equal to actual residual divided by its standard 
error): -2.19 to 2.90 
 
4.5 Latent growth curve model of change in disease activity  
4.5.1 Mean disease activity over time  
Table 4-4 gives mean values of DAS28 at each data collection visit for the 
YEAR cohort as a whole, and then for YEAR B and C separately.  As expected, 
DAS28 decreased with time, which was likely due to treatment for RA.  
However, the mean values did not reduce steadily with time, and the greatest 
reduction in DAS28 occurred initially, from baseline to 3 months.  After the initial 
fall, mean DAS28 continued to decline, but at a slower rate.  In YEAR B, mean 
DAS28 actually increased slightly towards the end of data collection, from 18 to 
24 months.     
0
.1
.2
.3
.4
D
e
n
s
it
y
-2 -1 0 1 2 3
Standardized residuals
 164 
 
Table 4-4 Means and standard errors of Disease Activity Score from a 
count of twenty-eight swollen and tender joints (DAS28) in Yorkshire Early 
Arthritis Register 
 Mean DAS28 (SE) 
Time 
YEAR 
(whole cohort) 
YEAR B YEAR C 
Baseline 5.01 (0.07) 5.32 (0.05) 4.70 (0.06) 
3 months 3.61 (0.05) 3.91 (0.07) 3.38 (0.06) 
6 months 3.62 (0.05) 3.81 (0.07) 3.45 (0.07) 
12 months  3.21 (0.07) 3.42 (0.07) 3.04 (0.06) 
18 months  3.10 (0.05) 3.26 (0.08) 2.98 (0.07) 
24 months  3.02 (0.05) 3.32 (0.08) 2.79 (0.06) 
DAS28, disease activity score based upon count of 28 tender and swollen joints and C-
reactive protein; SE, standard error; YEAR, Yorkshire Early Arthritis Register. 
 
4.5.2 Linear growth curve model of change in disease activity  
Data from 1397 participants of YEAR were included in the current analysis. In 
18 cases, DAS28 was missing from all visits and these were excluded. The 
linear model did not fit the data well, which was expected, as the mean values 
of DAS28 did not decrease by the same amount at each visit (as shown in 
Table 4-4), and therefore were not expected to follow a linear trend with time.  
The poor fit of the model was confirmed by the 2 value: 939.03, degrees of 
freedom (df)= 20, statistical probability of obtaining a 2 value as high, or higher, 
if the model was a perfect fit to the data, p <0.0001.  Furthermore, the CFI value 
was small (0.537) and RMSEA too high for good model fit (0.181; 90% CI 0.172 
to 0.191).  
Although the model was a poor fit to the data and was rejected, it is described 
here for the purpose of comparison with subsequent models.  Parameters 
estimated by the model are displayed in Table 4-5.  The estimated mean 
intercept from the model, which represented the mean DAS28 at baseline, was 
4.43 (SE 0.06, p<0.001), which was lower than the mean value of 5.01 
calculated directly from the data (Table 4-5).  This discrepancy between the 
model-estimated value and the sample mean DAS28 at baseline was reflected 
by the relatively high value of the intercept variance (0.92).  The mean slope of 
the model, which represented the mean change in DAS28 per unit time, where 
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one unit of time was 3 months, was -0.17 (SE 0.01, p<0.001).  In other words, 
according to the model, DAS28 decreased by 0.17 units on average, every 3 
months.  The negative value of the covariance (-0.02) indicated that a higher 
baseline DAS28 (or intercept) was associated with greater reduction in DAS28 
per unit time (or slope), and although its value was small, it was statistically 
significant (p=0.033).  Thus, the model implied that rate of change in DAS28 
was greater with higher baseline DAS28.  The model included YEAR cohort as 
a time- invariant covariate and therefore, the effects of cohort on intercept and 
slope were estimated.  The model implied that for YEAR C cases, mean 
baseline DAS28 (intercept) was 0.57 units lower than for cases from YEAR B 
(SE 0.07, p <0.001).  This was close to the difference of 0.62 units, obtained by 
simply subtracting mean baseline DAS28 in YEAR C from that of YEAR B.  The 
difference in the rate of change in DAS28 was not statistically significant 
(estimate 0.02, SE 0.01 and p = 0.193), which implied that DAS28 declined by 
the same amount every 3 months in YEAR B and C.  The differences in the 
sample means and means estimated in the model are illustrated in Figure 4-5, 
which compares the linear growth curve estimated by the model and the actual 
mean values of DAS28 against time.  
Table 4-5 Parameters estimated by the linear growth curve model of 
change in disease activity over time in Yorkshire Early Arthritis Register  
Parameter Estimate (SE) p 
Mean intercept 4.43 0.06 <0.001 
Intercept variance 0.92 0.07 <0.001 
Mean linear slope -0.17 0.01 <0.001 
Linear slope variance 0.02 0.00 <0.001 
Intercept/ linear slope covariance 
 
-0.02 0.01 0.033 
Regression of parameters on YEAR C cohort    
Mean intercept on YEAR cohort -0.57 0.07 <0.001 
Mean slope on YEAR cohort 0.02 0.01 0.193 
P, statistical probability; SE, standard error, YEAR, Yorkshire Early Arthritis Register 
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Figure 4-5 Graph to show how the sample mean Disease Activity Score from a count of 28 joints (DAS28) changed with time, 
compared to the means estimated by the linear growth curve model of change in DAS28 in Yorkshire Early Arthritis Register  
Estimated means refers the means estimated by the linear growth curve, which are shown compared to the sample means. 
DAS28, disease activity score based upon count of 28 swollen and tender joints and C-reactive protein. 
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4.5.3 Quadratic growth curve model of change in disease activity 
As the linear model was not a good fit to the data and the sample means 
appeared to follow a curved rather than linear change over time, a quadratic 
component was added to the model. The estimates produced by the model 
are shown in Table 4-6.   Again, there was poor fit of the model suggested by 
the 2 value of 403.321, df 15, p=<0.0001, CFI of 0.805 and RMSEA of 0.136 
(90% CI 0.125- 0.148).  The mean intercept estimated by the quadratic 
model, which represented the mean DAS28 at baseline, was 5.02 (SE 0.05, 
p<0.001).  The mean linear slope was -0.64 (SE0.03, p<0.001), which 
implied that DAS28 initially reduced by 0.64 units every 3 months, and the 
mean quadratic slope was 0.05 (SE 0.00, p<0.001) which implied that the 
rate of reduction in DAS28 reduced slightly with time.   
In this model, the variances of the intercept, linear and quadratic slope 
values, which represented variation in baseline DAS28 and change in 
DAS28 over time were 0.73 (SE 0.07, P<0.001), 0.16 (SE 0.02, p<0.001) 
and 0.00 (SE 0.00, p<0.001), respectively.  The covariance between 
intercept (baseline DAS28) and linear slope (initial rate of change in DAS28) 
was -0.003, suggesting that initial rate of reduction in DAS28 was slightly 
more marked with increasing baseline DAS28, however, this result was not 
statistically significant (SE 0.03, p=0.924).  The covariance between the 
intercept and quadratic slope (-0.004, SE 0.003, p=0.239) was also non-
significant, but its slight negative value indicated that fall in DAS28 may have 
become more marked with time in cases with higher baseline DAS28.  The 
covariance between linear and quadratic slopes was -0.0017 (SE 0.003, 
p<0.001), so in cases with higher initial rate of change in DAS28 (that is, a 
positive change in DAS28 score, so it may have increased initially), the rate 
of fall in DAS28 should have increased with time.  This is a plausible finding, 
especially as a delay in drop in DAS28 could be attributed to a delay in 
treatment for RA.  However, the magnitude of the covariance was small, 
indicating that although this relationship between initial rate of change in 
DAS28 and subsequent change in this rate was detected, the size of the 
effect was not large.  
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The model implied that there were significant differences for the two cohorts 
and that the mean intercept, or baseline DAS28 was 0.67 units lower in 
YEAR C (SE 0.07, p<0.001).  Furthermore, the mean initial rate of change 
(linear slope) was more positive in YEAR C.  That is, DAS28 did not fall as 
quickly for participants of YEAR C, where the model estimated initial fall in 
DAS28 was 0.51, compared to a fall in DAS28 of 0.64 units per 3 months in 
YEAR B.  There was also a statistically significant difference in quadratic 
slope between cohorts: the overall quadratic slope was positive, which 
implied that the rate of reduction in DAS28 slowed with time.  The estimate 
for the quadratic slope component of the model was 0.05 for YEAR C, 
compared to 0.06 in YEAR B.  This very small difference of 0.01 units of 
DAS28 is unlikely to have clinical significance.  
 
Inspection of the growth curve (shown in Figure 4-6) suggested an 
improvement over the linear model illustrated in Figure 4-5 in terms of the 
shape of the curve, but there were significant differences between the fitted 
curve and the sample means, especially at 3, 12 and 18 months.  Therefore, 
to improve the fit of the curve, the next model allowed free estimation of 
factor loadings related to the effect of time on DAS28 at certain time points. 
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Table 4-6 Parameters estimated by the quadratic growth curve model of 
change in disease activity over time in Yorkshire Early Arthritis 
Register  
Parameter 
Estimate (SE) p 
Mean intercept 5.07 (0.05) <0.001 
Intercept variance 0.58 0.12 <0.001 
Mean linear slope -0.64 (0.03) <0.001 
Linear slope variance 0.18 0.04 <0.001 
Mean quadratic slope 0.06 (0.00) <0.001 
Quadratic slope variance 0.00 0.00 <0.001 
Intercept/ linear slope covariance 0.03 0.06 0.656 
Intercept/ quadratic slope covariance -0.01 0.01 0.242 
Linear slope/ quadratic slope covariance 
 
-0.02 0.01 <0.001 
Regression of parameters on YEAR C 
cohort 
   
Mean intercept on YEAR cohort -0.67 0.07 <0.001 
Mean linear slope on YEAR cohort 0.13 0.04 0.002 
Mean quadratic slope on YEAR cohort -0.014 0.005 0.003 
P, (statistical) probability; SE, standard error; YEAR, Yorkshire Early Arthritis 
Register. 
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Figure 4-6 Graph to show how the sample mean Disease Activity Score from a count of 28 joints (DAS28) changed with time, 
compared to the means estimated by the quadratic growth curve model of change in disease activity in Yorkshire Early 
Arthritis Register  
Estimated means refers the means estimated by the quadratic growth curve, which are shown compared to the sample means. 
DAS28, disease activity score based upon count of 28 swollen and tender joints and C-reactive protein. 
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4.5.4 Freed loading growth curve model of change in disease 
activity   
The third growth curve model applied to investigate change in DAS28 was a 
freed loading model, in which the factor loadings of linear slope onto DAS28 
at baseline and 24 months were specified as 0 and 1, respectively, whilst the 
remaining factor loadings from linear slope to DAS28 at 3,6,12 and 18 
months were freely estimated by the model (freed loading models were 
explained in Chapter 2, 2.5.4.2).  The model fit was an improvement on 
previous models, as implied by the lower 2 value of 155.657, df 16, 
p<0.0001.  The CFI value was also improved (0.930) and RMSEA was 
acceptable: 0.079 (90% CI 0.68, 0.091).  The parameters estimated by the 
model are displayed in Table 4-7.  The model-estimated intercept, or mean 
baseline DAS28, was 5.31 (SE 0.06), and was closer to the sample mean 
baseline DAS28 of 5.32 than the intercepts of the linear or quadratic models.  
The mean linear slope estimated by the model (or mean change in DAS28) 
was -2.00, which implied that DAS28 reduced by 2.00 units per 24 months.  
However, the variance of this estimate (1.75) suggested that there was 
considerable inter-individual variation in this rate of change in DAS28.  The 
linear slopes at 3,6,12, and 18 months were freely estimated by the model 
and the estimates of linear slope at these time points represented change in 
DAS28 as a proportion of overall change in DAS28 at 24 months (which was 
fixed at 1).  At 3 months, most of the change in DAS28 had occurred, with an 
estimated factor loading from linear slope to DAS28 at 3 months of 0.67.  
The corresponding factor loadings to DAS28 at 6, 12, and 18 months were 
0.74, 0.94 and 0.97, respectively.  Thus, the model implied that mean DAS28 
followed a downward trend from baseline to 24 months with maximal 
reduction at 24 months.  When these model-implied results are compared to 
the sample means (Table 4-4), the growth curve described by this model 
seems appropriate.  The model-estimated covariance between intercept and 
linear slope was -0.91 (SE 0.12, p<0.001), which implied that higher baseline 
DAS28 (or intercept) was associated with a greater rate of reduction of 
DAS28 (or linear slope).  As higher initial DAS28 has a greater potential for 
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negative change, this was anticipated and was closer to what was expected 
than the results of the previous models: the value of this covariance was -
0.02 (SE 0.01, p=0.033) according to the linear model and 0.03 (SE 0.06, 
p=0.656) according to the quadratic model.   
Table 4-7 also lists values of the variances of the random error, or 
measurement error, for the value of DAS28 at each time point.  R square 
values were calculated, using the sample means and variances of DAS28 at 
each time point, and indicated that variation in DAS28 explained by the 
model was between 80% and 99%, except for DAS28 measured at 12 
months, which was only 45%.  It is also noteworthy that the estimates of 
variance in measurement error were all statistically significant.   
Therefore, the model explained most of the variability in DAS28 over time 
and fit indices indicated a reasonable fit of the model to the data, which was 
confirmed by graphical representation of the model, shown in Figure 4-7.  
Here, model predicted means are compared to the sample means and there 
appears to be better fit than the previous two models.  However, there was 
considerable inter-individual variation, as indicated by the estimates of 
variance and shown in Figure 4-8, where recorded DAS28 scores from a 
random sample of 140 cases (approximately 10%) were plotted to show that 
trend in DAS28 varied considerably between individuals.  Further 
investigation into the variation in DAS28 growth curves between participants 
was therefore warranted and is provided by exploration of growth class 
analysis in the following analysis (Section 4.6).  
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Table 4-7 Parameters estimated by the freed loading growth curve 
model of change in disease activity over time in Yorkshire Early 
Arthritis Register  
Parameter Estimate SE p 
Mean intercept 5.31 0.06 <0.001 
Intercept variance 1.37 0.15 <0.001 
Mean linear slope  -2.00 0.07 <0.001 
Linear slope variance 1.75 0.20 <0.001 
Linear slope at baseline 0.00   
Linear slope at 3m 0.67 0.02 <0.001 
Linear slope at 6m 0.74 0.02 <0.001 
Linear slope at 12m 0.94 0.02 <0.001 
Linear slope at 18m 0.97 0.02 <0.001 
Linear slope at 24m 1.00   
Intercept/ linear slope covariance 
 
-0.91 0.12 <0.001 
Regression of parameters on YEAR C cohort    
Mean intercept on YEAR cohort -0.62 0.08 <0.001 
Mean linear slope on YEAR cohort 0.18 0.10 0.064 
    
Variances of error associated with measurement of: SE R2 
DAS28 at baseline 0.64 0.15 0.80 
DAS28 at 3 months 1.63 0.08 0.99 
DAS28 at 6 months 1.29 0.07 0.94 
DAS28 at 12 months 0.85 0.05 0.45 
DAS28 at 18 months 0.91 0.06 0.81 
DAS28 at 24 months 0.93 0.06 0.80 
DAS28, disease activity based upon count of 28 joints; P, statistical probability; R 2, 
R-Square value, or variance in parameter explained by the model; SE, standard 
error.   
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Figure 4-7 Graph to show how the sample mean Disease Activity Score from a count of 28 joints (DAS28) changed with time, 
compared to the means estimated by the freed loading growth curve model of change in disease activity in Yorkshire Early 
Arthritis Register  
Estimated means refers the means estimated by the freed loading growth curve, which is shown compared to the sample means. 
DAS28, disease activity score based upon count of 28 swollen and tender joints and C-reactive protein. 
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Figure 4-8 Graph to show actual values of Disease Activity Score from a count of 28 joints (DAS28) from a random sample of 
140 cases from Yorkshire Early Arthritis Register 
DAS28, disease activity score based upon count of 28 swollen and tender joints and C-reactive protein 
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4.6 Identification of latent trajectories of change in disease 
activity 
Using the freed loading growth curve described in 4.5.4, increasing numbers of 
trajectories were applied to the model and indices of fit (including AIC, BIC, 
LMR-LRT and BLRT, as described in 2.5.4.3) were compared in order to 
determine the optimal number of trajectories.  Also presented here are the  
numbers of cases within each class, average probability of class membership, 
and descriptions and graphical representations of each trajectory.  Table 4-6 
displays the fit indices for successive numbers of trajectories, together with the 
numbers of cases assigned to each class.  Based upon this information, the 2 
class model (trajectories are shown in Figure 4-9) was accepted as the best fit.  
This is because the BIC does not improve significantly when a third class is 
added to the 2 class model.  Furthermore, entropy reduced from 0.605 to 0.516 
with the addition of a third class, suggesting the three class model did not fit the 
data as well.  Inspection of the 3 trajectories, which are graphically displayed in 
Figure 4-10, reveals that class 1 cases had DAS28 scores that were highest at 
baseline, and remained high (>4.75) throughout follow up, class 2 cases had 
the lowest DAS28 scores at baseline and throughout, whilst class 3 cases had 
high DAS28 at the start, which then fell dramatically and by 18 months, the 
trajectory was similar to that of class 2.   
In the 2 class model, a quarter of cases were assigned to class 1 and the 
remainder to class 2.  Class 1 may be described as ‘high DAS28’, because for 
this trajectory mean DAS28 remained high, over 4.7, throughout the study.  The 
mean probability of a patient assigned to trajectory 1 actually belonging to this 
class was 0.81 and therefore, there was a probability of 0.19 of actually 
belonging to trajectory 2.  For the 75% of cases assigned to class 2, ‘low 
DAS28’, mean DAS28 fell sharply from 0 to 3 months and then continued to 
reduce throughout follow up, to approximately 2.7 at 24 months.  There was a 
probability of 0.90 that a patient assigned to trajectory 2 belonged to this class 
and 0.10 that they should have been classified in the other.     
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Out of interest, a 4 class model also was tested, but was rejected for several 
reasons.  The first reason was that the solution produced non equal highest log-
likelihood values, indicating that it was a local maximum.  Finding local maxima 
is a recognised problem associated with LCGA, especially with higher numbers 
of trajectory classes, and indicates that the solution provided by the software 
was the best for the given start values, but may not be the best overall solution 
(Berlin et al., 2014).  The number of random starts were increased from 500 to 
600 to give the final 4 class model, but the decrease in BIC was modest 
compared to that of the 3 class model and entropy was only 0.594, which was 
lower than that of the model with 2 classes. 
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Table 4-8 Fit indices and numbers of cases in each trajectory for models of change in disease activity with increasing numbers 
of trajectory classes 
Number of 
trajectory 
classes in 
model 
Number of cases assigned 
to each class, based on the 
estimated model (%) 
AIC BIC Adjusted BIC 
LMR-LRT  
p-value 
BLRT 
p-value Entropy 
1 Trajectory 1 1398  (100) 86563 87469 86920    
2 Trajectory 1  359 (25)        20244 20349 20285 <0.0001 <0.0001 0.605 
Trajectory 2 1038 (75) 
3 Trajectory 1  312 (25) 20236 20356 20283 0.0014 <0.0001 0.516 
Trajectory 2 257 (18) 
Trajectory 3  797 (57) 
4 Trajectory 1  11 (1) 20215 20351 20269 0.0184 <0.0001 0.594 
Trajectory 2 374 (27) 
Trajectory 3  365 (26) 
Trajectory 4 647 (46) 
*For the 4 class model, log-likelihood values were not equal, indicating that the solution was probably a local maximum. 
AIC, Akaike information criteria; BIC, Bayesian information criteria; BLRT, Bootstrap likelihood ratio test; LMR-LRT, Lo, Mendell and Rubin likelihood 
ratio test; p, statistical probability 
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Figure 4-9 Illustration of the two latent trajectory classes of change in Disease Activity Score based upon counts of 28 joints 
(DAS28) 
The proportion of cases assigned to each trajectory class is given as a percentage of the whole cohort.  
DAS28, disease activity score based upon count of 28 swollen and tender joints and C-reactive protein. 
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Figure 4-10 Illustration of the three latent trajectory classes of change in Disease Activity Score based upon counts of 28 joints 
(DAS28) 
The proportion of cases assigned to each trajectory class is given as a percentage of the whole cohort.  
DAS28, disease activity score based upon count of 28 swollen and tender joints and C-reactive protein. 
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4.7 Predictors of disease activity trajectory class membership 
For trajectory class 2, the ‘low DAS28’ group,  membership was more likely in 
male patients (OR 1.49; 95% CI 1.12, 1.90; p=0.007) and less likely in cases 
who were ACPA positive (OR 0.58; 95% CI 0.37, 0.92; p=0.020), or those 
reporting higher baseline fatigue.  There was a 10% reduction in the odds of 
falling into the low disease activity trajectory per cm of baseline fatigue VAS: 
OR=0.90; 95% CI 0.86, 0.94; p<0.001.  Membership of either YEAR cohort did 
not significantly affect the trajectory class membership and neither did IMD 
quartile, RF, or possession of one or more shared epitope alleles.  In a prior 
model that did not include fatigue VAS (results are shown in Appendix 7), IMD 
significantly predicted DAS28 trajectory.  IMD quartile 1, which represented the 
most deprived, compared to the least deprived areas was associated with 
membership of the less favourable trajectory: OR 1.50; 95% CI 1.10, 2.04, 
p=0.030.  As this suggested that there may be an association between baseline 
variables and IMD, mean values were compared across the 4 quartiles of IMD, 
shown in Appendix 8.  Mean fatigue VAS was highest for those represented by 
IMD 2 and lowest for the least deprived, IMD 4.  A one-way between groups 
analysis of variance indicated that there was a small but statistically significant 
difference of 0.71cm of fatigue VAS between IMD groups 2 and 4 (p=0.030). 
To see whether there was a difference if 2 copies of the shared epitope were 
present, a further model was tested, comparing the effect of one and two copies 
to no shared epitope alleles, but the effects were not statistically significant: 
regression coefficient for one copy was -0.118 (p=0.545) and for two copies -
0.357 (p=0.110).  The results of the multinomial logistic regression analysis of 
class 2 membership are displayed in Table 4-9. 
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Table 4-9  Results of multinomial logistic regression analysis of predictors 
of‎class‎2‎trajectory‎(‘low‎disease‎activity’)‎membership 
Predictor Coefficient Odds ratio (95% CI) p 
YEAR C cohort 0.06 1.06 (0.78, 1.41) 0.690 
Male gender 0.40 1.49 (1.12, 1.90) 0.007 
Age (years) -0.00 1.00 (0.99, 1.01) 0.661 
RF positive -0.10 0.90 (0.60, 1.37) 0.631 
ACPA positive -0.55 0.58 (0.37, 0.92) 0.020 
Shared epitope positive -0.24 0.79 (0.54, 1.16) 0.223 
IMD quartile 1 -0.34 0.71 (0.49, 1.04) 0.082 
2 -0.24 0.79 (0.54, 1.15) 0.217 
3 0.03 1.03 (0.70, 1.52) 0.890 
Fatigue VAS (cm) -0.10 0.90 (0.86,  0.94) <0.001 
Results of multinomial logistic regression analysis.   
Outcome variable was membership of class 2 trajectory, described in 4.6. 
Statistically significant (p<0.05) coefficients are highlighted in bold. 
For IMD, the referent category was the 4th quartile, which was the least deprived group:  
higher levels of deprivation were represented by reducing quartile number . 
Independent variables were measured at baseline. 
ACPA, anti-citrullinated peptide antibodies; CI, confidence interval; cm, centimetres; p, 
probability (statistical significance); RF, rheumatoid factor; VAS, visual analogue score; 
YEAR, Yorkshire Early Arthritis Register. 
4.7.1 Sub analysis of Yorkshire Early Arthritis Register C  
In order to test whether trajectory class was influenced by factors such as BMI, 
smoking and the presence of comorbidities, a sub analysis of all 713 cases from 
YEAR C with at least one DAS28 measurement was undertaken.  Although this 
analysis was likely to have less power than the analysis of the whole cohort, the 
covariates of interest were not collected as part of YEAR B (or were largely 
missing, in the case of comorbidities) and therefore YEAR B could not be 
included in the present analysis.  The growth curve model and its latent classes 
were identified again, for this smaller sample, and then the predictors of 
trajectory class membership were identified.  
4.7.1.1 Latent growth curve model of change in disease activity in 
Yorkshire Early Arthritis Register C 
As anticipated, the growth curve that best fit the data from YEAR C was a freed 
loading model, which is the same model type that was the best fit for the whole 
cohort.  Table 4-10 gives fit indices for the linear, quadratic and freed loading 
 183 
 
growth curve models applied to YEAR C and shows that the freed loading 
model had the lowest Chi-square and RMSEA values and the highest CFI.  
Table 4-10 Fit statistics for successive models of change in disease 
activity in Yorkshire Early Arthritis Register C 
Model 2 df p CFI  RMSEA 
Linear 403.9 16 <0.0001 0.649 0.184 
Quadratic 206.6 12 <0.0001 0.824 0.151 
Freed 
loading  
87.1 12 <0.0001 0.932 0.094 
CFI, comparative fit index; df, degrees of freedom; p, (statistical) probability; RMSEA, 
root mean square error  of approximation; 2 Chi Square. 
 
Table 4-11 gives the estimates derived from the freed loading model of change 
in DAS28 in YEAR C, which were similar to those for the whole cohort (Table 4-
7), but with a lower value of the intercept, which represents the lower baseline 
mean DAS28 in YEAR C. 
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Table 4-11 Parameters estimated by the freed loading growth curve model 
of change in disease activity over time in Yorkshire Early Arthritis 
Register C 
Parameter Estimate SE p 
Mean intercept 4.68 0.06 <0.001 
Intercept variance 1.48 0.20 <0.001 
Mean linear slope  -1.89 0.07 <0.001 
Linear slope variance 1.70 0.26 <0.001 
Linear slope at baseline 0.00   
Linear slope at 3m 0.65 0.03 <0.001 
Linear slope at 6m 0.68 0.03 <0.001 
Linear slope at 12m 0.89 0.03 <0.001 
Linear slope at 18m 0.93 0.03 <0.001 
Linear slope at 24m 1.00   
Intercept/ linear slope covariance -0.93 0.22 <0.001 
m, months; SE, standard error; p, (statistical) probability. 
4.7.1.2 Identification of latent trajectories of change in disease activity 
in Yorkshire Early Arthritis Register C 
Two trajectory classes were also selected for the YEAR C sub analysis, based 
upon the fit indices shown in Table 4-12 and the fact that in the 3 class model, 
the solution was likely to have been a local maximum because log- likelihood 
ratios were not equal for multiple starting values.  The 2 trajectories are 
illustrated in Figure 4-11.  Class 1, which included 77% of the cases from YEAR 
C, was more favourable, with a mean DAS28 that dropped steeply from 
baseline to 3 months and then continued to fall down to approximately 2.27 at 
24 months.  On the other hand, the less favourable class 2 included 23% of 
cases with higher mean DAS28 at baseline that remained persistently moderate 
throughout follow up (>4.47), with a slight overall reduction from 3 to 24 months.  
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Table 4-12 Fit indices and numbers of cases in each trajectory for models with increasing numbers of trajectory classes of 
disease activity in Yorkshire Early Arthritis Register C 
 
Number of 
trajectory 
classes in 
model 
Number of cases assigned 
to each class, based on the 
estimated model (%) 
AIC BIC Adjusted BIC 
LMR-LRT  
p-value 
BLRT 
p-value Entropy 
1 Trajectory 1 713  (100) 43794 44516 44014    
2 Trajectory 1  549 (77) 10915 10997 10940 0.0007 <0.0001 0.663 
Trajectory 2 164 (23) 
3* Trajectory 1  257 (36) 10903 10999 10932 0.2368 <0.0001 0.645 
Trajectory 2 82 (11) 
Trajectory 3  374 (52) 
*For the 3 class model, log-likelihood values were not equal, indicating that the solution was probably a local maximum. 
AIC, Akaike information criteria; BIC, Bayesian information criteria; BLRT, Bootstrap likelihood ratio test; LMR-LRT, Lo, Mendell and Rubin likelihood 
ratio test; p, (statistical) probability. 
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Figure 4-11 Illustration of the two latent trajectory classes of change in Disease Activity Score based upon counts of 28 joints 
(DAS28) for Yorkshire Early Arthritis Register C 
The proportion of cases assigned to each trajectory class is given as a percentage of the whole cohort.  
DAS28, disease activity score based upon counts of 28 joints and C-reactive protein. 
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4.7.1.3 Predictors of disease activity trajectory class membership in 
Yorkshire Early Arthritis Register C 
Table 4-13 summarises the results of the multinomial logistic regression 
analysis of predictors of trajectory class 2 (least favourable) membership.  
Predictors of trajectory class membership 2 were: ACPA positivity (OR 1.99; 
95% CI 1.05, 3.77; p=0.034), higher BMI, and greater baseline fatigue.  A 
single unit increase in baseline BMI was associated with a 4% increase in 
the odds of membership of trajectory class 2 and a 1cm increase in baseline 
VAS was associated with a 10% increase in the odds of trajectory class 2 
membership.  Contrary to the analysis of the whole cohort, gender did not 
have a significant effect on trajectory class in YEAR C.  Lower SES was 
almost significant (at the 5% level of statistical significance) as a predictor of 
membership of the poorer outcome trajectory.  Compared to those in the 4th 
quartile of IMD (that is, the high SES quartile), those in the 1st quartile were 
more likely to belong to the less favourable class 2 trajectory: OR 1.83; 
95%CI 0.99, 3.40; p=0.054.  In a prior model that did not include fatigue VAS 
(shown in Appendix 7, Table 7B), the lower 2 quartiles of IMD predicted 
worse DAS28 trajectory: OR of membership of more favourable trajectory 
was 0.54; 95% CI  0.32, 0.88; p=0.039 and 0.55; 95% CI 0.34, 0.90; p=0.045 
for the lowest and second-lowest quartiles of IMD, respectively.  Similarly, in 
the model without fatigue, male gender predicted the more favourable 
DAS28 cohort: OR 2.13; 95% CI 1.46, 3.10; p=0.001.  A relationship 
between fatigue VAS and IMD quartile has already been observed (Section 
4.7 and Appendix 8), and furthermore, mean baseline fatigue VAS was 
greater in women than men: 5.01cm, compared to 3.99cm.  Age, RF 
positivity, baseline number of pack years of cigarette smoking and the 
presence of comorbidities were not significant predictors of trajectory class 
membership.  
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Table 4-13  Results of multinomial logistic regression analysis of 
predictors of disease activity class 2 trajectory (less favourable) 
membership for Yorkshire Early Arthritis Register C 
Predictor Coefficient Odds ratio (95% CI) p 
Male gender -0.11 0.90 (0.58, 1.38) 0.618 
Age (years) -0.00 1.00 (0.98, 1.01) 0.839 
RF positive -0.14 0.87 (0.49, 1.55) 0.640 
ACPA positive 0.69 1.99 (1.05, 3.77) 0.034 
Shared epitope 
positive 
0.13 1.14 (0.85, 1.51) 0.384 
IMD quartile 1 0.61 1.83 (0.99, 3.40) 0.054 
2 0.43 1.53 (0.83, 2.82) 0.171 
3 0.34 1.40 (0.74 2.67) 0.304 
BMI (Kg/m2) 0.04 1.04 (1.00, 1.07) 0.033 
Smoking (pack 
years) 
0.01 1.01 (0.99, 1.02) 0.185 
Comorbidities  0.22 1.24 (0.76, 2.02) 0.386 
Fatigue VAS (cm) 0.09 1.10 (1.03, 1.17) 0.006 
Results of multinomial logistic regression analysis.   
Outcome variable was membership of class 2 trajectory, described in 4.7.1.3. 
Statistically significant (p<0.05) coefficients are highlighted in bold. 
For IMD, the referent category was the 4th quartile, which was the least deprived 
group:  higher levels of deprivation were represented by reducing quartile number . 
Independent variables were measured at baseline. 
One pack year was the equivalent of smoking 20 cigarettes per day for one year.  
Comorbidities were classified as present /absent. 
ACPA, anti-citrullinated peptide antibodies; BMI, body mass index; CI, confidence 
interval; cm, centimetres; IMD, index of multiple deprivation; Kg/m2, kilograms per 
metre square; p, (statistical ) probability; RF, rheumatoid factor; VAS, visual 
analogue score. 
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4.8 Summary of predictors of change in disease activity  
The present chapter has explored potential predictors of change in disease 
activity, measured by DAS28, over 24 months in early RA using both cross-
sectional and longitudinal methods.  In the cross-sectional approach, linear 
regression with MI to account for missing data was used to investigate 
change in DAS28 from baseline to 6 and 12 months.  The results are 
summarised in Table 4-14.  As expected, higher baseline DAS28 was 
associated with greater subsequent fall, which is likely because there is 
greater scope for reduction, the greater the initial value.  Another expected 
finding was that DAS28 continued to fall after the 6 month assessment, as 
optimisation of RA treatment continued, and therefore, decrease in DAS28 
from baseline was greater after 12 months than 6 months.  Reduction in 
DAS28 was more marked for male patients and greater baseline fatigue VAS 
was predictive of lesser reduction in DAS28.  Male gender as a predictor of 
superior outcome in RA is well described (1.8.2.1), so this result was in 
keeping with previous findings; however, fatigue as a predictor of outcome 
has not been previously reported.  Contrary to previous reports (reviewed in 
1.8.2.3) autoantibodies and symptom duration were not statistically 
significant predictors of change in DAS28 in the cross sectional analyses, but 
it is noteworthy that ACPA status was the most frequently missing variable 
and this could possibly have distorted the results.   
Data from YEAR B and C were analysed together in the regression models, 
but differences between the 2 cohorts were considered and ‘cohort’ was 
included as a predictor variable, together with interactions between ‘cohort’ 
and each of the other predictor variables.  Higher baseline DAS28 was 
associated with a greater fall in DAS28 after 12 months, as described above, 
however this effect was less marked for YEAR C cases.  In addition, YEAR C 
patients had a slightly greater (0.21 unit) fall in DAS28 after 6 months, which 
could be due to different treatment approaches, where YEAR C patients 
were offered MTX as first line treatment and YEAR B were offered SSA.  
Another difference between the two cohorts related to the effect of baseline 
pain VAS on change in DAS28 after 12 months: for YEAR B cases, there 
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was a very small (0.06 unit) lesser reduction in DAS28 per cm of baseline 
pain VAS, whilst the effect in YEAR C was even smaller (0.01 unit), but in the 
opposite direction, that is, associated with a greater decline in DAS28.  
Although the effects of pain VAS are in opposing directions for YEARs B and 
C, the sizes of these effects are probably small enough to be considered 
negligible.   
Table 4-14 Summary of results from linear regression analyses of 
change in disease activity after six and twelve months 
 Predictors of change in DAS28 from baseline  
 6 months  12 months 
Mean change from 
baseline 
-1.36 -1.75 
Significant baseline predictors of greater reduction: 
 Male gender  
 YEAR C cohort  
  Pain VAS (YEAR C, 
small/ negligible effect) 
 DAS28 DAS28 
Significant baseline predictors of lesser reduction:  
 Fatigue VAS Fatigue VAS 
  Pain VAS (YEAR B) 
Variation in outcome explained by model:  
 27% 33% 
DAS28, disease activity score based upon counts of 28 joints; EMS, early morning 
stiffness; VAS, visual analogue score; YEAR, Yorkshire Early Arthritis Register. 
 
The longitudinal analyses used a latent growth curve to describe change in 
DAS28 over time, and then LCGA to determine an optimal number of growth 
curve trajectories, of which 2 were identified.  Multinomial logistic regression 
was applied to identify baseline predictors of trajectory class membership.  
The same analyses were repeated using only YEAR C data in order to test 
the influence of additional covariates that were not available in YEAR B.  
Table 4-15 summarises the results of these analyses.  Male gender was 
predictive of more favourable outcome in the analysis that included the whole 
YEAR cohort, whilst ACPA positivity and greater fatigue VAS predicted 
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worse outcome.  Additionally, the sub analysis of YEAR C data revealed that 
greater BMI was also associated with membership of the less favourable 
trajectory class.  Covariates that were not significant predictors of trajectory 
class were RF status, shared epitope status, pack years of smoking and 
comorbidities.  However, limitations of the sub analysis included loss of 
power due to the smaller number of cases.  
Table 4-15   Summary of results from multinomial logistic regression 
analyses of predictors of disease activity trajectory class 
 Whole cohort  
N=1398 
YEAR C sub-analysis  
N=713 
Cases in less 
favourable class 
359 (25%) 164 (23%) 
Cases in more 
favourable class 
1038 (75%) 549 (77%) 
Significant baseline predictors of more favourable trajectory: 
 Male gender  
   
Significant baseline predictors of less favourable trajectory: 
 ACPA positive ACPA positive 
 Fatigue Fatigue 
  Higher BMI 
ACPA, anti-citrullinated peptide antibodies; BMI, body mass index; YEAR, Yorkshire 
Early Arthritis Register. 
 
To some extent the findings from the present Chapter have confirmed 
previously published findings, for example, that male gender is associated 
with better outcome and that social deprivation is associated with worse 
outcome.  The additional finding that high BMI predicted a less favourable 
disease course in YEAR C is also in keeping with prior results.  However, 
fatigue as a predictor of disease activity is not commonly reported.  The next 
chapter will address how HAQ-DI changes with time, using the same 
techniques reported here, before the effects of change in DAS28 on change 
in HAQ-DI are examined.  
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Chapter 5 Change in disability over time 
5.1 Introduction 
This Chapter focuses on factors influencing  change in HAQ-DI in early RA.  
Functional capacity is part of the ‘core set’ of outcomes for clinical trials in 
RA identified in order to standardise outcome reporting in RA studies (Boers 
et al., 1994) and HAQ-DI was the chosen method of measuring this in YEAR.  
The importance of disability as a sequelae of RA was highlighted in patients 
from ERAS, in whom functional impairment at baseline was associated with 
future requirement of joint replacement surgery and the necessary instalment 
of devices and adaptations to facilitate activities of daily living, such as wheel 
chair use (Young et al., 2000).  Results in this Chapter are presented in the 
same sequence as Chapter 4 with the cross-sectional analysis of factors 
influencing change in HAQ-DI after 6 and 12 months presented first, followed 
by  an examination of the growth curve of change in HAQ-DI over time, then 
identification of trajectories of change in HAQ-DI over time within the cohort.  
Finally, factors predicting trajectory class membership were explored in the 
whole cohort, and then in a sub analysis of YEAR C, using the additional 
covariates available in YEAR C but not YEAR B, which were smoking, BMI, 
and presence or absence of comorbidities.  As in the analyses involving 
DAS28, MI was used to account for missing data in the cross sectional 
analysis and maximum likelihood estimation was used for the longitudinal 
analyses of change in HAQ-DI over time.   
The present analyses were enhanced by the use of HAQ-DI as a continuous 
variable, which is possible because of its Rasch transformation performed by 
Dr Elizabeth Hensor (described in Section 2.5.1).  In comparison, previously 
published work has used HAQ as a categorical, or even dichotomous 
variable (as discussed in 1.8.3).  This new approach may add more 
information. 
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5.2 Baseline predictors of change in disability after six 
months 
In the cross sectional linear regression analysis of predictors of change in 
HAQ-DI, male gender was associated with greater reduction in HAQ-DI, 
whilst greater baseline fatigue and age at baseline predicted a lesser 
reduction in HAQ-DI after both 6 and 12 months.  On average, HAQ-DI 
reduced by 2.02 units after 6 months (SE 0.12), according to the estimated 
mean change obtained from the imputed data.  The constant from the model 
of change in HAQ-DI after 6 months, which was -2.03 (negative change 
indicated fall in HAQ-DI), was consistent with this estimate.  The complete 
case linear regression model explained only 13% of the variance in change 
in HAQ-DI, so factors not included in the current model may better explain 
this variance.  The growth curve analysis described in 5.4 explored change in 
HAQ-DI with time and permitted deviation from the linear change described 
by the present regression model.  Table 5-1 shows the results of the linear 
regression model of change in HAQ-DI after 6 months.  HAQ-DI improved 
(reduced) by an average of 0.82 units more for males than females (SE 0.24, 
p 0.001) and on average, reduction in HAQ-DI after 6 months was 0.23 units 
less per 10 years of age (SE 0.10, p 0.024).  Each cm of baseline fatigue 
VAS predicted a reduction in HAQ-DI that was 0.10 units less after 6 months 
(SE 0.04, p 0.023).  There were no significant interactions in the model.  The 
Wald test indicated that the effects of the interactions between YEAR cohort 
and categories of EMS duration were non- significant, for both the MI 
analysis (F statistic 0.52, 363 df, p 0.6699) and the complete case analysis 
(F statistic 0.84, 539 df, p 0.4696).  Therefore the effects of baseline 
predictors were the same for YEAR B and C.  
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Table ‎5-1 Predictors of change in function from baseline to six months 
in Yorkshire Early Arthritis Register  
 
 
 
 
 Multiple imputation analysis 
 N=1416 
Complete case analysis 
N=564 
Coefficient 
(β) 
SE p Coefficient 
(β) 
SE p 
YEAR C -0.26 0.24 0.281 0.38 0.36 0.385 
Male gender -0.82 0.24 0.001 -0.47 0.37 0.207 
Age† 0.23 0.10 0.024 -0.05 0.13 0.702 
SD 0.03 0.03 0.279 0.03 0.04 0.448 
RF positive -0.16 0.39 0.695 -0.27 0.45 0.547 
ACPA positive 0.72 0.42 0.098 0.38 0.43 0.382 
Pain VAS  -0.11 0.06 0.053 -0.13 0.08 0.084 
Fatigue VAS  0.10 0.04 0.023 0.10 0.06 0.100 
EMS 40-75 min 0.18 0.31 0.559 0.47 0.46 0.310 
90-210 
min 
-0.59 0.55 0.280 0.39 0.50 0.434 
≥220 min -1.35 0.86 0.114 -0.71 0.57 0.213 
DAS28 0.05 0.10 0.659 -0.08 0.16 0.616 
HAQ-DI -0.34 0.03 <0.00
01 
-0.29 0.05 <0.0001 
Constant -2.03 0.55 <0.00
01 
-2.05 0.50 <0.0001 
Results of linear regression analysis.  Outcome variable was change in HAQ-DI 
after 6 months (HAQ-DI at 6 months – baseline HAQ-DI). 
Statistically significant (p<0.05) coefficients are highlighted in bold. 
†Age was entered into the model (as age in years)/10. 
For EMS, the referent category was 0-35 minutes. 
Independent variables were measured at baseline. 
ACPA, anti-citrullinated peptide antibodies; DAS28, disease activity score from 
counts of 28 joints; EMS, early morning stiffness duration; HAQ-DI, disability 
component of health assessment questionnaire; min, minutes; N, number (of 
cases); p, (statistical) probability; RF, rheumatoid factor; SD, symptom duration; SE, 
standard error; VAS, visual analogue score (measured in centimetres); YEAR, 
Yorkshire Early Arthritis Register. 
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As described for the analyses of change in DAS28 (4.3 and 4.4), the MI 
analysis was compared to analysis of cases with complete data (complete 
case analysis), which is shown alongside the MI results in Table 5-1.  
Although the effect of cohort was not statistically significant in either model, 
the coefficients suggested opposite effects: compared to YEAR B, YEAR C 
cases’ HAQ-DI fell by 0.26 units more according to the MI model but 
decreased by 0.38 units less according to the complete case model.  Mean 
HAQ-DI after 6 months was lower in YEAR C when all available data were 
considered: mean HAQ-DI from 1113 cases was 8.06 (SE 0.22) in YEAR B 
and 7.43 in YEAR C (SE 0.21), which explains why the MI analysis 
suggested that YEAR C cases’ HAQ-DI fell more over 6 months than YEAR 
B cases.  Conversely, when only the 564 cases with complete data were 
considered, HAQ-DI at 6 months was higher for YEAR C than YEAR B (7.87, 
SE 0.31 and 7.66, SE 0.30, respectively.)  This discrepancy highlights the 
potential pitfalls encountered by losing data when incomplete cases are 
disregarded.  Another difference in the analyses is found in the coefficients 
relating to the effect of age on change in HAQ-DI: the MI analysis suggested 
that increasing age at baseline was associated with less of a reduction in 
HAQ-DI after 6 months, whilst the complete case analysis indicated that 
increasing baseline age was associated with a slightly greater fall in HAQ-DI 
after 6 months, of 0.05 units per 10 years of age at baseline (SE 0.13, p 
0.702).  Scatterplots shown in Figures 5-1 and 5-2 illustrate why these 
results differed: when all available data were taken into account (Figure 5-1), 
there was a very slight positive change in HAQ-DI associated with increasing 
baseline age.  Conversely, when only the cases used in the complete case 
analysis were considered (Figure 5-2), the effect of baseline age was in the 
opposite direction, that is, increasing baseline age was associated with a 
slight fall in HAQ-DI after 6 months. 
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Figure ‎5-1 Scatterplot with line of best fit to show how change in 
function after 6 months varies with baseline age in all cases from 
Yorkshire Early Arthritis Register 
Close inspection of the line of best fit indicates that change in HAQ-DI is slightly 
more positive (that is, reduction in HAQ-DI is less) with increasing age at baseline. 
6m, 6 months; HAQ-DI, disability index component of health assessment 
questionnaire. 
 
Figure ‎5-2  Scatterplot with line of best fit to show how change in 
function after 6 months varies with baseline age in Yorkshire Early 
Arthritis Register cases included in complete case analysis of change 
in function after 6 months  
Close inspection of the line of best fit reveals that change in HAQ-DI is slightly more 
negative (that is, greater reduction in HAQ-DI) with increasing age at baseline.  6m, 
6 months; HAQ-DI, disability index component of health assessment questionnaire. 
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As for the analyses of change in DAS28 presented in 4.3 and 4.4, fit of the 
linear regression model was assessed.  Figure 5-3 is a scatterplot of the 
residual versus fitted values from the model of change in HAQ-DI after 6 
months.  There is no pattern to the points on the plot, which excludes 
deviation from the assumption of homoscedasticity.  Figure 5-4 is a 
histogram depicting the distribution of the residuals, which were 
approximately normally distributed with a mean close to zero.  However, 
there were three cases where the residuals’ values were outside the range of 
-3.3 to 3.3.  These values were -3.97, 3.58 and 4.45, suggesting that these 
cases could be outliers in the model.  The three cases were deleted and the 
model was re-applied to the resulting dataset, however, this had little impact 
on the regression coefficients and standard errors, and therefore the three 
outlying cases were considered not to affect the results and were retained in 
the dataset.  
 
Figure ‎5-3 Residual versus fittted plot for the linear regression model of 
change in function according to Disability Index component of the 
Health Assessment Questionnaire (HAQ-DI) after 6 months for 
participants of Yorkshire Early Arthritis Register 
Residual values represented the difference between observed change in HAQ-DI 
and change in HAQ-DI predicted by the model, whilst fitted values are those 
predicted by the model.  
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Figure ‎5-4 Histogram to show distribution of residuals from the linear 
regression analysis of change in function according to Disability Index 
component of the Health Assessment Questionnaire (HAQ-DI) after 6 
months in Yorkshire Early Arthritis Register  
Residual values represent the difference between actual change in HAQ-DI and 
change in HAQ-DI predicted by the model. 
Range of standardised residual values (equal to actual residual divided by its 
standard error): -3.97 to 4.45. 
 
5.3 Baseline predictors of change in disability after twelve 
months 
Mean reduction in HAQ-DI after 12 months, calculated from the MI dataset, 
was 2.57 (SE 0.14).  The constant from the linear regression analysis of 
change in HAQ-DI after 12 months (representing the change in HAQ-DI for 
the ‘baseline patient’, see Paragraph 4.3) approached this value, at -2.36.  
The complete case model explained only 18% of the variability in change in 
HAQ-DI after 12 months (adjusted R square value).  The results are shown 
in Table 5-2.  As for the model of change in HAQ-DI after 6 months, fall in 
HAQ-DI was greater for males than females: HAQ-DI improved (reduced) by 
an average of 0.89 units more after 12 months (SE 0.26, p 0.001).  Similarly, 
greater age at baseline predicted less improvement in function (reduction in 
HAQ-DI): on average, reduction in HAQ-DI after 12 months was 0.28 units 
less per 10 years of age (SE 0.10, p 0.004).  Furthermore, each cm of 
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baseline fatigue VAS predicted a reduction in HAQ-DI that was 0.11 units 
less after 12 months (SE 0.05, p 0.017).  It is also noteworthy that in this 
model, the main effect of cohort approached statistical significance, with 
YEAR C patients having a 0.48 unit greater fall in HAQ-DI than YEAR B 
patients (SE 0.26, p 0.072).  This may reflect the differences between 
treatment strategies in YEAR B (SSA) and YEAR C (MTX).  Duration of EMS 
also approached statistical significance, and patents who reported ≥220 
minutes of EMS at baseline achieved a fall in HAQ-DI that was on average 
0.68 units more than cases reporting 0-35 minutes of stiffness at baseline 
(SE 0.38, p 0.075).  There were no significant interaction effects in the MI 
model, so coefficients relating to the independent variables can be applied 
across both YEAR cohorts.  The results of the Wald test for a significant 
interaction between cohort and EMS duration were negative when applied for 
both MI and complete case models (MI: F statistic = 0.22, df 763, p= 0.8850 
and complete case model: F statistic 0.01, df 525 and p= 0.9985).   
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Table ‎5-2 Predictors of change in function from baseline to twelve 
months in Yorkshire Early Arthritis Register 
 
 
 
 Multiple imputation analysis 
 N=1416 
Complete case analysis 
N=550 
Coefficient 
(β) 
SE p Coefficient 
(β) 
SE p 
YEAR C -0.48 0.26 0.072 -0.09 0.38 0.803 
Male gender -0.89 0.26 0.001 -1.35 0.39 0.001 
Age† 0.28 0.10 0.004 0.25 0.14 0.072 
SD 0.02 0.04 0.528 0.06 0.04 0.152 
RF positive 0.08 0.35 0.811 -0.20 0.48 0.679 
ACPA positive 0.56 0.34 0.107 0.87 0.46 0.057 
Pain VAS  -0.02 0.07 0.716 0.11 0.11 0.297 
Fatigue VAS  0.11 0.05 0.017 0.14 0.06 0.024 
EMS 40-75 min -0.04 0.32 0.912 0.31 0.19 0.530 
90-210 
min 
0.04 0.35 0.919 0.52 0.86 0.547 
≥220 min -0.68 0.38 0.075 -1.69 1.33 0.207 
DAS28 -0.05 0.11 0.641 -0.14 0.17 0.395 
HAQ-DI -0.43 0.03 <0.00
01 
-0.39 0.05 <0.0001 
Interaction effect:        
Cohort*Pain VAS Not included in model -0.23 0.13 0.076 
Constant -2.36 0.35 <0.00
01 
-3.11 0.88 <0.0001 
Results of linear regression analysis.  Outcome variable was change in HAQ-DI 
after 12 months (HAQ-DI at 12 months – baseline HAQ-DI). 
Statistically significant (p<0.05) coefficients are highlighted in bold. 
†Age was entered into the model (as age in years)/10. 
*Indicates an interaction effect between 2 variables. 
For EMS, the referent category was 0-35 minutes. 
Independent variables were measured at baseline. 
ACPA, anti-citrullinated peptide antibodies; DAS28, disease activity score from 
counts of 28 joints; EMS, early morning stiffness duration; min, minutes; N, number 
(of cases); p, (statistical) probability; RF, rheumatoid factor; SD, symptom duration; 
SE, standard error; VAS, visual analogue score (measured in centimetres); YEAR, 
Yorkshire Early Arthritis Register. 
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Table 5-2 also includes results from the analysis of complete cases, which 
shows a significant interaction effect indicating that the effect of baseline pain 
VAS was different for YEAR B and C participants.  Whilst YEAR B cases 
experienced a 0.11 unit lesser fall in HAQ-DI per cm of baseline pain VAS, 
YEAR C cases experienced a 0.23 unit greater fall in HAQ-DI per cm of 
baseline VAS, which is an effect in the same direction as the coefficient for 
pain VAS produced by the MI model.  Another difference between the MI and 
complete case models is that the coefficients corresponding to the effect of 
RF were in opposite directions.  In the MI analysis, the regression coefficient 
suggested that RF positive patients saw a lesser improvement (reduction) in 
HAQ-DI than the RF negative patients (0.08, SE 0.35 p 0.811), whilst 
analysis of the complete cases suggested that RF positive patients saw a 
0.20 unit greater decline in HAQ-DI than RF negative patients (SE 0.48, p 
0.679).  As with previous discrepancies between the MI and complete case 
models, the explanation can be found by inspection of the data: the mean 
change in HAQ-DI was slightly greater for RF positive patients amongst 
complete cases, but not when all cases were analysed, as shown in Table 5-
3.   
Table ‎5-3 Comparison of mean twelve month change in Disability Index 
component of Health Assessment Questionnaire (HAQ-DI) for 
rheumatoid factor positive and negative cases, in all cases and those 
included in the complete case linear regression analysis 
 All cases where data 
were available* 
N=974 
Cases included in complete 
case analysis 
N=550 
Change in 
HAQ-DI 
RF 
negative 
-2.73 -2.63 
RF 
positive 
-2.57 -2.67 
Change in HAQ-DI was calculated by subtracting baseline HAQ-DI from that at 12 
months. 
*All cases included those with available data including baseline RF, HAQ-DI and 12 
month HAQ-DI. 
HAQ-DI, disability index component of the health assessment questionnaire; N, 
number (of cases); RF, rheumatoid factor. 
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Model fit was assessed in the same manner as the previous linear 
regression models.  Figure 5-5 is a plot of the residual versus fitted values, 
showing that there was no discernible pattern.  This is reassuring that the 
assumption of homoscedasticity was met.  A histogram representing the 
distribution of the standardised residuals is shown in Figure 5-6, which 
reveals an approximately normal distribution with a mean close to zero.  The 
spread of the values of the standardised residuals was within the range of -
3.3 to 3.3, which is reassuring that there were no outliers.  
 
Figure ‎5-5 Residual versus fittted plot for the linear regression model of 
change in function according to Disability Index component of the 
Health Assessment Questionnaire (HAQ-DI) after 12 months for 
participants of Yorkshire Early Arthritis Register 
Residual values represented the difference between observed change in HAQ-DI 
and change in HAQ-DI predicted by the model, whilst fitted values are those 
predicted by the model.  
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Figure ‎5-6 Histogram to show distribution of residuals from the linear 
regression analysis of change in function according to Disability Index 
component of the Health Assessment Questionnaire (HAQ-DI) after 12 
months in Yorkshire Early Arthritis Register  
Residual values represent the difference between actual change in HAQ-DI and 
change in HAQ-DI predicted by the model. 
Range of standardised residual values (equal to actual residual divided by its 
standard error): -2.97 to 3.27. 
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5.4 Latent growth curve model of change in disability  
5.4.1  Mean disability over time 
Table 5-4 gives mean values of HAQ-DI at each data collection visit for the 
YEAR cohort as a whole, and also for YEAR B and C separately.  HAQ-DI 
decreased with time, with the greatest reduction after the initial 6 months.  It 
then continued to decline, but at a slower rate.   
Table ‎5-4 Means and standard errors of Disability Index component of 
the Health Assessment Questionnaire (HAQ-DI) in Yorkshire Early 
Arthritis Register  
 Mean HAQ-DI (SE) 
Time 
YEAR 
(whole cohort) 
YEAR B YEAR C 
Baseline 9.81 (0.12) 10.21 (0.17) 9.41 (0.18) 
6 months 7.73 (0.15) 8.06 (0.22) 7.43 (0.21) 
12 months  7.13  (0.15) 7.59 (0.22) 6.73 (0.21) 
18 months  6.93 (0.16) 7.42 (0.25) 6.55 (0.22) 
24 months  6.71 (0.16) 7.34 (0.25) 6.22 (0.22) 
HAQ-DI, disability index component of health assessment questionnaire ; SE, 
standard error; YEAR, Yorkshire Early Arthritis Register. 
 
5.4.2 Linear growth curve model of change in disability  
As HAQ-DI was never captured for 7 individuals, the growth curve analyses 
of HAQ-DI included 1409 cases from YEAR.  The linear model was a poor fit 
to the data, suggested by the 2 value of 385.711, df=13, p<0.0001, the CFI 
of 0.898 and RMSEA of 0.143 (90%CI 0.131,  0.156).  This was expected, as 
the pattern of fall in mean HAQ-DI did not appear to follow a linear trend 
(Table 5-4), however, the linear growth curve is described here and in Table 
5-5 so that it can be compared to subsequent models.  The mean intercept, 
which represented the mean HAQ-DI at baseline estimated by the model, 
was 9.31 out of a total possible HAQ-DI of 24 (SE 0.18, p<0.001).  However, 
the variance of this estimate was considerable: (13.67, SE 0.81, p<0.001), 
suggesting that there was a lot of inter-individual variation in this value.  The 
mean linear slope was -0.54 (SE 0.05, p<0.001), which implied that on 
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average, HAQ-DI reduced by 0.54 units per 6 months: much lower than 
expected.  (Subtraction of mean 6 month HAQ-DI from mean baseline HAQ-
DI suggested a change of 2.08 units, Table 5-4.)  The model implied a 
difference in intercept between the 2 cohorts, which was 9.31 for YEAR B 
and 8.40 for YEAR C (0.91 units lower, SE 0.24, p<0.001).  Examination of 
the mean baseline HAQ-DI values shown in Table 5-4 reveals that whilst the 
value for YEAR C is indeed lower (9.41, compared to 10.21 in YEAR B), the 
model estimated values are less than expected.  The model implied that the 
difference in rate of change in HAQ-DI between the 2 cohorts was not 
significant (-0.01, SE=0.07, p=0.911).  The growth curve is illustrated in 
Figure 5-7, which compares change in mean HAQ-DI described by the model 
to observed mean HAQ-DI values.  
Table ‎5-5 Parameters estimated by the linear growth curve model of 
change in Disability Index component of the Health Assessment 
Questionnaire (HAQ-DI) over time in Yorkshire Early Arthritis Register  
Parameter Estimate (SE) p 
Mean intercept 9.31 0.18 <0.001 
Intercept variance 13.67 0.81 <0.001 
Mean linear slope -0.54 0.05 <0.001 
Linear slope variance 0.35 0.06 <0.001 
Intercept/ linear slope covariance 0.65 0.17 <0.001 
    
Regression of parameters on YEAR C 
cohort 
   
Mean intercept on YEAR cohort -0.91 0.24 <0.001 
Mean linear slope on YEAR cohort -0.01 0.07 0.911 
p, (statistical) probability; SE, standard error; YEAR, Yorkshire Early Arthritis 
Register. 
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Figure ‎5-7 Graph to show how the sample mean Disability Index component of the Health Assessment Questionnaire (HAQ-DI) 
changed with time, compared to the means estimated by the linear growth curve model of change in HAQ-DI in Yorkshire Early 
Arthritis Register  
HAQ-DI, disability index component of health assessment questionnaire.   
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5.4.3  Quadratic growth curve model of change in disability  
This model was specified with an additional quadratic component, to allow for 
non-linear change in HAQ-DI with time.  There was improved model fit 
compared to the linear model, as indicated by the following indices: 2 = 70.2, 
df= 8, p<0.0001; CFI 0.983, RMSEA 0.074 (90% CI 0.059, 0.091).  Table 5-6 
gives the model estimated parameters that describe this growth curve.  The 
mean intercept estimated by the model, representing mean baseline HAQ-DI, 
was 10.08 (SE 0.18, p<0.001), which is much closer to the actual mean HAQ-DI 
value for YEAR B of 10.21 shown in Table 5-4.  The model implied a statistically 
significant difference in this value across the cohorts, with the intercept value for 
YEAR C being 9.20 (0.88 units lower than for YEAR B, SE 0.24, p<0.001), 
which was lower than the actual mean value of 9.41 shown in Table 5-4.  Mean 
linear slope was -1.80, suggesting that mean HAQ-DI fell by an average of 1.80 
units per 6 months initially, however, the relatively large variance of this 
parameter (5.79, SE 0.80, p<0.001) indicated variation within the cohort.  There 
was no statistically significant difference between cohorts for this parameter.  
The mean quadratic slope value of 0.30 (SE 0.03, p<0.001) indicated that the 
rate of decline in HAQ-DI reduced with time, and again, this effect was not 
statistically different between YEARs B and C.  Covariances between intercept 
and linear slope and between intercept and quadratic slope were non-
significant, suggesting the rate of change in HAQ-DI did not vary according to 
baseline HAQ-DI.  There was a significant covariance of - 1.14 between linear 
and quadratic slope (SE 0.17, p<0.001), indicating that a lesser initial fall in 
HAQ-DI was associated with a greater subsequent rate of fall in HAQ-DI.  
Whilst the overall quadratic slope (0.30) implied that the rate of fall in HAQ-DI 
slowed with time, this covariance suggested that for cases with lesser initial fall 
in HAQ-DI (or a more positive linear slope value), HAQ-DI should fall more 
quickly with time.  The growth curve is represented graphically in Figure 5-8, 
which compares model- estimated means to observed mean values from the 
cohort.  Whilst this curve appears to fit the data better, there is potential for the 
model to be improved.  Therefore, a freed loading model was tested and is 
described in Paragraph 5.4.4. 
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Table ‎5-6 Parameters estimated by the quadratic growth curve model of 
change in Disability Index component of the Health Assessment 
Questionnaire (HAQ-DI) in Yorkshire Early Arthritis Register  
Parameter Estimate (SE) p 
Mean intercept 10.08 0.18 <0.001 
Intercept variance 13.31 1.04 <0.001 
Mean linear slope -1.80 0.16 <0.001 
Linear slope variance 5.79 0.80 <0.001 
Mean quadratic slope 0.30 0.03 <0.001 
Quadratic slope variance 0.25 0.04 <0.001 
Intercept/ linear slope covariance -0.01 0.77 0.989 
Intercept/ quadratic slope covariance -0.03 0.15 0.848 
Linear slope/ quadratic slope covariance 
 
-1.14 0.17 <0.001 
Regression of parameters on YEAR C 
cohort 
   
Mean intercept on YEAR cohort -0.88 0.24 <0.001 
Mean linear slope on YEAR cohort 0.02 0.21 0.916 
Mean quadratic slope on YEAR cohort -0.01 0.05 0.804 
p, (statistical) probability; SE, standard error, YEAR, Yorkshire Early Arthritis Register.   
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Figure ‎5-8 Graph to show how the sample mean Disability Index component of the Health Assessment Questionnaire 
(HAQ-DI) changed with time, compared to the means estimated by the quadratic growth curve model of change in HAQ-DI 
in Yorkshire Early Arthritis Register  
 HAQ-DI, disability index component of health assessment questionnaire.
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5.4.4  Freed loading model of change in disability  
Improvement of this model over the previous two was indicated by the 
preferable indices of fit : 2 52.347, df 16, p<0.0001; CFI 0.988; RMSEA 0.055 
(90% CI 0.041, 0.070).  The mean intercept estimated by the model implied that 
HAQ-DI at baseline was 10.24 in YEAR B and 9.36 in YEAR C (a difference of 
0.88, SE 0.25, p<0.001). These estimates are closer to the observed mean 
values shown in Table 5-4 (10.21 and 9.41, respectively) than those obtained in 
the linear and quadratic models.  However, there was substantial variance 
related to this estimate (17.49, SE 2.04, p<0.001), reflecting the wide range of 
HAQ-DI scores recorded at baseline.  Mean linear slope, mean change in HAQ-
DI per unit time (one unit of time was specified as 24 months in this model), was 
-2.64 (SE 0.19, p<0.001).  Again there was substantial variance related to this 
estimate (13.92, SE 2.10, p<0.001).  There was no significant difference in 
mean linear slope between the YEAR cohorts.  Linear slopes at 6, 12 and 18 
months were freely estimated by the model and their respective values were 
0.76, 0.99, and 1.02.  This implies that most (76%) of the overall fall in mean 
HAQ-DI had occurred by 6 months and the lowest value was reached by 18 
months.  Mean HAQ-DI then rose slightly from 18 to 24 months.  Covariance 
between intercept and linear slope was statistically significant and indicated that 
cases with higher baseline HAQ-DI  saw a steeper initial rate of decline in HAQ-
DI (by 4.98 units of HAQ-DI per 24 months per unit of baseline HAQ-DI, SE 
2.03, p=0.014).  This is in keeping with expected results, as a higher baseline 
score has greater potential to decline.  The growth curve is illustrated 
graphically in Figure 5-9, which compares observed and predicted means and 
shows a close fit to the data.  
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Table ‎5-7 Parameters estimated by the freed loading model of change in 
Disability Index component of the Health Assessment Questionnaire 
(HAQ-DI) in Yorkshire Early Arthritis Register 
Parameter 
Estimate SE p 
Mean intercept 10.24 0.18 <0.0001 
Intercept variance 17.49 2.04 <0.0001 
Linear slope at baseline 0.00   
Linear slope at 6m 0.76 0.03 <0.0001 
Linear slope at 12m 0.99 0.03 <0.0001 
Linear slope at 18m 1.02 0.03 <0.0001 
Linear slope at 24m 1.00   
Mean linear slope -2.64 0.19 <0.0001 
Linear slope variance 13.92 2.10 <0.0001 
Intercept/ linear slope covariance -4.98 2.03 0.014 
    
Regression of parameters on YEAR C 
cohort 
   
Mean intercept on YEAR cohort -0.88 0.25 <0.0001 
Mean linear slope on YEAR cohort -0.03 0.25 0.895 
P, statistical probability; SE, standard error, YEAR, Yorkshire Early Arthritis Register.   
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Figure ‎5-9 Graph to show how mean Disability Index component of the Health Assessment Questionnaire (HAQ-DI) 
changed with time, compared to the means estimated by the freed loading growth curve model of change in HAQ-DI in 
Yorkshire Early Arthritis Register  
HAQ-DI, disability index component of health assessment questionnaire. 
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5.5 Identification of latent trajectories of change in disability 
A LCGA was conducted, using the freed loading growth curve model described 
in Section 5.4.4.  This analysis was similar to the one performed for DAS28, 
described in Chapter 4, Section 4.6.  Table 5-8 gives the fit indices for models 
containing successive numbers of trajectories together with the numbers of 
cases included in each trajectory class.  Based upon this information, the 2 
class model was selected.  This is because for the 3 class model, lowest log-
likelihood values were not equal indicating that the solution was a local 
maximum and furthermore, the value for BIC was only a modest improvement 
compared to that of the 2 class model.  Although Entropy was preferable for the 
3 class model compared to 2 class one (0.646 compared to 0.502, 
respectively), the 3 class LMR-LRT was not statistically significant (p= 0.0681), 
indicating that this model did not fit the data as well.   
The 2 trajectory classes are illustrated in Figure 5-10.  The first class, which 
encompassed just under half (47%) of the cohort, could be described as ‘high 
HAQ-DI’, because after an initial slight fall in HAQ-DI, its value remains above 
11 for the duration of follow up.  The average probability that the most likely 
latent class membership was class 1 for cases grouped into trajectory class 1 
by the model was 0.84 (and therefore the average probability that such cases 
were most likely to be in the other latent class was 0.16).  The remainder of the 
cohort (53% of cases) fell into class 2, or ‘low HAQ-DI’.  In this trajectory class, 
mean HAQ-DI (equivalent to the intercept) was 8.05 at baseline and then fell 
until it reached its lowest value at 18 months (102% of the mean fall in HAQ-DI 
at 24 months), before increasing slightly from 18 to 24 months.  Within this 
class, the average probability of most likely latent class membership being class 
2 was also 0.84, and 0.16 that the most likely latent class was class 1. 
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Table ‎5-8 Fit indices and numbers of cases in each trajectory for models of change in disability with increasing numbers of 
trajectory classes 
Number of 
trajectory 
classes in 
model 
Number of cases assigned 
to each class, based on the 
estimated model (%) 
AIC BIC Adjusted BIC 
LMR-LRT  
p-value 
BLRT 
p-value Entropy 
1 Trajectory 1 1409  (100) 34045 34176 34096    
2 Trajectory 1  664 (47) 28805 28899 28842 0.0060 <0.0001 0.502 
Trajectory 2 745 (53) 
3* Trajectory 1  203 (14) 28760 28870 28803 0.0681 <0.0001 0.646 
Trajectory 2 537 (38) 
Trajectory 3  669 (48) 
*For the 3 class model, log-likelihood values were not equal, indicating that the solution was possibly a local maximum. 
AIC, Akaike information criteria; BIC, Bayesian information criteria; BLRT, Bootstrap likelihood ratio test; LMR-LRT, Lo, Mendell and Rubin likelihood 
ratio test; p, (statistical) probability. 
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Figure ‎5-10 Illustration of the two latent trajectory classes of change in Disability Index of the Health Assessment Questionnaire 
(HAQ-DI) 
The proportion of cases assigned to each trajectory class is given as a percentage of the whole cohort.  
HAQ-DI, disability index component of health assessment questionnaire.  
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5.6 Predictors of disability trajectory class membership 
Predictors of membership of the ‘high HAQ-DI’ trajectory class, which was the 
worst prognostic group, were similar to predictors of the ‘high DAS28’ trajectory 
class (Chapter 4, Section 4.7 and Table 4-9).  Specifically, men were less likely 
to be classed in the ‘high HAQ-DI’ group (OR 0.51, 95% CI 0.42, 0.63, p<0.001) 
and those from more socially deprived areas were more likely to be classed in 
this group, compared to those from the least socially deprived 4th quartile.  The 
OR for IMD quartile 1 was 2.66, (95% CI 2.01, 3.51; p <0.001) and OR for IMD 
quartile 2 was 1.59, (95% CI 1.21, 2.08; p=0.005), but the OR for IMD quartile 3 
was not significantly different to that of quartile 4.  Other statistically significant 
predictors of HAQ-DI trajectory class were consistent with those described in 
the linear regression analyses of change in HAQ-DI (Sections 5.2 and 5.3): 
fatigue VAS and age.  The OR for membership of the high HAQ-DI trajectory 
class was 1.02 (95% CI 1.02, 1.03; p<0.001) for age, suggesting that the odds 
of membership of class 2 increases by 2% per year of age at baseline.  
Furthermore, the OR relating to fatigue VAS was 1.12 (95% CI 1.09, 1.16; 
p<0.001), indicating that for every 1cm increase in fatigue VAS at baseline, the 
odds of class 2 membership increased by 12%.  These results are shown in 
Table 5-9. 
In order to further explore these findings and to see whether the significant 
effects of age and SES could be explained by smoking, alcohol use, obesity or 
comorbidities, a further analysis using only cases from YEAR C was conducted 
and is presented in Section 5.6.1. 
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Table ‎5-9 Results of multinomial logistic regression analysis of predictors 
of‎class‎1‎trajectory‎(‘high‎HAQ-DI’)‎membership 
Predictor Coefficient Odds ratio (95% CI) p 
YEAR C cohort 0.06 1.07 (0.88, 1.29)  0.582 
Male gender -0.67 0.51 (0.42, 0.63)  <0.001 
Age 0.02 1.02 (1.02, 1.03)  <0.001 
RF positive -0.03 0.98 (0.74, 1.29)  0.882 
ACPA positive 0.21 1.23 (0.90, 1.68)  0.286 
Shared epitope 
positive 
0.07 1.08 (0.90, 1.29)  0.503 
IMD quartile 1 0.98 2.66 (2.01, 3.51)  <0.001 
2 0.46 1.59 (1.21, 2.08)  0.005 
3 0.11 1.12 (0.85, 1.47)  0.507 
Fatigue VAS 0.12 1.12 (1.09, 1.16)  <0.001 
Results of multinomial logistic regression analysis.   
Outcome variable was membership of class 1 trajectory, described in 5.4. 
Statistically significant (p<0.05) coefficients are highlighted in bold. 
For IMD, the referent category was the 4th quartile, which was the least deprived group:  
higher levels of deprivation were represented by reducing quartile number . 
Independent variables were measured at baseline. 
ACPA, anti-citrullinated peptide antibodies; CI, confidence interval; IMD, index of 
multiple deprivation; p, probability (statistical significance); RF, rheumatoid factor; VAS, 
visual analogue scale; YEAR, Yorkshire Early Arthritis Register. 
 
5.6.1 Sub analysis of Yorkshire Early Arthritis Register C cases 
5.6.1.1 Latent growth curve model of change in disability in Yorkshire 
Early Arthritis Register C 
There were no recorded HAQ-DI values for 2 cases in YEAR C, so this sub-
analysis used data from 723 participants.  In order to select the optimal growth 
model to fit the data, the process of fitting linear, quadratic and then freed 
loading models, described in Section 5.4 for the whole YEAR cohort, was 
repeated for this selection of the data.  As expected, the freed loading model 
was the best fit according to the fit indices, which are displayed in Table 5-10. 
There was reasonable model fit, with 2 =26.5, df = 7, p = 0.0004, CFI=0.991 
and RMSEA 0.062.  
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Table ‎5-10 Fit statistics for successive models of change in disability in 
Yorkshire Early Arthritis Register C 
Model 2 df p CFI  RMSEA 
Linear 217.3 10 <0.0001 0.907 0.169 
Quadratic 37.6 6 <0.0001 0.986 0.085 
Freed 
loading  
26.5 7 0.0004 0.991 0.062 
CFI, comparative fit index; df, degrees of freedom; p, (statistical) probability; RMSEA, 
root mean square error of approximation; 2 Chi-square. 
The freed loading model of change in HAQ-DI in YEAR C is described by 
parameters displayed in Table 5-11.  According to this model, mean HAQ-DI at 
baseline was 9.36 in YEAR C, which is slightly different to the mean value of 
9.41 estimated directly from the data (Table 5-4).  The variance of this intercept 
value was large: 17.49 (SE 2.37), reflecting significant inter-individual variability.  
The mean change in HAQ-DI for YEAR C was -2.73 units per 24 months, where 
the negative value represents a mean fall in HAQ-DI, however the variance of 
this value was also large: 13.11 (SE 2.50, p <0.001).  The model indicated that 
the greatest fall in HAQ-DI occurred in the first 6 months, as 73% of the total 
mean fall in HAQ-DI over 24 months had occurred by this point.  A further 
reduction in mean HAQ-DI was implied by the model and by 12 months, 99% of 
the mean total fall in HAQ-DI over 24 months had been achieved.  
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Table ‎5-11 Parameters estimated by the freed loading growth curve model 
of change in disease activity over time in Yorkshire Early Arthritis 
Register C 
Parameter Estimate SE p 
Mean intercept 9.36 0.18 <0.001 
Intercept variance 17.49 2.37 <0.001 
Mean linear slope  -2.73 0.18 <0.001 
Linear slope variance 13.11 2.50 <0.001 
Linear slope at baseline 0.00   
Linear slope at 6m 0.73 0.04 <0.001 
Linear slope at 12m 0.99 0.03 <0.001 
Linear slope at 18m 0.99 0.03 <0.001 
Linear slope at 24m 1.00   
Intercept/ linear slope covariance -4.32 2.33 0.064 
m, months; SE, standard error; p, (statistical) probability. 
 
5.6.1.2 Identification of latent trajectories of change in disability in 
Yorkshire Early Arthritis Register C 
Fit indices for models with successive numbers of trajectory classes are shown 
in Table 5-12.  This time the 3 class model was selected as the most suitable 
because the addition of a further class yielded unequal highest log-likelihood 
values, which suggested that the solution was a locum maximum.  Furthermore, 
the LMR-LRT value was not statistically significant for the 4 class model.  
Compared to the 2 class model, there was an improvement in Entropy value 
and BIC was smaller (although the difference in BIC between the 2 and 3 class 
models was modest).  The 3 trajectory classes are illustrated in Figure 5-11.  
Class 1 describes a ‘middle HAQ-DI’ trajectory, where the baseline HAQ-DI 
value is just over 10, it then reduces to between 8 and 9 and stays at this level 
for the remainder of follow up.  Class 2 (‘low HAQ-DI’) describes the most 
favourable trajectory because baseline HAQ-DI is the lowest of the 3, HAQ-DI 
reduces the most and stays lowest compared to the other 2 trajectories.  Class 
3 (‘high HAQ-DI’) is the least favourable trajectory because HAQ-DI starts high 
(13.5) and remains high throughout follow up. 
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Table ‎5-12 Fit indices and numbers of cases in each trajectory for models with increasing numbers of trajectory classes of 
disability in Yorkshire Early Arthritis Register C 
Number of 
trajectory 
classes in 
model 
Number of cases assigned 
to each class, based on the 
estimated model (%) 
AIC BIC Adjusted BIC 
LMR-LRT  
p-value 
BLRT 
p-value Entropy 
1 Trajectory 1 723  (100) 17437 17529 17465    
2 Trajectory 1  364 (50) 15133 15209 15156 0.0024 <0.0001 0.619 
Trajectory 2 359 (50) 
3 Trajectory 1  318 (44) 15098 15185 15125 0.0277 <0.0001 0.714 
Trajectory 2 287 (40) 
Trajectory 3  118 (16) 
4* Trajectory 1  161 (22) 15084 15184 15115 0.2258 <0.0001 0.747 
 Trajectory 2 267 (37)       
 Trajectory 3  275 (38)       
 Trajectory 4 20 (3)       
*For the 4 class model, log-likelihood values were not equal, indicating that the solution was probably a local maximum. 
AIC, Akaike information criteria; BIC, Bayesian information criteria; BLRT, Bootstrap likelihood ratio test; LMR-LRT, Lo, Mendell and Rubin likelihood 
ratio test; p, (statistical) probability. 
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Figure ‎5-11 Illustration of the three latent trajectory classes of change in Disability Index component of Health Assessment 
Questionnaire (HAQ-DI) in Yorkshire Early Arthritis Register C 
The proportion of cases assigned to each trajectory class is given as a percentage of the whole cohort.  
HAQ-DI, disability index component of health assessment questionnaire.  
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5.6.1.3 Predictors of disability trajectory class membership in Yorkshire 
Early Arthritis Register C 
A multinomial logistic regression model was used to determine predictors of 
membership of trajectory classes 1 (middle HAQ-DI) and 2 (low HAQ-DI), 
compared to class 3 (high HAQ-DI).  Consistent with the analysis of the whole 
YEAR cohort (section 5.6), males were more likely to be in the most favourable 
class (2) (OR 3.54; 95% CI 2.15, 5.82; p<0.001) than the least favourable class 
(3) and membership of the low HAQ-DI class 2 was less likely than membership 
of the high HAQ-DI class in cases who were from the most deprived areas, 
represented by IMD quartile 1: OR 0.19; 95% CI  0.10, 0.36; p<0.001.  Similarly, 
cases from IMD quartile 1 (the most deprived) were less likely to be in the 
middle HAQ-DI class (1) than the high HAQ-DI class (3): OR 0.45; 95% CI 0.25, 
0.81, p= 0.024.  Unlike the analysis of the whole YEAR cohort, there was no 
statistically significant difference between IMD quartiles 2 and 3 compared to 
quartile 4, however this may have been due to the reduction in statistical power 
in the present analysis, which included fewer cases than the previous.  Fatigue 
VAS was another significant predictor of less favourable HAQ-DI trajectory in 
both the analysis of YEAR C and the whole cohort.  In YEAR C, there was a 
21% reduction in the odds of membership of class 2 (low HAQ-DI) compared to 
class 3 (high HAQ-DI) per cm of baseline fatigue (p<0.001) and a 12% 
reduction in the odds of membership of class 1 (middle HAQ-DI) compared to 
class 3 (p= 0.002). 
Furthermore, consistent with predictors of DAS28 trajectory class in YEAR C 
(Chapter 4, Section 4.7.1.3), patients with higher BMI were more likely to fall 
into HAQ-DI trajectory class 3 (high HAQ-DI) than class 2 (low HAQ-DI): there 
was a 5% reduction in the odds of falling into the most favourable, compared to 
the least favourable trajectory class per Kg/m
2
 of BMI (p= 0.031).  Although age 
was not a statistically significant predictor of trajectory class membership, it did 
approach statistical significance as a predictor of membership of the low HAQ-
DI class (2) compared the high HAQ-DI class (3): OR 0.98; 95% CI  0.97, 1.00; 
p=0.068.  These results are displayed in Table 5-13. 
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Table ‎5-13 Results of multinomial logistic regression analysis of 
predictors of disability class  trajectory membership for Yorkshire Early 
Arthritis Register C 
Predictors of class 1 (‘middle HAQ-DI’) compared to class 3 (‘high HAQ-
DI) 
Predictor Coefficient Odds ratio (95% CI) p 
Male gender 0.32 1.38 (0.85, 2.21)  0.271 
Age -0.01 0.99 (0.97, 1.01)  0.256 
RF positive -0.06 0.95 (0.54, 1.65)  0.871 
ACPA positive -0.52 0.59 (0.31, 1.30)  0.183 
Shared epitope positive -0.05 0.96 (0.72, 1.28)  0.799 
IMD quartile 1 -0.80 0.45 (0.25, 0.81)  0.024 
2 -0.45 0.64 (0.35, 1.18)  0.227 
3 -0.06 0.94 (0.49, 1.83)  0.884 
BMI (Kg/m2) -0.03 0.98 (0.95, 1.00)  0.124 
Smoking (pack years) 0.00 1.00 (0.99, 1.01)  0.521 
Comorbidities  0.40 0.67 (0.43, 1.05)  0.139 
Fatigue VAS (cm) -0.13 0.88 (0.82, 0.94)  0.002 
Predictors of class 2 (‘low HAQ-DI’) compared to class 3 (‘high HAQ-DI’) 
Predictor Coefficient Odds ratio (95% CI) p 
Male gender 1.26 3.54 (2.15, 5.82)  <0.001 
Age -0.02 0.98 (0.97, 1.00)  0.068 
RF positive -0.10 0.99 (0.54, 1.83)  0.979 
ACPA positive -0.68 0.51 (0.25, 1.02)  0.111 
Shared epitope positive -0.21 0.82 (0.59, 1.12)  0.293 
IMD quartile 1 -1.68 0.19 (0.10, 0.36)  <0.001 
2 -0.554 0.57 (0.30, 1.10)  0.158 
3 -0.05 0.95 (0.48, 1.89)  0.903 
BMI (Kg/m2) -0.06 0.95 (0.91, 0.99)  0.031 
Smoking (pack years) -0.10 0.99 (0.98, 1.00)  0.114 
Comorbidities  -0.49 0.61 (0.37, 1.00)  0.099 
Fatigue VAS (cm) -0.23 0.79 (0.74, 0.85)  <0.001 
Results of multinomial logistic regression analysis.   
Outcome variable was membership of class 3 trajectory, described in 5.6.1.2. 
Statistically significant (p<0.05) coefficients are highlighted in bold. 
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For IMD, the referent category was the 4th quartile, which was the least deprived group:  
higher levels of deprivation were represented by reducing quartile number. 
Independent variables were measured at baseline. 
One pack year was the equivalent of smoking 20 cigarettes per day for one year.  
Comorbidities were classified as present /absent. 
ACPA, anti-citrullinated peptide antibodies; BMI, body mass index; CI, confidence 
interval; cm, centimetres; IMD, index of multiple deprivation; Kg/m2, kilograms per 
metre square; p, (statistical) probability; RF, rheumatoid factor; VAS, visual analogue 
score; YEAR, Yorkshire Early Arthritis Register. 
5.7 Summary of predictors of change in disability 
As in Chapter 4, which explored change in disease activity, the present Chapter 
investigated predictors of change in function, measured by HAQ-DI, using both 
cross sectional (linear regression) and longitudinal (latent growth curve and 
LCGA) statistical techniques.  Again, missing data were managed using MI in 
the linear regression analyses and maximum likelihood estimation in the 
longitudinal analyses, so that bias in the estimates as a result of missing data 
could be minimised and statistical power retained by including all cases where 
possible.  
The results of the analyses of change in HAQ-DI are summarised in Table 5-14.  
The linear regression analysis revealed a greater mean reduction in HAQ-DI 
from baseline to 6 and 12 months in male patients compared to females and 
that HAQ-DI reduced less in older patients and those with higher baseline 
fatigue VAS.  Change in HAQ-DI was described by growth curve models 
(Section 5.4.2 to 5.4.4) and then LCGA identified 2 latent trajectory classes 
within the cohort: high HAQ-DI and low HAQ-DI (Section 5.5).  Membership of 
the least favourable, high HAQ-DI trajectory class was more likely with greater 
age at baseline, lower area-level SES and greater baseline fatigue VAS.  It was 
less likely for male patients to fall into this trajectory class than females.  A sub 
analysis, using data from YEAR C cases only, was conducted to examine the 
effects of predictors not collected in YEAR B.  In this sub analysis, 3 trajectory 
classes of HAQ-DI were identified: high, middle and low HAQ-DI.  Contrary to 
the results of the whole cohort analysis, age was not a significant predictor of 
trajectory class membership.  This may have been due to a loss of statistical 
power owing to the smaller number of cases in the sub analysis.  Otherwise, 
significant predictors were the same in YEAR C as in the whole cohort, with the 
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addition of BMI: higher BMI measured at baseline was associated with lower 
odds of membership of the low HAQ-DI, compared to the high HAQ-DI  
trajectory class.
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Table ‎5-14 Summary of results of analyses of change in disability 
 Linear regression analysis of change in HAQ-DI 
from baseline to: 
Multinomial logistic regression analyses of predictors of 
trajectory class: 
  6 m 12 m  Whole cohort YEAR C 
Model characteristics:       
Mean HAQ-DI change from 
baseline 
2.02 2.57 High HAQ-DI 
class: N  
664 (47%) 118 (16%) 
Variation in HAQ-DI explained 
by model 
13% 18% Middle HAQ-DI 
class: N 
Not applicable 318 (44%) 
   Low HAQ-DI class: 
N 
745 (53%) 287 (40%) 
Significant baseline predictors of more favourable (greater) reduction in HAQ-DI: 
 Male gender Male gender  Male gender Male gender  
HAQ-DI HAQ-DI    
Significant baseline predictors of less favourable (lesser) reduction in HAQ-DI: 
 Age Age  Social 
deprivation 
Social 
deprivation 
Fatigue  Fatigue  Age  
   Fatigue  Fatigue  
    BMI 
BMI, body mass index; HAQ-DI, disability index component of health assessment questionnaire; m, months;  N, number (of cases); VAS, visual 
analogue score; YEAR, Yorkshire Early Arthritis Register. 
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There were similarities between the predictors of change in DAS28 
(summarised in Chapter 4, Tables 4-14 and 4-15), and predictors of change in 
HAQ-DI.  Specifically, greater baseline fatigue, female gender and lower area 
level SES were associated with less favourable course in terms of both DAS28 
and HAQ-DI and furthermore, in both YEAR C sub analyses of DAS28 and 
HAQ-DI trajectory class predictors, greater BMI was also associated with less 
favourable outcome.  However, there were some differences in baseline 
predictors of change in DAS28 and HAQ-DI.  For example, increasing baseline 
age was a significant predictor of less favourable outcome in some of the 
models of change in HAQ-DI but not of change in DAS28.  Furthermore, some 
predictors of change in DAS28 were different between YEARs B and C 
(summarised in Chapter 4, Section 4.8) and cases from YEAR B had a lower 
mean reduction in DAS28 after 6 months than YEAR C cases, whereas 
predictors of change in HAQ-DI were the same for YEAR B and C and there 
was no significant difference in change in HAQ-DI between the 2 cohorts.  
Therefore, whilst some factors influencing DAS28 and HAQ-DI in early RA were 
the same, the differences will be taken into account in the final analysis of the 
relationship between DAS28 and HAQ-DI.  
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Chapter 6 The relationship between disease activity and 
disability over time 
6.1 Introduction  
The results presented so far have revealed that baseline predictors of change in 
DAS28 in the YEAR cohort were gender, social deprivation, fatigue, and BMI 
(summarised in Chapter 4, Section 4.8).  Furthermore, some of the analyses 
suggested that YEAR cohort affected change in DAS28, although it is not 
possible to determine whether this was due to baseline differences between the 
2 cohorts, or an effect of the different treatment regimes.  One of the analyses 
also found that higher baseline EMS was associated with greater fall in DAS28.  
The analyses of change in HAQ-DI, summarised in Chapter 5, Section 5.7, 
indicated that baseline predictors relevant to change in DAS28 were also 
significant for HAQ-DI, with some differences (discussed in Chapter 5, 5.7), 
such as age as a predictor of change in HAQ-DI.  This Chapter focuses on how 
change in DAS28 influenced change in HAQ-DI.  It is expected that as disease 
activity falls with treatment for RA, disability should also reduce.  However, as 
other factors, such as co-morbidity, age and psychosocial differences can 
influence disability, the relationship between DAS28 and HAQ-DI may not be 
straightforward.   
In this Chapter the relationship between DAS28 and HAQ-DI was described 
using a parallel process growth curve model (described in Section 2.5.4.2 and 
illustrated in Figure 2-6) and then a dual process trajectory model (described in 
Chapter 2, Section  2.5.4.3). 
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6.2 Correlation between disease activity and disability 
An initial examination of the correlations between DAS28 and HAQ-DI at each 
time point, shown in Table 6-1, reveals that all Pearson correlations between 
these variables were statistically significant (p<0.0001).  The correlation 
between DAS28 and HAQ-DI was lowest at the baseline visit (0.44 for the 
overall YEAR cohort) and highest at 6 months in the overall YEAR cohort (0.62) 
and at 12 months for YEAR C (0.63).   
Table ‎6-1 Pearson correlations between disease activity scores from a 
count of 28 swollen and tender joints (DAS28) and Disability Index 
components of Health Assessment Questionnaire (HAQ-DI) 
Time 
Overall YEAR 
(N) 
YEAR B 
(N) 
YEAR C 
(N) 
Baseline   0.44 (1219) 0.41 (617) 0.45 (602) 
6 months 0.62 (938) 0.62  (447) 0.62 (491) 
12 months 0.57 (967) 0.50  (444) 0.63 (523) 
18 months 0.59 (798) 0.56  (339) 0.61 (459) 
24 months 0.54 (811) 0.50  (344) 0.56 (467) 
Values represent Pearson correlations between DAS28 and HAQ-DI at the time points 
indicated.  
DAS28, disease activity score based upon count of 28 tender and swollen joints and C-
reactive protein; HAQ-DI, disability index component of the health assessment 
questionnaire; N, number (of cases with data available); YEAR, Yorkshire Early 
Arthritis Register. 
6.3 Parallel process growth curve model of change in disease 
activity and disability over time 
This analysis included 1415 YEAR cases for whom there was at least one 
recorded value for DAS28 or at least one HAQ-DI.  The freed loading models of 
change in disease activity and change in function (described in Sections 4.5.4 
and 5.4.4, respectively) were selected for combination in a parallel process 
growth model.  The resulting model approached adequate fit to the data, with fit 
indices as follows: 2 783.62, df= 64, CFI = 0.907, RMSEA = 0.089.  Table 6-2 
gives the estimates obtained.  As expected, linear slope for DAS28 and HAQ-DI 
did not change or were with 0.01 of those estimated by the previous freed 
loading models of change in DAS28 and HAQ-DI.  Differences in intercepts and 
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slopes between YEAR B and C cohorts were also similar to those previously 
reported and furthermore, estimates of covariances between intercept and  
slope for DAS28 and between intercept and slope for HAQ-DI were within 0.1 of 
those reported for the respective singular models.  The covariances between 
DAS28 and HAQ-DI intercepts and slopes were pertinent to revealing how 
HAQ-DI changed with DAS28.  The covariance between intercepts was 2.87 
(SE 0.15, p<0.001), which implied that baseline HAQ-DI increased by 2.87 per 
unit of baseline DAS28.  Between the slopes, covariance was 3.51 (SE 0.25, 
p<0.001), so mean HAQ-DI changed in the same direction as mean DAS28 and 
fell by 3.5 units per unit fall in DAS28.  Increased baseline DAS28 (or intercept), 
was associated with a 1.16 unit greater decline in HAQ-DI (or slope) over 24 
months.  This is likely because greater baseline DAS28 was associated with 
greater baseline HAQ-DI and therefore increased potential reduction in this 
value.  The relationship between baseline HAQ-DI and rate of change in DAS28 
was indicated by the covariance between HAQ-DI intercept and DAS28 slope, 
of -1.61 (SE 0.22, p<0.001).  Thus, increased baseline HAQ-DI was associated 
with greater reduction in DAS28.  The explanation for this is similar to that of the 
covariance between baseline DAS28 and HAQ-DI slope, and is also likely to be 
because higher baseline HAQ-DI occurred in cases with higher DAS28 and 
therefore increased potential to decline with time.  
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Table ‎6-2 Parameters estimated by parallel process model of change in 
disease activity and function over time in Yorkshire Early Arthritis 
Register  
Parameter Estimate SE p 
Mean DAS28 Intercept  5.30 0.06 <0.001 
Mean DAS28 slope -1.97 0.07 <0.001 
Linear DAS28 slope at baseline 0.00   
Linear DAS28 slope at 3m 0.68 0.02 <0.001 
Linear DAS28 slope at 6m 0.75 0.02 <0.001 
Linear DAS28 slope at 12m 0.95 0.02 <0.001 
Linear DAS28 slope at 18m 0.98 0.02 <0.001 
Linear DAS28 slope at 24m 1.00   
Mean HAQ-DI Intercept 10.24 0.18 <0.001 
Mean HAQ-DI slope -2.66 0.19 <0.001 
Linear HAQ-DI slope at baseline 0.00   
Linear HAQ-DI slope at 3m 0.59 0.04 <0.001 
Linear HAQ-DI slope at 6m 0.75 0.03 <0.001 
Linear HAQ-DI  slope at 12m 0.97 0.03 <0.001 
Linear HAQ-DI slope at 18m  1.01 0.03 <0.001 
Linear HAQ-DI slope at 24m 1.00   
Covariances between latent variables    
Slope DAS28 with intercept DAS28 -0.83 0.15 <0.001 
Intercept HAQ-DI with intercept DAS28 2.87 0.19 <0.001 
Intercept HAQ-DI with slope DAS28 -1.61 0.22 <0.001 
Slope HAQ-DI with intercept DAS28 -1.16 0.19 <0.001 
Slope HAQ-DI with slope DAS28 3.51 0.25 <0.001 
Slope HAQ-DI with intercept HAQ-DI -3.64 1.03 <0.001 
Regression of parameters on YEAR C cohort    
Intercept DAS28 -0.62 0.08 <0.001 
Slope DAS28 0.18 0.09 0.054 
Intercept HAQ-DI -0.89 0.25 <0.001 
Slope HAQ-DI -0.08 0.25 0.741 
DAS28, disease activity score based upon counts of 28 joints and C-reactive protein; 
HAQ-DI, disability index component of health assessment questionnaire; m, months; p, 
statistical probability; SE, standard error, YEAR, Yorkshire Early Arthritis Register. 
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6.4 Dual trajectory analysis of change in disease activity and 
disability 
This model, which simultaneously estimated trajectories for DAS28 and HAQ-
DI, identified trajectories similar to those previously described by the LCGAs in 
Sections 4.6 and 5.5, respectively.  The dual trajectory analysis classified 24% 
of the cohort into the high DAS28 category and 76% into the low DAS28 
category, which is similar to the 26% and 74%, respectively, classified by the 
earlier model.  Furthermore, the dual trajectory analysis found that 49% and 
51% of the cohort were categorised into high and low HAQ-DI trajectories, 
respectively, which is comparable to the 47% and 52% of cases classified into 
these respective categories by the earlier model.  As there were 2 trajectory 
classes for both DAS28 and HAQ-DI, 4 combinations of trajectories, or dual 
trajectory groups, were possible.  These are described in Table 6-3.  The least 
favourable dual trajectory group was group 1, in which both DAS28 and HAQ-DI 
trajectories were ‘high’.  As anticipated, group 2 was small because very few 
individuals who followed the high DAS28 trajectory also followed the low HAQ-
DI trajectory (20 cases, representing 1% of the cohort).  Most cases were 
classified into the most favourable group 4, in which  both DAS28 and HAQ-DI 
were low.  However, just over one quarter of the cohort followed  a high HAQ-DI 
category, despite following a low DAS28 trajectory. 
Table ‎6-3 Description of dual trajectory groups  
Group Percentage 
of cohort 
DAS28 trajectory HAQ-DI trajectory 
1 23 High DAS High HAQ-DI 
2 1 High DAS Low HAQ-DI 
3 26 Low DAS28 High HAQ-DI 
4 50 Low DAS28 Low HAQ-DI 
DAS28, disease activity score based upon counts of 28 joints and C-reactive protein; 
HAQ-DI, disability index component of health assessment questionnaire.  
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Table 6-4 gives the probabilities of membership of each HAQ-DI trajectory, 
conditional on DAS28 trajectory.  This confirms that cases from the high DAS28 
trajectory were most likely to be in the high HAQ-DI trajectory, p=0.94, but not 
very likely to be associated with low HAQ-DI, p=0.06.  Although cases from the 
low DAS28 trajectory were more likely to follow the low HAQ-DI trajectory 
(p=0.66), a significant number followed the High HAQ-DI trajectory (p=0.34). 
Table ‎6-4 Probability of disability trajectory conditional on disease activity 
trajectory 
 HAQ-DI trajectory: 
DAS28 trajectory: High Low 
High 0.94 0.06 
Low 0.34 0.66 
DAS28, disease activity score based upon counts of 28 joints and C-reactive protein; 
HAQ-DI, disability index component of health assessment questionnaire. 
 
6.5 Predictors of disease activity and disability trajectory 
groups 
Predictors of group membership were considered, but as only 20 individual 
cases were assigned to group 2, they were excluded from the analysis.  
Baseline DAS28-P(CRP) was calculated as described in Chapter 2, Section 
2.5.4.3.1, and added as a covariate in the regression analysis of predictors of 
DAS28/ HAQ-DI dual trajectory class.  The spread of values of this variable was 
similar to DAS28-P described by McWilliams et al. (2012), with a median of 0.50 
and an inter-quartile range of 0.44 to 0.54.  Correlation between baseline values 
of DAS28-P and DAS28 was also similar to the correlation between these 
values reported by McWilliams et al: 0.39.  As its values were small, DAS28-
P(CRP) was multiplied by 10 before it was entered into the model so that the 
results could be interpreted more easily.  
Results of the multinomial logistic regression analysis are shown in Table 6-5.  
Compared to membership of the most favourable group 4, cases were more 
likely to be assigned to the least favourable group 1 if they resided in the most 
socially deprived area compared to the least socially deprived (OR 1.52; 95% CI 
1.00, 2.31; p =0.049), reported more fatigue at baseline and had a higher 
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DAS28 at baseline.  There was a 6% increase in odds of being in group 1 
compared to group 4 per cm of baseline fatigue VAS (p=0.020) and the odds of 
being in group 1, compared to group 4, were increased by 75% per unit of 
DAS28 at baseline (p<0.001).  Men were less likely than women to be in group 
1 compared to group 4 (OR 0.70; 95% CI 0.52, 0.95; p<0.001), and cases from 
YEAR C were also less likely than YEAR B cases to be in group 1: OR 0.70; 
95% CI 0.52, 0.95, p=0.020.  Although the effect of RF on membership of group 
1 was not statistically significant, the effect of ACPA positivity approached 
significance, such that a positive antibody increased the odds of being in this 
less favourable category: OR=1.17, 95% CI 0.99, 2.82, p=0.056. 
Dual trajectory group 3 followed the ‘low DAS28’ trajectory and ‘high HAQ-DI’ 
trajectories, so it is possible that factors other than RA were contributing to the 
disability measured by HAQ-DI in this group.  Predictors of membership of this 
group were different to predictors of group 1 membership and included 
increasing age, with increased odds of group 3 compared to group 4 
membership of 3% per year of age at baseline (p< 0.001).  Cases were also 
more likely to be in group 3 if they were included in IMD quartile 1 compared to 
IMD quartile 4 (OR 2.15; 95% CI 1.44, 3.20; p< 0.001), and classification into 
IMD quartile 2 compared to IMD quartile 4 was almost statistically significant: 
OR for group 3 membership was 1.47 (95% CI 0.99, 2.20, p=0.058).  Other 
predictors of group 3 membership were higher baseline DAS28-P(CRP) and 
increased fatigue at baseline: a 1cm increase in fatigue VAS at baseline was 
associated with increased odds of group 3 compared to group 4 membership by 
9% (p=0.001) whilst a 10 fold increase in DAS28-P(CRP) was associated with 
an increase in odds of group 3 compared to group 4 membership of 35% 
(p<0.001).  Again, males were less likely than females to be in the less 
favourable group 3 than group 4: OR 0.54; 95% CI 0.40, 0.73; p<0.001.  Cohort 
(YEAR B or C) had no significant effect on membership of this group and 
neither did baseline DAS28.   
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Table ‎6-5 Results of multinomial logistic regression analysis of predictors 
of trajectory group membership 
Predictors of group 1 membership (‘high DAS28 and high HAQ-DI) compared to 
group 4 (‘low DAS28 and low HAQ-DI) membership 
Predictor Coefficient Odds ratio (95% CI) p 
YEAR C cohort -0.36 0.70 (0.52, 0.95) 0.020 
Male gender -0.58 0.56 (0.41, 0.77) <0.001 
Age (years) 0.00 1.00 (0.99, 1.01) 0.781 
RF positive 0.15 1.17 (0.74, 1.83) 0.510 
ACPA positive 0.51 1.67 (0.99, 2.82) 0.056 
Shared epitope 
positive 
0.17 1.18 (0.89, 1.57) 0.252 
IMD quartile 1 0.42 1.52 (1.00, 2.31) 0.049 
2 0.25 1.28 (0.84, 1.93) 0.248 
3 -0.01 0.99 (0.65, 1.51) 0.965 
Fatigue VAS (cm) 0.06 1.06 (1.01, 1.12)  0.020 
DAS28-P(CRP)* 0.15 1.16 (0.95, 1.41)  0.145 
DAS28  0.56 1.75 (1.53, 2.00)  <0.001 
Predictors of group 3 membership (‘low DAS28 and high HAQ-DI) compared to 
group 4 (‘low DAS28 and low HAQ-DI) membership 
 Coefficient Odds ratio 95% CI p 
YEAR C cohort -0.02 0.98 (0.74, 1.31) 0.901 
Male gender -0.62 0.54 (0.40, 0.73) <0.001 
Age (years) 0.03 1.03 (1.02, 1.04) <0.001 
RF positive -0.10 0.90 (0.61, 1.34) 0.610 
ACPA positive 0.25 1.28 (0.81, 2.01) 0.289 
Shared epitope 
positive 
0.14 1.15 (0.89, 1.49)  0.290 
IMD quartile 1 0.77 2.15 (1.44, 3.20)  <0.001 
2 0.39 1.47 (0.99, 2.20)  0.058 
3 0.08 1.09 (0.72, 1.64)  0.691 
Fatigue VAS (cm) 0.09 1.09 (1.04, 1.14)  0.001 
DAS28-P(CRP)* 0.30 1.35 (1.17, 1.57)  <0.001 
DAS28  -0.03 0.97 (0.86, 1.10)  0.649 
Results of multinomial logistic regression analysis.   
*DAS28-P(CRP) was multiplied by 10 before entry into the model. 
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Outcome variables were membership of trajectory groups 1 and 3 and the referent 
group was 4, as described in Table 6-3. 
Statistically significant (p<0.05) coefficients are highlighted in bold. 
For IMD, the referent category was the 4th quartile, which was the least deprived group:  
higher levels of deprivation were represented by reducing quartile number . 
Independent variables were measured at baseline. 
ACPA, anti-citrullinated peptide antibodies; CI, confidence interval; cm, centimetres; 
DAS28, disease activity score based upon counts of 28 joints; DAS28-P(CRP), pain 
index component of DAS28, calculated using CRP; IMD, index of multiple deprivation; 
p, probability (statistical significance); RF, rheumatoid factor; VAS, visual analogue 
scale; YEAR, Yorkshire Early Arthritis Register. 
Although data on comorbidities were not complete, with approximately 50% of 
this information missing in YEAR B and 10% in YEAR C (as described in 
Chapter 3, Section 3.4), a crude analysis was undertaken to determine whether 
there was a heavier burden of comorbidity in group 3 compared to the other 
groups.  There were more YEAR B cases in group 1 than groups 3 and 4: 59% 
of group 1 were from YEAR B, compared to 45% and 46% in groups 3 and 4, 
respectively.  Therefore, comorbidity data were missing more often for group 1 
and could not be compared to the other groups easily.  However, there were 
similar numbers of YEAR B cases in groups 3 and 4 and, as shown in Table 6-
6, all comorbidities except renal disease were more frequent in group 3 than 
group 4.  The average number of comorbidities in group 3 was greater than for 
group 4: 0.55 compared to 0.32, respectively. 
Table ‎6-6 Percentage of cases reporting comorbidities by trajectory group 
Group YEAR 
B: % 
of 
cases 
HT IHD DM COPD Renal 
disease  
CVD PVD Chronic 
liver 
disease 
Average 
number of 
comorbidities 
1 59 16 6 5 8 2 2 0 0 0.29 
3 45 23 15 7 13 1 4 3 1 0.55 
4 46 16 5 3 9 2 2 2 1 0.32 
Numbers shown are percentages of the whole group.   
%, percent; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular 
disease; DM, diabetes mellitus; HT, hypertension; IHD, ischaemic heart disease; PVD, 
peripheral vascular disease; YEAR, Yorkshire Early Arthritis Register.  
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6.6 Summary  
This final Chapter of results is the first description of a longitudinal analysis of 
the relationship between disease activity and disability in which both DAS28 
and HAQ-DI were analysed as continuous variables.  The advantage of this 
type of analysis is that change over time has been captured, which can be 
useful when considering outcomes of disease; and furthermore, as HAQ-DI was 
not broken down into categories, statistical power was retained.  The parallel 
process model of change in disease activity and disability confirmed that HAQ-
DI and DAS28 both reduced over time and that the baseline values for both 
variables were lower in YEAR C than YEAR B.  The dual trajectory analysis 
identified 4 different dual trajectory groups and half of the YEAR cases were 
classified within the most favourable group, with lower DAS28 and HAQ-DI 
trajectories.  As expected, very few cases from the high DAS28 trajectory were 
classified within the low HAQ-DI trajectory.   
Just under one quarter of the cases from YEAR were within the least favourable 
group, where both DAS28 and HAQ-DI trajectories were high.  Membership of 
this least favourable, compared to the most favourable group, was more likely in 
females, YEAR B cases, patients from more deprived areas and cases 
reporting higher fatigue and with higher DAS28 at baseline.  The association 
between DAS28 at baseline and membership of this group suggests that for 
these individuals, inflammation due to RA was greater than for cases in the low 
DAS28/ low HAQ-DI group.  This is supported by the finding that DAS28-
P(CRP) , representing non-inflammatory components of DAS28, was not a 
significant predictor of membership of this group.  
The majority of the remaining cases, representing 26% of the cohort, fell within 
the group characterised by low DAS28 and high HAQ-DI.  Membership of this 
group compared to the most favourable group was also more likely in females, 
older patients, those from more deprived areas, and those reporting higher 
levels of fatigue; but membership of this group was not influenced by YEAR 
cohort (B or C).  A crude comparison of the numbers of comorbidities in the 
different trajectory groups implied that pre-existing medical conditions probably 
contributed to the disability reported by this group.  It is likely that disability in 
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this group was also influenced by symptoms of RA unrelated to inflammation.  
This hypothesis is supported by the influence of DAS28-P(CRP) at baseline: 
odds of membership of the ‘low DAS28 /high HAQ-DI’ trajectory increased by 
35% per 10 units of baseline DAS28-P(CRP) (p<0.001, Table 6-5), implying that 
the higher level of disability reported by this group is related to the non-
inflammatory components of the DAS28 at baseline: TJC and patient VAS.   
The findings of all results chapters are discussed further in Chapter, 7. 
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Chapter 7 Discussion 
7.1 Introduction 
This chapter addresses the main findings of the Thesis, including the 
significance of fatigue as a predictor of outcome in Section 7.2.1.  Findings from 
the Thesis are put in the context of the recent literature in Section 7.3, before 
strengths and limitations of this study are discussed (Section 7.4), including 
recruitment to YEAR, management of RA in YEAR compared to modern 
practice and the statistical methodology used.  Directions for further research 
are proposed throughout and expanded in Section 7.5. 
7.2 Summary of main Thesis findings 
Recent decades have seen great progress in the treatment of RA and this was 
reviewed in Chapter 1, Section 1.6.  The importance of suppression of 
inflammation during early disease is now widely recognised and patients are 
managed using a ‘treat to target’ approach (also reviewed in Section 1.6).  
Pharmacological therapy may include biological agents which are more 
expensive than synthetic DMARDs such as MTX and SSA, and in addition, are 
more immune-suppressive, leaving the patient at greater risk of infection.  
Therefore, to ensure that benefits of treatment outweigh its risks, an ideal 
therapeutic approach would be stratified so that aggressive drugs are targeted 
towards patients most likely to benefit from suppression of inflammation.   
The work in this Thesis has identified one potential deficiency in the 
contemporary approach to management of RA in the UK and provided 
additional evidence for two further problems which have been described 
previously.  Furthermore, as well as adding to evidence of the importance of 
fatigue as a significant symptom in RA, baseline fatigue was demonstrated as a 
consistent predictor of outcome.  The clinical implications of this finding require 
further investigation and are discussed in greater detail in Section 7.2.1.  The 
novel finding of this work came from the dual trajectory analyses, which 
identified four different disease activity / disability trajectory groups in the YEAR 
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cohort, the least favourable of which were the high DAS28 / high HAQ-DI and 
the low DAS28/ high HAQ-DI groups.  The former group is likely to include 
patients with persistent inflammation resulting in disability, whereas the latter 
represented patients who reported disability despite suppression of 
inflammation.  Membership of this group was more likely in cases with a greater 
proportion of baseline DAS28 attributable to its subjective components, but was 
not predicted by actual DAS28 at baseline.  This suggests that therapies 
directed at non-inflammatory manifestations of RA should be explored as they 
may have a positive influence on future disability.  This is an area of interest for 
future research, which may include investigations into the impact of 
interventions such as improving coping strategies, or non-pharmacological 
management of pain for patients with early RA.   
The second problem with RA management in the UK highlighted in this Thesis 
is that it is guided by the DAS28.  As described above and in Section 1.8.1, this 
parameter can be affected by co-existent problems in RA, such as fibromyalgia, 
via its subjective components TJC and VAS.  Cases with a greater proportion of 
baseline DAS28 attributable non-inflammatory components (that is, those with 
higher DAS28-P) were more likely to follow a high HAQ-DI trajectory.  This 
suggests that for such patients a treatment regime based upon DAS28 does not 
address the full impact of RA and consideration should be given to non-
inflammatory manifestations.  A more suitable marker of disease activity for 
guidance of pharmacological treatment would accurately reflect inflammation, 
as this is the target of such therapy.   
Further work is required to determine the safety and cost-effectiveness of using 
biologic agents in patients with persistent inflammation due to RA, using an 
alternative to DAS28 to define whether such treatments are used.  For example, 
application of the recently developed modified disease activity score (m-
DAS28), described by Baker et. al., (2014).  The m-DAS28 measured at 
baseline included SJC, CRP and a physician’s assessment of disease activity 
scored using a VAS, but not TJC or patient’s assessment of disease activity.  It 
performed better than baseline DAS28 in the prediction of radiographic 
progression at 52 weeks amongst the clinical trial participants involved in the 
study.  Therefore, the m-DAS28 may be a truer measure of inflammation due to 
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RA than the DAS28 and is possibly a superior value on which to base treatment 
decisions.  
The impact of ‘moderate DAS28’ is the third deficiency in contemporary RA 
management highlighted in this Thesis and is illustrated by cases following the 
high DAS28 / high HAQ-DI trajectory.  As shown in Section 4.6, mean disease 
activity in the high DAS28 group was >4.7 throughout follow up, but remained 
below the threshold of 5.1 stipulated by NICE as a requirement for the 
commencement of biologic agents (discussed in Chapter 1, Section 1.6).  
Therefore, there was inadequate suppression of inflammation in this group, 
which was likely to have contributed to persistent disability, but may not have 
been supressed by escalation of treatment under current UK guidelines.   
 
7.2.1 Fatigue as a predictor of outcome in rheumatoid arthritis 
Baseline fatigue VAS was a statistically significant predictor of worse outcome 
in all prediction models.  That is, greater baseline fatigue VAS was associated 
with lesser improvement in DAS28 after 6 and 12 months and worse DAS28 
trajectory (summarised in Table 4-14 and 4-15, respectively), as well as lesser 
improvement in HAQ-DI after 6 and 12 months and worse HAQ-DI trajectory 
(summarised in Table 5-14).  It also predicted membership of both high DAS28/ 
high HAQ-DI and low DAS28/ high HAQ-DI trajectory groups, compared to the 
more favourable low DAS28/ low HAQ-DI trajectory group.  This latter result is 
of interest, as baseline fatigue predicted membership of both groups.  That is, 
the group with disability attributable to persistent disease activity and the group 
with persistent disability despite suppression of disease activity.  This finding 
likely reflects the probable multiple reasons behind the symptom of fatigue in 
RA, as proposed by Hewlett’s conceptual model (discussed in Section 1.5.2.6).  
Whilst biological consequences of active RA such as anaemia and persistent 
inflammation could have driven fatigue in the high DAS28 / high HAQ-DI group, 
the psychosocial drivers of fatigue (depression and poor social support) may 
have been more prominent for the low DAS28/ high HAQ-DI group.   
In a study from NOAR, reviewed in Chapter 1, Section 1.8.4.3, learned 
helplessness was associated with worse HAQ.  Further work from this cohort 
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showed that baseline learned helplessness (measured using the rheumatology 
attitudes index) also predicted HAQ, fatigue and pain after 2 years (Camacho et 
al., 2013).  Learned helplessness was not measured in YEAR, but may have 
been a factor underlying the observed relationship between fatigue and worse 
outcome, especially in the low DAS28/ high HAQ-DI trajectory group.  Further 
evidence to demonstrate the impact of psychosocial factors on fatigue in RA 
came from BRASS (a cohort which was described in Chapter 1, Section 1.7.1) 
in a study that used cluster analysis to describe 3 groups of patients 
characterised according to SJC, pain, sleep disturbance, fatigue, depression, 
illness burden (including symptoms such as impaired concentration and 
memory, migraine and headache) and pain catastrophising (Lee et al., 2014).  
One group, which included 57 of the 169 patients in the study, had low disease 
activity, yet the highest fatigue (measured using the fatigue numeric rating scale 
component of the multidimensional HAQ), pain catastrophising and patient 
global health VAS.  The authors concluded that in this group of patients, factors 
other than inflammation due to RA, such as chronic pain, were contributing to 
the high levels of fatigue and pain.  
It would be possible to test which factors contribute to fatigue amongst the two 
adverse trajectory groups in YEAR by extending the structural equation model 
described by Nicassoio (2012), discussed in Section 1.5.2.6.  Additional 
variables should be considered, including the presence of anaemia, level of co-
morbidity, learned helplessness and social support.  The model could then be 
tested to see whether the impact of these variables on fatigue are different 
across the two trajectory groups.  If this hypothesis is confirmed, it could aid 
future stratification of therapy for RA: the group with fatigue driven by 
inflammation would be expected to benefit more from corticosteroid and 
DMARD treatment, whilst the group with fatigue driven predominantly by 
psychological and social factors may benefit from additional treatment, such as 
cognitive behavioural therapy.  The impact of such treatment on future disability 
could be assessed. 
The findings of the present study have reinforced previous work by Zink and 
Zink (2010), which demonstrated that fatigue is associated with worse outcome 
in RA.  In a study including 1057 patients with RA and symptom duration <24 
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months, greater fatigue at baseline was associated with worse global health 
score after 8 years (OR= 1.82; 95% CI 1.21, 2.75), as well as increased 
likelihood of study drop-out due to all causes including death (OR= 2.3; 95% CI 
1.3, 4.2) and frailty (OR= 2.3, 95% CI 1.2, 4.5).  Although fatigue is recognised 
as a significant and troublesome symptom of RA, further research is required in 
order to fully understand its aetiology, clinical significance and successful 
treatment, before this symptom can usefully guide clinical decisions.   
7.3 Comparison of Thesis findings to published evidence 
RA disease registers are valuable research tools which have enabled the study 
of RA epidemiology and outcomes.  Despite common underlying principles and 
purposes of such RA registers, the cohorts described are heterogeneous.  Of 
the UK registers, the YEAR cases included in the present study are most similar 
to ERAS and ERAN, as these cohorts recruited patients during a similar time-
period, from multiple centres with a consultant made diagnosis of RA whose 
symptom duration was less than 24 months (described in Table 1-2).  YEAR 
was also similar to this cohort in terms of proportion of female patients and 
those who were ACPA and RF positive (described in Section 3.2).  YEAR is 
different to NOAR, where cases were recruited based upon persistent swelling 
of joints and therefore included patients with undifferentiated inflammatory 
arthritis.  The cohort from the Leiden clinic in the Netherlands also included 
patients with ‘recent onset’ (less than 2 years) arthritis, but not specifically RA 
(van Aken et al., 2003).  Cases from this cohort were selected for inclusion in 
some analyses if they met RA classification criteria (van den Broek et al., 2012, 
van der Woude et al., 2012, van Nies et al., 2010).  Other international registers 
described in Table 1-2 used different criteria for inclusion, such as meeting 
1987 ACR criteria (BARFOT), or persistent synovitis with other clinical variables 
(CATCH); or included a cross section of cases with RA with variable symptom 
durations (BRASS).  These differences should be borne in mind when 
comparing results to those from YEAR. 
Some findings from YEAR, such as better outcomes amongst male patients and 
the association of increasing age at baseline with greater disability, were 
expected and in keeping with previous studies, as discussed in Sections 1.8.2 
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and 1.8.4.  However, there were some differences from previously published 
results, which are discussed here. 
7.3.1 Comparison of latent class growth analyses of change in 
disease activity and disability 
The findings of the disease activity LCGA were different to those of a Dutch 
study of 568 cases with early RA, with similar inclusion criteria to YEAR 
(Siemons et al., 2013), which identified 3 trajectories of change in DAS28.  
Whilst the research question and statistical methodologies of the Dutch study 
were broadly similar to the present analysis, significant differences in the 
treatment protocols likely explain the different results.  Participants of the Dutch 
study, which began recruitment in 2006, were treated according to a ‘treat to 
target’ approach, whereby patients were offered MTX at a dose of 15mg, then 
25mg, and additional DMARDs were included if DAS28 <2.6 was not achieved.  
This included TNF inhibitors, which according to NICE, cannot be used in UK 
treated patients if DAS28 <5.1.  It is therefore not altogether surprising that 83% 
of the Dutch study participants followed the ‘fast response’ trajectory, whereby 
sustained remission was achieved by 9 months.  In this cohort, fewer patients 
would have maintained a ‘moderate DAS28’ (discussed in Section 7.3) than in 
YEAR.  Interestingly, the ‘poor outcome’ trajectory, which represented 19 
(3.3%) of Dutch cases, was a different shape to the trajectories described in 
YEAR, with an initial improvement, followed by a subsequent rise in DAS28 
after 6 months that returned to the baseline level.  A similar trajectory may have 
been present in YEAR, but was possibly not distinguishable from cases with 
persistently moderate DAS28.  Other differences in the two studies that are 
likely to explain the disparate results include follow up length, which was 12 
months in the Dutch study, and possibly the statistical approach, which was 
GMM using a quadratic model in the analysis by Siemons.   
The disability LCGA applied to YEAR identified 2 trajectories of change in HAQ-
DI and the analysis applied to YEAR C identified 3.  Different numbers of 
trajectories have been identified in 2 other cohorts: in both ERAS and NOAR, 4 
trajectories were identified using LCGA (Norton et al., 2014).  The difference 
between the present analysis and those from ERAS and NOAR is likely to be 
due to the follow-up time, which was 15 years in the latter 2 cohorts, compared 
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to only 2 in YEAR.  Nevertheless, some predictors of adverse trajectory class 
membership, such as increased age at baseline and female gender, were 
similar in YEAR.  More information could have been gained from longer follow 
up in YEAR, but outcomes at 12 months remain of interest as they have been 
shown to better predict disability at 5 years than baseline predictors (Wiles et 
al., 2000)  
7.3.2 The relationship between disease activity and disability 
The parallel process growth curve model described in Section 6.3 implied that 
DAS28 and HAQ-DI changed in the same direction with time.  In the 
subsequent dual trajectory analysis, very few patients (1%) fell into trajectory 
group 2, which was described by high DAS28 and low HAQ-DI trajectories.  
Examination of the raw data confirmed that in these 20 cases, the values of 
DAS28 and HAQ-DI were correct.  It is possible that these individuals represent 
the previously described ‘robustus’ phenotype of RA (de Haas et al., 1973), in 
which individuals have little pain and good retention of function, despite active 
inflammation due to RA.   
It is likely that co-morbidity has a significant impact upon disability in the low 
DAS28/ high HAQ-DI trajectory group, and in fact the mean number of 
comorbidities was greater in this trajectory group compared to the low DAS28/ 
low HAQ-DI group and the high DAS28 / high HAQ-DI group (0.55, compared to 
0.32 and 0.29, respectively).  The ‘co-morbidities present/ absent’ variable was 
not included in the multinomial logistic regression model of predictors of 
trajectory group membership, as there would have been reduced statistical 
power when applied to the model of predictors of 3 different categories.  As 
shown in Table 6-5, increased age at baseline predicted membership of this low 
DAS28/ High HAQ-DI trajectory group, with odds of this group, compared to the 
more favourable low DAS28 /low HAQ-DI, increased by 3% per year of age at 
baseline.  This observation was probably attributable to the increased likelihood 
of comorbidity in older patients. 
7.3.3 Autoantibodies did not predict outcome in Yorkshire Early 
Arthritis Register 
The evidence reviewed in Chapter 1, Section 1.7.2.3 indicated that remission 
was less likely in patients with autoantibodies, such as RF and ACPA.  In 
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YEAR, the presence of RF or ACPA did not predict a lesser reduction in DAS28 
in the cross-sectional analyses of change in DAS28 after 6 and 12 months, but 
ACPA were associated with the less favourable DAS28 trajectory in the analysis 
that utilised DAS28 data from baseline to 24 months.  It is possible that the 
results were affected by missing data, because ACPA status was missing  in 
46% and 33% of cases in YEAR B and C, respectively (Chapter 3, Table 3-2).  
However, the rates of missingness for RF status were relatively small: 4% and 
8% in YEAR B and C, so this was an unlikely cause of the discrepancy between 
the results of the cross sectional analyses and those previously published.  For 
these analyses, MI was used to minimise bias caused by missing data, and 
although the risk of bias increases with greater quantities of missing data, 
simulation studies have shown that this effect is worse if complete case analysis 
is used compared to MI (Janssen et al., 2010).  Indeed, the complete case 
analysis of change in DAS28 after 12 months, reported as recommended, to 
compare to the results obtained using MI (as explained in Chapter 2, Section 
2.5.5.2), did show that ACPA predicted less improvement in DAS28: 0.32 units 
of DAS28, p=0.037: Chapter 4, Table 4-3.  The major difference between the 
cross-sectional analyses of change in DAS28 and those reviewed in Chapter 1, 
Section 1.8.2.3 was that the YEAR analysis examined absolute change in 
DAS28 after 6 and 12 months, whereas the Leiden clinic data spanned 5 to 10 
years, with sustained remission as the primary outcome of the analyses 
reported.  Therefore, antibodies may have a more significant role as a predictor 
of long term disease activity than short term, and this may explain why the 
longitudinal DAS28 trajectory analysis, in which data from baseline to 24 
months were utilised, identified an association between ACPA and worse 
outcome.  There have been reports of associations between RF and ACPA 
positivity and disease activity, but in established RA, rather than early disease.  
In a study of 855 cases from the Veterans Affairs Rheumatoid Arthritis registry 
in the USA, which was mostly comprised of male participants with a mean 
disease duration of 11.8 years and variable follow up duration of at least 6 
months, RF and ACPA were associated with greater area under DAS28 curve 
with regression coefficients of 0.17; p=0.025 and 0.23; p=0.003, respectively 
(Miriovsky et al., 2010).  Furthermore, a Moroccan cross-sectional study of 245 
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cases of RA with a mean disease duration of 9.6 years found that DAS28 
(measured at a single visit) was higher in RF positive, compared to RF negative 
cases (6.6 compared to 5.8, respectively, p=0.002) and in ACPA positive, 
compared to ACPA negative cases (5.8 compared to 4.5, respectively, p=0.001) 
(Ibn Yacoub et al., 2012).  Whilst it is acknowledged that there are likely 
significant differences between these cohorts and YEAR; for example, the 
Veteran’s cohort was mainly male and the Moroccan cohort had likely received 
different treatment and probably had greater disease activity than YEAR, 
indicated by the high DAS28 scores; it would be interesting to test the 
hypothesis that antibodies predict longer term disease activity by examining the 
relationship between antibody status and disease activity in YEAR cases after 
several year’s follow up.  Whilst there is evidence that antibodies predict bony 
erosion in RA and are associated with less likelihood of remission (reviewed in 
Chapter 1, Section 1.8.2.3), there are relatively few studies reporting the 
relationship between antibody status and disease activity in early RA, which 
may be as a result of publication bias (whereby publication in journals is less 
likely if studies yield negative results). 
RF and ACPA did not predict change in HAQ-DI after 6 and 12 months, or 
HAQ-DI trajectory.  In this respect, predictors of HAQ-DI trajectory in YEAR 
were similar to those reported in ERAS and NOAR, where RF was also not a 
significant predictor (Norton et al., 2014).  As discussed in Chapter 1, Section 
1.8.4.2, reports of the influence of autoantibodies on functional outcome in RA 
have differed from study to study, but the relationship described in some studies 
may have been mediated by the development of erosions.  Radiographic 
change has not been included in the present analysis, but is available for a 
proportion of YEAR cases.  A future analysis could therefore examine the 
relationship between HAQ-DI and erosions in YEAR, by including radiographic 
erosion as a time-varying covariate in the model of change in HAQ-DI.   
7.3.4 Shared epitope alleles as predictors of outcome 
As part of YEAR data collection, information on whether or not cases carried the 
HLA-DRB1 shared epitope was recorded.  Available data included the number 
of alleles (that is, 0,1, or 2), but for the main analysis, a binary variable was 
entered into the statistical models to indicate presence or absence of at least 
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one copy of the HLA-DRB1 shared epitope allele.  This variable did not predict 
membership of DAS28 trajectory class and furthermore, when the number of 
shared epitope alleles was included in the model (as 1 or 2 alleles compared to 
no alleles), the effect was also not statistically significant (Chapter 4, Section 
4.7).  The number of alleles was only tested in the analysis of the whole cohort 
because inclusion of this ordinal variable in the model necessitated an 
additional predictor variable and as the number of cases in the analysis of 
YEAR C data was smaller, statistical power would have been diminished.  
These results appear to be contrary to the evidence presented in Chapter 1, 
Section 1.8.2.2 and Table 1-5, in which presence of shared epitope alleles was 
associated with more severe disease.  However, a major difference between 
the reviewed articles and the present study was the outcome variable 
employed, which in the previous studies was more severe disease indicated by 
treatment failure and requirement of additional therapy to manage the disease.  
In two of these studies (Gonzalez-Gay et al., 2002 and , Hider et al., 2009), the 
decision to increase treatment was not based upon DAS28, but was decided by 
the physician, and furthermore, the paper by Hider (2009) was from NOAR, 
which included cases with early inflammatory arthritis rather than RA, so the 
population studied was different to YEAR.  Therefore, the results from these 
studies are difficult to compare to those from YEAR.  In the Japanese study 
conducted by Mori and colleagues (Mori et al., 2010), DMARD failure and 
eligibility for biological therapy was indicated by presence of 6 or more tender 
and swollen joints and CRP ≥ 2mg/dl in 47 of 50 ‘non-responders’ and evidence 
of progression of radiographic damage due to RA in 3 of 50 cases.  Using the 
SJC, TJC and CRP noted by the authors of this study, the equivalent DAS28 
indicative of treatment failure would be ≥4.62, which is similar to the ‘high 
DAS28’ trajectory described in Chapter 4, Section 4.6 and Figure 4-10.  Thus, 
predictors of high DAS28 trajectory group membership would be expected to be 
similar to those of treatment failure in Mori’s study.  However, when applied to a 
logistic regression analysis, carriage of shared epitope alleles was not a 
significant predictor of treatment failure if non-*04 alleles were also included.  
This is therefore consistent with the findings in the present YEAR analysis, in 
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which the effects of different types of shared epitope allele were not 
investigated.  
7.3.5 The impact of social deprivation on outcome 
Area-level social deprivation, measured using IMD, was not a statistically 
significant predictor of DAS28 trajectory, but was almost significant in the 
analysis that involved only YEAR C cases (discussed in Chapter 4, Section 
4.7.1.3).  This analysis indicated that lower SES (higher deprivation) was 
associated with the less favourable DAS28 trajectory, which was expected: OR 
0.83; 95%CI 0.99, 3.40; p=0.054.  Interestingly, in a prior model that did not 
include fatigue VAS (shown in Appendix 7), IMD significantly predicted DAS28 
trajectory in the whole cohort and in YEAR C (discussed in Chapter 4, Sections 
4.7 and 4.7.1.3) and furthermore, male gender was significantly associated with 
more favourable DAS28 trajectory in the YEAR C analysis that did not include 
fatigue VAS.  This suggests possible relationships between fatigue and SES, 
and fatigue and gender, and illustrates the importance of considering potential 
confounders for inclusion in statistical models.  Table 8A in Appendix 8 shows 
that mean baseline fatigue VAS was lowest for cases from IMD quartile 4 (least 
deprived) and highest for IMD quartile 2.  Mean baseline fatigue VAS was 
1.08cm greater in women than men (Chapter 4, Section 4.7.1.3).   
Cases classified into the most deprived quartiles of IMD were more likely to fall 
into the less favourable HAQ-DI trajectories (Chapter 5, Section 5.6 and 
5.6.1.3).  This finding was in keeping with the results from the ERAS and NOAR 
cohorts (Norton et al., 2014), and the BROSG (Reviewed in Chapter 1, Table 1-
6).  Potential causes of this finding are numerous and may relate to increased 
co-morbidities in patients from more socially deprived areas, later presentation 
owing to reduced access to health care, reduced adherence to medication 
owing to cost of prescriptions, or poorer general health and wellbeing as a result 
of a lower level of education and poor lifestyle choices.  Smoking is also an 
important consideration, but was controlled for in the analysis of YEAR C data, 
so is unlikely to have confounded the results, which are displayed in Section 
5.6.1.3.  Comorbidity was also controlled for in the analysis of YEAR C data, 
although the limitations of the comorbidity variable used have been noted 
(discussed in Section 7.3.8).   
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7.3.6 Smoking did not predict outcome in Yorkshire Early Arthritis 
Register 
As explained in Chapter 2, Section 2.1, data on smoking were not available for 
YEAR B participants and therefore the effect of smoking on DAS28 and HAQ-DI 
trajectories was examined in YEAR C participants only.  The smoking variable 
was entered into the models as the quantity smoked by the individual, 
measured in pack years (described in Chapter 2, Section 2.5.2).  The quantity 
of cigarettes smoked was not a significant predictor of DAS28 or HAQ-DI 
trajectory, with OR close to 1.0 (shown in Table 4-13 in Chapter 4 and Table 5-
13 in Chapter 5).  This is contrary to the evidence presented in Chapter 1, 
Section 1.8.2.6, which suggested that disease activity may be worse in smokers 
and that there may be a possible dose effect, with increased disease activity 
associated with greater numbers of cigarettes smoked.  SES was controlled for 
in the analysis of YEAR C data, which is a key difference between this analysis 
and the studies that found smoking predicted worse disease activity.  It is 
possible that the association of SES with smoking could explain why the results 
from previous studies were different to those of the present study.  Although the 
difference in pack years smoked across the quartiles of IMD in YEAR C was not 
significantly different according to a one-way between groups analysis of 
variance (shown in Appendix 8), the mean quantity of pack years smoked did 
reduce from IMD1 (most deprived) to IMD4 (least deprived): 16.8 to 11.4, 
respectively.  The evidence reviewed in Chapter 1, Section 1.8.4.4, also 
indicated that functional outcome is worse in smokers; however, these studies 
included patients with established RA and did not consider bony erosions as a 
potential confounder of their results.  Although the present analyses also did not 
include erosion as a covariate, the cases had early RA, so there should have 
been fewer erosions in this cohort.   
The accuracy of the smoking variable depended upon the patient’s correct 
recollection of the quantity of cigarettes they had smoked and the number of 
years they had smoked for.  Studies utilising laboratory indicators of cigarette 
smoking have confirmed that use of tobacco products has been under-reported 
at interview, which is likely due to its association with adverse health outcomes 
(reviewed by Coughlin, 1990).  Therefore, the smoking variable used in the 
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YEAR cohort could have been inaccurate and this may have influenced the 
results, however, this would similarly apply for most published studies.  
7.3.7 Body mass index as a predictor of outcome 
There is evidence of an association between higher BMI and worse disease 
activity in RA (reviewed in Chapter 1, Section 1.8.2.7) and the present analysis 
was in keeping with these results.  In the analysis of YEAR C data, the odds of 
membership of the least favourable of the DAS28 trajectories increased by 4% 
per Kg/m2 of baseline BMI, p=0.033, shown in Table 4-13.  The present analysis 
did not investigate why higher BMI was associated with adverse outcome, but 
the potential for obesity to influence inflammatory markers, and therefore 
DAS28, has already been discussed (Chapter 1, Section 1.8.2.7).  
Although the mean BMI of patients of the YEAR cohort was 27.3 (as reported in 
Chapter 3, Table 3-1), which is in the ‘overweight’ range, this was not unusually 
high for the UK population.  Statistics published by the National Obesity 
Observatory estimated that 81% of men and 68% of women aged 55-64 in the 
2009 health survey for England were overweight or obese (National Obesity 
Observatory, 2011).   
An alternative mechanism linking BMI and DAS was proposed by Heimans and 
colleagues (2011), in a study from the BeSt cohort (Heimans et al., 2013).  In 
their study of 508 patients with RA, assigned to 4 different treatment regimes, 
mean TJC over 1 year was 1.4 joints greater in obese individuals (BMI ≥25) 
than non-obese (95% CI 0.6, 2.2), and mean VAS pain was 6.2mm greater 
(95% CI 3.0, 9.4), compared to SJC and CRP, which were not significantly 
different between the 2 groups (0.6 joints, 95% CI -0.02, 1.2 and 0.7 mg/L, 95% 
CI -1.5, 2.9, respectively).  Thus, the authors suggested that DAS was greater 
in obese individuals from the BeSt cohort owing to its subjective components 
(that is, VAS and TJC), rather than objective measures of inflammation.  The 
cause of this observation is not clear and it is possible that in the present study, 
increased pain and the influence of obesity on CRP may have had a compound 
effect resulting in elevated DAS28.  
In the analysis of YEAR C data, increased BMI was associated with a reduction 
in the odds of falling into a more favourable HAQ-DI trajectory: 5% reduction in 
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odds per kg/m2 BMI; p=0.031 (Chapter 5, Section 5.6.1.3).  This finding is in 
keeping with results from NOAR (reviewed Chapter 1, Section 1.8.4.5).  The 
cause of the association between BMI and HAQ-DI could be related to other co-
morbidities, as although the presence of comorbidity was controlled for in the 
analysis, the limitations of this variable are noted (discussed in Section 7.3.8).  
The association between obesity and other conditions, such as osteoarthritis 
(which was not asked about as part of the YEAR protocol), could explain a 
reduced functional outcome in patients with higher BMI.  The causal relationship 
could also be in the reverse direction: patients with worse RA are less able to 
exercise and therefore have a higher BMI; however, as BMI was measured at 
baseline in patients with early arthritis, this is less likely.  A further possible 
explanation of the observed association may be pain: BMI was a predictor of 
persistence of chronic widespread pain after 11 years in a large cohort study of 
27, 574 individuals resident in Norway (Mundal et al., 2014).  In this study, 
chronic widespread pain was present in 17% of individuals at the baseline 
assessment and was persistent in 53% of these after 11 years.  In a 
multivariable logistic regression model adjusted for age, gender, depression, 
anxiety, smoking, alcohol intake, marital status, and presence of a chronic 
disease, individuals who were overweight and obese at baseline were more 
likely to have persistent widespread pain: OR (overweight, BMI 25-29.9) 1.18; 
95% CI 1.01, 1.32; OR (obese, BMI ≥30.0) 1.66; 95% CI 1.37-2.01.  Thus, 
increased BMI has been associated with presence and persistence of pain, and 
this, together with the pro-inflammatory nature of adipose, may explain the 
relationship between BMI and HAQ-DI.  
Paradoxically, although predictive of worse disease activity, increased BMI has 
been associated with reduced erosive damage in RA (Baker et al., 2014b).  As 
data on BMI were only available for YEAR C, it was not added as a covariate in 
the regression analysis of predictor of DAS28/HAQ-DI trajectory, but this would 
have been of interest.  Given the association with greater pain in RA, higher 
baseline BMI may be expected to predict membership of the low DAS28 / high 
HAQ-DI trajectory and be associated with higher DAS28-P. 
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7.3.8 Comorbidities and their impact on outcome 
This study was not designed to examine the effect of comorbidities on disease 
activity in RA and different methods of data collection would have been adopted 
if this had been the original intention.  Thus, although the presence of 
comorbidities did not predict DAS28 or HAQ-DI trajectory in YEAR C (Chapter 
4, Section 4.7.1.3), it is recognised that this variable was not adequately 
measured.  Comorbidity might have influenced disease activity in YEAR, 
because some illnesses may have precluded the use of certain DMARDs; for 
example, MTX could have been avoided in a patient with known pulmonary 
fibrosis.  Results from ERAS indicated an association between adverse HAQ 
trajectory and greater comorbidity, although this relationship was observed after 
3 and 5 years and not at baseline (Norton et al., 2013).  The dichotomous 
variable used in the analysis was a crude estimation of comorbidity and a 
different method of measuring comorbidities, such as the Charlson index of 
comorbidity (Charlson et al., 1987), used by Norton et.al. (2013), may have 
been preferable.  However, the Charlson index was designed to predict 
mortality amongst medical inpatients: an altogether different group of patients to 
the cohort in question.  At present, there is no validated measure of the burden 
of comorbidity designed specifically for use in RA, although this is an area 
under development.   
7.4 Strengths and limitations  
YEAR aimed to capture data on patients newly diagnosed with RA and follow 
their progress over the first 2 years.  Occasionally circumstances were 
encountered that may have adversely affected the quality of the data available 
for analysis.  This Section outlines the strengths and limitations of the study and 
statistical analyses. 
7.4.1 Yorkshire Early Arthritis Register and its relevance to 
contemporary practice 
The YEAR cohort was established to investigate whether outcomes in RA could 
be predicted by “conventional prognostic factors” (as detailed in Chapter 2, 
Section 2.5.1).  The participants of YEARs B and C were recruited between 
1997 and 2009, during a period of evolution of the treatment of RA, bought 
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about by the emergence of biological therapies.  YEAR cases were treated in 
the traditional ‘step-up’ fashion of adding or increasing DMARD therapy if 
disease activity was apparent, which is different to the modern practice of ‘early 
and aggressive’ therapy (reviewed in Chapter 1, Section 1.6).  This difference to 
contemporary practice was more marked for YEAR B, which employed SSA 
rather than MTX, and did not include an intramuscular steroid injection at 
baseline in the protocol (although corticosteroids may have been given by the 
treating rheumatologist).  Despite the differences between modern therapeutic 
approaches and YEAR treatment protocols, the information from this register 
may still be useful.  YEAR shares one advantage with many other inflammatory 
arthritis registers: it captured data on patients treated within a realistic clinical 
setting and therefore the results are likely to be more generalizable than the 
results from clinical trials with rigid protocols.  As NICE guidelines limit the use 
of biological therapies for UK patients with RA to those with DAS28 values of 
greater than 5.1 (shown in Chapter 1, Figure 1-2), patients with moderate 
disease activity must rely on synthetic DMARDs, such as MTX and SSA, for 
management of their arthritis.  YEAR contains data on patients managed with 
these agents, so the results within this Thesis are relevant for such modern-day 
patients with early RA, including paharmacogenetics studies that will be 
dependent on access to cohorts treated with a single DMARD.   
7.4.2 Cases excluded from Yorkshire Early Arthritis Register C 
A limitation of the present study is that some cases with early RA were not 
included in the register and were instead recruited to randomised controlled 
trials, as discussed in Chapter 2, Section 2.2.5.  As 367 cases of early RA 
patients were thus excluded from YEAR C, the data do not represent all incident 
cases of RA in the Yorkshire centres involved in the study and this must be 
borne in mind when interpreting the data and comparing to other cohorts.  It is 
likely that this anomaly contributed to some of the baseline differences between 
YEAR B and C, which were highlighted in Chapter 3, Table 3-1.  For example, 
mean baseline DAS28 and HAQ-DI were both higher in YEAR B because 
selection for two of these clinical trials depended upon cases having higher 
DAS28 and therefore some patients with more active disease were recruited 
into these studies instead of YEAR C (discussed in Chapter 3, Section 3.2).  
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Another difference between the 2 cohorts was that symptom duration was 
longer in YEAR C than in YEAR B.  It was anticipated that this would be the 
other way around: awareness of the need for prompt secondary care referral of 
patients with signs and symptoms of early inflammatory arthritis by primary care 
physicians should have increased with time and therefore, YEAR C cases 
should have had a shorter symptom duration at baseline.  The EMPIRE study 
(Nam et al., 2014b) recruited 110 patients with symptom duration of 3 months or 
less, whilst  IDEA (Nam et al., 2014a) recruited 112 cases with symptoms for 3-
12 months, which may explain the longer symptom duration YEAR C cases.   
7.4.3 The definition of symptom duration 
Owing to the importance of early therapeutic intervention in RA, the definition of 
symptom onset for clinical trials has received some interest.  Historically, 
several different methods have been used to define symptom onset in RA, 
including the patient reported date of symptom onset (as in the YEAR cohort), 
date of first joint swelling, or date of meeting criteria for the definition of RA 
(Raza et al., 2012).  Recently, EULAR published recommendations on how to 
capture symptom onset in for RA research, which were as follows (Gerlag et al., 
2012):  
1. Record the date of the first musculoskeletal symptom that the 
rheumatologist considered was attributable to RA,  
2. Record the date of first joint swelling that persisted to presentation,  
3. Record the date that either 1987 ACR, or 2010 ACR/EULAR criteria for 
RA were first met, according to the patient’s history (that is, through 
information that may be obtained retrospectively), 
4. Record the date that either 1987 ACR, or 2010 ACR/EULAR criteria for 
RA were first met, in the opinion of the rheumatologist. 
Although IACON, the successor to YEAR, does capture these data, YEAR B 
and C were established before these recommendations were published, and 
symptom onset was defined by asking patients the date that their symptoms 
started.  Therefore, the symptom duration variable used in analyses within this 
Thesis may have been inaccurate, as the data required each patient to recall 
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the information and may also have been subject to recall bias.  The wording of 
this question likely explains why patients with symptom durations of greater 
than 12 months were included, despite the YEAR protocol, which specified that 
patients should have symptom durations less than 12 months.  The decision to 
include subjects in YEAR was at the discretion of the rheumatologist, who may 
not have agreed that the patient’s reported date of symptom onset was actually 
attributable to RA.  Unfortunately, the clinical record form did not capture 
symptom duration in the opinion of the rheumatologist.  Due to this potential 
discrepancy, patients with symptom durations of up to 24 months were included 
in the analyses.  This duration was chosen as a cut-off as it allowed retention of 
the majority of cases.  Furthermore, 12 months seemed a plausible discrepancy 
between patient and physician reported onset of symptoms, allowing for a 
possible ‘sub clinical’ period of arthralgia prior to diagnosis, which has been 
noted in some patients who subsequently develop clinically evident 
inflammatory arthritis (van Steenbergen et al., 2014).  In 36 and 25 cases in 
YEAR B and C, respectively, data were not included in the analysis as the 
symptom duration exceeded 24 months.  During the data validation process, 
where possible, symptom onset was checked against the clinical notes for 
cases with symptom durations of greater than 24 months or missing.  In some 
cases where the clinical notes were reviewed, the symptom onset recorded did 
seem in keeping with onset of RA, and some of these patients had already 
received treatment for inflammatory arthritis.    
Some of the cases with symptom duration missing were also excluded from the 
analysis.  The decision to omit these cases from the analysis, rather than use 
MI to allow for the missing values, was based upon the finding that subjects with 
symptom durations of up to 15 years had been recruited to YEAR (Chapter 3, 
Section 3.2).  As the focus of this study was early RA, it was crucial to avoid 
including cases with longstanding disease.  Although MI would have been 
useful to minimise bias in estimates due to missing symptom duration, it could 
not be used to distinguish between early and late RA. 
7.4.4 Measurement of autoantibodies 
Measurement of RF was at performed at baseline, 12 and 24 months in both 
YEAR B and C, but ACPA status was not measured at the time of data 
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collection.  Instead, this test was performed retrospectively on stored samples 
and in some cases, patients were asked to provide a new blood sample after 
data collection was complete (described in Chapter 2, Section 2.2.4).  The 
limitations associated with the timing of ACPA testing in YEAR was previously 
discussed in relation to another study (Morgan et al., 2009) and evidence that a 
small proportion of patients who are ACPA-negative at baseline may become 
ACPA-positive with time, and vice-versa, has been acknowledged (Kastbom et 
al., 2004, Meyer et al., 2006).  As the ACPA test is more widely applied in 
contemporary practice, future studies will have the advantage of a true baseline 
value. 
7.4.5 Patient reported outcomes and their relationship to disease 
activity and disability  
Previous analyses of predictors of outcome in early RA (such as those reviewed 
in Chapter 1, Sections 1.8.2 and 1.8.4) have focused on objective or semi-
objective measurements like age at presentation, antibody status, smoking 
history and BMI.  The cross sectional analyses of YEAR data evaluated the 
influence of 3 subjective measurements as predictors of outcome, which were 
EMS, fatigue and pain at baseline.  The rationale for including these as 
predictors was that TJC and VAS components of DAS28 are subjective and 
may be influenced by non-inflammatory processes like chronic pain and 
fibromyalgia, so could contribute to an elevated DAS28 in cases with minimal 
inflammation.  Therefore, higher levels of baseline pain, fatigue and EMS may 
be associated with higher DAS28 at 6 and 12 months, reflecting symptoms 
attributable to non-inflammatory causes.   
In the cross sectional analyses of change in DAS28 and HAQ-DI, duration of 
EMS was applied as a categorical predictor variable.  The question “for how 
long are your joints stiff in the morning?” can pose some difficulty for patients, 
who are unlikely to have noted the exact timing of improvement of joint stiffness.  
The value given by the patients is therefore an approximate one and 
furthermore, is not always specific to RA (reviewed by Sokka, 2011).  Although 
it was not a statistically significant predictor of outcome, difficulties encountered 
in the measurement of stiffness would mean that it would be difficult to apply as 
an indicator of prognosis.  Furthermore, as this question related stiffness in the 
  
258 
 
morning, EMS duration should not last beyond 5 or 6 hours (for example, 
stiffness all day should not be classified as EMS and may reflect a cause other 
than RA), so some cases reporting EMS >220 minutes (approximately 3.6 
hours) may have been reporting stiffness that was unrelated to RA. 
7.4.6 Data management 
As described in Chapter 3, Section 3.4, there was a significant amount of 
missing data, with 22% of values unrecorded.  To account for this, missing data 
management techniques were employed for the statistical analyses to minimise 
the impact of missingness.  A superior approach would have been to employ a 
rigid system that would identify gaps in the dataset as they occurred, so that the 
data could then be obtained.  As most of the missing values occurred because 
patients failed to attend appointments, this could have been achieved by 
regularly reminding patients of their missed appointments and offering an 
alternative date as close as possible to the missed visit.  In practice, although 
the YEAR dataset was reviewed periodically, a more systematic approach may 
have been costly and difficult to achieve: contacting patients required the 
attention of a dedicated staff member and in addition, NHS clinic appointments 
are often booked well in advance, so that the next available appointment may 
be some months ahead of the missed one.  
7.4.7 Outcome measures 
The outcome measures used in this Thesis were DAS28 and HAQ-DI, which 
were discussed in Chapter 1, Sections 1.8.1 and 1.8.3, respectively.  One 
advantage of the DAS28 is that it is a well recognised and comprehensible 
measure: it has been in use for almost 20 years and now forms part of UK 
guidelines on the management of RA (reviewed in Chapter 1, Table 1-3).  
However, more recently, the limitations of the DAS28 have been highlighted, 
including its elevation due to non-inflammatory pain and fibromyalgia 
(McWilliams et al., 2012).   
The HAQ-DI is also a well-established and recognised outcome measure, as 
discussed in Chapter 1, Section 1.8.3.  There have been no previous 
descriptions of the use of a Rasch-transformed version of this variable as an 
outcome measure and Dr Hensor’s work on this is currently unpublished.  The 
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transformed HAQ-DI is a strength of the present analysis because the use of a 
continuous (rather than categorical or dichotomous) value retains statistical 
power.  
7.4.8 The use of visual analogue scales 
As the pain and fatigue variables are subjective, they can be difficult to quantify 
and the YEAR data collection protocol made use of a VAS to capture individual 
patient’s perception of pain and fatigue, as described in Chapter 2, Section 
2.2.2.  Baseline VAS for pain and fatigue were applied to the regression models 
as predictor variables, whilst disease activity VAS was considered as an 
auxiliary variable in the management of missing data using MI or maximum 
likelihood estimation (Chapter 3, Sections 3.5.1 and 3.5.2, respectively).  On 
each of these occasions, the VAS was used as an interval variable.  Although 
often applied in quantitative analysis, data from VAS may not represent a true 
interval scale, so that the difference in the concept being measured may not be 
the same between 1 and 2 cm on the VAS, compared to 8 and 9 cm, for 
example.  The use of VAS for this type of analysis has been the subject of much 
debate (for example, Franchignoni et al., 2012, Harms-Ringdahl, 2012, Price et 
al., 2012) and Rasch-transformed values have been suggested as preferable 
for use in parametric analyses (reviewed by Grimby et al., 2012).  More 
recently, a Rasch analysis of data from 221 cases with chronic musculoskeletal 
pain awaiting joint replacement surgery found that whilst mean pain VAS 
measured over 7 days at baseline was internally valid, unidimensional change 
in VAS from baseline did not represent a linear scale (Kersten et al., 2014).  
This means that pain VAS as a raw variable, or change in VAS, is not suitable 
as an outcome variable in parametric analysis because measured change may 
under or over-represent actual change in pain.  In this Thesis, pain VAS was 
used as a predictor rather than an outcome, so the resulting estimates may not 
have been affected by the problems with VAS discussed here.  Much of the 
research on the suitability of VAS in parametric analysis has focused on pain, 
and I am not aware of any studies addressing similar issues relating to fatigue 
VAS.  A 2007 review of fatigue measurement tools used for RA identified 5 
different anchor statements to represent 0cm on fatigue VAS, and 7 different 
anchor statements to represent 10cm, from a total of 26 articles that used VAS 
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to measure fatigue (Hewlett et al., 2007).  Indeed, there was a difference in the 
wording used for the fatigue VAS in YEAR B and C (described in Chapter 2, 
Section 2.2.2) and although such heterogeneity can make comparisons 
between studies difficult, the fatigue VAS from YEAR B and C were grouped 
together for the purpose of the analyses that included data from both cohorts.  
Any differences in model estimates that may have occurred due to the wording 
of the fatigue VAS question would have been identified by the interaction term 
(between fatigue and YEAR cohort), but this was not significant in any of the 
models studied.  Measurement of fatigue using a VAS was assessed using a 
cohort of 7760 patients with RA from the USA, in a study that compared VAS to 
3 other scales used to measure fatigue: the vitality component of the short-form 
36, brief fatigue inventory (previously used for cancer research), and 
multidimensional assessment of fatigue scale (Wolfe, 2004).  Correlations with 
VAS were 0.71, 0.76 and 0.80, respectively.  The authors also reported that the 
VAS was sensitive to change and concluded that it was quick to complete and 
suitable for use in clinical practice.  
Another consideration is that the VAS were not normally distributed (shown in 
Appendix 6), with proportionally larger quantities of patients reporting pain VAS 
of 10cm and fatigue VAS of 0cm, as described in Chapter 3, Section 3.3.  This 
was especially notable for fatigue, where 148 and 159 cases from YEAR B and 
C, respectively, reported no fatigue (or 0cm on fatigue VAS).  This observation 
could have been due to the way in which this question was asked, as well as 
the nature of VAS.  As described in Chapter 2, Section 2.2.2, only cases who 
responded positively to a question about whether or not they experienced 
abnormal fatigue (YEAR B), or felt unusually tired (YEAR C) were asked to 
complete the VAS.  In this way, the opportunity to complete a fatigue VAS was 
removed from a significant number of cases.  It is possible that people who 
responded ‘no’ to the initial question would have indicated a small amount of 
fatigue on the VAS, rather than zero, which is how their response was 
interpreted.  Although a similar effect was seen for pain VAS, the modal value 
for this variable was 10cm and is therefore not explained by the question asked 
of YEAR C participants: “do you have any pain associated with your rheumatoid 
arthritis?”. 
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7.4.9 Measurement of social deprivation 
As a marker of SES, IMD was obtained using the patient’s postal code.  
Although this variable has the advantage of being a low-cost and easily 
obtainable estimate of SES, it has been associated with the following problems:  
1.  The IMD includes a ‘health’ domain (as described in Chapter 2, Section 
2.5.2), which could potentially affect it’s use as a predictor of outcome for 
health research.  Although one study into the effect of removing the health 
domain from the 2004 IMD showed that the relationship between IMD and 
health outcomes identified in the 2004 census was not affected, the authors 
did recommend that the health domain be removed for research into other 
health outcomes that utilised the IMD (Adams and White, 2006).  For the 
present analyses, the health domain of the IMD was not removed and may 
have therefore confounded the results.  
2. The IMD is a measure of area-level, rather than personal level deprivation, 
and each LSOA could include a heterogeneous population of individuals 
with differing socio-economic statuses.  This situation is a common problem 
for measures of area level deprivation and personal deprivation may be a 
more important indicator of some health outcomes (Sloggett and Joshi, 
1998).  IMD was selected for use in analyses of YEAR data because 
postcode was routinely collected at baseline, whereas personal indicators of 
SES were not recorded. 
3. The IMD 2007 was used for the present analyses, but this index is based 
upon census data and subsequent ranking of LSOA, which are both subject 
to change over time.  Therefore, the IMD rank in 2007 may not be an 
accurate representation of area-level deprivation for all of the patients in 
YEAR, who were recruited between 1997 and 2009. 
4. Another previously recognised problem with area-level deprivation is that 
the health outcome studied may have influences SES (reviewed by Mackie 
et al., 2012).  However, this was an unlikely cause of the observations from 
analyses of YEAR data, because the cases all had early RA and postcode 
at baseline was used as an indicator of SES. 
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This association of SES and poor outcome, consistent with previous reports, is 
important as it may indicate a potential target group for intervention to improve 
outcome in RA.  However, in order for this information to be used, a better 
understanding of the cause of this relationship is required, and further study is 
warranted.  
7.4.10 The differences between Yorkshire Early Arthritis 
Register B and C 
In order to allow for the differences between YEAR B and C, ‘cohort’ was 
included as a covariate in all statistical models and furthermore, in the cross 
sectional analyses, interaction terms between ‘YEAR cohort’ and other predictor 
variables were included.  Fall in DAS28 after 6 months was 0.21 units greater 
for YEAR C cases (p=0.026), but there was no statistically significant difference 
in fall in DAS28 after 12 months between YEAR B and C.  Although change in 
HAQ-DI after 6 and 12 months was not statistically significantly different 
between YEAR B and C, change after 12 months approached significance.  For 
YEAR C, fall in HAQ-DI was 0.48 units greater than for YEAR B patients 
(p=0.072).  Furthermore, there was a 30% increase in the odds of membership 
of the high DAS28/ high HAQ-DI trajectory group for YEAR B cases, compared 
to the low DAS28 / low HAQ-DI group.   
The effect on change in DAS28 after 6 months may be attributable to the 
corticosteroid given as part of the treatment protocol at baseline in YEAR C.  An 
improved treatment strategy over time and the preferential use of MTX in YEAR 
C may have influenced these results; however, it was not possible to fully 
examine the effects of the different DMARDs used.  Although there were often 
deviations from the treatment protocols (described in Chapter 2, Section 2.3) 
due to individual patient preference, or where treatment was not tolerated, or 
suspended due to infective illness, the majority of YEAR B cases were offered 
SSA as an initial treatment, whilst MTX was usually offered fist-line in YEAR C.  
Therefore, some of the differences in outcome between YEAR B and C might 
be due to these different initial treatments.  Unfortunately, it was not possible to 
test this further because there was considerable inter-individual variation in 
treatment received.  For example, there was variation in the doses of each drug 
prescribed, whether or not drugs were given in combination, and whether 
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DMARDs had to be suspended for clinical or personal reasons.  Consistent with 
the rest of the dataset, missing information was also a problem relating to the 
treatment received.  During the period of time that YEAR C recruitment was 
ongoing, the use of biological therapies for RA was emerging.  There were only 
7 cases for whom TNF inhibitors were prescribed: for 6 of these, biological 
therapy began after the 12 month visit and in the other case, it was started 9 
months after baseline.  A higher quantity of patients offered biologic therapy 
may have been expected, but the exclusion of some potential YEAR patients 
due to recruitment into clinical trials (described in Chapter 2, Section 2.2.5) may 
have influenced this number.  Thus, as only 7 patients were known to have 
used biological therapy during YEAR follow up, this treatment is unlikely to have 
affected the results.   
Other possible causes for better outcome in YEAR C may be that there was 
closer follow up of these cases, with an additional scheduled visit at 3 months.  
Furthermore, some YEAR C cases with higher baseline DAS28 were excluded 
so that they could participate in clinical trials (discussed in 7.4.1), and those 
remaining in the register may have had milder disease.  
7.4.11 Longitudinal data analysis 
Latent growth curves were used to describe change in DAS28 and HAQ-DI over 
time and LCGA was used to identify trajectories of change within the cohort.  
Although these techniques of analysing longitudinal data with repeated 
measures of the same variable were developed decades ago, their application 
to RA research is emerging.  The strengths of longitudinal analysis versus cross 
sectional techniques were outlined in Chapter 1, Section 1.7.2.1.  For the 
present analyses of change in DAS28 and HAQ-DI trajectories, LCGA was 
chosen in preference to latent class-GMM because of its simplicity and ease of 
application.  There appears to be no evidence of superiority of either approach.  
The main difference between these 2 techniques is that for LCGA, all cases 
within a given trajectory are presumed to follow that trajectory and the variance 
is therefore zero, whilst latent class-GMM allows for inter-individual variation 
and variance of trajectory groups is provided within the results.  These 2 
techniques were amongst 5 different methods of classifying trajectories 
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compared in a recent study that included data manipulated to follow pre-
determined trajectories (Twisk and Hoekstra, 2012).  The results from this study 
implied that LCGA was preferable to latent class-GMM when the altered data 
followed linear trajectories, but neither performed well when the trajectories 
were quadratic.  The authors suggested that whilst longitudinal methods 
appeared to be superior to cross sectional techniques, LCGA was likely to 
estimate a greater number of trajectories compared to latent class-GMM; 
however, the analysis of YEAR B and C data identified only 2 trajectories of 
DAS28 and HAQ-DI, which is a relatively small number and unlikely to be 
greater than that estimated by an alternative method.  
7.4.12 Handling of missing data 
Missing data is a common problem amongst longitudinal studies to which YEAR 
was particularly susceptible, with 22% of all observations required for the 
present analyses missing (detailed in Chapter 3, Section 3.4).  In order to 
minimise the impact of missing variables, as many values absent from the 
database as possible were obtained through the data validation process 
described in Chapter 2, Section 2.4.  Furthermore, statistical missing data 
management techniques including multiple imputation and maximum likelihood 
estimation were employed.  As described in Chapter 1, Section 1.7.2.2, these 
methods require that the data are MAR and therefore this was an assumption of 
all of the analyses in this Thesis.  Sensitivity analysis was not conducted, but 
would have been useful to determine how the results would have been affected 
if the MAR assumptions were not met. 
7.5 Future directions 
Much research on predictors of outcome in RA has been conducted with an 
ultimate goal of developing personalised treatment strategies for individual 
patients and development within this area is ongoing.  With this target in mind, 
the work in this Thesis has raised several areas of potential focus for future 
study.   
If the purpose of treatment in early RA is to supress inflammation and improve 
physical function, then the results presented herein suggest that both of these 
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targets should be considered together: it is not enough to simply reduce 
inflammation and expect that disability will be improved or prevented.  However, 
despite following a low DAS28 trajectory, there may have been ongoing 
synovial inflammation for some YEAR cases within this trajectory group.  
Therefore, in order to describe the relationship between disease activity and 
disability more accurately, a study to determine the level of disability amongst 
cases for whom inflammation is fully suppressed (as far as possible with 
modern treatments) would be necessary.  This may involve a study of patients 
with RA for whom DMARD treatment is escalated whenever there is apparent 
synovial inflammation.  For this to be possible, a true biomarker of synovial 
inflammation is required.  Currently used indicators of RA disease activity, such 
as the DAS28, are influenced by factors other than inflammation, such as 
chronic pain (as discussed in Section 1.8.1) and alternative measures may 
perform better (such as the m-DAS28, described in Section 7.2).  A longitudinal  
observational study to evaluate the presence and causes of disability despite 
full suppression of inflammation in early RA would add to current knowledge in 
several ways.  Firstly, an observational study would reflect actual clinical 
practice and the results would be more readily applicable to everyday patient 
management.  There is also much to learn from cases for whom full 
suppression of inflammation is not achievable.  These may be patients who 
cannot take certain DMARDs due to co-morbidity, or cases who fail to attend 
their appointments or adhere to medication (there may be myriad reasons for 
this, such as drug side effects, caring responsibilities, poor literacy or financial 
reasons).  It is essential to understand why RA disease activity cannot be 
controlled for every patient during this era of biological therapies.  Inequalities in 
health across socioeconomic groups are well recognised, but despite free 
access to healthcare provided by the NHS in the UK, little progress has been 
made to improve health of individuals from poor social backgrounds.   
It is not clear why disability persisted in some YEAR cases despite apparent 
suppression of inflammation, but this could be due to the impact of comorbid 
conditions on physical function.  As discussed in Section 7.3.8, there is currently 
no measure of comorbidity specifically for use in outpatients with RA, however 
this is an area that does require development.  Large research databases 
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containing anonymised patient information from primary care consultations have 
been established and are likely to be of great value for investigating the impact 
of co morbidity in conditions such as RA.  Through linkage of data between 
primary care and disease specific registers such as YEAR, co-morbidity as a 
factor contributing to disability can be explored.  Other possible contributors to 
disability in early RA also deserve attention, including psychological parameters 
such as learned helplessness and social factors like level of education and 
social support.   
As discussed in Section 7.2.1, the results presented in this Thesis support 
current evidence that fatigue in RA is driven by a multitude of factors, which are 
likely to be both biological and psychosocial.   Fatigue at baseline also predicted 
worse outcome and although the reasons for this observation are unknown, 
they warrant exploration: it is possible that drivers of fatigue in RA could 
contribute to a tool that may be used to guide treatment of RA.  For example, in 
a patient recently diagnosed with RA with severe fatigue, anaemia, high CRP 
and a large number of SJC, immediate treatment with a biological agent (for 
example) may be more suitable than for a different patient with recent onset RA 
who has severe fatigue at baseline, higher ratio of TJC to SJC, higher pain 
VAS, lower CRP and a history of depression.  For the latter patient, suppression 
of inflammation may be satisfactorily achieved with MTX and SSA, whilst 
complementary therapies and patient support may play a more important role in 
management.   
An initial probing analysis to test the hypothesis that drivers of fatigue are 
different for the two adverse trajectory classes in YEAR could be conducted 
using a structural equation model.  The model should include ‘biological drivers 
of fatigue’ (CRP, anaemia, possibly m-DAS) and ‘psychosocial drivers of 
fatigue’ (SES, level of social support, anxiety and depression), as well as co-
morbidity, in order to describe each component’s contribution to fatigue.  It 
would then be possible to show whether the different ‘drivers of fatigue’ 
influence this outcome equally across the 2 trajectory groups.    
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7.6 Concluding comments 
Through analysis of data obtained from YEAR, the work in this Thesis showed 
that half of patients followed a good prognostic trajectory group (low DAS28/ 
low HAQ-DI).  The remainder either demonstrated evidence of continued 
inflammation and poor function, or poor function despite suppression of 
inflammation.  This indicates that treatment with synthetic DMARDs alone may 
not be adequate to suppress inflammation and maintain function in a subgroup 
of patients with RA.  Furthermore, for some individuals, non-inflammatory 
aspects of RA may be a significant factor contributing to continued disability.  
Further research is required to determine whether additional therapeutic 
intervention can benefit such individuals.  The impact of comorbidity in these 
cases remains of interest and is another area for future study, which is likely to 
be possible through linkage to data from primary care research databases. 
Fatigue at baseline consistently predicted adverse outcome and was associated 
with both persistent disability related to ongoing inflammation and persistent 
disability despite suppression of inflammation.  The reasons underlying these 
findings are likely to be multi-factorial, but the key contributors to fatigue may 
differ between the two groups, with psychological and social factors more 
prominent in those whose inflammation was supressed, but who had ongoing 
disability.  Understanding specific drivers of fatigue for individual patients may 
help to inform treatment decisions in early RA and this is an area of interest for 
future research. 
  
  
268 
 
References 
Adams, J. & White, M. 2006. Removing the health domain from the Index of 
Multiple Deprivation 2004-effect on measured inequalities in census 
measure of health. J Public Health (Oxf), 28, 379-83. 
Aho, K., Koskenvuo, M., Tuominen, J., et al. 1986. Occurrence of rheumatoid 
arthritis in a nationwide series of twins. J Rheumatol, 13, 899-902. 
Al-Katma, M. K., Bissada, N. F., Bordeaux, J. M., et al. 2007. Control of 
periodontal infection reduces the severity of active rheumatoid arthritis. J 
Clin Rheumatol, 13, 134-7. 
Aletaha, D., Nell, V. P., Stamm, T., et al. 2005. Acute phase reactants add little 
to composite disease activity indices for rheumatoid arthritis: validation of 
a clinical activity score. Arthritis Res Ther, 7, R796-806. 
Aletaha, D., Neogi, T., Silman, A. J., et al. 2010. 2010 rheumatoid arthritis 
classification criteria: an American College of Rheumatology/European 
League Against Rheumatism collaborative initiative. Ann Rheum Dis, 69, 
1580-8. 
Anderson, D. R., Grillo-Lopez, A., Varns, C., et al. 1997. Targeted anti-cancer 
therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in 
the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans, 
25, 705-8. 
Andersson, M. L., Bergman, S. & Soderlin, M. K. 2013. The Effect of 
Socioeconomic Class and Immigrant Status on Disease Activity in 
Rheumatoid Arthritis: Data from BARFOT, a Multi-Centre Study of Early 
RA. Open Rheumatol J, 7, 105-11. 
Appelboom, T. & Soyfoo, M. S. 2010. Tobacco: from pre-Columbian use to the 
appearance of rheumatoid arthritis in the Old World? Arthritis Rheum, 62, 
1561-2. 
Arend, W. P. 1993. Interleukin-1 receptor antagonist. Adv Immunol, 54, 167-
227. 
Arnett, F. C., Edworthy, S. M., Bloch, D. A., et al. 1988. The American 
Rheumatism Association 1987 revised criteria for the classification of 
rheumatoid arthritis. Arthritis Rheum, 31, 315-24. 
  
269 
 
Arnold, M. B., Bykerk, V. P., Boire, G., et al. 2014. Are there differences 
between young- and older-onset early inflammatory arthritis and do these 
impact outcomes? An analysis from the CATCH cohort. Rheumatology 
(Oxford). 
Baka, Z., Buzas, E. & Nagy, G. 2009. Rheumatoid arthritis and smoking: putting 
the pieces together. Arthritis Res Ther, 11, 238. 
Baker, J. F., Conaghan, P. G., Smolen, J. S., et al. 2014. Development and 
validation of modified disease activity scores in rheumatoid arthritis: 
superior correlation with magnetic resonance imaging-detected synovitis 
and radiographic progression. Arthritis Rheumatol, 66, 794-802. 
Bakker, M. F., Jacobs, J. W., Welsing, P. M., et al. 2012. Low-dose prednisone 
inclusion in a methotrexate-based, tight control strategy for early 
rheumatoid arthritis: a randomized trial. Ann Intern Med, 156, 329-39. 
Bansback, N., Zhang, W., Walsh, D., et al. 2012. Factors associated with 
absenteeism, presenteeism and activity impairment in patients in the first 
years of RA. Rheumatology, 51, 375-84. 
Bartok, B. & Firestein, G. S. 2010. Fibroblast-like synoviocytes: key effector 
cells in rheumatoid arthritis. Immunol Rev, 233, 233-55. 
Bastard, J. P., Jardel, C., Bruckert, E., et al. 2000. Elevated levels of interleukin 
6 are reduced in serum and subcutaneous adipose tissue of obese 
women after weight loss. J Clin Endocrinol Metab, 85, 3338-42. 
Bax, M., van Heemst, J., Huizinga, T. W., et al. 2011. Genetics of rheumatoid 
arthritis: what have we learned? Immunogenetics, 63, 459-66. 
Bejarano, V., Quinn, M., Conaghan, P. G., et al. 2008. Effect of the early use of 
the anti-tumor necrosis factor adalimumab on the prevention of job loss 
in patients with early rheumatoid arthritis. Arthritis Rheum, 59, 1467-74. 
Bellamy, N., Duffy, D., Martin, N., et al. 1992. Rheumatoid arthritis in twins: a 
study of aetiopathogenesis based on the Australian Twin Registry. Ann 
Rheum Dis, 51, 588-93. 
Berlin, K. S., Williams, N. A. & Parra, G. R. 2014. An introduction to latent 
variable mixture modeling (part 1): overview and cross-sectional latent 
class and latent profile analyses. J Pediatr Psychol, 39, 174-87. 
  
270 
 
Boers, M., Kostense, P. J., Verhoeven, A. C., et al. 2001. Inflammation and 
damage in an individual joint predict further damage in that joint in 
patients with early rheumatoid arthritis. Arthritis Rheum, 44, 2242-6. 
Boers, M., Tugwell, P., Felson, D. T., et al. 1994. World Health Organization 
and International League of Associations for Rheumatology core 
endpoints for symptom modifying antirheumatic drugs in rheumatoid 
arthritis clinical trials. J Rheumatol Suppl, 41, 86-9. 
Bombardier, C., Barbieri, M., Parthan, A., et al. 2012. The relationship between 
joint damage and functional disability in rheumatoid arthritis: a systematic 
review. Ann Rheum Dis, 71, 836-44. 
Boyd, T. A., Bonner, A., Thorne, C., et al. 2013. The Relationship Between 
Function and Disease Activity as Measured by the HAQ and DAS28 
Varies Over Time and by Rheumatoid Factor Status in Early 
Inflammatory Arthritis (EIA). Results from the CATCH Cohort. Open 
Rheumatol J, 7, 58-63. 
Boyesen, P., Haavardsholm, E. A., Ostergaard, M., et al. 2011. MRI in early 
rheumatoid arthritis: synovitis and bone marrow oedema are independent 
predictors of subsequent radiographic progression. Ann Rheum Dis, 70, 
428-33. 
Breedveld, F. 1998. New tumor necrosis factor-alpha biologic therapies for 
rheumatoid arthritis. Eur Cytokine Netw, 9, 233-8. 
Bruce, B. & Fries, J. F. 2003. The Stanford Health Assessment Questionnaire: a 
review of its history, issues, progress, and documentation. J Rheumatol, 
30, 167-78. 
Byrne, B. M. 2010. Structural equation modeling with AMOS: basic concepts, 
applications and programming, New York, Routledge. 
Calixto, O. J. & Anaya, J. M. 2014. Socioeconomic status. The relationship with 
health and autoimmune diseases. Autoimmun Rev, 13, 641-654. 
Camacho, E. M., Verstappen, S. M., Chipping, J., et al. 2013. Learned 
helplessness predicts functional disability, pain and fatigue in patients 
with recent-onset inflammatory polyarthritis. Rheumatology (Oxford), 52, 
1233-8. 
  
271 
 
Camacho, E. M., Verstappen, S. M., Lunt, M., et al. 2011. Influence of age and 
sex on functional outcome over time in a cohort of patients with recent-
onset inflammatory polyarthritis: results from the Norfolk Arthritis 
Register. Arthritis Care Res (Hoboken), 63, 1745-52. 
Camacho, E. M., Verstappen, S. M. & Symmons, D. P. 2012. Association 
between socioeconomic status, learned helplessness, and disease 
outcome in patients with inflammatory polyarthritis. Arthritis Care Res 
(Hoboken), 64, 1225-32. 
Carpenter, J. R., Kenward, M. G. & White, I. R. 2007. Sensitivity analysis after 
multiple imputation under missing at random: a weighting approach. Stat 
Methods Med Res, 16, 259-75. 
Cascao, R., Rosario, H. S., Souto-Carneiro, M. M., et al. 2010. Neutrophils in 
rheumatoid arthritis: More than simple final effectors. Autoimmun Rev, 9, 
531-5. 
Celeux, G. & Soromenho, G. 1996. An entropy criterion for assessing the 
number of clusters in a mixture model. Journal of Classification, 13, 195-
212. 
Charlson, M. E., Pompei, P., Ales, K. L., et al. 1987. A new method of 
classifying prognostic comorbidity in longitudinal studies: development 
and validation. J Chronic Dis, 40, 373-83. 
Choi, J., Joseph, L. & Pilote, L. 2013. Obesity and C-reactive protein in various 
populations: a systematic review and meta-analysis. Obes Rev, 14, 232-
44. 
Choy, E. H., Hazleman, B., Smith, M., et al. 2002. Efficacy of a novel PEGylated 
humanized anti-TNF fragment (CDP870) in patients with rheumatoid 
arthritis: a phase II double-blinded, randomized, dose-escalating trial. 
Rheumatology (Oxford), 41, 1133-7. 
Ciftci, O., Yilmaz, S., Topcu, S., et al. 2008. Impaired coronary microvascular 
function and increased intima-media thickness in rheumatoid arthritis. 
Atherosclerosis, 198, 332-7. 
Ciranni, R., Garbini, F., Neri, E., et al. 2002. The "Braids Lady" of Arezzo: a 
case of rheumatoid arthritis in a 16th century mummy. Clin Exp 
Rheumatol, 20, 745-52. 
  
272 
 
Coakley, F. V., Samanta, A. K. & Finlay, D. B. 1994. Ultrasonography of the 
tibialis posterior tendon in rheumatoid arthritis. Br J Rheumatol, 33, 273-
7. 
Cobb, S. 1965. The Epidemiology of Rheumatoid Arthritis. Arthritis Rheum, 8, 
76-9. 
Collins, L. M., Schafer, J. L. & Kam, C. M. 2001. A comparison of inclusive and 
restrictive strategies in modern missing data procedures. Psychol 
Methods, 6, 330-51. 
Colville-Nash, P. R. & Scott, D. L. 1992. Angiogenesis and rheumatoid arthritis: 
pathogenic and therapeutic implications. Ann Rheum Dis, 51, 919-25. 
Combe, B., Cantagrel, A., Goupille, P., et al. 2003. Predictive factors of 5-year 
health assessment questionnaire disability in early rheumatoid arthritis. J 
Rheumatol, 30, 2344-9. 
Combe, B., Rincheval, N., Benessiano, J., et al. 2013. Five-year favorable 
outcome of patients with early rheumatoid arthritis in the 2000s: data 
from the ESPOIR cohort. J Rheumatol, 40, 1650-7. 
Conaghan, P. G., Hensor, E. M. A., Keenan, A.-M., et al. 2010. Persistently 
moderate DAS-28 is not benign: loss of function occurs in early RA 
despite step-up DMARD therapy. Rheumatology, 49, 1894-1899. 
Conaghan, P. G., McGonagle, D., Wakefield, R., et al. 1999. New approaches 
to imaging of early rheumatoid arthritis. Clin Exp Rheumatol, 17, S37-42. 
Conaghan, P. G., O'Connor, P., McGonagle, D., et al. 2003. Elucidation of the 
relationship between synovitis and bone damage: a randomized 
magnetic resonance imaging study of individual joints in patients with 
early rheumatoid arthritis. Arthritis Rheum, 48, 64-71. 
Cooles, F. A. & Isaacs, J. D. 2011. Pathophysiology of rheumatoid arthritis. Curr 
Opin Rheumatol, 23, 233-40. 
Corbett, M., Dalton, S., Young, A., et al. 1993. Factors predicting death, survival 
and functional outcome in a prospective study of early rheumatoid 
disease over fifteen years. Br J Rheumatol, 32, 717-23. 
Coughlin, S. S. 1990. Recall bias in epidemiologic studies. J Clin Epidemiol, 43, 
87-91. 
  
273 
 
da Cunha, V. R., Brenol, C. V., Brenol, J. C., et al. 2012. Metabolic syndrome 
prevalence is increased in rheumatoid arthritis patients and is associated 
with disease activity. Scand J Rheumatol, 41, 186-91. 
da Silva, J. A., Phillips, S. & Buttgereit, F. 2011. Impact of impaired morning 
function on the lives and well-being of patients with rheumatoid arthritis. 
Scand J Rheumatol Suppl, 125, 6-11. 
Dalhy, D. 2012. Growth mixture modelling for life course epidemiology. In: Tu, 
Y.-K. & Greenwood, D. C. (eds.) Modern Methods for Epidemiology. 
Springer. 
de Haas, W. H., de Boer, W., Griffioen, F., et al. 1973. Rheumatoid arthritis, 
typus robustus. Ann Rheum Dis, 32, 91-2. 
de Pablo, P., Dietrich, T. & McAlindon, T. E. 2008. Association of periodontal 
disease and tooth loss with rheumatoid arthritis in the US population. J 
Rheumatol, 35, 70-6. 
Department For Communities and Local Government, 2004. The English 
indices of deprivation 2004. Rev. [ed.]. ed. London: Office of the Deputy 
Prime Minister. 
Ding, C. & Jones, G. 2003. Technology evaluation: MRA, Chugai. Curr Opin 
Mol Ther, 5, 64-9. 
Dirven, L., Visser, K., Klarenbeek, N. B., et al. 2012. Towards personalized 
treatment: predictors of short-term HAQ response in recent-onset active 
rheumatoid arthritis are different from predictors of rapid radiological 
progression. Scand J Rheumatol, 41, 15-9. 
Doran, M. F., Pond, G. R., Crowson, C. S., et al. 2002. Trends in incidence and 
mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-
year period. Arthritis Rheum, 46, 625-31. 
Drossaers-Bakker, K. W., de Buck, M., van Zeben, D., et al. 1999. Long-term 
course and outcome of functional capacity in rheumatoid arthritis: the 
effect of disease activity and radiologic damage over time. Arthritis 
Rheum, 42, 1854-60. 
Elliott, M. J., Maini, R. N., Feldmann, M., et al. 1994. Randomised double-blind 
comparison of chimeric monoclonal antibody to tumour necrosis factor 
alpha (cA2) versus placebo in rheumatoid arthritis. Lancet, 344, 1105-10. 
  
274 
 
Entezami, P., Fox, D. A., Clapham, P. J., et al. 2011. Historical perspective on 
the etiology of rheumatoid arthritis. Hand Clin, 27, 1-10. 
Evans, W. J., Morley, J. E., Argiles, J., et al. 2008. Cachexia: a new definition. 
Clin Nutr, 27, 793-9. 
ERAS Study Group, 2000. Socioeconomic deprivation and rheumatoid disease: 
What lessons for the health service? Ann Rheum Dis, 59, 794-799. 
Eyre, S., Bowes, J., Diogo, D., et al. 2012. High-density genetic mapping 
identifies new susceptibility loci for rheumatoid arthritis. Nat Genet, 44, 
1336-40. 
Felson, D. T., Anderson, J. J., Boers, M., et al. 1993. The American College of 
Rheumatology preliminary core set of disease activity measures for 
rheumatoid arthritis clinical trials. The Committee on Outcome Measures 
in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum, 36, 729-40. 
Felson, D. T., Anderson, J. J., Boers, M., et al. 1995. American College of 
Rheumatology. Preliminary definition of improvement in rheumatoid 
arthritis. Arthritis Rheum, 38, 727-35. 
Felson, D. T. & Lavalley, M. P. 2014. The ACR20 and defining a threshold for 
response in rheumatic diseases: too much of a good thing. Arthritis Res 
Ther, 16, 101. 
Felson, D. T., Smolen, J. S., Wells, G., et al. 2011. American College of 
Rheumatology/European League Against Rheumatism provisional 
definition of remission in rheumatoid arthritis for clinical trials. Arthritis 
Rheum, 63, 573-86. 
Fontecchio, G., Ventura, L. & Poma, A. M. 2012. Further genomic testing and 
histological examinations confirm the diagnosis of rheumatoid arthritis in 
an Italian mummy from the 16th century. Ann Rheum Dis, 71, 630. 
Forslind, K., Hafstrom, I., Ahlmen, M., et al. 2007. Sex: a major predictor of 
remission in early rheumatoid arthritis? Ann Rheum Dis, 66, 46-52. 
Foster, C. S., Forstot, S. L. & Wilson, L. A. 1984. Mortality rate in rheumatoid 
arthritis patients developing necrotizing scleritis or peripheral ulcerative 
keratitis. Effects of systemic immunosuppression. Ophthalmology, 91, 
1253-63. 
  
275 
 
Franchignoni, F., Salaffi, F. & Tesio, L. 2012. How should we use the visual 
analogue scale (VAS) in rehabilitation outcomes? I: How much of what? 
The seductive VAS numbers are not true measures. J Rehabil Med, 44, 
798-9; discussion 803-4. 
Fransen, J. & van Riel, P. L. 2009. Outcome measures in inflammatory 
rheumatic diseases. Arthritis Res Ther, 11, 244. 
Fries, J. F., Spitz, P., Kraines, R. G., et al. 1980. Measurement of patient 
outcome in arthritis. Arthritis Rheum, 23, 137-45. 
Furst, D. E. 1990. Rheumatoid arthritis. Practical use of medications. Postgrad 
Med, 87, 79-92. 
Gabbay, E., Tarala, R., Will, R., et al. 1997. Interstitial lung disease in recent 
onset rheumatoid arthritis. Am J Respir Crit Care Med, 156, 528-35. 
Garrod, A. E. 1890. A treatise on rheumatism and rheumatoid arthritis, Griffin. 
Gaujoux-Viala, C., Nam, J., Ramiro, S., et al. 2014. Efficacy of conventional 
synthetic disease-modifying antirheumatic drugs, glucocorticoids and 
tofacitinib: a systematic literature review informing the 2013 update of the 
EULAR recommendations for management of rheumatoid arthritis. Ann 
Rheum Dis, 73, 510-5. 
Geiler, T., Kriegsmann, J., Keyszer, G. M., et al. 1994. A new model for 
rheumatoid arthritis generated by engraftment of rheumatoid synovial 
tissue and normal human cartilage into SCID mice. Arthritis Rheum, 37, 
1664-71. 
Gerlag, D. M., Raza, K., van Baarsen, L. G., et al. 2012. EULAR 
recommendations for terminology and research in individuals at risk of 
rheumatoid arthritis: report from the Study Group for Risk Factors for 
Rheumatoid Arthritis. Ann Rheum Dis, 71, 638-41. 
Gobernado, J. M., Leiva, C., Rabano, J., et al. 1984. Recovery from rheumatoid 
cerebral vasculitis. J Neurol Neurosurg Psychiatry, 47, 410-3. 
Goldbach-Mansky, R. & Lipsky, P. E. 2003. New concepts in the treatment of 
rheumatoid arthritis. Annu Rev Med, 54, 197-216. 
  
276 
 
Gonzalez-Gay, M. A., Hajeer, A. H., Garcia-Porrua, C., et al. 2002. Patients 
chosen for treatment with cyclosporine because of severe rheumatoid 
arthritis are more likely to carry HLA-DRB1 shared epitope alleles, and 
have earlier disease onset. J Rheumatol, 29, 271-5. 
Graell, E., Vazquez, I., Larrosa, M., et al. 2009. Disability measured by the 
modified health assessment questionnaire in early rheumatoid arthritis: 
prognostic factors after two years of follow-up. Clin Exp Rheumatol, 27, 
284-91. 
Graham, J. W. 2009. Missing data analysis: making it work in the real world. 
Annual review of psychology, 60, 549-76. 
Greenland, S. & Finkle, W. D. 1995. A critical look at methods for handling 
missing covariates in epidemiologic regression analyses. Am J 
Epidemiol, 142, 1255-64. 
Gregersen, P. K., Silver, J. & Winchester, R. J. 1987. The shared epitope 
hypothesis. An approach to understanding the molecular genetics of 
susceptibility to rheumatoid arthritis. Arthritis Rheum, 30, 1205-13. 
Gremese, E., Carletto, A., Padovan, M., et al. 2013. Obesity and reduction of 
the response rate to anti-tumor necrosis factor alpha in rheumatoid 
arthritis: an approach to a personalized medicine. Arthritis Care Res 
(Hoboken), 65, 94-100. 
Grimby, G., Tennant, A. & Tesio, L. 2012. The use of raw scores from ordinal 
scales: time to end malpractice? J Rehabil Med, 44, 97-8. 
Haavardsholm, E. A., Boyesen, P., Ostergaard, M., et al. 2008. Magnetic 
resonance imaging findings in 84 patients with early rheumatoid arthritis: 
bone marrow oedema predicts erosive progression. Ann Rheum Dis, 67, 
794-800. 
Hallert, E., Husberg, M., Jonsson, D., et al. 2004. Rheumatoid arthritis is 
already expensive during the first year of the disease (the Swedish TIRA 
project). Rheumatology, 43, 1374-82. 
Hameed, K. & Gibson, T. 1997. A comparison of the prevalence of rheumatoid 
arthritis and other rheumatic diseases amongst Pakistanis living in 
England and Pakistan. Br J Rheumatol, 36, 781-5. 
  
277 
 
Hardt, J., Herke, M. & Leonhart, R. 2012. Auxiliary variables in multiple 
imputation in regression with missing X: a warning against including too 
many in small sample research. BMC medical research methodology, 12, 
184. 
Haringman, J. J., Gerlag, D. M., Zwinderman, A. H., et al. 2005. Synovial tissue 
macrophages: a sensitive biomarker for response to treatment in patients 
with rheumatoid arthritis. Ann Rheum Dis, 64, 834-8. 
Harms-Ringdahl, K. 2012. How should we use the visual analogue scale (VAS) 
in rehabilitation outcomes? III: On the validation requirements for 
assessments using VAS with ratio properties. J Rehabil Med, 44, 801-2; 
discussion 803-4. 
Harper, K., Balzano, C., Rouvier, E., et al. 1991. CTLA-4 and CD28 activated 
lymphocyte molecules are closely related in both mouse and human as 
to sequence, message expression, gene structure, and chromosomal 
location. J Immunol, 147, 1037-44. 
Harrison, M. J., Tricker, K. J., Davies, L., et al. 2005. The relationship between 
social deprivation, disease outcome measures, and response to 
treatment in patients with stable, long-standing rheumatoid arthritis. J 
Rheumatol, 32, 2330-2336. 
Haukoos, J. S. & Newgard, C. D. 2007. Advanced statistics: missing data in 
clinical research--part 1: an introduction and conceptual framework. Acad 
Emerg Med, 14, 662-8. 
Heimans, L., van den Broek, M., le Cessie, S., et al. 2013. Association of high 
body mass index with decreased treatment response to combination 
therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res 
(Hoboken), 65, 1235-42. 
Hewlett, S., Cockshott, Z., Byron, M., et al. 2005. Patients' perceptions of 
fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. 
Arthritis Rheum, 53, 697-702. 
Hewlett, S., Hehir, M. & Kirwan, J. R. 2007. Measuring fatigue in rheumatoid 
arthritis: a systematic review of scales in use. Arthritis Rheum, 57, 429-
39. 
  
278 
 
Hider, S. L., Silman, A. J., Thomson, W., et al. 2009. Can clinical factors at 
presentation be used to predict outcome of treatment with methotrexate 
in patients with early inflammatory polyarthritis? Ann Rheum Dis, 68, 57-
62. 
Hippisley-Cox, J., Coupland, C., Vinogradova, Y., et al. 2007. Derivation and 
validation of QRISK, a new cardiovascular disease risk score for the 
United Kingdom: prospective open cohort study. BMJ. 
Horton, N. J. & Kleinman, K. P. 2007. Much ado about nothing: A comparison of 
missing data methods and software to fit incomplete data regression 
models. Am Stat, 61, 79-90. 
Hox, J. & Stoel, R. 2005. Multilevel and SEM approaches to growth curve 
modeling. Encyclopedia of statistics in behavoiral science. Chichester, 
UK: John Wiley & sons. 
Humphreys, J. H., Verstappen, S. M., Hyrich, K. L., et al. 2013a. The incidence 
of rheumatoid arthritis in the UK: comparisons using the 2010 
ACR/EULAR classification criteria and the 1987 ACR classification 
criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis, 72, 
1315-20. 
Humphreys, J. H., Verstappen, S. M., Mirjafari, H., et al. 2013b. Association of 
morbid obesity with disability in early inflammatory polyarthritis: results 
from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken), 65, 122-
6. 
Humphreys, J. H., Warner, A., Chipping, J., et al. 2014. Mortality trends in 
patients with early rheumatoid arthritis over 20 years: Results from the 
Norfolk Arthritis Register. Arthritis Care Res (Hoboken). 
Hyrich, K. L., Watson, K. D., Silman, A. J., et al. 2006. Predictors of response to 
anti-TNF-alpha therapy among patients with rheumatoid arthritis: results 
from the British Society for Rheumatology Biologics Register. 
Rheumatology (Oxford), 45, 1558-65. 
Ibn Yacoub, Y., Amine, B., Laatiris, A., et al. 2012. Rheumatoid factor and 
antibodies against citrullinated peptides in Moroccan patients with 
rheumatoid arthritis: association with disease parameters and quality of 
life. Clin Rheumatol, 31, 329-34. 
  
279 
 
Jacobi, C. E., Mol, G. D., Boshuizen, H. C., et al. 2003. Impact of 
socioeconomic status on the course of rheumatoid arthritis and on 
related use of health care services. Arthritis Care Res (Hoboken), 49, 
567-573. 
Jansen, L. M., van Schaardenburg, D., van Der Horst-Bruinsma, I. E., et al. 
2000. Predictors of functional status in patients with early rheumatoid 
arthritis. Ann Rheum Dis, 59, 223-6. 
Janssen, K. J., Donders, A. R., Harrell, F. E., Jr., et al. 2010. Missing covariate 
data in medical research: to impute is better than to ignore. J Clin 
Epidemiol, 63, 721-7. 
Jayakumar, K., Norton, S., Dixey, J., et al. 2012. Sustained clinical remission in 
rheumatoid arthritis: prevalence and prognostic factors in an inception 
cohort of patients treated with conventional DMARDS. Rheumatology 
(Oxford), 51, 169-75. 
Jimenez-Boj, E., Nobauer-Huhmann, I., Hanslik-Schnabel, B., et al. 2007. Bone 
erosions and bone marrow edema as defined by magnetic resonance 
imaging reflect true bone marrow inflammation in rheumatoid arthritis. 
Arthritis Rheum, 56, 1118-24. 
Jones, M. W. & Kaufmann, J. C. 1976. Vertebrobasilar artery insufficiency in 
rheumatoid atlantoaxial subluxation. J Neurol Neurosurg Psychiatry, 39, 
122-8. 
Jung, t. & Wickrama, K. A. S. 2008. An introduction to latent class growth 
analysis and growth mixture modeling Social and personality psychology 
compass, 302-317. 
Kapit W, E. L. 1993. The anatomy colouring book, New York, Harper Collins 
publishers. 
Kastbom, A., Strandberg, G., Lindroos, A., et al. 2004. Anti-CCP antibody test 
predicts the disease course during 3 years in early rheumatoid arthritis 
(the Swedish TIRA project). Ann Rheum Dis, 63, 1085-9. 
Kerola, A. M., Kauppi, M. J., Kerola, T., et al. 2012. How early in the course of 
rheumatoid arthritis does the excess cardiovascular risk appear? Ann 
Rheum Dis, 71, 1606-15. 
  
280 
 
Kersten, P., White, P. J. & Tennant, A. 2014. Is the pain visual analogue scale 
linear and responsive to change? An exploration using Rasch analysis. 
PloS one, 9, e99485. 
Kiely, P., Walsh, D., Williams, R., et al. 2011. Outcome in rheumatoid arthritis 
patients with continued conventional therapy for moderate disease 
activity--the early RA network (ERAN). Rheumatology (Oxford), 50, 926-
31. 
Kirwan, J. R. 1995. The effect of glucocorticoids on joint destruction in 
rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose 
Glucocorticoid Study Group. N Engl J Med, 333, 142-6. 
Kirwan, J. R. & Reeback, J. S. 1986. Stanford Health Assessment 
Questionnaire modified to assess disability in British patients with 
rheumatoid arthritis. Br J Rheumatol, 25, 206-9. 
Klarenbeek, N. B., Koevoets, R., van der Heijde, D. M., et al. 2011. Association 
with joint damage and physical functioning of nine composite indices and 
the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann 
Rheum Dis, 70, 1815-21. 
Klareskog, L., Padyukov, L. & Alfredsson, L. 2007. Smoking as a trigger for 
inflammatory rheumatic diseases. Curr Opin Rheumatol, 19, 49-54. 
Klareskog, L., Stolt, P., Lundberg, K., et al. 2006. A new model for an etiology of 
rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-
restricted immune reactions to autoantigens modified by citrullination. 
Arthritis Rheum, 54, 38-46. 
Kline, R. B. 2011. Principles and practice of structural equation modeling, New 
York, London, The Guilford Press. 
Knevel, R., Schoels, M., Huizinga, T. W., et al. 2010. Current evidence for a 
strategic approach to the management of rheumatoid arthritis with 
disease-modifying antirheumatic drugs: a systematic literature review 
informing the EULAR recommendations for the management of 
rheumatoid arthritis. Ann Rheum Dis, 69, 987-94. 
Knol, M. J., Janssen, K. J., Donders, A. R., et al. 2010. Unpredictable bias when 
using the missing indicator method or complete case analysis for missing 
confounder values: an empirical example. J Clin Epidemiol, 63, 728-36. 
  
281 
 
Koziel, J., Mydel, P. & Potempa, J. 2014. The link between periodontal disease 
and rheumatoid arthritis: an updated review. Curr Rheumatol Rep, 16, 
408. 
Landre-Beauvais, A. J. 2001. The first description of rheumatoid arthritis. 
Unabridged text of the doctoral dissertation presented in 1800. Joint 
Bone Spine, 68, 130-43. 
Lawrence, J. S. 1970. Heberden Oration, 1969. Rheumatoid arthritis--nature or 
nurture? Ann Rheum Dis, 29, 357-79. 
Lee, D. M. & Weinblatt, M. E. 2001. Rheumatoid arthritis. Lancet, 358, 903-11. 
Lee, Y. C., Frits, M. L., Iannaccone, C. K., et al. 2014. Subgrouping of patients 
with rheumatoid arthritis based on pain, fatigue, inflammation, and 
psychosocial factors. Arthritis Rheumatol, 66, 2006-14. 
Leff, R. D. & Akre, S. P. 1986. Obesity and the erythrocyte sedimentation rate. 
Ann Intern Med, 105, 143. 
Letourneau, L., Dessureault, M. & Carette, S. 1991. Rheumatoid iliopsoas 
bursitis presenting as unilateral femoral nerve palsy. J Rheumatol, 18, 
462-3. 
Lorenz, H. M. 2002. Technology evaluation: adalimumab, Abbott laboratories. 
Curr Opin Mol Ther, 4, 185-90. 
Lu, B., Rho, Y. H., Cui, J., et al. 2014. Associations of smoking and alcohol 
consumption with disease activity and functional status in rheumatoid 
arthritis. J Rheumatol, 41, 24-30. 
Lundberg, K., Wegner, N., Yucel-Lindberg, T., et al. 2010. Periodontitis in RA-
the citrullinated enolase connection. Nat Rev Rheumatol, 6, 727-30. 
Ma, M. H., Ibrahim, F., Walker, D., et al. 2012. Remission in early rheumatoid 
arthritis: predicting treatment response. J Rheumatol, 39, 470-5. 
Mackie, S. L., Taylor, J. C., Twigg, S., et al. 2012. Relationship between area-
level socio-economic deprivation and autoantibody status in patients with 
rheumatoid arthritis: multicentre cross-sectional study. Ann Rheum Dis, 
71, 1640-5. 
Mackinnon, A. 2010. The use and reporting of multiple imputation in medical 
research - a review. Journal of internal medicine, 268, 586-93. 
  
282 
 
Mahoney, F. I. & Barthel, D. W. 1965. Functional Evaluation: The Barthel Index. 
Md State Med J, 14, 61-5. 
Manfredsdottir, V. F., Vikingsdottir, T., Jonsson, T., et al. 2006. The effects of 
tobacco smoking and rheumatoid factor seropositivity on disease activity 
and joint damage in early rheumatoid arthritis. Rheumatology (Oxford), 
45, 734-40. 
Masdottir, B., Jonsson, T., Manfredsdottir, V., et al. 2000. Smoking, rheumatoid 
factor isotypes and severity of rheumatoid arthritis. Rheumatology 
(Oxford), 39, 1202-5. 
Maska, L., Anderson, J. & Michaud, K. 2011. Measures of functional status and 
quality of life in rheumatoid arthritis: Health Assessment Questionnaire 
Disability Index (HAQ), Modified Health Assessment Questionnaire 
(MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), 
Health Assessment Questionnaire II (HAQ-II), Improved Health 
Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis 
Quality of Life (RAQoL). Arthritis Care Res (Hoboken), 63 Suppl 11, S4-
13. 
Massey, H., Darby, M. & Edey, A. 2012. Thoracic complications of rheumatoid 
disease. Clin Radiol. 
Mattey, D. L., Brownfield, A. & Dawes, P. T. 2009. Relationship between pack-
year history of smoking and response to tumor necrosis factor 
antagonists in patients with rheumatoid arthritis. J Rheumatol, 36, 1180-
7. 
McCluskey, P. J., Watson, P. G., Lightman, S., et al. 1999. Posterior scleritis: 
clinical features, systemic associations, and outcome in a large series of 
patients. Ophthalmology, 106, 2380-6. 
McGonagle, D., Conaghan, P. G., O'Connor, P., et al. 1999. The relationship 
between synovitis and bone changes in early untreated rheumatoid 
arthritis: a controlled magnetic resonance imaging study. Arthritis 
Rheum, 42, 1706-11. 
McInnes, I. B. & Schett, G. 2011. The pathogenesis of rheumatoid arthritis. N 
Engl J Med, 365, 2205-19. 
  
283 
 
McWilliams, D. F., Zhang, W., Mansell, J. S., et al. 2012. Predictors of change 
in bodily pain in early rheumatoid arthritis: an inception cohort study. 
Arthritis Care Res (Hoboken), 64, 1505-13. 
Meenan, R. F., Gertman, P. M. & Mason, J. H. 1980. Measuring health status in 
arthritis. The arthritis impact measurement scales. Arthritis Rheum, 23, 
146-52. 
Messmer, E. M. & Foster, C. S. 1999. Vasculitic peripheral ulcerative keratitis. 
Surv Ophthalmol, 43, 379-96. 
Meyer, O., Nicaise-Roland, P., Santos, M. D., et al. 2006. Serial determination 
of cyclic citrullinated peptide autoantibodies predicted five-year 
radiological outcomes in a prospective cohort of patients with early 
rheumatoid arthritis. Arthritis Res Ther, 8, R40. 
Miriovsky, B. J., Michaud, K., Thiele, G. M., et al. 2010. Anti-CCP antibody and 
rheumatoid factor concentrations predict greater disease activity in men 
with rheumatoid arthritis. Ann Rheum Dis, 69, 1292-7. 
Monsarrat, P., Vergnes, J. N., Cantagrel, A., et al. 2013. Effect of periodontal 
treatment on the clinical parameters of patients with rheumatoid arthritis: 
study protocol of the randomized, controlled ESPERA trial. Trials, 14, 
253. 
Mor, A., Abramson, S. B. & Pillinger, M. H. 2005. The fibroblast-like synovial cell 
in rheumatoid arthritis: a key player in inflammation and joint destruction. 
Clin Immunol, 115, 118-28. 
Morgan, A. W., Thomson, W., Martin, S. G., et al. 2009. Reevaluation of the 
interaction between HLA-DRB1 shared epitope alleles, PTPN22, and 
smoking in determining susceptibility to autoantibody-positive and 
autoantibody-negative rheumatoid arthritis in a large UK Caucasian 
population. Arthritis Rheum, 60, 2565-76. 
Mori, S., Hirose, J. & Yonemura, K. 2010. Contribution of HLA-DRB1*04 alleles 
and anti-cyclic citrullinated antibodies to development of resistance to 
disease-modifying antirheumatic drugs in early rheumatoid arthritis. Clin 
Rheumatol, 29, 1357-66. 
  
284 
 
Mundal, I., Grawe, R. W., Bjorngaard, J. H., et al. 2014. Prevalence and long-
term predictors of persistent chronic widespread pain in the general 
population in an 11-year prospective study: the HUNT study. BMC 
Musculoskelet Disord, 15, 213. 
Myasoedova, E., Crowson, C. S., Kremers, H. M., et al. 2010. Is the incidence 
of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 
1955-2007. Arthritis Rheum, 62, 1576-82. 
Nagin, D. S. & Tremblay, R. E. 2001. Analyzing developmental trajectories of 
distinct but related behaviors: a group-based method. Psychol Methods, 
6, 18-34. 
Nam JL , V. E., Hensor EMA ,Wakefield RJ,   Conaghan PG,  Green MJ, Gough 
A ,  Quinn M,  Reece R, Cox SR , Buch MH ,  van der Heijde DM,  Emery 
P 2013. A multicentre randomised placebo-controlled trial of etanercept 
and methotrexate to induce remission in patients with newly diagnosed 
inflammatory arthritis: the EMPIRE TRIAL (Etanercept and Methotrexate 
in Patients to Induce Remission in Early Arthritis). Unpublished work. 
Nam, J. L., Villeneuve, E., Hensor, E. M., et al. 2014a. Remission induction 
comparing infliximab and high-dose intravenous steroid, followed by 
treat-to-target: a double-blind, randomised, controlled trial in new-onset, 
treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis, 
73, 75-85. 
Nam, J. L., Villeneuve, E., Hensor, E. M., et al. 2014b. A randomised controlled 
trial of etanercept and methotrexate to induce remission in early 
inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis, 73, 1027-36. 
National Institute for Health and Care Excellence 2009. Rheumatoid arthritis: 
The management of rheumatoid arthritis in adults. 
National Institute for Health and Care Excellence 2010. Rheumatoid arthritis-
certolizumab pegol. Technology appraisal guidance 186. 
National Institute for Health and Care Excellence 2012. Rheumatoid arthritis-
tocilizumab (rapid review TA198) (TA247). In: guidance, N. t. a. (ed.). 
National Institute for Health and Care Excellence 2013. Rheumatoid arthritis- 
abatacept (2nd line) (rapid review of TA234) (TA280). In: 280, N. t. a. g. 
(ed.). 
  
285 
 
National Institute for Health and Care Excellence 2011. Rheumatoid arthritis 
(after the failure of previous anti-rheumatic drugs)-golimumab (TA225).  
Technology appraisal guidance 225. 
National Institute for Health and Clinical Excellence 2007. Adalimumab, 
etanercept and infliximab for the treatement of rheumatoid arthritis. NICE 
technology appraisal guidance 130  
National Obesity Observatory, 2011, June. Adult Weight. Solutions for Publid 
health [Online]. Available: www.noo.org.uk. 
Nicassio, P. M. 2010. Arthritis and psychiatric disorders: disentangling the 
relationship. J Psychosom Res, 68, 183-5. 
Nikolaus, S., Bode, C., Taal, E., et al. 2013. Fatigue and factors related to 
fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res 
(Hoboken), 65, 1128-46. 
Nishimura, K., Sugiyama, D., Kogata, Y., et al. 2007. Meta-analysis: diagnostic 
accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid 
factor for rheumatoid arthritis. Ann Intern Med, 146, 797-808. 
Norton, S., Fu, B., Scott, D. L., et al. 2014. Health Assessment Questionnaire 
disability progression in early rheumatoid arthritis: Systematic review and 
analysis of two inception cohorts. Semin Arthritis Rheum. 
Norton, S., Sacker, A., Dixey, J., et al. 2013. Trajectories of functional limitation 
in early rheumatoid arthritis and their association with mortality. 
Rheumatology (Oxford), 52, 2016-24. 
Oien, R. F., Hakansson, A. & Hansen, B. U. 2001. Leg ulcers in patients with 
rheumatoid arthritis--a prospective study of aetiology, wound healing and 
pain reduction after pinch grafting. Rheumatology, 40, 816-20. 
Olsen, I. C., Kvien, T. K. & Uhlig, T. 2012. Consequences of handling missing 
data for treatment response in osteoarthritis: a simulation study. 
Osteoarthritis Cartilage. 
Ortiz, P., Bissada, N. F., Palomo, L., et al. 2009. Periodontal therapy reduces 
the severity of active rheumatoid arthritis in patients treated with or 
without tumor necrosis factor inhibitors. J Periodontol, 80, 535-40. 
  
286 
 
Ostergaard, M., Emery, P., Conaghan, P. G., et al. 2011. Significant 
improvement in synovitis, osteitis, and bone erosion following golimumab 
and methotrexate combination therapy as compared with methotrexate 
alone: a magnetic resonance imaging study of 318 methotrexate-naive 
rheumatoid arthritis patients. Arthritis Rheum, 63, 3712-22. 
Oude Voshaar, M. A., ten Klooster, P. M., Taal, E., et al. 2011. Measurement 
properties of physical function scales validated for use in patients with 
rheumatoid arthritis: a systematic review of the literature. Health Qual 
Life Outcomes, 9, 99. 
Pallant, J. 2010. SPSS survival manual : a step by step guide to data analysis 
using SPSS, Maidenhead, McGraw Hill/Open University Press. 
Panoulas, V. F., Metsios, G. S., Pace, A. V., et al. 2008. Hypertension in 
rheumatoid arthritis. Rheumatology, 47, 1286-98. 
Pasulka, P. S., Bistrian, B. R. & Blackburn, G. L. 1985. Obesity and erythrocyte 
sedimentation rates. Ann Intern Med, 103, 304. 
Pellman, E., Kumari, S. & Greenwald, R. 1986. Rheumatoid iliopsoas bursitis 
presenting as unilateral leg edema. J Rheumatol, 13, 197-200. 
Pincus, T., Ferraccioli, G., Sokka, T., et al. 2002. Evidence from clinical trials 
and long-term observational studies that disease-modifying anti-
rheumatic drugs slow radiographic progression in rheumatoid arthritis: 
updating a 1983 review. Rheumatology (Oxford), 41, 1346-56. 
Pinho Mde, N., Oliveira, R. D., Novaes, A. B., Jr., et al. 2009. Relationship 
between periodontitis and rheumatoid arthritis and the effect of non-
surgical periodontal treatment. Braz Dent J, 20, 355-64. 
Pollard, L. C., Choy, E. H., Gonzalez, J., et al. 2006. Fatigue in rheumatoid 
arthritis reflects pain, not disease activity. Rheumatology (Oxford), 45, 
885-9. 
Preacher, K. J., Wichman, A. L., MacCallum, R. C., et al. 2008. Relationships 
between LGM and multilevel modelling. In: Liao, T. F. (ed.) Latent 
Growth Curve Modeling. Thousand Oaks, California: Sage. 
  
287 
 
Prevoo, M. L., van 't Hof, M. A., Kuper, H. H., et al. 1995. Modified disease 
activity scores that include twenty-eight-joint counts. Development and 
validation in a prospective longitudinal study of patients with rheumatoid 
arthritis. Arthritis Rheum, 38, 44-8. 
Prevoo, M. L., van Gestel, A. M., van, T. H. M. A., et al. 1996. Remission in a 
prospective study of patients with rheumatoid arthritis. American 
Rheumatism Association preliminary remission criteria in relation to the 
disease activity score. Br J Rheumatol, 35, 1101-5. 
Price, D. D., Staud, R. & Robinson, M. E. 2012. How should we use the visual 
analogue scale (VAS) in rehabilitation outcomes? II: Visual analogue 
scales as ratio scales: an alternative to the view of Kersten et al. J 
Rehabil Med, 44, 800-1; discussion 803-4. 
Puolakka, K., Kautiainen, H., Mottonen, T., et al. 2005. Predictors of productivity 
loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum 
Dis, 64, 130-3. 
Putrik, P., Ramiro, S., Kvien, T. K., et al. 2014. Inequities in access to biologic 
and synthetic DMARDs across 46 European countries. Ann Rheum Dis, 
73, 198-206. 
Quinn, M. A., Conaghan, P. G., O'Connor, P. J., et al. 2005. Very early 
treatment with infliximab in addition to methotrexate in early, poor-
prognosis rheumatoid arthritis reduces magnetic resonance imaging 
evidence of synovitis and damage, with sustained benefit after infliximab 
withdrawal: results from a twelve-month randomized, double-blind, 
placebo-controlled trial. Arthritis Rheum, 52, 27-35. 
Quinn, M. A., Gough, A. K., Green, M. J., et al. 2006. Anti-CCP antibodies 
measured at disease onset help identify seronegative rheumatoid 
arthritis and predict radiological and functional outcome. Rheumatology 
(Oxford), 45, 478-80. 
Rall, L. C. & Roubenoff, R. 2004. Rheumatoid cachexia: metabolic 
abnormalities, mechanisms and interventions. Rheumatology, 43, 1219-
23. 
  
288 
 
Rantapaa-Dahlqvist, S., de Jong, B. A., Berglin, E., et al. 2003. Antibodies 
against cyclic citrullinated peptide and IgA rheumatoid factor predict the 
development of rheumatoid arthritis. Arthritis Rheum, 48, 2741-9. 
Raychaudhuri, S. 2010. Recent advances in the genetics of rheumatoid arthritis. 
Curr Opin Rheumatol, 22, 109-18. 
Raza, K., Saber, T. P., Kvien, T. K., et al. 2012. Timing the therapeutic window 
of opportunity in early rheumatoid arthritis: proposal for definitions of 
disease duration in clinical trials. Ann Rheum Dis, 71, 1921-3. 
Ribeiro, J., Leao, A. & Novaes, A. B. 2005. Periodontal infection as a possible 
severity factor for rheumatoid arthritis. J Clin Periodontol, 32, 412-6. 
Ritchie, D. M., Boyle, J. A., McInnes, J. M., et al. 1968. Clinical studies with an 
articular index for the assessment of joint tenderness in patients with 
rheumatoid arthritis. Q J Med, 37, 393-406. 
Robinson, H. S. 1966. Rheumatoid arthritis--atlanto-axial subluxation and its 
clinical presentation. Can Med Assoc J, 94, 470-7. 
Rodrigues, A. M., Reis, J. E., Santos, C., et al. 2014. A1.1 Obesity is a risk 
factor for worse treatment response in rheumatoid arthritis patients- 
results from reuma.pt. Ann Rheum Dis, 73 Suppl 1, A1. 
Rodriguez-Gomez, M., Willisch, A., Fernandez, L., et al. 2004. Bilateral giant 
iliopsoas bursitis presenting as refractory edema of lower limbs. J 
Rheumatol, 31, 1452-4. 
Rojas-Serrano, J., Pérez, L., García, C., et al. 2011. Current smoking status is 
associated to a non-ACR 50 response in early rheumatoid arthritis. A 
cohort study. Clin Rheumatol, 30, 1589-1593. 
Rothschild, B. M. 2002. Not the Lucy, not the one. Clin Exp Rheumatol, 20, 741-
3. 
Rothschild, B. M., Woods, R. J., Rothschild, C., et al. 1992. Geographic 
distribution of rheumatoid arthritis in ancient North America: implications 
for pathogenesis. Semin Arthritis Rheum, 22, 181-7. 
Rubin, D. 1987. Multiple imputation for non response in surveys. , New York, 
Wiley. 
  
289 
 
Saevarsdottir, S., Wallin, H., Seddighzadeh, M., et al. 2011. Predictors of 
response to methotrexate in early DMARD naive rheumatoid arthritis: 
results from the initial open-label phase of the SWEFOT trial. Ann 
Rheum Dis, 70, 469-75. 
Salaffi, F., Bazzichi, L., Stancati, A., et al. 2005. Development of a functional 
disability measurement tool to assess early arthritis: the Recent-Onset 
Arthritis Disability (ROAD) questionnaire. Clin Exp Rheumatol, 23, 628-
36. 
Sayah, A. & English, J. C., 3rd 2005. Rheumatoid arthritis: a review of the 
cutaneous manifestations. J Am Acad Dermatol, 53, 191-209; quiz 210-
2. 
Schadt, C. 2012. Pyoderma gangrgenosum: Pathogenesis, clinical features and 
diagnosis. In: Basow, D. S. (ed.) UpToDate. Waltham, MA: UpToDate. 
Schellekens, G. A., de Jong, B. A., van den Hoogen, F. H., et al. 1998. Citrulline 
is an essential constituent of antigenic determinants recognized by 
rheumatoid arthritis-specific autoantibodies. J Clin Invest, 101, 273-81. 
Schellekens, G. A., Visser, H., de Jong, B. A., et al. 2000. The diagnostic 
properties of rheumatoid arthritis antibodies recognizing a cyclic 
citrullinated peptide. Arthritis Rheum, 43, 155-63. 
Schett, G., Hayer, S., Zwerina, J., et al. 2005. Mechanisms of Disease: the link 
between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol, 1, 
47-54. 
Schreiber, J., Koschel, D., Kekow, J., et al. 2010. Rheumatoid pneumoconiosis 
(Caplan's syndrome). Eur J Intern Med, 21, 168-72. 
Sheehy, C., Evans, V., Hasthorpe, H., et al. 2014. Revising DAS28 scores for 
remission in rheumatoid arthritis. Clin Rheumatol. 
Siemons, L., Ten Klooster, P. M., Vonkeman, H. E., et al. 2013. Distinct 
trajectories of disease activity over the first year in early rheumatoid 
arthritis patients following a treat-to-target strategy. Arthritis Care Res 
(Hoboken). 
Silman, A. J., MacGregor, A. J., Thomson, W., et al. 1993. Twin concordance 
rates for rheumatoid arthritis: results from a nationwide study. Br J 
Rheumatol, 32, 903-7. 
  
290 
 
Silman, A. J. & Pearson, J. E. 2002. Epidemiology and genetics of rheumatoid 
arthritis. Arthritis Res, 4 Suppl 3, S265-72. 
Sloggett, A. & Joshi, H. 1998. Deprivation indicators as predictors of life events 
1981-1992 based on the UK ONS Longitudinal Study. J Epidemiol 
Community Health, 52, 228-33. 
Smedegard, G. & Bjork, J. 1995. Sulphasalazine: mechanism of action in 
rheumatoid arthritis. Br J Rheumatol, 34 Suppl 2, 7-15. 
Smolen, J. S. & Aletaha, D. 2004. Patients with rheumatoid arthritis in clinical 
care. Ann Rheum Dis, 63, 221-5. 
Smolen, J. S., Breedveld, F. C., Schiff, M. H., et al. 2003. A simplified disease 
activity index for rheumatoid arthritis for use in clinical practice. 
Rheumatology (Oxford), 42, 244-57. 
Soderlin, M. K., Petersson, I. F., Bergman, S., et al. 2011. Smoking at onset of 
rheumatoid arthritis (RA) and its effect on disease activity and functional 
status: experiences from BARFOT, a long-term observational study on 
early RA. Scand J Rheumatol, 40, 249-55. 
Sokka, T. 2011. Morning stiffness and other patient-reported outcomes of 
rheumatoid arthritis in clinical practice. Scand J Rheumatol Suppl, 125, 
23-7. 
Sokka, T., Kautiainen, H., Pincus, T., et al. 2009. Disparities in rheumatoid 
arthritis disease activity according to gross domestic product in 25 
countries in the QUEST-RA database. Ann Rheum Dis, 68, 1666-72. 
Sox, H. C., Jr. & Liang, M. H. 1986. The erythrocyte sedimentation rate. 
Guidelines for rational use. Ann Intern Med, 104, 515-23. 
Squirrell, D. M., Winfield, J. & Amos, R. S. 1999. Peripheral ulcerative keratitis 
'corneal melt' and rheumatoid arthritis: a case series. Rheumatology 
(Oxford), 38, 1245-8. 
Stastny, P. 1976. Mixed lymphocyte cultures in rheumatoid arthritis. J Clin 
Invest, 57, 1148-57. 
Stebbings, S., Herbison, P., Doyle, T. C., et al. 2010. A comparison of fatigue 
correlates in rheumatoid arthritis and osteoarthritis: disparity in 
associations with disability, anxiety and sleep disturbance. 
Rheumatology (Oxford), 49, 361-7. 
  
291 
 
Sterne, J. A., White, I. R., Carlin, J. B., et al. 2009. Multiple imputation for 
missing data in epidemiological and clinical research: potential and 
pitfalls. BMJ, 338, b2393. 
Stone, J. & Dana, R. Clinical manifestations and diagnosis of scleritis. In: 
UpToDate, Trobe (J), Romain, P L (ed), UpToDate, Waltham, MA. 
(Accessed on 23rd January 2014). 
Summers, G. D., Deighton, C. M., Rennie, M. J., et al. 2008. Rheumatoid 
cachexia: a clinical perspective. Rheumatology, 47, 1124-31. 
Symmons, D. P., Barrett, E. M., Bankhead, C. R., et al. 1994. The incidence of 
rheumatoid arthritis in the United Kingdom: results from the Norfolk 
Arthritis Register. Br J Rheumatol, 33, 735-9. 
Symmons, D. P. & Silman, A. J. 2003. The Norfolk Arthritis Register (NOAR). 
Clin Exp Rheumatol, 21, S94-9. 
Szekanecz, Z., Besenyei, T., Szentpetery, A., et al. 2010. Angiogenesis and 
vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol, 22, 299-
306. 
Tak, P. P., Smeets, T. J., Daha, M. R., et al. 1997. Analysis of the synovial cell 
infiltrate in early rheumatoid synovial tissue in relation to local disease 
activity. Arthritis Rheum, 40, 217-25. 
Tennant, A. & Conaghan, P. G. 2007. The Rasch measurement model in 
rheumatology: what is it and why use it? When should it be applied, and 
what should one look for in a Rasch paper? Arthritis Rheum, 57, 1358-
62. 
Tennant, A., Hillman, M., Fear, J., et al. 1996. Are we making the most of the 
Stanford Health Assessment Questionnaire? Br J Rheumatol, 35, 574-8. 
Toohey, A. K., LaSalle, T. L., Martinez, S., et al. 1990. Iliopsoas bursitis: clinical 
features, radiographic findings, and disease associations. Semin Arthritis 
Rheum, 20, 41-7. 
Toussirot, E. 2010. Predictive factors for disability as evaluated by the health 
assessment questionnaire in rheumatoid arthritis: a literature review. 
Inflamm Allergy Drug Targets, 9, 51-9. 
  
292 
 
Toutouzas, K., Sfikakis, P. P., Karanasos, A., et al. 2013. Myocardial ischaemia 
without obstructive coronary artery disease in rheumatoid arthritis: 
hypothesis-generating insights from a cross-sectional study. 
Rheumatology, 52, 76-80. 
Twisk, J. & Hoekstra, T. 2012. Classifying developmental trajectories over time 
should be done with great caution: a comparison between methods. J 
Clin Epidemiol, 65, 1078-87. 
van Aken, J., van Bilsen, J. H., Allaart, C. F., et al. 2003. The Leiden Early 
Arthritis Clinic. Clin Exp Rheumatol, 21, S100-5. 
van Bokhorst-de van der Schueren, M. A., Konijn, N. P., Bultink, I. E., et al. 
2012. Relevance of the new pre-cachexia and cachexia definitions for 
patients with rheumatoid arthritis. Clin Nutr. 
van den Broek, M., Dirven, L., de Vries-Bouwstra, J. K., et al. 2012. Rapid 
radiological progression in the first year of early rheumatoid arthritis is 
predictive of disability and joint damage progression during 8 years of 
follow-up. Ann Rheum Dis, 71, 1530-3. 
van der Heijde, D. M., van 't Hof, M. A., van Riel, P. L., et al. 1990. Judging 
disease activity in clinical practice in rheumatoid arthritis: first step in the 
development of a disease activity score. Ann Rheum Dis, 49, 916-20. 
van der Heijden, G. J., Donders, A. R., Stijnen, T., et al. 2006. Imputation of 
missing values is superior to complete case analysis and the missing-
indicator method in multivariable diagnostic research: a clinical example. 
J Clin Epidemiol, 59, 1102-9. 
van der Woude, D., Visser, K., Klarenbeek, N. B., et al. 2012. Sustained drug-
free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven 
therapy: a comparison of two cohort studies. Rheumatology (Oxford), 51, 
1120-8. 
van der Woude, D., Young, A., Jayakumar, K., et al. 2009. Prevalence of and 
predictive factors for sustained disease-modifying antirheumatic drug-
free remission in rheumatoid arthritis: results from two large early arthritis 
cohorts. Arthritis Rheum, 60, 2262-71. 
  
293 
 
van Everdingen, A. A., Jacobs, J. W., Siewertsz Van Reesema, D. R., et al. 
2002. Low-dose prednisone therapy for patients with early active 
rheumatoid arthritis: clinical efficacy, disease-modifying properties, and 
side effects: a randomized, double-blind, placebo-controlled clinical trial. 
Ann Intern Med, 136, 1-12. 
van Gestel, A. M., Haagsma, C. J. & van Riel, P. L. 1998. Validation of 
rheumatoid arthritis improvement criteria that include simplified joint 
counts. Arthritis Rheum, 41, 1845-50. 
van Gestel, A. M., Prevoo, M. L., van 't Hof, M. A., et al. 1996. Development and 
validation of the European League Against Rheumatism response criteria 
for rheumatoid arthritis. Comparison with the preliminary American 
College of Rheumatology and the World Health 
Organization/International League Against Rheumatism Criteria. Arthritis 
Rheum, 39, 34-40. 
van Halm, V. P., Nielen, M. M., Nurmohamed, M. T., et al. 2007. Lipids and 
inflammation: serial measurements of the lipid profile of blood donors 
who later developed rheumatoid arthritis. Ann Rheum Dis, 66, 184-8. 
van Nies, J. A. B., de Jong, Z., van der Helm-van Mil, A. H. M., et al. 2010. 
Improved treatment strategies reduce the increased mortality risk in early 
RA patients. Rheumatology, 49, 2210-2216. 
van Steenbergen, H. W., van Nies, J. A., Huizinga, T. W., et al. 2014. 
Subclinical inflammation on MRI of hand and foot of anti-citrullinated 
peptide antibody-negative arthralgia patients at risk for rheumatoid 
arthritis. Arthritis Res Ther, 16, R92. 
Vessey, M. P., Villard-Mackintosh, L. & Yeates, D. 1987. Oral contraceptives, 
cigarette smoking and other factors in relation to arthritis. Contraception, 
35, 457-64. 
Visser, M., Bouter, L. M., McQuillan, G. M., et al. 1999. Elevated C-reactive 
protein levels in overweight and obese adults. Jama, 282, 2131-5. 
Walsh, N. C. & Gravallese, E. M. 2010. Bone remodeling in rheumatic disease: 
a question of balance. Immunol Rev, 233, 301-12. 
  
294 
 
Ward, J. R. 1988. Role of disease-modifying antirheumatic drugs versus 
cytotoxic agents in the therapy of rheumatoid arthritis. Am J Med, 85, 39-
44. 
Weinberger, M., Samsa, G. P., Hanlon, J. T., et al. 1991. An evaluation of a 
brief health status measure in elderly veterans. J Am Geriatr Soc, 39, 
691-4. 
Weiss, M. M. 1989. Corticosteroids in rheumatoid arthritis. Semin Arthritis 
Rheum, 19, 9-21. 
Wellcome Trust Case Control Consortium. 2007. Genome-wide association 
study of 14,000 cases of seven common diseases and 3,000 shared 
controls. Nature, 447, 661-78. 
Wessels, J. A., Huizinga, T. W. & Guchelaar, H. J. 2008. Recent insights in the 
pharmacological actions of methotrexate in the treatment of rheumatoid 
arthritis. Rheumatology (Oxford), 47, 249-55. 
Wolfe, F. 2004. Fatigue assessments in rheumatoid arthritis: comparative 
performance of visual analog scales and longer fatigue questionnaires in 
7760 patients. J Rheumatol, 31, 1896-902. 
Wolfe, F., Michaud, K. & Pincus, T. 2004. Development and validation of the 
health assessment questionnaire II: a revised version of the health 
assessment questionnaire. Arthritis Rheum, 50, 3296-305. 
Yeap, S. S. 2009. Rheumatoid arthritis in paintings: a tale of two origins. Int J 
Rheum Dis, 12, 343-7. 
Young, A., Dixey, J., Cox, N., et al. 2000. How does functional disability in early 
rheumatoid arthritis (RA) affect patients and their lives? Results of 5 
years of follow-up in 732 patients from the Early RA Study (ERAS). 
Rheumatology (Oxford), 39, 603-11. 
Young, A., Dixey, J., Williams, P., et al. 2011. An evaluation of the strengths 
and weaknesses of a register of newly diagnosed rheumatoid arthritis, 
1986-2010. Rheumatology (Oxford), 50, 176-83. 
Zheng, J., Ibrahim, S., Petersen, F., et al. 2012. Meta-analysis reveals an 
association of PTPN22 C1858T with autoimmune diseases, which 
depends on the localization of the affected tissue. Genes Immun, 13, 
641-52. 
  
295 
 
Zhou, H., Jang, H., Fleischmann, R. M., et al. 2007. Pharmacokinetics and 
safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, 
in subjects with rheumatoid arthritis. J Clin Pharmacol, 47, 383-96.
  
296 
 
Appendix 1 Health Assessment Questionnaire 
Tick the one response which best describes your usual abilities over the past week. 
 Without 
ANY 
difficulty  
(0) 
 
With SOME 
difficulty  
(1) 
 
With 
MUCH 
difficulty  
(2) 
 
Unable  
to do  
(3) 
1. DRESSING & GROOMING  
Are you able to: 
    
 Dress yourself, including tying 
shoelaces and doing buttons? 
    
 Shampoo your hair? 
 
    
2. RISING 
Are you able to: 
    
 Stand up from an armless straight 
chair? 
    
 Get in and out of bed? 
 
    
3.  EATING  
 Are you able to: 
    
 Cut your meat? 
 
    
 Lift a full cup or glass to your 
mouth? 
    
 Open a new carton of milk 
(or soap powder)? 
    
4.  WALKING 
Are you able to: 
 
    
 Walk outdoors on flat ground? 
 
    
 Climb up five steps? 
 
    
 
PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE 
ACTIVITIES 
 
Walking stick 
Devices used for dressing (button hook, zipper pull, 
long-handled shoe horn)  
Walking frame  
Built up or special utensils 
 
Crutches 
 
Wheelchair Special or built up chair 
Other (Please specify) 
 
 
Please tick any categories for which you usually need help from another person. 
Dressing and grooming 
  
Rising Eating  Walking 
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Tick the one response which best describes your usual abilities over the past week. 
 Without 
ANY 
difficulty  
(0) 
With SOME 
difficulty  
(1) 
With 
MUCH 
difficulty  
(2) 
Unable  
to do  
(3) 
5. HYGIENE 
Are you able to: 
    
 Wash and dry your entire body? 
 
    
 Take a bath? 
 
    
 Get on and off the toilet? 
 
    
6. REACH 
Are you able to: 
    
 Reach and get down a 5lb object 
(eg a bag of potatoes) from just 
above your head? 
    
 Bend down to pick clothing from 
the floor? 
    
7. GRIP 
 Are you able to: 
    
 Open car doors? 
 
    
 Open jars which have previously 
been opened? 
    
 Turn taps on and off? 
 
    
8. ACTIVITIES 
Are you able to: 
    
 Run errands and shop? 
 
    
 Get in and out of a car? 
 
    
 Do chores such as vacuuming, 
housework or light gardening? 
    
 
PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE 
ACTIVITIES 
Raised toilet seat  Bath rail Bath seat Long-handled appliances for 
reach 
Jar opener 
(for jars previously opened) 
Other  
(please specify) 
 
Please tick any categories for which you usually need help from another person. 
Hygiene 
  
Reach Gripping and opening things Errands  
and housework 
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Appendix 2 Joint count from Yorkshire Early Arthritis Register 
B clinical record form 
 
Swollen/Tender Joint count: Complete ALL joint count 
(Indicate with a tick or cross the swollen/tender joints present) 
 
Right  S T  T S  Left 
     TMJ      
T=Tender 
S=Swollen 
   Sternoclavicular      
   ACJ      
  * * Shoulder * *    
   * * Elbow * *    
   * * Wrist * *    
* * * * * MCP tender * * * * * 
* * * * * MCP swollen * * * * * 
* * * * * PIP tender * * * * * 
* * * * * PIP swollen * * * * * 
     
DIP tender 
     
     
DIP swollen 
     
     Hip      
   * * Knee * *    
     Ankle      
     Midtarsal      
     
MTP tender 
     
     
MTP swollen 
     
     
PIP tender 
     
     
PIP swollen 
     
 
*28 Swollen/Tender Joint Count 
ACJ, Acromioclavicular joint; DIPJ, distal interphalangeal joint; MCPJ, metacarpophalangeal 
joint; MTPJ, metatarsal phanangeal joint; PIPJ, proximal interphalangeal joint; TMJ, 
temperomandibular joint. 
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Appendix 3 Joint count from Yorkshire Early Arthritis Register C clinical record form 
Indicate which joints are *tender*       Indicate which joints are *swollen*  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There are no tender 
joints 
There are no swollen 
joints TMJ 
Elbow 
Wrist 
MCPJ 
PIPJ 
Hip 
Knee 
Sternoclav 
ACJ 
DIPJ 
Ankle 
Midtarsal 
MTPJ 
PIPJ 
Shoulder 
 5        4      3        2      1 
 1       2      3       4     5 
 5        4      3        2      1  1       2      3       4     5 
 5        4      3        2      1 
 1       2      3       4     5 
 5        4      3        2      1  1       2      3       4     5 
  
300 
 
Appendix 4 Medication record from Yorkshire Early Arthritis Register C clinical record form 
DMARDs Commenced today 
Have DMARDs been commenced today?   No/NA 
          Yes complete details  
   Methotrexate (MTX) 
 As per protocol guidelines (7.5mg/week for 4 weeks,  
15 mg/week maintenance) 
 Other                please complete the following table 
Initiation Maintenance 
Week‎…… 
Wk 1 
  7.5mg 
  10 mg 
  
12.5mg 
  15 mg 
  .…mg 
Wk ……. 
  7.5mg 
  10 mg 
  
12.5mg 
  15 mg 
  .…mg 
Wk …… 
  7.5mg 
  10 mg 
  
12.5mg 
  15 mg 
  .…mg 
Wk ……. 
  7.5mg 
  10 mg 
  
12.5mg 
  15 mg 
  .…mg 
  7.5mg 
  10 mg 
  12.5mg 
  15 mg 
   …….mg 
   Sulphasalazine (SSA) 
Initiation Maintenance 
Week…… 
Wk 1 
  0.5g 
 Other 
     ……..
g 
Wk ……. 
  1g 
 Other 
     ……..
g  
Wk …… 
  1.5g 
 Other 
     ……..
g  
 
Wk …… 
  2g 
  Other 
     
……..g 
 
  1g 
  1.5g 
  2g 
   Hydroxychloroquine (HCQ) 
   200 mg daily 
   400 mg daily
DMARDs Prescribed in previous visit/Maintenance Dose 
If the patient has been taking DMARDs, please complete the details for the appropriate DMARD 
 Methotrexate (MTX)    
What is the maintenance dose? 
     5 mg    17.5 mg 
  7.5mg    20 mg 
  10 mg    22.5mg 
  12.5mg    25mg 
  15 mg    Other  ……….. 
      
 Sulphasalazine (SSA)  
What is the maintenance dose?  
1g         1.5g         2g     2.5g         3g 
 
 Hydroxychloroquine (HCQ) 
What is the maintenance dose?   
200 mg/day        400 mg/day     
 
 
DMARDs Side Effects 
Has the patient reported any side effects with the DMARDS? 
Yes  No 
If yes, was this due to: 
  Gastro-intestinal side effects 
  Liver function test results 
  Renal 
  Skin rash 
  Haematological abnormalities 
  Other problems (please describe)  
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Appendix 5 Rasch transformation of the disability index of the 
Health Assessment Questionnaire  
In order to use HAQ-DI as a continuous variable in all analyses, it was 
transformed using a Rasch model.  This transformation was performed by Dr 
Elizabeth Hensor, the YEAR data analyst, using RUMM2030 (RUMM laboratory 
Pty ltd. 1998-2010).   
Using baseline HAQ-DI values, subsets were selected so that there were 15 
patients with each score from 0-23.  Only 7 patients had a baseline HAQ-DI 
score of 24 and all were included.  Estimates from this group were used 
(subjects with missing items were excluded), then anchored on reaching and 
rising in the entire dataset (including those with missing values), to obtain 
estimates for all cases.  The summary statistics for the model are shown below: 
Item location mean 0 
Item location SD 0.672 
Item Fit Residual mean -0.242 
Item Fit Residual SD 1.245 
Person location mean -0.103 
Person location SD 2.384 
Person Fit Residual mean -0.302 
Person Fit Residual SD 1.043 
Total-Item Chi Square 63.532 
Degrees of freedom 48 
P= 0.066 
PSI with extremes 0.91349 
PSI without extremes 0.90829 
CA with extremes 0.94365 
CA without extremes 0.93251 
Where SD is standard deviation, P is probability PSI is person separation index 
and CA is Crohnbach’s alpha.  
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Item fit details are shown in the following table: 
HAQ Domain 
Fit 
Residuals 
Chi 
square 
Probability 
F-statistic 
Probability LD DIF 
Hygiene 0.46 0.132 0.182 NONE NONE 
Reaching -1.474 0.356 0.128 NONE NONE 
Gripping 1.1 0.128 0.223 NONE NONE 
Activities -2.069 0.099 0.019 NONE NONE 
Dressing -1.321 0.382 0.184 NONE NONE 
Rising 0.573 0.414 0.353 NONE NONE 
Eating -0.328 0.347 0.227 NONE NONE 
Walking 1.126 0.296 0.335 NONE NONE 
DIF, differential item functioning; LD, local dependency  
Person-item threshold distribution is illustrated in the figure below: 
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Appendix 6 Variable distributions 
 
 
Figure 6A Histograms to show distributions of age in Yorkshire Early 
Arthritis Register B and C 
The upper figure (A) represents data from YEAR B. (Mode 67 years, median 59 years and 
mean 58 years.) 
The lower figure (B) represents data from YEAR C. (Mode 61 years, median 58 years and 
mean 58 years.) 
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Figure 6B Histograms to show distributions of symptom duration in 
Yorkshire Early Arthritis Register B and C 
The upper figure (A) represents data from YEAR B. (Mode 4.0 months, median 6.0 months 
and mean 6.5 months.) 
The lower figure (B) represents data from YEAR C. (Mode 4.3 months, median 6.6 months 
and mean 7.5 months.) 
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Figure 6C Histograms to show distributions of pain visual analogue score 
in Yorkshire Early Arthritis Register B and C 
The upper figure (A) represents data from YEAR B. (Mode 10.0cm, median 6.8cm and 
mean 6.3cm.) 
The lower figure (B) represents data from YEAR C. (Mode 10.0cm, median 5.9cm and 
mean 5.6cm.) 
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Figure 6D Histograms to show distributions of pain and fatigue visual 
analogue scores in Yorkshire Early Arthritis Register  
The upper figure (A) represents data from YEAR B. (Mode 0.0cm, median 5.5cm and mean 
4.8cm.) 
The lower figure (B) represents data from YEAR C. (Mode 0.0cm, median 5.0cm and mean 
4.0cm.) 
cm, centimetres; VAS, visual analogue score. 
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Figure 6E Histograms to show distributions of baseline disease activity 
scores from counts of 28 joints and health assessment questionnaire 
scores in Yorkshire Early Arthritis Register.  
The upper left figure (A) represents baseline DAS28 from YEAR B. (Mode 5.4, median 5.4 
and mean 5.3.) 
The upper right figure (B) represents baseline DAS28 from YEAR C. (Mode 5.0, median 4.8 
and mean 4.7.) 
The bottom left figure (C) represents baseline HAQ-DI from YEAR B. (Mode 9.0, median 
10.2, mean 10.2.) 
The bottom right figure (D) represents baseline HAQ-DI from YEAR C. (Mode 8.0, median 
9.5, mean 9.4.) 
DAS28, disease activity score based upon count of 28 joints; HAQ-DI, disability component 
of the health assessment questionnaire; YEAR, Yorkshire early arthritis register. 
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Figure 6F Histograms to show distributions change in disease activity 
scores from counts of 28 joints and health assessment questionnaire 
scores after six months in Yorkshire Early Arthritis Register  
The upper left figure (A) represents change in DAS28 after 6 months in YEAR B. (Mode -
1.6, median -2.0 and mean -1.5.) 
The upper right figure (B) represents change in DAS28 after 6 months in YEAR C. (Mode -
1.3 median -1.1 and mean -1.2.) 
The bottom left figure (C) represents change in HAQ-DI after 6 months in YEAR B. (Mode 
0.0 , median -2.0, mean -2.2.) 
The bottom right figure (D) represents change in HAQ-DI after 6 months in YEAR C. (Mode 
0.0, median -1.0, mean -1.9.) 
Change in DAS28 and HAQ-DI were calculated by subtracting the scores at baseline from 
those at 6 months.  
DAS28, disease activity score based upon count of 28 joints; HAQ-DI, disability component 
of the health assessment questionnaire; YEAR, Yorkshire early arthritis register. 
0
.0
5
.1
.1
5
.2
.2
5
D
e
n
s
it
y
-5.00 0.00 5.00
Change DAS28 6m
0
.1
.2
.3
D
e
n
s
it
y
-5 0 5
Change DAS28 6m
0
.0
5
.1
.1
5
.2
-20 -10 0 10 20
Change HAQ-DI 6m
0
.1
.2
.3
D
e
n
s
it
y
-20 -10 0 10
Change HAQ-DI 6m
A B 
C D 
YEAR B YEAR C 
YEAR B YEAR C 
  
309 
 
  
  
 
Figure 6G Histograms to show distributions change in disease activity 
scores from counts of 28 joints and health assessment questionnaire 
scores after twelve months in Yorkshire Early Arthritis Register  
The upper left figure (A) represents change in DAS28 after 12 months in YEAR B. (Mode -
1.84, median -1.95 and mean -1.93.) 
The upper right figure (B) represents change in DAS28 after 12 months in YEAR C. (Mode 
-2.0 median -1.6 and mean -1.6.) 
The bottom left figure (C) represents change in HAQ-DI after 12 months in YEAR B. (Mode 
0.0, median -2.5, mean -2.8.) 
The bottom right figure (D) represents change in HAQ-DI after 12 months in YEAR C. 
(Mode 0.0, median -2.0, mean -2.5.) 
Change in DAS28 and HAQ-DI were calculated by subtracting the scores at baseline from 
those at 12 months.  
DAS28, disease activity score based upon count of 28 joints; HAQ-DI, disability component 
of the health assessment questionnaire; YEAR, Yorkshire early arthritis register. 
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Appendix 7 Predictors of disease activity trajectory (fatigue 
excluded) 
Table 7A Results of multinomial logistic regression analysis of predictors 
of‎class‎2‎trajectory‎(‘low‎disease‎activity’)‎membership 
 
Predictor Coefficient Odds ratio (95% CI) p 
YEAR C cohort -0.05 0.95 (0.77, 1.19) 0.727 
Male gender -0.53 0.59 (0.47, 0.75) <0.001 
Age 0.00 1.00 (0.99, 1.01) 0.763 
RF positive 0.17 1.19 (0.86, 0.64) 0.382 
CCP positive 0.38 1.46 (1.01, 2.11) 0.094 
Shared epitope positive 0.16 1.18 (0.96, 1.45) 0.184 
IMD quartile 1 0.41 1.50 (1.10, 2.04) 0.030 
2 0.29 1.33 (0.97, 1.82) 0.133 
3 -0.11 0.90 (0.65, 1.24) 0.581 
Results of multinomial logistic regression analysis using data from whole YEAR cohort.   
Outcome variable was membership of class 2 trajectory, described in Chapter 4, 
Section 4.6. 
Statistically significant (p<0.05) coefficients are highlighted in bold. 
For IMD, the referent category was the 4th quartile, which was the least deprived group:  
higher levels of deprivation were represented by reducing quartile number . 
Independent variables were measured at baseline. 
CCP, cyclic citrullinated peptide antibody; CI, confidence interval; IMD, index of 
multiple deprivation; p, probability (statistical significance); RF, rheumatoid factor; 
YEAR, Yorkshire Early Arthritis Register. 
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Table 7B Results of multinomial logistic regression analysis of predictors 
of class 1 trajectory (more favourable) membership for Yorkshire Early 
Arthritis Register C 
 
Predictor Coefficient Odds ratio (95% CI) p 
Male gender 0.75 2.13 (1.46 3.10) 0.001 
Age 0.00 1.00 (0.99 1.02) 0.719 
RF positive -0.06 0.94 (0.57 1.51) 0.831 
CCP positive -0.38 0.69 (0.41 1.53) 0.232 
Shared epitope 
positive 
-0.14 0.87 (0.69 1.10) 0.337 
IMD quartile 1 -0.63 0.54 (0.32 0.88) 0.039 
2 -0.60 0.55 (0.34 0.90) 0.045 
3 -0.28 0.76 (0.45 1.26) 0.367 
BMI (kg/m2) -0.04 0.96 (0.93 0.99) 0.032 
Smoking (pack 
years) 
-0.01 0.99 (0.99 1.00) 0.163 
Comorbidities  -0.15 0.86 (0.58 1.29) 0.539 
Results of multinomial logistic regression analysis.   
Outcome variable was membership of class 1 trajectory, described in Chapter 4, 
section 4.7.1.3. 
Statistically significant (p<0.05) coefficients are highlighted in bold. 
For IMD, the referent category was the 4th quartile, which was the least deprived group:  
higher levels of deprivation were represented by reducing quartile number . 
Independent variables were measured at baseline. 
One pack year was the equivalent of smoking 20 cigarettes per day for one year.  
Comorbidities were classified as present /absent. 
BMI, body mass index CCP, cyclic citrullinated peptide antibody; CI, confidence 
interval; IMD, index of multiple deprivation; p, probability (statistical significance); RF, 
rheumatoid factor. 
 
  
312 
 
Appendix 8 Comparison of baseline variables across quartiles 
of index of multiple deprivation scores 
Table 8A Comparison of mean baseline variables across quartiles of index 
of multiple deprivation score 
  
 
Mean baseline values by IMD quartile (SD)   
 1 2 3 4 F* P* 
Age 
/years 
56.2  (14.9) 56.9  (14.7) 58.5  (13.8) 58.9  (14.2) 2.30 0.030 
DAS28  5.2 (1.4) 5.0  (1.5) 5.0  (1.4) 4.9  (1.4) 1.66 0.174 
Fatigue 
VAS /cm 
4.9  (3.2) 5.0  (3.3) 4.6  (3.3) 4.3  (3.2) 3.53 0.014 
Number 
of PY  
16.8  (20.4) 14.2  (24.4) 14.1  (18.6) 11.4  (18.9) 1.96 0.119 
BMI  27.6 (6.6) 27.0  (6.6) 27.0  (4.7) 27.7  (6.1) 0.74 0.531 
HAQ-DI  11.0  (4.8) 10.1 (4.6) 9.3  (4.5) 9.0  (4.2) 12.65 <0.001 
*F-statistic and statistical probability, p refer to results of a one-way between groups 
analysis of variance. 
BMI, body mass index (measured in kilograms per metre squared); cm, centimetres; 
DAS28, disease activity score based upon counts of 28 joints and C-reactive protein; 
HAQ-DI, disability index component of health assessment questionnaire (Rasch 
transformed variable used); IMD, index of multiple deprivation; PY, pack years; SD, 
standard deviation; VAS, visual analogue score. 
 
 
